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ABSTRACT 
 
 This manuscript reflects our most recent advancements in the recognition of 
nucleic acids.  Chapter one focuses on previously established methods in nucleic acid 
recognition.  Nucleic acid targeting by small molecules affords a unique way to 
potentially inhibit biological functions, which is different from targeting enzyme and 
protein bio-macromolecules.  We seek to further develop an aminoglycoside approach to 
targeting nucleic acids.   Since aminoglycosides were first introduced, over 60 years ago, 
as treatment for tuberculosis, natural product discovery and demands for therapeutically 
more effective aminoglycosides, with lowered toxicity, have dominated the landscape of 
aminoglycoside research.  More recently, our group has established neomycin as a major 
groove binding ligand capable of binding nucleic acids outside of their traditional target, 
the A-site of 16S rRNA in the 20S subunit of ribosomal RNA.  These non-A-site 
structures shared a common motif, A-form conformation within the helix.   
 To this end, chapter two of this manuscript focuses on advancements in 
targeting DNA:RNA hybrids.  DNA:RNA hybrids are viable therapeutic targets as they 
appear in a number of biological processes: transcription, reverse transcription, DNA 
replication, mitochondrial DNA replication and telomerase activity.  Surprisingly, the 
number of ligands which target DNA:RNA hybrids is fewer than ten!  We report the 
development of a novel neomycin-methidium chloride conjugate capable of targeting 
DNA:RNA hybrids with selectivity as well as high affinity.   
iii 
 Chapters three and four introduce our most recent advancements in targeting 
DNA.  Prior work by our group suggested conjugation of neomycin to a minor groove 
binding ligand can be used as a method of targeting the DNA duplex.  Although these 
dual recognition conjugates demonstrated the ability to stabilize the duplex, 
improvements in affinity remained.  A departure from previous work, we focus on 
targeting GC-rich DNA, over AT-rich DNA; as reports suggest GC-rich DNA is capable 
of displaying A-form characteristics.  When designing our minor groove binding ligand, 
we utilized DNA minor groove-polyamide, pairing rules established by Dervan.  
Subsequent conjugation to neomycin to polyamides comprised of N-methylimidazole and 
N-methylpyrrole afforded us a library of polyamide conjugates.  In chapter three, we 
focus on the development and bioanalytical studies of tetramer polyamide – neomycin 
conjugates.  Chapter four discusses our most recent advancements in the development of 
hairpin polyamide - neomycin conjugates which were designed to target GC-rich DNA. 
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CHAPTER I 
 
NUCLEIC ACIDS AND THEIR INTERACTION WITH LIGANDS 
 
Nucleic Acids – A Historical Perspective & Overview.  In 1869 Miescher isolated 
deoxyribonucleic acid, DNA, from the nuclei of white blood cells (1).  The materials 
extracted from the nucleus were acidic in nature and named nucleic acids.  It was not 
long before scientists discovered nucleic acids were buried within the nuclei of all cells.  
In 1908 Levene and Mandel reported the isolation of nucleotides from thymus DNA (2, 
3).  This discovery was significant as it suggested nucleic acids were actually comprised 
of smaller subunits.  Levene identified the four bases adenine (A), cytosine (C), guanine 
(G), and thymine (T) as the subunit building blocks of DNA (4).   
In 1944 (5), Oswald T. Avery, Colin MacLeod and Maclyn McCarty claimed 
nucleic acids were the carriers of genetic information.  Historically, this claim bordered 
on the heretical as it marked a significant departure from the biologist driven belief that 
proteins functioned as the carriers of genetic material.  Biologists strongly believed the 
carriers of genetic information must be more complex than simplistic nucleic acids.  The 
damning evidence to the biologists’ claim followed in 1949 (6).   
In 1947, X-ray experiments conducted on fiber DNA revealed two notable 
observations.  First, an interesting reflection on the X-ray pattern was observed by 
Astbury and interpreted as stacking of the nucleosides (7).  Second, X-ray experiments 
2 
suggested significant hydrogen bonding occurred within the structure, as reported by 
Gulland (8).  This data was eventually used to prove that nucleosides were held together 
by hydrogen bonds about a central helical axis.   
Furberg published the first crystal structure of a nucleoside – cytidine in 1950 (9).  
In 1952, data suggested that the arrangement of nucleosides were not random and 
nucleosides were inter-stand connected by hydrogen bonds (10).  Todd and co-workers 
confirmed, in 1953, nucleosides were intra-strand connected through 3’, 5’ 
phosphodiester bonds and produced a linear polymer – DNA (11).  Rosalind Franklin’s 
work in 1953 suggested the DNA was a helix with phosphate groups occupying the 
outside of the helix (12).  Her work marked a major leap forward in the elucidation of 
DNA structure.   
A 1953 Nature manuscript by Watson and Crick (13) proposed DNA structure 
existed as a double-stranded helix, comprised of repeating, paired nucleosides, held 
together by phosphate groups.  The pair accommodated previously reported observations, 
by placing the heterocyclic bases along the helical axis and the sugar-phosphate 
backbones in a winding anti-parallel fashion around the central axis.  
DNA RNA proteinstranscription translationreplication
 
Figure 1.1.  The ‘central dogma of molecular biology’.   
 
Crick eventually proposed the ‘central dogma of molecular biology’, Figure 1.1.  
The framework of the dogma suggests DNA acted as the carrier of genetic information.   
Replication of the genetic code, DNA replication, was confirmed in 1958 (14).  
3 
Beginning in 1961, Holley, Khorana and Nirenberg solved the rules by which the flow of 
information encoded in DNA is transcribed to RNA, which in turn is translated into 
proteins (15, 16, 17, 18, 19, 20, 21, 22, 23, 24).  For breaking the genetic code, they were 
awarded the 1968 Nobel Prize in Physiology or Medicine.   
The years which followed saw a number of significant advancements in nucleic 
acid research as recounted in the following review (1).  Some advancements include 
methods for sequencing DNA, 1977 (25), in vitro amplification of DNA and the 
introduction of polymerase chain reaction, PCR, in 1983 (26).   Major advancements in 
DNA sequencing included the complete sequencing of a free-living organism genome 
(27), eukaryotic organism genome (28) and human chromosome and human genome 
(29).   
Admittedly, the birth of the nucleic acid field of study began many centuries ago 
when humans observed simple inheritance phenomenon in nature.  In fact, the study of 
genetics began in 1856 with experiments in a monastery garden conducted by Gregory 
Mendel, far before the work of Watson and Crick (13).  Nevertheless, a direct result of 
work conducted in the late 1940s to mid-1950s, the elucidation of DNA structure opened 
a floodgate of scientific investigations.  Currently, our work seeks to deepen our 
understanding of nucleic acid recognition by small molecules.  Targeting nucleic acids 
affords us the potential to regulate dependent biophysical functions.  This is the basis for 
the subsequent research presented in this manuscript.   
 
4 
Nucleic Acids – Presenting the Case.  Prior to a discussion on nucleic acid structure a 
case emphasizing the importance of targeting nucleic acids must be made.  The transfer 
of genetic information follows three principles: 
(i) The genetic information of an organism is encoded within its DNA.  This 
genetic information directs most biological functions of the organism.  Furthermore, 
genetic information can be replicated with high fidelity.   
(ii) The information stored in DNA can be transcribed into ribonucleic acid, RNA, 
through transcription.  The resulting RNA transcript of the parent DNA strand retains 
high fidelity as well.   
(iii) RNA translates genetic information into functional proteins through 
translation.  Proteins are very complex in nature, dependent on constituent amino acids, 
account for the majority of non-aqueous mass of a cell and act as the workhouse in a 
number of cellular functions.   
These principles make up the ‘central dogma of molecular biology’, Figure 1.1 
(14).   
 A ligand designed to bind to nucleic acids has the potential to disrupt any number 
of biochemical processes involved in transcription or translation.  Through disruption of 
transcription or translation, the synthesis of dependent proteins can be artificially 
controlled.  To this end we seek to design ligands capable of binding nucleic acids at 
affinities high enough to disrupt biological processes.  Furthermore, these ligands can 
exploit the secondary structure of nucleic acids (preferential binding to a specific nucleic 
5 
acid) as well as the primary structure (specific binding to preserved sequences within 
nucleic acids).   
 Primary Structure: Nucleic acids provide an enticing synthetic target.  Nucleic 
acids are comprised of repeating nucleotides, which contain three major components, 
Figure 1.2 (30). 
PURINES
PYRIMIDINES
Adenine Guanine
Cytosine UracilThymine
   = ribose/
H = deoxyribose
nucleoside/
deoxynucleoside
nucleotide/
deoxynucleotide
1
2
3
4
5
6
7
8
9
1'
2'3'
4'
5'
4
3
65
2
1
 
Base Nucleoside Deoxynucleoside Ribonucleotide Deoxyribonucleotide 
adenine adenosine 2’-deoxyadenosine 
adenosine 
5’-phosphate 
2’-deoxyadenosine 
5’-phosphate 
guanine guanosine 2’-deoxyguanosine 
guanosine 
5’-phosphate 
2’-deoxyguanosine 
5’-phosphate 
cytosine cytidine 2’-deoxycytidine 
cytidine 
5’-phosphate 
2’-deoxycytidine 
5’-phosphate 
thymine ---------- thymidine ---------- 
thymidine 
5’-phosphate 
uracil uridine ---------- 
uridine 
5’-phosphate 
---------- 
Figure 1.2.  Structural elements and naming of bases, nucleosides and nucleotides, 
adapted from Saenger (30).   
 
(i) Bases – Nucleic acids are planar, aromatic, heterocyclic compounds which fall 
into two classifications, purines and pyrimidines.  Adenine and guanine populate the 
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purine class of bases while the pyrimidine class of bases consists of cytosine, thymine 
and uracil.  DNA and RNA contain four bases, three of which, adenine, guanine and 
cytosine, are used in both DNA and RNA.  Thymine is exclusive to DNA while uracil is 
exclusive to RNA.  The bases are connected to the sugar at the N-9 position of purine 
bases and the N-1 position of pyrimidine bases. 
(ii) Sugar – The sugar acts as a bridge between the DNA bases and the phosphate 
backbone.  The ribose sugar is a furanose bound to the bases at the anomeric carbon 
through β-glycosidic linkages.  A D-ribose or a 2-deoxy-D-ribose sugar bound to a base 
constitutes a nucleoside of RNA or DNA, respectively.  
(iii) Phosphate Backbone – Phosphate groups join two adjacent nucleosides 
through an ester linkage to phosphoric acid at the 5’- or 3’- hydroxyl group.  A nucleotide 
is a nucleoside that is phosphorylated at one of the free sugar hydroxyls.  The sequence of 
nucleotides defines the primary structure of the nucleic acid.  Furthermore, nucleoside 
and nucleotide function does not end with nucleic acids.  Adenosine-5'-triphosphate 
(ATP) is a nucleotide known as the ‘energy currency in cells’ (31).  Cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (GMP) (32) act as cellular 
process regulators (33).   
Secondary Structure: Assembling the nucleotides in a sequential fashion gives 
rise to nucleic acid secondary structure.  The assembly of two nucleotide subunits is a 
dinucleotide while three nucleotide subunits is a trinucleotide.  In general, twenty or 
fewer nucleotides constitute an oligonucleotide and the term polynucleotide is used to 
describe a nucleic acid composed of many subunits.  As nucleotide subunits are 
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assembled in a linear fashion the polar nature of the ribose-phosphate backbone give rise 
to the helical scaffold with pyrimidine and purine bases facing inward near 90o to the 
helical axis (30).  When paired through Watson-Crick base pairing, two helical strands of 
nucleic acids form a double helix.  The center of the helix is a spiraling cantilevered 
staircase of planar aromatic bases. β-glycosidic linkages between base and sugar are 
asymmetrical; the resulting double helix has two characteristic grooves, a major and a 
minor groove. 
Nucleic acid secondary structure is not limited to a double helix.  Nucleic acids 
can exist as triple helixes (34, 35, 36, 37) (association of a third strand to an existing 
duplex), tetraplex (38) (formed by a quartet of guanine bases), bulges (39), loops (40, 41) 
and stems (42) (generally found in RNA), to highlight a few.  While these structures 
receive mention within the manuscript the focus remains on duplex nucleic acid 
structures.   
The double helix is a dynamic molecule and exists in multiple conformations.  β-
glycosidic linkages are not the only contributors to overall double helix geometry. 
Conformational changes can be driven by changes in the duplex hydration state (43, 44), 
the presence of a hydroxyl group at the 2-position of the ribose sugar and base sequence.   
These conformational differences provide a diverse catalog of structures suitable for 
targeting by small binding ligands.   
B-form conformation is highlighted by conformational features such as C2’-endo 
ribose sugar pucker, an axial rise between base pairs of 0.33 nm, the helical axis is not 
displaced and 16 bases constitute a helical turn, Figure 1.3.  These features give rise to a 
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helix with a major groove, which is shallower and wider than the A-form counterpart, 
while the minor groove is deeper and narrower than the A-form counterpart. A-form  
A-form  B-form 
3'
3'
2'
2'
5' 5'
4'4'
   = ribose/
H = deoxyribose
1'1'
1'
2'3'
4'
5'
 
C3’-endo  C2’-endo 
 
 
 
Figure 1.3. Schematic of structural differences between A-form and B-form nucleic 
acids.   
 
conformation has characteristic major (deeper and narrower) and minor (shallower and 
wider) grooves.  Several conformational features are noteworthy: the sugar pucker is C3’-
endo, the rise between base pairs is smaller at 0.23 nm, there is a negative displacement 
of the helical axis and 18 base pairs constitute a helical turn.   
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Targeting Nucleic Acids.  Ligands designed to target duplex nucleic acids fall into two 
categories based on their mode of interaction.  These include intercalators that insert 
themselves between adjacent base pairs through π-π stacking interactions and ligands that 
bind in the grooves of the nucleic acid duplex.   
Intercalation:  Intercalation was the first proposed mechanism of ligand-nucleic 
acid interaction (45).  The compounds in this class are planar and comprised of fused 
aromatic six-membered rings.  The planarity of these ligands allows them to insert 
themselves between adjacent base pairs of a nucleic acid.  Classic intercalators are 
highlighted by ethidium bromide (46, 47, 48), thiazole orange (49, 50), acridine orange 
(45, 51), actinomycin (52, 53, 54), quinacrine (55), proflavine (56, 57), coralyne chloride 
(58) and daunomycin (59).  This mode of targeting nucleic acids does have drawbacks, 
Figure 1.4.   
ethidium bromide thiazole orange
acridine orange
daunomycin
quinacrine
proflavine
coraltne chloride
 
Figure 1.4.  Chemical structures of representative intercalators.   
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Generally these ligands do not display sequence specificity, although a slight preference 
for 5’-purine, 3’-pyrimidine sequences has been reported (60).  However, reports suggest 
intercalation favors certain conformations of nucleic acids (61).  Furthermore, a 
necessary product of intercalation is that adjacent base pairs within the duplex are forced 
apart and a concomitant elongation of the duplex follows.   
Improvements in intercalator binding affinity have been achieved through the 
synthesis of intercalator-intercalator dimers.  Dervan reported the synthesis of a 
methidium dimer which bound calf thymus DNA with Ka values of 109 M-1; which is 
higher than the 105 M-1 value observed with the monomer (62).  Utilizing an intercalator 
to increase binding affinity by conjugating the intercalating moiety to a major groove 
binding moiety has also been reported.  Our group reported conjugation of a major 
groove binding ligand, neomycin, to a number of different intercalators (63, 64, 65).  Not 
only was an increase in binding affinity observed, these conjugates also showed an ability 
to specifically target different conformations of nucleic acids as well.   
Finally, a biological precedent for this method of targeting nucleic acids can be 
established.  Topoismerases are a class of enzymes responsible for the cutting, removal 
and eventual reattachment of small oligomers of DNA during DNA replication.  
Doxorubicin, trade name Adramycin, an intercalator, has shown the ability to halt cellular 
replication by preventing the reattachment of the oligomers, in turn arresting the 
replication process (66).  Especially useful where controlling DNA replication is desired, 
intercalators find use in cancer chemotherapy (66, 67, 68).   
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The second category of ligand duplex nucleic acid interactions involves molecules 
which bind either the major groove or the minor groove.  As previously mentioned, 
asymmetric β-glycosidic linkages between base and sugar give rise to the grooves found 
in nucleic acid duplexes.  While the characteristics of these grooves can vary 
significantly, the grooves remain quite distinct from each other and pose unique 
environments for targeting by small ligands.   
Watson-Crick base pair stacking presents the potential for four total base pair 
combinations about the helical axis, Figure 1.5.  The base pairs present different 
functionalities to each of the groves which are unique to each base pair.  For instance, an 
A/T base pair presents the following: a H-bond acceptor, H-bond donor, H-bond acceptor 
and a methyl group to the face of the major groove.  This motif is made available by the 
nitrogen at the 7-position and the amine at the 6-position of the purine followed by the 
carbonyl at the 4-position and the methyl at the 5-position of the pyrimidine, respectively.  
At the same time, this A/T base pair presents a palindrome motif to the minor groove face 
involving a H-bond acceptor, a hydrogen and a H-bond acceptor (N-3, C-2 of the purine, 
O-2 of the pyrimidine).  Therefore, the combination of base pairs affords the major 
groove with four unique surfaces for approaching ligands, while the minor groove 
contains two unique surfaces.  
 Minor Groove Binding:  Minor groove binding ligands are comprised of 
heterocyclic rings which form a crescent shaped molecule, Figure 1.6.  The deeper, 
narrower, minor groove dictates that these molecules are relatively flat and occupy a 
number of base pairs.  Minor groove binding ligands with optimal geometries have also  
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Figure 1.5.  A schematic depicting DNA base pairs and the functional groups accessible through the major and minor grooves 
of nucleic acid duplexes, adapted from Alberts (69).   
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been shown to bind the minor groove with a 2:1 binding stoichiometry.  The incoming 
second molecule occupies the same binding site with an opposite (head-to-tail) 
orientation with respect to the first molecule (70, 71, 72, 73).  Since these molecules tend 
to be relatively flat, minor groove binding ligands possess a secondary intercalative 
binding mode as observed with 4',6-diamidino-2-phenylindol (DAPI) (74). 
netropsin
distamycin A
Hoechst 33258
berenil
 4',6-diamidino-2-phenylindole
 
Figure 1.6.  Chemical structures of representative minor groove binders.   
 
Targeting the minor groove of nucleic acids has seen significant success in recent 
years.  Minor groove binding ligands have the ability to bind DNA at high affinities, 
while also binding at high specificity (75, 76, 77, 78, 79, 80).  Naturally occurring 
polyamides netropsin and distamycin A (70, 81, 82), Hoechst 33258 (83, 84, 85), Berenil 
(86) and DAPI (87, 88) are all examples of minor groove binding ligands.  Prior to the 
synthesis of novel polyamides by Peter Dervan, minor groove binding ligands such as 
distamycin A, netropsin and Hoechst 33258, displayed preference for AT-rich DNA.  
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Affinities for these ligands to their target sequences were in the range of micromolar to 
nanomolar:  netropsin (Ka = ~106 M-1 to ~107 M-1) (81), distamycin A (Ka = ~106 M-1) 
(81) and Hoechst 33258 (Kd = 10-9 M-1) (85).   
Dervan utilized N-methylimidazole and 2-hydroxy-N-methylpyrrole to 
successfully bind a number of different sequences of DNA (89).  Furthermore, covalent 
linkage of two polyamides in a head-to-tail fashion allowed Dervan to control the binding 
stoichiometry and increase the binding affinity of these ligands to DNA (90, 91), as 
discussed in chapter 4.  To date, sequences as long as 16 base pairs have been bound by 
polyamides at very high affinities (78).   
Minor groove binding ligands have found success as therapeutic agents in a 
number of different applications, due to their ability to bind sequence specifically (92) to 
the surface of the minor groove.  The therapeutic potential of minor groove binding 
ligands have been examined for their use in cancer therapies (92, 93, 94, 95, 96, 97), and 
as antibacterial (98, 99, 100, 101), antiprotozal (102, 103) or antifungal agents (102, 104, 
105).  These ligands succeed by targeting DNA and the sequences responsible for gene 
expression, which in turn inhibits synthesis of the target protein.   
For example, a distamycin A analog was designed to target the sequence 5’-
AATTAATCAT-3’, the promoter site of the bacteria C. albicans with nanomolar Kd 
values (106).  The  basic leucine zipper  (bZip) protein binding site, 5’-
ATATATAGGGTA-3’, was targeted by a novel hairpin polyamide acridine conjugate 
with Ka = 1.8 x 1010 M-1 (107).  In an effort to develop small ligand transcription 
activators, a number of hairpin polyamide – protein conjugates were developed as 
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transcription factor mimics.  These conjugates combined a sequence selective, 5’ – 
TGACCAT – 3’, component (polyamide) and protein binding component (108).  The 
wrenchnolol component binds the Sur-2 protein, a subunit of human mediator complexes 
that links transcription activators to RNA polymerase II in human cells (108).   
Hairpin polyamides have been shown to target the HIV-1 transcription factor IID 
at nanomolar affinities (106, 109, 110, 111) as well as the HIV long terminal repeat 
(112).  The NF-κB Transcription factor, 5’-GGGACTTTCC-3’, was targeted using 
hairpin polyamides, achieving excellent binding affinities (113).  Hairpin polyamides 
have successfully targeted the inverted CCAAT boxes (ICBs) of topoisomerase IIα 
promoter (114).  Furthermore, a number of promoter sites (TATA, NRE, P53, ZIF268) 
were successfully targeted at nanomolar binding affinities with hairpin polyamides (115).  
Inhibition of protein binding to sequences preserved in the Human Estrogen-Related 
Receptor 2 and Estrogen Receptor α have been achieved through the binding of hairpin 
polyamides to DNA.  Specifically, targeting the sequences 5’ – TGATCA – 3’, 5’ – 
AGTGAT – 3’ and 5’ – AGGTCA – 3’ with hairpin polyamides can decrease protein 
binding by 10 to 100 fold (116).   
Major Groove Binding:  The potential for four distinguishable surfaces per base 
pair greatly diversifies the surface of the major groove.  The unique, sequence dependent 
surface of the major groove is a major contributing factor in protein – nucleic acid 
interactions.  However, targeting the major groove of duplex nucleic acids requires 
ligands with surfaces of intricately distributed functional groups that complement the 
surface of the major groove.  Furthermore, while intercalators and minor groove binding 
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ligands distribute their charges over a planar surface, a ligand which binds the major 
groove must provide a larger three-dimensional scaffold for these functional groups.  
This is a necessary requirement to bind the larger groove dimensions.   
Due to these requirements there are very few ligands that bind the major groove 
of duplex nucleic acids, as shown in Figure 1.7.  Synthetically functionalized ligands 
with metallic centers have been developed to meet these requirements and bind the major 
groove of DNA (117, 118).  Protein mimicking ligands, based on a scaffold of amino 
acids, have also been synthesized to bind the major groove of DNA (119).   
Carbohydrates that bind in the major groove also receive attention.  Carbohydrates are a 
relatively small class of molecules that act as DNA-cleavage agents, neocarzinostatin 
(120), as well as DNA alkylating agents, altromycin B (121).  Carbohydrates are also 
employed as the major groove binding component of a dual recognition molecule, as 
reported for nocalamycin, respinomycin, NB-506 (intercalator-major groove binders) and 
neomycin-Hoechst 33258 (major-minor groove binder) (63).  The binding of proteins to 
nucleic acid duplexes predominantly occur through the major groove.  Inhibition of 
protein binding, through occupation of the major groove with ligands, offers a potential 
therapeutic approach to blocking transcription (122, 123).   
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neocarzinostatin hedamycin
NB-506
altromycin B
nogalamycin
rebeccamycin
 
Figure 1.7.  Chemical structures of representative major groove binders.   
 
The requirements necessary to bind the minor groove of duplex nucleic acids are well 
understood; the ability to arrest natural cellular functions by occupying the major groove 
remains less understood and may suffice to explain the low population of this class of 
ligands.  Aminoglycosides represent a small subset of the class of molecules that bind the 
major groove of nucleic acids. 
Our group has shown aminoglycoside antibiotics bind non-traditional nucleic acid 
targets.  In fact, our group has spent considerable time understanding aminoglycoside – 
nucleic acid interactions.  We have established neomycin, an aminoglocoside antibiotic, 
as an excellent molecule to probe small molecule – nucleic acid interactions.   
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Aminoglycosides – A Closer Examination (124).  Aminoglycoside antibiotics are 
carbohydrates comprised of a scaffold of amino sugars joined to a central hexose ring, 
Figure 1.8.  The aminoglycoside, streptomycin, was isolated from soil bacteria samples 
by Selman Waksman in 1944 (125).  Fame followed when streptomycin became the first 
antiobiotic effective against tuberculosis.  Through the remaining years of the 1940s, a 
number of streptamine relatives were discovered giving rise to the streptomycin family.  
Second generation aminoglycosides followed; derived from 2-deoxystreptamine (DOS), 
this family of aminoglycosides includes neomycin (1949), neamine (1951), kanamycin A 
(1957), kanamycin B (1958) and paromomycin (1959), among others.  While the number 
of aminoglycoside antibiotics class increased with each passing year, the mechanism of 
action remained a mystery.  It wasn’t until the late 1950s that protein synthesis was 
identified as the primary target for streptomycin’s antibacterial action (102, 112, 116, 
121, 124, 126, 127, 128).  Spotts, in 1961 (129), proposed the ribosome as the likely 
target for streptomycin.  In a whirlwind of research, work by Davies and others 
established the 30S subunit of ribosomal RNA (rRNA) as the natural target of 
streptomycin (127, 128). 
Experiments designed to investigate the fidelity preserved during translation led 
to the understanding that aminoglycosides induce errors during translation.  Discovery of 
an increasing number of aminoglycosides, highlighted by the discovery of the 
gentamycin class, propelled the field through the next few decades.  As the years 
progressed, scientific interest in aminoglycosides slowly dwindled and it wasn’t until the  
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Figure 1.8.  Structures of aminoglycosides with a 2-deoxystreptamine ring.   
 
late 1990s that aminoglycosides saw renewed interest.  Advancements in nucleic acid 
synthesis and combinatorial chemistry as well as a need to improve existing drugs and 
expand potential targets fueled the resurgence of interest in aminoglycosides.   
The resurgence of interest in aminoglycoside research was amazingly one-sided.  
The rebirth saw a large increase in the number of aminoglycoside targets.  
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Aminoglycoside targets expanded to include the 5’-untranslated region of thymidylate 
synthase mRNA (130), HIV RNA Rev response (131), catalytic RNA molecules (group I 
introns (132), ribonuclease P RNA (133), hairpin ribozyme (134), hammerhead ribozyme 
(135) and the hepatitis delta virus ribozyme (136).  In fact, aminoglycosides bound to 
HIV RNA have been shown to inhibit the binding of viral proteins to their targets, thus 
preventing native DNA degradation (131).  Our group suggested the ability of 
aminoglycosides to bind to the multitude of newly discovered targets was driven by the 
ability to bind A-form nucleic acids, a structural motif shared by all RNA targets (124, 
132, 137). 
As previously discussed, RNA structures are not the only nucleic acids known to 
have a propensity for the A-form conformation.  Based on observations made by 
Robinson and Wang, in 1966 (138), that suggested the binding of neomycin to DNA 
induced changes in the DNA generally associated with an A-from conformation; our 
group demonstrated the ability of neomycin to bind a number of non-traditional A-from 
nucleic acids.  Since these discoveries, the list of A-form nucleic acids shown to bind 
neomycin has expanded to include the RNA triplex (139), DNA:RNA hybrid duplex 
(140, 141), RNA duplex (132), DNA triplex (142), A-form DNA duplex and the DNA 
tetraplex (143). 
Since our work in the mid to late 1990’s, our group has utilized neomycin to 
probe the binding of a number of non-traditional nucleic acids structures.  Furthermore 
we achieved an increased binding affinity to these nucleic acids through conjugation of 
neomycin to intercalators (pyrene (65), BQQ (64), ethidium bromide (140, 141)) as well 
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as groove binders such as Hoechst 33258 (144, 145).  To this date, we continue to 
explore neomycin based approaches to nucleic acid binding.   
Chapter two of this dissertation focuses on binding DNA:RNA hybrids, reported 
by our group (124, 140, 141).  To this end, we report the design synthesis along with 
biophysical and bioanalytical studies of novel neomycin-methidium chloride conjugates.  
Attention will then turn to our neomycin based approach to targeting the DNA duplex.   
Finally, our group had previously demonstrated the ability to bind the B-form 
DNA duplex through novel neomycin – Hoechst 33258 conjugates (144, 145).  
Expanding on this approach we report the development, synthesis and subsequent 
spectroscopic studies of neomycin – polyamide conjugates.  Chapter three focuses on 
tetramer polyamide – neomycin conjugates while chapter four focuses on hairpin 
polyamide – neomycin conjugate, designed to target GC-rich DNA.    
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CHAPTER II 
 
TARGETING DNA:RNA HYBRIDS 
 
INTRODUCTION1 
Six years after the report on the double-helical structure of DNA by Watson and 
Crick (1), the DNA:RNA hybrid was proposed to address the interaction between DNA 
and RNA (2).  The first synthetic DNA:RNA hybrid structure was formed in 1960 (3).  A 
year later, the first DNA:RNA hybrid helix was formed (4, 5).  X-ray fiber diffraction 
studies (6) confirmed the conformation of the DNA:RNA hybrid was different than B-
form DNA.  The crystal structure of a DNA:RNA hybrid was solved in 1982 (7), while 
solution based conformational studies followed shortly (8).  Surprisingly, a survey of 
articles, from the conceptual inception of the DNA:RNA hybrid to present, suggest the 
global helical structure of DNA:RNA hybrids has only had scholastic consent since the 
mid-1990’s.    
In 1959, Rich published a foundational paper in which DNA:RNA hybrids were 
first reported (2).  He proposed DNA:RNA hybrid formation occurred through the 
hybridization of a single-stranded DNA template strand and a newly formed RNA strand.  
Experimental data would support this hypothesis in 1960 (9).  Temin (10) and Baltimore 
(11), independently, and simultaneously, reported the use of reverse transcriptase in the 
synthesis of a new DNA strand via a RNA template strand.  This process would become 
                                                          
1 As discussed in our paper (120) 
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known as reverse transcription affording the second example of DNA:RNA hybrid 
formation.  In 1975, the first example of DNA:RNA hybrid formation in the replication 
of DNA was discovered (12).    
An extensive survey of DNA:RNA hybrid stability while varying (i) the 
percentage of (A)n:(T or U)n content, (ii) oligomeric length and (iii) the percentage of 
d(Py) content in each of the strands, offers the most complete analysis of hybrid stability 
(31).  In general:  (i) an inverse relationship is displayed between the percentage of 
(A)n:(T or U)n content in the hybrid duplex and the thermal stability.  (ii) Hybrid duplexes 
of equal d(Py) and d(Pu) content are thermally similar when comparing the d(Pu):r(Py) 
and d(Py):r(Pu) forms.  (iii) Decreasing oligomeric length decreases the thermal stability.  
(iv) Isolation of (A)n:(T or U)n content to continuous tracts results in a lower thermally 
stable duplex than when the same percentage of (A)n:(T or U)n content is dispersed 
throughout the sequence.  (v) Continuous tract (A)n:(T or U)n content results in 
d(Py):r(Pu) thermal stability lower than the corresponding d(Pu):r(Py) form, at 
physiological conditions, as expected.   
 It has also been suggested that DNA:RNA hybrid stability is related to the ability 
of the hybrid duplex to associate with a third single strand (32, 33).  The d(Py):r(Pu) 
hybrid does not associate with a third strand of DNA, while d(Pu):r(Py) hybrids easily 
accommodate a third strand to form d(Pu):r(Py):d(Pu) (33).  The inability to associate a 
third strand represents an inability to overcome a conformational energy barrier, a direct 
result of a more stable hybrid duplex form (32).  Furthermore, with the exception of long 
33 
 
stretches of (A)n:(T or U)n, the stability of duplexes can also be attributed to the relative 
stability of the ribose chain.   
The first DNA:RNA hybrid structure was solved in 1967 using X-ray fiber 
diffraction (6).  The DNA:RNA hybrid resisted conformational changes upon relative 
humidity changes, a technique commonly used to drive the A-form to B-form transition 
in duplex DNA.  This observation, coupled with solution studies of DNA:RNA hybrids 
(34, 35), spurned a 20 year debate on the conformation and structure of DNA:RNA 
hybrids.   
Polymeric poly(rA):poly(dT) is a polymorphic structure.  Parallel circular 
dichorism (CD) (36) and Raman (37) experiments refutes a complete B-form model for 
the DNA:RNA hybrid, evidence that poly(rA):poly(dT) is polymorphic, the conformation 
dependent on a number of factors.  Further analysis, 13P solid state NMR, suggests 
poly(rA):poly(dT) is capable of existing in an A-like conformation at relative low 
humidity (38) while increasing the solvation from 87% to 92% yields a B-like 
conformation (39).  1D nuclear Overhauser effect (NOE), observed by NMR and 
empirical evidence model building, suggests an in situ model for poly(rA):poly(dT) based 
on B-form DNA with some exceptions (40).  Currently, it is generally accepted that the 
conformation of poly(rA):poly(dT) is polymorphic, capable of undergoing an A- to B- 
type transition upon relative humidity changes.  Fully hydrated this hybrid exists as a A-
type duplex closer in overall conformation to B-form DNA (41, 42).    
 Poly(dA):poly(rU) was extensively studied using X-ray diffraction methods (43).  
The model proposed by Arnott and co-workers suggested a heteromerous structure for the 
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hybrid.  This term was used to describe the overall conformation of the duplex in which 
one strand, the d(Pu) strand, displays B-form characteristics while the other strand, the 
r(Py) strand, displays A-form characteristics.  The global conformation of 
poly(dA):poly(rU) is strongly driven by the r(Py) strand and the global conformation of 
the hybrid is an A-type duplex closer in conformation to the A-form of RNA (32).   
Congruently, the analogous DNA:RNA hybrid, poly(dI):poly(rC) displayed 
similar heteromerous conformation (32, 44).  However, the r(Py) has a diminutive effect 
on the overall conformation of the poly(rI):poly(dC) duplex, when compared to 
poly(dA):poly(rU), resulting in an A-type duplex closer to B-form DNA than 
poly(dA):poly(rU) (43).  Surprisingly, the d(Pu) strands of both d(Pu):r(Py) type hybrids 
are conformationally similar to one another (43).  Therefore differences in conformation 
between poly(dI):poly(rC) and poly(dA):poly(rU) are a result of the differences in 
conformation of the r(Py) strands.   
 Mixed base polymeric DNA:RNA hybrids poly(dAC):poly(rGU) and 
poly(dGU):poly(rAC) have also been studied (36).  CD studies suggest the hybrids, 
poly(dAC):poly(rGU) and poly(dGU):poly(rAC), are more similar to the analogous A-
form RNA duplex.  Furthermore, conformational differences between the individual 
heteroduplexes mirror differences observed in the polymeric analogs poly(dA):poly(rU) 
and poly(rA):poly(dT).  These differences arise from the ability of r(AC) to induce an 
RNA-like conformation.  Therefore, poly(dGU):poly(rAC) is more A-like than 
poly(dAC):poly(rGU).  These duplexes are susceptible to dehydration which drives the 
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conformation of the heteroduplexes to a complete A-form conformation, further evidence 
that these duplexes are A-like but retain B-form characteristics.   
Refinement of the secondary structure of poly(rA):poly(dT) suggests the sugar 
puckers, regardless of strand, were a slight variant of the C2’-endo conformation (38, 40).  
However, in order to facilitate the 2’-hydroxyl, a displacement of the RNA bases from 
the helical axis is observed.  This displacement results in a concomitant change in the tilt 
and twist of these bases as well as a change in the backbone torsion angle.  However, it 
will be shown later that there exists a high energy barrier for which the ribose sugar of 
RNA must pass in order to convert to C2’-endo, a barrier which is significantly lower to 
pass with the ribose of DNA (45).  In fact, the existence of C2’-endo sugar pucker for the 
ribose strand in poly(rA):poly(dT) is a result of hydration and results in helical 
parameters (pitch, axial rise per residue and residues per turn) that mimic B-form.  
Subsequent dehydration converts the global ribose sugar pucker to C3’-endo and results in 
parameters closer in agreement to A-form (39).  Furthermore, the analogous 
poly(rI):poly(dC) crystallized with helical parameters in closer agreement to A-form (44), 
Table 1.1.    
 Unlike the case of d(Py):r(Pu), in which global conformational changes can be 
accommodated in both strands of the duplex, d(Pu):r(Py) type polymeric duplexes are not 
as forgiving.  Dominated by the conformational stubbornness of the r(Py) strand to 
remain in an A-form state with C3’-endo sugar pucker, global helical parameters tend to 
be more A-form in characteristic, whereas B-form characteristics come from the d(Pu) 
strand (43, 46, 47).  The previously described heteromerous nature of poly(dA):poly(rU) 
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and poly(dI):poly(dC) arises from the overwhelming tendencies for the ribose sugars to 
adopt a C3’-endo sugar pucker whereas the deoxyribose sugar is found in a C2’-endo 
conformation.  The result, these sugar puckers contribute to a DNA:RNA hybrid minor 
and major groove which is globally closer to A-form.  Furthermore, poly(dA):poly(rU) is 
closer in conformation to A-form than poly(dI):poly(rC).  Further analysis of helical 
structure reveals poly(dA):poly(rU) is less propeller twisted than poly(dI):poly(rC) ( -4o 
and -14o, respectively) resulting in a less rigid hybrid duplex.    
 DNA:RNA hybrids have been shown to be involved in transcription (13).  It has 
been suggested that termination of the transcription process concludes with the release of 
the RNA strand from an unstable DNA:RNA hybrid (14), furthermore, the lability some 
hybrid sequences may aid the disassociation of the RNA strand from the DNA template 
(15, 16).  DNA:RNA hybrids are formed during reverse transcription.  Reverse 
transcription relies on the dual activity of reverse transcriptase (RT) (17, 18):  (i) RT acts 
as a polymerase, forming DNA:RNA hybrid intermediates and (ii) as a ribonuclease H 
(RNase H) active enzyme, specifically degrading the RNA portions of DNA:RNA hybrid 
duplex domains.   
The discussion of DNA replication is seemingly unbefitting when addressing 
DNA:RNA hybrid duplexes, however DNA:RNA hybrids play an important role in DNA 
replication.  Okazaki fragments (19) are bridged when DNA primase synthesizes a short 
RNA primer of approximately ten nucleotides in length on template DNA strands.  
Finally DNA:RNA hybrids are also present in mitochondrial DNA.  Human 
mitochondrial DNA (mtDNA), is present in the mitochondria of the cell; the mechanism 
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of replication is similar to that of nuclear DNA, however, the priming of mtDNA for 
DNA replication requires the use of RNA primers (20).  DNA:RNA hybrids are 
prerequisites to the initiation of transcription and serve as primers for DNA replication of 
the leading strand (13, 21, 22). 
There is no question that DNA:RNA hybrids are biologically significant.  Even 
though reports have found DNA:RNA hybrids of therapeutic interest to be prevalent 
[reports of the persistent existence of DNA:RNA hybrids in human cytomegalovirus have 
been made  (23)], extensive studies of DNA:RNA hybrids as potential targets for 
therapeutic approaches remain with the following notable exceptions.   
The reverse transcription of HIV-1 has required substantial attention  (24, 25).  
HIV-1 contains two identical polypurine tracts (PPTs).  Reverse transcription (minus 
strand DNA synthesis) of both PPTs occurs after DNA strand transfer by reverse 
transcriptase, providing a unique r(Pu):d(Py) type of DNA:RNA hybrid (18).  This 
unique PPT DNA:RNA hybrid exists until cleavage of both the RNA template strand (5’ 
to the PPT) and tRNA, separate events conducted by reverse transcriptase, occurs.   
 Telomerase activity, seemingly synonymous with G-quadraplex formation, is a 
well understood process, of which DNA:RNA hybrid targeting is an equally viable 
approach for telomerase inhibition.  Telomerase activity is associated with cellular 
immortality (26) and its potential as a universal cancer target has been proposed (27, 28).  
Telomeres exist as long repeats of a simple six base sequence, d(TTAGGG)n, in all 
vertebrates.  This non-coding extension of chromosomal DNA becomes shortened with 
each cellular division (29).  The 3’ tail of the parent DNA telomere is longer than its 
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complement and forms a DNA:RNA hybrid upon binding to the active site of telomerase.  
Binding of small molecules to the DNA:RNA hybrid can potentially offer a therapeutic 
method for controlling telomerase activity, preventing telomere extension, by distorting 
the substrate/enzyme interaction, or preventing disassociation of the enzyme from the 
substrate (30).   
Although polymorphic in structure, DNA:RNA hybrids offer a unique structure to 
target and potentially inhibit biological functions.  However, a survey of literature reveals 
the existence of less than ten ligands which specifically bind DNA:RNA hybrids.   
Actinomycin D (AMD) has demonstrated the ability to inhibit reverse 
transcriptase activity (48, 49) through the inhibition of double stranded DNA synthesis 
(49).  A number of derivatives were synthesized (50), however, the preference of AMD 
for DNA duplexes dominates.  Association constants for these conjugates to the 
DNA:RNA hybrids were in the 104 M-1 to 105 M-1 Surprisingly, both conjugates of AMD 
display a unique selectivity for leukemia cells, inhibiting cellular growth by 50% at less 
than 1.0 nM!  Although the binding mode ultimately leading to retardation of leukemia 
cell growth is not known, the authors suggest the binding of these conjugates to 
DNA:RNA hybrids may perpetuate further development (51).   
 Naturally occurring polyamides, distamycin and netropsin, have been investigated 
for their ability to bind DNA:RNA hybrid Okazaki fragments (48, 49, 52, 53, 54).  These 
lexitropsins are known to bind A/T stretches of DNA, displacing the spine of hydration, 
in the minor groove (55).  A series of conformationally restrained bis-distamycin 
compounds, dimerized through the ortho/para or meta positions of benzene and pyridine 
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(2,5 - and 2,4 – type, respectively), were synthesized (56).  Ortho/para bis-distamycins 
were capable of binding both DNA duplexes as well as the Okazaki fragment at similar 
binding constants, ~ 108 M-1 and ~ 107 M-1 range, respectively.  Surprisingly, mono-
distamycins, linked to the benzene moiety, showed no binding to the duplexes.  The meta 
pyridyl bis-distamycins were also studied, however, affinity for the Okazaki duplex is in 
the ~106 M-1 range.  In an effort to design a synthetic approach to DNA:RNA hybrid 
targeting, clear candidates, at this point, have not been found.  The subsequent sections 
will make a case for both neomycin and ethidium bromide as moieties in which a scaffold 
for DNA:RNA hybrid targeting can be made.   
Aminoglycosides have been recognized as A-form nucleic acid major groove 
binders (57, 58, 59, 60).  Paramomycin, an aminoglycoside, and its complexation with 
DNA:RNA hybrids have been studied by Barbieri and co-workers (53).  Thermal 
stabilization of a mixed base RNA 8-mer duplex, afforded upon paramomycin 
complexation, was 6.3 oC, not surprising since aminoglycosides traditionally bind RNA.  
However, thermal stabilization of the DNA:RNA hybrid analog was on par with the RNA 
duplex at 6.2 oC.  Furthermore, the binding of paramomycin to the hybrid duplex was 
shown to induce a shift in the hybrid duplex to a more A-form like conformation.  
Unfortunately, the affinity of paramomycin for the RNA duplex was shown to be higher 
than the corresponding DNA:RNA hybrid.  However, the authors suggested the binding 
of paramomycin to the DNA:RNA hybrid was capable of inhibiting, both, RNase H- and 
RNase A-mediated cleavage of the RNA strand; a strong argument for an aminoglcoside 
approach to targeting DNA:RNA hybrids.   
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 Work with aminoglycosides and DNA:RNA hybrids was expanded to include 
aminoglycosides neomycin and ribistamycin using DNA:RNA hybrid chimeras, by Pilch 
and coworkers (18).  These chimeras are designed as constructs of the polypurine tract 
(PPT) of HIV-1, found at two unique steps in the reverse transcription of HIV-1.  
Containing the same DNA:RNA hybrid portion, these chimeras differ in the composition, 
RNA (18C:18R) or DNA (18C:18D), of the complement strand.  Confirming previously 
published results, RNase H cleavage of the DNA:RNA hybrid chimeras was inhibited by 
the presence of the aminoglycosides and a number of small molecule non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) (61).  In fact, of the aminoglycosides surveyed, 
neomycin was far superior at inhibiting RNase H cleavage, in both chimeras! 
Furthermore, thermal stabilization of the chimeras, afforded by the presence of 
aminoglycosides, reveals neomycin increases the stability of both chimeras to a larger 
extent than either paramomycin or ribostamycin.  Isothermal titration calorimetry derived 
binding constants for the aminoglycosides binding the two chimeras.  Neomycin 
displayed the highest affinity for the chimera 18C:18R at Ka = 1.1 x 10
6 M-1 (18C:18D at 
Ka = 5.3 x 10
5 M-1).  In both chimeras, the association constant for neomycin was greater 
than the other aminoglycosides studied.  Furthermore, it is clear that the addition of ring 
four to the 2-deoxy streptose moiety is paramount to high affinity binding of 
aminoglycosides to DNA:RNA hybrid structures.   
 Further application of neomycin based HIV-1 therapeutics has been reported by 
Turner and co-workers (62).  Surveying a number of classical nucleic acid binding 
ligands, the authors identify the ability of neomycin to bind the U3 region of PPT.  The 
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primary binding site for neomycin begins at the U3 position and extends seven base pairs 
into the RNase H primer grip region.  The DNA:RNA hybrid binding site is primarily 
composed of G/C base pairs with the terminal base pair in the binding site being A/T.  
The binding affinity, determined by direct ITC titration, was calculated at 1.45 x 107 M-1 
at 80 mM NaCl.  Furthermore, a secondary binding site, located three base pairs 
downstream from the U3 binding site and denoted (rA)4:(dT)4 was identified.  This 
complementary binding to the high affinity site is lower in affinity at 2.76 x 105 M-1 and 
only appears at lower ionic strength.  The authors further suggest the A-form nature of 
the DNA:RNA hybrid is not the primary factor in neomycin binding, rather the binding 
of neomycin is complex and also driven by favorable electrostatic surfaces.  Not only 
does this work continue to identify ligands capable of targeting DNA:RNA hybrids, it 
further substantiates aminoglycoside based approaches to DNA:RNA hybrid recognition 
and therapeutics.    
Ethidium bromide (3,8-diamino-5-ethyl-6-phenylphenathridinium bromide) 
belongs to a unique class of small molecules which bind double-stranded nucleic acid 
structures via an intercalative mechanism (63, 64).  The ability of ethidium bromide to 
bind to nucleic acid structures and the unique fluorescent properties make ethidium 
bromide a laboratory standard for the staining of nucleic acids (65).  The concert of 
ethidium bromide within biological systems has yielded potential anti-tumor (66, 67) and 
anti-viral (67, 68) properties.  The potential of ethidium as a therapeutic agent is a double 
edge sword.  The actual therapeutic potential of ethidium bromide remains unutilized due 
to its mutagenic and carcinogenic properties (69).   
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Ethidium bromide has been reported to interact with nucleic acid structures 
through a dual binding mode (65).  The primary binding mode involves the interaction 
between the negatively charged backbone, consisting of phosphate oxygens, and the 
phenanthridium ring nitrogen, which is positively charged.  This interaction is stabilized 
by the hydrophobic intercalative stacking interactions between ethidium bromide and the 
host double-stranded nucleic acid.  A second binding mode of ethidium bromide can be 
observed at high ligand concentrations.  In this mode, the high population of ethidium 
bromide molecules stack within the DNA grooves which is a direct result of the ionic 
interactions with the phosphate backbone (70).   
In a technique developed by Muller and Crothers (71), Chaires, and co-workers 
identified ethidium bromide as a DNA:RNA hybrid, poly(rA):poly(dT), specific binding 
ligand (72).  An ensuing report assayed 85 ligands against various nucleic acids and 
focused on binding to poly(rA):poly(dT).  This assay confirmed the presence of five 
ligands:  ellipticine, ethidium bromide, coralyne, propidium and TAS103, which uniquely 
recognized the poly(rA):poly(dT) structure; ethidium bromide showed the highest 
preference for poly(rA):poly(dT).  Complete thermodynamic profiles for ellipticine, 
propidium and ethidium bromide binding to poly(rA):poly(dT) yield binding constants 
for the three ligands, all in the magnitude of 105 M-1.  This assay was expanded to 
simultaneously provide the thermal stabilization afforded by the ligand on the 
preferentially targeted nucleic acid structure, while in competition with other nucleic acid 
structures (73).  Furthermore, experiments on complexes of poly(dA) and 
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poly(rU) suggest ethidium is capable of inducing a conversion of a 1:1 mixture of these 
homopolymers from a three stranded to a two stranded helix (74). 
 DNA:RNA hybrid targeting with ethidium bromide has been applied to targeting 
telomerase through its DNA:RNA hybrid duplex.  Friedman and coworkers have 
surveyed a number of compounds in an attempt to inhibit telomerase activity through 
DNA:RNA hybrid binding (75).    Surveying a number of intercalators, four ligands 
(ethidium bromide, rivanol, acridine orange and acridine yellow) were found to inhibit 
telomerase activity at IC50 values in the low micromolar range.  Furthermore, telomerase 
inhibition through the binding of these ligands to G-quadraplex structures, another 
substantiated method for achieving telomerase inhibition, was not observed (30).  
Affinity chromatography isolated the high affinity DNA:RNA binding species from a 
homogeneous mixture of binding ligands.  It was found that ethidium bromide uniquely 
binds a DNA:RNA hybrid duplex, derived from the hybrid formed during the catalytic 
cycle of telomerase, with the highest affinity, even in the presence of other binding 
ligands (75).  This work clearly validates ethidium bromide as another compound in the 
synthetic approach to targeting DNA:RNA hybrids.   
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EXPERIMENTAL 
Materials: 
Nucleic Acids.  DNA polymers [poly(dA), lot no. GD0056; poly(dT), lot no. GC0226; 
poly(dC), lot no. FL0056; poly(dG):poly(dC), lot no. GB0176; poly(dA):poly(dT), lot no. 
4117860021; poly(dG-dC):poly(dG-dC), lot no. 3017910011; poly(dA-dT):poly(dA-dT), 
lot no. 3107870011] and RNA polymers [poly(rA), lot no. 3104110011; poly(rU), lot no. 
GD0266; poly(rC), lot no. 8094220021]  were purchased from GE Healthcare/Amersham 
Biosciences (Piscataway, NJ). Concentrations were determined by UV absorbance using 
ε257 = 8600 (M
-1cm-1) for poly(dA); ε264 = 8520 (M 
-1cm-1) for poly(dT); ε247 = 7400 (M
-
1cm-1) for poly(dC),  ε253 = 7400 (M
-1cm-1) for poly(dG):poly(dC); ε254 = 8400 (M
-1cm-1) 
for poly(dA):poly(dT); ε262 = 6600 (M
-1cm-1)  for poly(dG-dC):poly(dG-dC); ε260 = 6000 
(M-1cm-1) for poly(dA-dT):poly(dA-dT); ε258 = 9800 (M
-1cm-1) for poly(rA); ε260 = 9350 
(M-1cm-1) for poly(rU) and ε269 = 6200 (M
-1cm-1) for poly(rC). Calf thymus DNA, lot no. 
GA0286, was purchased from GE Healthcare/Amersham Biosciences (Piscataway, NJ) 
and concentration were determined by UV absorbance using ε263 = 13846 (M
-1cm-1). 16S 
A-site rRNA (27nt) was purchased from Dharmacon Research, Inc. (Lafayette, CO). The 
16S A-site rRNA (27nt) was deprotected and purity checked by HPLC using standard 
Dhramacon protocols. The 16S A-site RNA (27nt) was quantitated using extinction 
coefficients provided by the supplier. Preparation of the 16S A-site RNA was 
accomplished by heating to 95oC, holding for 5 minutes, followed by slow cooling to 
room temperature and storage at 4oC. For RNA duplex poly(rA)poly(rU), DNA:RNA 
hybrid duplexes poly(dA):poly(rU) and poly(rA):poly(dT), DNA triplex 
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poly(dA):2poly(dT), and DNA:RNA hybrid triplex poly(dA):2poly(rU), individual 
polymeric strands were mixed in stoichometric ratios and formed by heating at 95 oC for 
5 minutes slowly cooling to room to room temperature and storage at  4 oC between 
experiments. For all experiments with polymeric DNA and RNA, solutions of individual 
strands were dialyzed extensively (48 hrs.) against buffer using SpectraPor Float-A-Lyzer 
dialysis units, MW cutoff 3500 Da (Spectrum Labs, Rancho Dominguez, CA) before 
quantitation. Buffer conditions for all experiments are noted throughout. 
 
Chemicals.  Neomycin B (sulfate salt) was purchased from ICN Biomedicals and used 
without further purification. Sodium cacodylate, NaCl, ethidium bromide and sodium 
phosphate salts (Na2HPO4 and NaH2PO4) were purchased from Fisher Scientific. 6-(4-
carboxyphenyl)-3,8-diamino-5-methylphenanthridinium chloride was purchased from 
Sigma and used without further purification. Quantitation of ethidium bromide (ε478 = 
5680 M -1cm-1) and NM (ε487 = 5811 M 
-1cm-1) in aqueous solutions were done using UV 
absorbance. All other reactions and solvents were purchased from Acros Organics and 
used without further purification. Reaction solvents were distilled over calcium hydride 
(pyridine, dichloromethane, DMF) or sodium metal (ethanol). Ethanol was further 
distilled over magnesium turnings. To ensure stability, all solutions containing ethidium 
bromide and NM were stored in polystyrene tubes wrapped in foil.  
 
Methods:   
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Competition Dialysis Experiments.  Competition dialysis experiments were conducted 
using DPA200 and a wide array of nucleic acid structures.  In the assay, solutions of 
different nucleic acid structures (of identical concentration) were dialyzed simultaneously 
against a common solution of ligand using appropriately buffered conditions (58, 72, 81).  
The nucleic acids were allowed to equilibrate with ligand over a period of 72 hours.  
After equilibration, the nucleic acids were analyzed by fluorescence and the amount of 
bound ligand to each nucleic acid structure was determined.  In these experiments, more 
ligand accumulated in the dialysis tube containing the structural form of highest binding 
affinity.  Since all of the DNA samples were in equilibrium with the same free ligand 
concentration, the amount of ligand bound is directly proportional to the binding constant 
for each conformational form (58).  The nucleic acid structures were chosen such that 
they covered a wide array of structures including quadruple helix structures – TGT 
tetraplex and AG3T2AG3 tetraplex; triple helices – poly(dA):2poly(rU) and 
poly(dA):2poly(dT); double helices – poly(rA):poly(rU), poly(rA):poly(dT), 
poly(dA):poly(rU), poly(dA):poly(dT), poly(dG):poly(dC), calf thymus DNA, 
Micrococcus lysodeikticus DNA, poly(dA-dT)2 and poly(dG-dC)2; single stranded 
nucleic acids – poly(dA), poly(dG), poly(rC), poly(rU), poly(rA) poly(dC), poly(dA) and 
poly(dT) and the A-site RNA construct.   
 
Computer Modeling.  Computer modeling was used to ensure the linker length, 
separating the two moieties would be sufficient; however computer models were not used 
to optimize linker length. The DNA:RNA hybrid duplex comprised of oligomers  
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d(GAAGAGAAGC)and r(GCUUCUCUUC) was extracted from pdb entry 1DRR. 
Utilizing the backbone of the DNA:RNA hybrid, the individual bases were adjusted to 
d(TTTTTTTTTT) and r(AAAAAAAAAA). The adjusted DNA:RNA hybrid was 
subsequently minimized. Conformational optimization of neomycin, docked in the 
closest proximity to the hydroxyl position of 6-(4-carboxyphenyl)-3,8-diamino-5-
methylphenanthridinium chloride, was carried out prior to attachment to 6-(4-
carboxyphenyl)-3,8-diamino-5-methylphenanthridinium chloride using a Monte Carlo 
routine (AMBER* force field and water as solvent) in MacroModel. Five of the six 
amines in neomycin were protonated, in agreement with NMR studies of neomycin1. 
Energy minimization reached a convergence threshold of 0.02 kJ/mol for all experiments.  
 
UV Thermal Denaturation Experiments.  All experiments were carried out using a 
Cary 100E UV/Vis spectrophotometer equipped with a thermoelectrically controlled 12-
cell holder. All samples were analyzed in quartz cells (1 cm pathlength). Lamp stability 
and wavelength alignment were checked prior to each experiment. Unless otherwise 
noted, prior to analysis heating from 10-100 oC at a rate of 0.2 deg/min, followed by slow 
annealing from 95-10 oC at a rate of 0.2 deg/min prior to monitoring at 260, 264 and 280 
nm performed. Nucleic acid samples were pre-formed in polystyrene tubes by heating at 
95 oC for 5 minutes slowly cooling to room temperature, followed by incubation at 4 oC 
for 18 hours. Samples were prepared by mixing ligand and nucleic acid solutions, at 
appropriate ratios, followed by incubation at 4 oC for 4 hours and sample degassing. In all 
experiments using polymeric DNA:RNA hybrids, [nucleic acid structure] = 20 µM/base 
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pair. Experiments using oligomeric DNA:RNA hybrids, [nucleic acid structure] = 20 
µM/base pair. Melting temperature (Tm) assignments were aided using first derivative 
analysis provided by the Cary software. 
 
Fluorescence Titrations.  Equilibrium binding experiments were done using a Photon 
Technology International instrument (Lawrenceville, NJ) at ambient (22 oC) temperature. 
A solution of DNA:RNA hybrid (serially diluted to 1 µM) was prepared. Serial additions 
of ligand (EtBr or NM) were titrated into the solution followed by excitation at 525 nm 
(slit width = 4 nm) and resulting emission curves (from 550-700 nm) were recorded. 
After each addition, the solution was mixed by pipetting up and down with a micro 
pipette. Sample equilibrium was monitored by continually exciting/scanning the sample 
at different times, and was usually reached within 5 minutes. All data were normalized to 
account for the (small) dilution of sample upon addition of substrate. 
 
CD Spectropolarimetry Titrations.  Circular dichroism (CD) experiments were done at 
20 oC using a Jasco J-810 spectropolarimeter. A concentrated solution of ligand was 
added to a solution of DNA:RNA hybrid and allowed to stir constantly before scanning 
from 300 - 210 nm. As with fluorescence experiments, equilibrium was determined by 
periodically scanning the sample over a period of time (up to 10 minutes) for the first few 
additions of ligand, and was reached within 5 minutes. All data were normalized to 
account for the (small) dilution of sample upon addition of ligand. 
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CD Thermal Denaturation Experiments.  Circular dichroism (CD) experiments were 
done at 20 oC using a Jasco J-810 spectropolarimeter. All samples were analyzed in 
quartz cells (1 cm pathlength). Nucleic acid samples were pre-formed in polystyrene 
tubes by heating at 95 oC for 5 minutes slowly cooling to room temperature, followed by 
incubation at 4 oC for 18 hours. Samples were prepared by mixing ligand and nucleic acid 
solutions, at appropriate ratios, followed by incubation at 4 oC for 4 hours and sample 
degassing. Unless otherwise noted, prior to analysis (heating from 0-90oC at a rate of 10 
deg/hr) and resulting emission curves (from 210-400 nm recorded in triplicate) samples 
were pre-formed in polystyrene tubes and heated at 95 oC for 5 minutes slowly cooling to 
room to room temperature. In all experiments, [nucleic acid structure] = 40 µM/base pair.  
 
Isothermal Titration Calorimetry Titrations.  Measurements were performed at 20 oC 
on a MicroCal VP-ITC (MicroCal, Inc., Northampton, MA). In a typical experiment, 8 
µL aliquots of ligand (150 µM for neomycin and ethidium bromide, 50 µM for NM) were 
injected into an isothermal sample chamber containing 1.46 mL of nucleic acid duplex 
solution that was 350 µM/bp. Each experiment of this type was accompanied by the 
corresponding control experiment in which 8 µL aliquots of identical drug solutions were 
injected into a solution of buffer alone. The duration of each injection was 10 s, and the 
delay between injections was 300 s. The initial delay prior to the first injection was 60 s. 
Each injection generated a heat burst curve (microcalories per second vs. seconds). The 
area under each curve was determined by integration using Origin (version 7.0) software 
to obtain a measure of the heat associated with that injection. The heat associated with 
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each drug-buffer injection was subtracted from the corresponding heat associated with 
each drug-DNA injection to yield the heat of drug binding for that injection.  
 
Differential Scanning Calorimetry Experiments.  Differential scanning calorimetry 
(DSC) experiments were undertaken in a Microcal MC2 instrument (Microcal, Inc.). 
DNA:RNA hybrids at a concentration of 100 µM/bp in cacodylate buffer was used for all 
experiments. Primary data were corrected by subtraction of a buffer-buffer baseline and 
normalized to the concentration of DNA base pairs. Baseline-corrected normalized data 
were transferred to Origin software (Microcal, Inc.) for integration and plotting. Samples 
of DNA-ligand complexes (NM, ethidium bromide and neomycin) for DSC were 
prepared by weighing appropriate amounts of solid ligand and dissolving it directly into 1 
mL of a 100 µM/bp DNA solution.  
 
Determination of Binding Constants by the ∆Tm Method.  The apparent ligand-
DNA:RNA hybrid association constants were estimated using the following equations. 
Isothermal titration calorimetry (ITC) techniques were used to estimate the association 
constant, KTm, Equation 1.  
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In equation 1, terms Tm0 and Tm are the melting temperatures of the native hybrid without 
and with ligand, as determined with UV thermal denaturation. n, the number of drug 
molecules bound per duplex, was determined using titrations of drug into duplex 
(fluorescence for ethidium bromide and 3 and CD for neomycin). ∆HDup, Watson-Crick 
duplex enthalpy, was determined with DSC. L is the free drug concentration at Tm, 
estimated at one-half the total drug concentration. The binding constant at the melting 
temperature, Tm, was extrapolated to a reference temperature (T) of 25 oC using the 
integrated van’t Hoff, Equation 2: 
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where, ∆HT was determined experimentally using ITC, R is the gas constant  and ∆Cp 
was determined using Equation 3.  
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Enthalpy values (∆H) were determined using binding enthalpies from excess site ITC 
titrations (used to identify the heat of interaction of the primary high affinity site), at 
various temperatures.  
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Synthesis.  Synthesis of additional compounds is located in the Appendix A.  In order of 
appearance: N-Boc neomycin-S(CH2)2NH2 (DPA10), p. 241; N-Boc neomycin-N3 
(DPA11), p. 241; N-Boc neomycin-NH2 (DPA12), p. 242; N-Boc-protected neomycin-
methidium conjugate (5), p. 243; and Neomycin-Methidium Conjugate (DPA201), p. 
244.   
 
R = NHBoc
R = NHBoc
4
DPA10 3
Cl–
Cl
–
O
OH
OH
R
O
O
O
S
NH 2
OO
R
OH
OH
R
OH
OH
R
R
R
O
N
H S
O
OO
R
OH
OH
R
OH
O
O
O
R
OH
OH
R
R
R
OH
N
+NH 2
NH 2
N +NH 2
NH 2
OH
O
+
 
Boc-protected Neomycin-Methidium Conjugate (4).  To a solution of 6-(4-
carboxyphenyl)-3,8-diamino-5-methylphenanthridinium chloride (3) (8.6 mg, 23.1 µmol) 
in dry DMF (3.0 mL), dicyclohexylcarbodiimide (4.8 mg, 23.1 µmol) and 
dimethylaminopyridine (1.0 mg, 0.01 mmol) were added. The solution was allowed to 
stir under positive N2 gas for 3 h. A solution of DPA10 (30.0 mg, 23.1 µmol) in dry DMF 
(3.0 mL) was added via cannula. The reaction was allowed to stir at room temperature 
under positive N2 for 28 h. The volatiles were removed in vacuo. The dry solid was 
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washed with CH2Cl2. The resulting solid was dried in vacuo. Flash chromatography (0%-
25% MeOH:CH2:Cl2) afforded 4 (30.8 mg, 80%) as a purple solid: Rf 0.2 in 85:15 
CH2Cl2:MeOH); UV max (95% CH3OH) 286, 510 nm; IR (KBr) 3405, 1600 cm
-1; 1H 
NMR  (500 MHz, MeOD) δ 8.60 (d, 1H, J = 9.1), 8.56 (d, 1H, J = 9.1), 7.90 (d, 2H, J = 
8.7, H18), 7.65 (d, 2H, J = 8.8), 7.56 (m, 1H, J = 9.1), 7.35-7.39 (m, 3H), 5.41 (br, 1H), 
4.92 (s, 1H), 4.34 (br, 2H), 4.04 (s, 1H), 4.00-3.98 (m, 1H), 3.89-3.80 (m, 1H), 3.76-3.71 
(m, 1H), 3.61-3.69 (m, 2H), 3.55-3.52 (m, 1H), 3.51 (d, 2H), 3.47 (br, 1H), 3.4-3.2 (m, 
1H), 3.19 (m, 1H), 2.93-2.91 (m, 4H), 2.85-2.83 (m, 4H), 2.81 (d, 2H), 2.79-2.70 (m, 
2H), 1.96-1.86 (m, 1H), 1.71 (br, 1H), 1.36-1.48 (m, 54H); 13C NMR (125 MHz, MeOD) 
δ 156.6, 167.8, 156.8, 151.5, 148.2, 136.9, 130.0, 128.8, 128.1, 127.8, 127.5, 127.4, 
126.8, 124.3, 120.1, 122.0, 117.9, 108.4, 99.1, 98.9, 98.2, 81.5, 80.3, 79.3, 79.1-79.3, 
77.9, 76.8, 73.1, 73.0, 71.5, 70.8, 70.2, 70.1, 66.1, 63.6, 53.3, 50.2, 43.3, 43.2, 41.7, 41.6, 
33.3, 27.3; MALDI-TOF m/z (rel. intensity) calculated for C51H76N10O15SCl [M + H]+ 
1600.09 found 1600.01. 
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Neomycin-Methidium Conjugate (DPA200).  To a solution of 4 (30.8 mg, 18.3 µmol) 
in 3.0 mL dichloromethane was added trifluoroacetic acid (3.0 mL). 1,2-ethanedithiol 
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(1.0 mL) was added and the solution was allowed to stir for 30 min. The volatiles were 
removed under vacuum. The resulting oil was washed with diethylether affording a 
maroon solid. The solid was dissolved in nanopure water. The solution was purified with 
preparatory HPLC using a reverse phase column, (0%-100% H2O:MeCN 0.1%TFA, 15 
min). The compound eluted at 20.93 min. Fractions containing the compound were 
lyophilized affording DPA200 (28.0 mg, 90%) as a maroon solid:  UV max (95% H2O) 
288, 514 nm; IR (KBr) 3410, 1605 cm-1; 1H NMR (500 MHz, D2O) 8.76 (d, 1H, J = 9.6), 
8.69 (d, 1H, J = 9.6), 7.86 (d, 2H, J = 8.7), 7.66 (d, 2H, J = 8.8), 7.52 (m, 1H, J = 9.6), 
7.35-7.39 (m, 3H), 5.37 (br, 1H), 5.09 (s, 1H), 4.53 (br, 2H), 4.23 (s, 1H), 4.01-3.88 (m, 
1H), 3.79-3.71 (m, 1H), 3.75-3.68 (m, 1H), 3.61-3.59 (m, 2H), 3.59-3.53 (m, 1H), 3.52 
(d, 2H), 3.47 (br, 1H), 3.29-3.21 (m, 1H), 3.17-3.03 (m, 1H), 2.91-2.89 (m, 4H), 2.89-
2.85 (m, 4H), 2.85 (d, 2H), 2.79 (m, 2H), 1.93 (m, 1H), 1.89 (br, 1H); 13C NMR (125 
MHz, D2O) δ 168.5, 155.3, 152.0, 147.3, 137.1, 131.2, 127.9, 127.8, 127.7, 127.2, 127.1, 
126.7, 126.6, 123.9, 122.4, 121.3, 117.3, 110.2, 107.9, 98.9, 97.6, 95.3, 85.1, 81.2, 76.5, 
74.9, 73.3, 72.8, 71.0, 70.4, 69.3, 68.4, 67.8, 67.3, 60.3, 53.9, 51.0, 50.9, 50.3, 48.7, 42.3, 
40.5, 40.4, 29.3; MALDI m/z (rel intensity) calculated for C46H67N10O13SCl [M + H]
+ 
1000.07 found [M + Na]+ 1000.14. 
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RESULTS AND DISCUSSION 
Design of Neomycin – Methidium Conjugate.  We hypothesize that conjugation of 
neomycin with a DNA:RNA hybrid specific binding intercalator, ethidium bromide, will 
yield a new class of molecules capable of preferentially binding DNA:RNA hybrids.  
Neomycin is expected to bind in the major groove, while ethidium bromide is expected to  
DPA200
DPA201
ethidium bromideneomycin
 
Figure 2.1.  Structures of compounds used in this study: DPA200 and DPA201, 
neomycin and ethidium bromide.  
 
bind via intercalation.  In an effort to estimate the potential binding affinity of our 
conjugate, we utilized the following principle: given optimized conditions if ligand 
molecule A and ligand molecule B bind to a receptor, ligand A-B can be expected to bind 
such that the binding constant of A-B equals the product of two individual binding 
constant values (Ka).  If one looks at the product of the individual Ka values for ethidium 
bromide and neomycin, one expects an optimized Ka in the 1012 M-1 range.  Even if 
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conditions are not optimized, the conjugate has the potential to bind our target 
DNA:RNA hybrids in the nanomolar range, Figure 2.1!  
When choosing a suitable position on neomycin and ethidium bromide, the 
following assumptions were made.  The amino groups on rings I, II and IV of neomycin 
are necessary in stabilizing and recognizing the nucleic acid grooves, aminoglycosides 
without any of these amino groups do not stabilize nucleic acids as efficiently (76).  The 
5’’-OH on ring III was thus chosen to provide linkage to the intercalating unit.  Two N-
Boc protected neomycin derivatives were designed to accommodate variable linker 
lengths for conjugation.   
Furthermore, when considering ethidium bromide, the electron donation afforded 
by the exocyclic amino groups dominate the electron withdrawing effects of the 
endocyclic iminium ion when examining the overall electron density of the molecule (65, 
77).  Therefore, these amino groups were not chosen for conjugation to neomycin.  
Fortunately, an ethidium bromide derivative (6-(4-carboxyphenyl)-3,8-diamino-5-
methylphenanthridinium chloride, 6) features an accessible functional group in the form 
of a carboxylic acid through which conjugation can easily be achieved leaving the overall 
binding moiety of the molecule unperturbed.   
 
Synthesis.  Synthesis of compound ‘N-Boc-neomycin amine’, DPA10, has previously 
been reported by our group and by Tor (78, 79, 80), Scheme 2.1.  Each of the six amino 
groups located on commercially available neomycin B sulfate were N-Boc protected.  
The hydroxyl at the 5’-position on ring three of neomycin was converted into a good 
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R = NHBoc
iv
DPA11 DPA12
v
TPS =
i
ii iii
1
2 DPA10
[SO42-]3
 
Scheme 2.1.  Reagents and conditions:  (i) (Boc)2O, DMF, H2O, Et3N, 60 oC, 5 h, 70%; 
(ii) Tps-Cl, pyridine, room temperature, 24 h, 68%; (iii) H2NCH2CH2SH, NaOEt/EtOH, 
room temperature, 10 h, 75%; (iv) 2, NaN3, DMF, 60 oC, 12 h, 89 %; (v) DPA11, 10% 
Pd/C, MeOH, H2 (g), 6 h, 98%. 
 
leaving group using 2,4,6-triisopropylbenznesulfonyl chloride (TPS) to afford compound 
2.  The TPS leaving group was subsequently displaced, using 2-aminoethanethiol 
hydrochloride in the presence of sodium metal, affording N-Boc-neomycin-amine, 
DPA10, in 38% overall synthetic yield.  The TPS leaving group was also displaced using 
sodium azide to afford the intermediate N-Boc-neomycin-azide, DPA11.   DPA11 was 
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reduced in the presence of H2 (g), to afford N-Boc-neomycin-5”-amine, DPA12, Scheme 
2.1.   
R = NHBoc
TFA -
i
DPA200
4
3
DPA10
ii
 
Scheme 2.2.  Reagents and conditions:  (i) DPA10, 6-(4-carboxyphenyl)-3,8-diamino-5-
methylphen-anthridinium chloride, DCC, DMAP, DMF, 28 h, 80%; (ii) 4, TFA/CH2Cl2, 
1,2-ethanedithiol, 5 h, 90%. 
 
6-(4-carboxyphenyl)-3,8-diamino-5-methylphen-anthridinium chloride 3 was 
coupled to DPA10 in the presence of dicyclohexylcarbodiimide/dimethylaminopyridine 
(DCC/DMAP) to afford the N-Boc-protected conjugate 4, Scheme 2.2.  Trifluoroacetic 
acid (TFA) deprotection of the N-Boc-protected conjugate 4 afforded the TFA salt of 
DPA201 in good yields, Scheme 2.2.   
R = NHBoc
TFA - DPA201
i
5
ii
3
DPA12
 
Scheme 2.3.  Reagents and conditions:  (i) DPA12, 6-(4-carboxyphenyl)-3,8-diamino-5-
methylphen-anthridinium chloride, DCC, DMAP, DMF, 28 h, 84%; (ii) 5, TFA/CH2Cl2, 
1,2-ethanedithiol, 5 h, 94%; 
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Compound 3 was activated with DCC/DMAP and DPA12 was added to afford the 
N-Boc protected conjugate 5, Scheme 2.3.  The N-Boc protected conjugate 5 was also 
deprotected using TFA.  The resulting deprotected conjugate DPA201 was afforded in 
good yields, Scheme 2.3.   
 
Competition Dialysis Experiments.  Competition dialysis experiment allow for the 
screening of a compound against a number of nucleic acid structures.  When the 
experiment was conducted at a concentration of 75 µM per base unit of nucleic acid 
structure, DPA200 displayed a notable preference for poly(dA):poly(rU), 
poly(rA):poly(dT), poly(dA):poly(rU), Figure 2.2.  Little to no interaction with nucleic 
acid single strands (poly(dA), poly(dG), poly (rC), poly(rU), poly(rA), poly(dC), 
poly(dA) or poly(dT)) were detected.   
In an effort to eliminatenon-specific binding to various nucleic acids, a potential 
artifact of high nucleic acid and ligand concentrations, the experiment was conducted at 
750 nM per base unit of nucleic acid, Figure 2.2.  At 750 nM, DPA200 displayed a clear 
preference for poly(dA):poly(rU).  A decrease in preference for poly(rA):poly(dT) and 
poly(rArU), with respect to poly(dA):poly(rU), by DPA200 was observed at 750 nM.  
Competition dialysis experiments were also conducted at 100 mM NaCl.  At lower salt 
concentration,  DPA200 demonstrated a clear preference of for poly(dA):poly(rU), 
Appendix A, Figure A8.   
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(a) 
 
(b) 
 
Figure 2.2.  Competition dialysis results of DPA200 with various nucleic acids.  The 
histograms show the amount of DPA200 bound to individual nucleic acids following 
dialysis.  Nucleic acids were dialyzed with DPA200 in buffer solution for 72 h.  In panel 
(a) [DPA200] = 1 µM, [nucleic acids] = 75 µM 750 nM per base unit of each polymer 
and panel (b) [DPA200] = 100 nM, [nucleic acids] = 750 nM 750 nM per base unit of 
each polymer.  Buffer:  6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM EDTA, pH 7.0, 185 
mM NaCl.    
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UV Monitored Thermal Denaturation Experiments.  In this experiment, pre-formed 
nucleic acid structures were incubated, individually, with the DPA200, Table 2.1, 
Appendix A, Figure A9.  The samples were denatured and monitored with UV-
spectroscopy.  An increase in absorbance was observed upon the disassociation of the 
nucleic acid into single strands.  The point at which the nucleic acid structure 
disassociates into its  
Table 2.1.  UV determined thermal melting temperatures of 
various nucleic acids in the presence of DPA200.  Values are 
reported in oC.   
 Tm0
a (oC) Tm
b (oC) ∆Tm
c (oC) 
A-site RNA 71.7 79.8 8.1 
calf thymus DNA 86.9 >95 >8.1 
poly(dA):2poly(dT) 23.1 - - 
 68.2 75.9 7.7 
poly(dA):poly(dT) 68.4 76.1 7.7 
poly(dA-dT):poly(dA-dT) 67.9 75.3 7.4 
poly(dG):poly(dC) 93.6 >95 - 
poly(rA):poly(rU) 57.1 91.4 34.3 
poly(dA):poly(rU) 43.6 90.5 46.9 
poly(rA):poly(dT) 62.3 82.4 20.1 
aTm0 represents the melting temperature of the native duplex.  
bTm represents the melting temperature of the duplex upon 
addition of neomycin at a rbd (ratio of DNA base pairs:drug) 
of 2.2.    c∆Tm represents the change in melting temperature 
between Tm0 and Tm.  Buffer:  10 mM sodium cacodylate, 0.5 
mM EDTA, pH 5.5, 100 mM NaCl.   
 
constituent single strands corresponds to the melting temperature, Tm, which was 
observed as the temperature in which the UV absorbance at 260 nm was halfway between 
the UV absorbance of the helix and single stranded forms.  It is expected that nucleic 
acids in which DPA200 display preferential binding for will show the highest 
stabilization of melting temperature when complexed with DPA200 over the native 
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unbound nucleic acid.  As expected, DPA200 complexed with poly(dA):poly(rU) 
afforded the highest thermal stabilization of an incredible 46.9 oC increase in Tm.  
DPA200 afforded a Tm increase of 34.3 oC for the poly(rA):poly(dT) complex, followed  
(a) (b) 
  
Figure 2.3.  Mixed melting profile of various nucleic acids. Panel (a) shows a melting 
profile for the mixed melting of various duplex nucleic acids with DPA200.  Panel (b) 
shows a derivative plot for the mixed melting of various duplex nucleic acids with 
DPA200 at rdd = 20, the solid line reflects native melting and the dashed line represent 
the melting with DPA200. The arrows indicate the peaks that are altered by addition of 
the DPA200.  In each panel, the peaks correspond to the following nucleic acids, 
poly(dG):poly(dC); peak 5, poly(dA):poly(dT); peak 4, poly(rA):poly(dT); peak 3, 
poly(rA):poly(rU); peak 2, poly(dA):poly(rU); peak 1. Individual polynucleotide 
concentration was 10 mM/bp; total polynucleotide concentration was 50 µM. Buffer: 1.5 
mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA and 46.25 mM NaCl at pH 7.0. 
 
by the poly(rA):poly(rU) complex at Tm = 20.1 
oC.  Not only does DPA200 show a high 
preference for DNA:RNA hybrids, but the poly(dA):poly(rU) thermal stabilization 
afforded by DPA200 is significantly higher than any other nucleic acid structure. 
Most recently, an assay using thermal denaturation of mixtures containing various 
nucleic acids in the presence of ligand was developed to determine structural and 
sequence selectivity (82).  In this thermal denaturation experiment, a number of nucleic 
acids with different melting temperatures were combined in solution and denatured in the 
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presence of a ligand at very low ligand to nucleic acid ratios.  At such low ratios, the 
nucleic acid preferred by the ligand will display a thermal stabilization, while other 
nucleic acids will remain unchanged.  As seen in Figure 2.3, when assayed against a 
solution containing poly(dA):poly(rU), poly(rA):poly(dT), poly(dA):poly(dT), 
poly(rA):poly(rU) and poly(dG):poly(dC), at rbd = 20, only the melting temperature of 
poly(dA):poly(rU) is increased, while all other duplexes remain unchanged.  In fact, 
increasing the concentration to rbd = 10 affords stabilization for poly(dA):poly(rU) (2.0 
oC) and poly(rA):poly(dT) (0.9 oC), Appendix A, Figure A10.  The smaller changes in 
Tm, as observed in the mixed melting experiments, are consistent with the previously 
reported data (82).  These experiments proved irrefutable evidence that DPA200 
preferentially binds to poly(dA):poly(rU).  The difference in stabilization of the two 
hybrids when complexed to DPA200 can be attributed to the conformational differences 
adopted by the two hybrids as poly(dA):poly(rU) adopts a more A-like conformation than 
poly(rA):poly(dT) (32). 
 
Design of Thermal Denaturation Experiments.  In an effort to further explore the 
stability of DPA200 – nucleic acid complexes a number of thermal denaturation 
experiments were performed.  UV monitored thermal denaturation experiments were 
conducted in the presence of increasing molar ratios of DPA200 and DPA201 to 
poly(rA):poly(dT) and poly(dA):poly(rU).  Themal melting experiments were conducted 
in the presence of neomycin, ethidium bromide and DPA200 at equivalent ratios of 
ligand to DNA:RNA hybrid in an effort to compare the thermal stabilization afforded by 
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DPA200 to its constituent parts.  As the amount of ligand required to saturate the 
DNA:RNA hybrids was not identical, thermal denaturation experiments were also 
conducted at each ligand saturation point.  Finally, UV monitored thermal denaturation 
experiments were also expanded to include the RNA duplex poly(rA):poly(rU) and the 
DNA duplex poly(dA-dT)2.  These techniques have previously been used by our research 
group (79, 83, 84, 85, 86).   
 
UV Monitored Thermal Denaturation Experiments.  UV monitored thermal 
denaturation experiments were also conducted at pH 6.8 and 20 mM NaCl.  Biphasic 
transitions were observed for complexes of poly(dA):poly(rU) and DPA200, where the 
duplex was not saturated with ligand, Appendix A, Figure A11.  However, at rbd of 4, 
the melting temperature of the poly(dA):poly(rU) – DPA200 complex was 31.4 oC higher 
than melting temperature of the duplex without ligand.  The ∆Tm of the 
poly(rA):poly(dT) – DPA200 complex was only 9.8 oC higher than the duplex alone.   At 
pH 6.8 and 100 mM NaCl, UV monitored thermal denaturation of poly(dA):poly(rU) and 
poly(rA):poly(dT) in the presence of increasing concentration of DPA200 was 
conducted.  The hybrid melting temperature increased with increasing amount of 
DPA200, Table 2.2, Figure 2.4.  The magnitude of stabilization afforded by DPA200 
varied significantly between hybrid duplexes.  At a rbd of 9.6, the poly(dA):poly(rU) – 
DPA200 complex melting temperature was 21.9 oC higher than the native duplex.  
However, the melting temperature of the poly(rA):poly(dT) – DPA200 complex was 
much lower where the ∆Tm was only 6.1 
oC.   
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Table 2.2.  UV determined thermal denaturation temperatures of DNA:RNA hybrids with various ligands.   All values are 
reported in oC. 
  
poly(dA):poly(rU) poly(rA):poly(dT)  poly(dA):poly(rU) poly(rA):poly(dT) 
  Tm
a ∆Tm
b Tm ∆Tm  Tm ∆Tm Tm ∆Tm 
2
0
 
m
M
 
N
a
C
l
 
p
H
 
6
.
8
 
native (rbd =) 33.2 60.7 native (rbd = 4.0) 33.2 60.7 
DPA200 
(20.0) 
34.6 1.4 
64.2 3.5 neomycin 
36.9 3.4 
61.1 0.4 
61.2 28.0 53.3 20.1 
DPA200 (10.0) 39.5 6.3 67.1 6.4 ethidium bromide  37.1 3.9 67.9 7.2 
63.5 30.3 53.2 20 
DPA200 (6.6) 43.2 10.0 68.4 7.7 neomycin +  
ethidium bromide 
50.5 17.3 68.7 8.0 
64.7 31.5 
DPA200 (4.0) 64.6 31.4 70.5 10.7 DPA200 64.6 31.4 70.5 9.8 
1
0
0
 
m
M
 
N
a
C
l
 
p
H
 
6
.
8
 
native (rbd =) 48.9 63.8 native (rbd = 9.6) 49.2 63.8 
DPA200 (20.0) 52.1 3.2 64.8 1.0 neomycin  52.0 2.8 69.1 5.3 
DPA200 (10.0) 68.4 19.5 67.1 3.3 ethidium bromide 36.9 -12.3 67.9 4.1 
54.7 5.5 
DPA200 (6.6) 73.4 24.5 70.3 6.5 neomycin +  
ethidium bromide  
37.2 -12.0 
68.1 4.3 
51.8 2.6 
DPA200 (4.0) 80.4 31.5 70.6 6.8 DPA200  71.1 21.9 69.9 6.1 
1
0
0
 
m
M
 
N
a
C
l
 
p
H
 
5
.
5
 
native 45.6 62.3 native (rbd = 9.6) 45.6 62.3 
neomycin 
(rbd = 6.0) (rbd = 8.0) neomycin  67.9 22.3 69.3 7.0 
70.5 24.9 68.1 5.8 
ethidium 
bromide 
(rbd = 4.4) (rbd = 4.2) ethidium bromide  
52.3 6.7 
65.4 3.1 
66.4 20.8 71.0 8.7 69.3 23.7 
DPA200 (rbd = 9.6) (rbd = 6.5) 
neomycin +  
ethidium bromide  
48.8 3.2 67.7 5.4 
90.5 44.9 92.8 30.5 DPA200 90.5 44.9 82.4 20.1 
aTm represents the melting temperature of the native duplex.  
b∆Tm represents the change in melting temperature upon addition 
of ligands at a rbd.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA (salt and pH conditions noted above).    
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 (a) (b) 
  
(c) (d) 
  
Figure 2.4.  UV thermal denaturation profiles of poly(rA):poly(dT) (a, b) and 
poly(dA):poly(rU) (c, d) with various ligands.   Panels (a, c) represent the duplex with 
DPA200 at varying rbd values, while panels (b, d) represent the duplex (A) was with 
neomycin (B), ethidium bromide (C), neomycin and ethidium bromide (D) and DPA200 
(E) at 5 µM.  Ligands were added at varying rbd (ratio of drug:base pairs) values to the 
duplex [20 µM/bp].  The samples were incubated at 4 oC for 12 h prior to analysis, slow 
heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer:  10 mM sodium cacodylate, 0.5 mM 
EDTA, pH 6.8, 100 mM NaCl. 
  
UV monitored thermal denaturation experiments were also conducted on 
complexes of DNA:RNA hybrid and neomycin, ethidium bromide or a non-covalent 
mixture of ethidium bromide and neomycin at rbd of 9.6 at a pH of 6.8 and 100 mM NaCl, 
Table 2.2.  The melting temperature of the poly(rA):poly(dT) – DPA200 complex was 
6.1 oC higher than the melting temperature of the native duplex, Figure 2.4.  The change 
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in melting temperatures of the poly(rA):poly(dT) complexes with neomycin (∆Tm = 5.3), 
ethidium bromide (∆Tm = 4.1), non-covalent combination of neomycin and ethidium 
bromide (∆Tm = 4.3) were all lower than the poly(rA):poly(dT) – DPA200 complex 
Appendix A, Figure A11. The melting temperature of the poly(dA):poly(rU) – 
neomycin complex was only 2.8 oC higher than the duplex alone, Figure 2.4.  The UV 
melting profile of the poly(dA):poly(rU) – ethidium bromide complex was biphasic 
which suggested simultaneous destabilization and stabilization of the duplex, ∆Tm was -
12.3 oC and 5.5 oC, respectively.  The UV melting profile of the poly(dA):poly(rU) – 
non-covalent combination of neomycin and ethidium bromide complex was also 
biphastic, ∆Tm was -12.0 ∆Tm 2.6 
oC, respectively.   
The melting temperature poly(dA):poly(rU) – DPA200 complex was 21.9 oC 
higher than native duplex.  Similar observations were recorded for the same complexes at 
a pH of 5.5 and 100 mM NaCl, Appendix A, Figure A12.  At pH 6.8 and 100 mM NaCl, 
UV monitored thermal denaturation of poly(dA):poly(rU) and poly(rA):poly(dT) in the 
presence of increasing concentration of DPA201 was conducted, Figure 2.5.  The 
stabilization afforded by DPA201 varied significantly between the duplexes, as seen with 
DPA200.  At lower concentrations of DPA201, the UV melting profile of 
poly(rA):poly(dT) was biphasic,potentially due to incomplete saturation of the duplex by 
the conjugate.  However, at rbd = 6.6 and rbd = 4, the poly(rA):poly(dT) – DPA201 
complex increased in thermal stability by 4.2 oC and 10 oC.  Under identical conditions 
and rbd = 4.0, DPA201 stabilizes the duplex by 4 oC more than DPA200.   
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(a) (b) 
  
Figure 2.5.  UV thermal denaturation profiles of poly(rA):poly(dT) (a) and 
poly(dA):poly(rU) (b) with DPA201.   The panels represent the duplex with DPA201 at 
varying rbd values.  Ligands were added at varying rbd (ratio of drug:base pairs) values to 
the duplex [20 µM/bp].  The samples were incubated at 4 oC for 12 h prior to analysis, 
slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer:  10 mM sodium cacodylate, 0.5 
mM EDTA, pH 6.8, 100 mM NaCl. 
 
Poly(dA):poly(rU) melting temperature increased with increasing amount of DPA201.  
At a rbd of 4.0, the poly(dA):poly(rU) – DPA200 complex melting temperature was 25.8 
oC higher than the native duplex.  The stabilization afforded by DPA200 on 
poly(dA):poly(rU) is 5.7 oC higher, at rdb = 4.0, than the stabilization afforded by 
DPA201 on poly(dA):poly(rU).   
UV monitored thermal denaturation experiments were conducted at 
spectroscopically determined saturated amounts of ligand at a pH of 5.5 and 100 mM 
NaCl, page, Table 2.2, Appendix A, Figure A12.  The poly(rA):poly(dT) – DPA200 
complex was 30.5 oC higher than the melting temperature of the native duplex.  While the 
poly(rA):poly(dT) complexes with saturated amounts of neomycin and ethidium bromide 
were larger than the melting temperature of the duplex alone, the stabilization afforded by 
neomycin was only 5.8 oC and ethidium bromide was only 8.7 oC.  UV monitored melting  
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Table 2.3.  CD determined thermal denaturation temperatures of DNA:RNA 
hybrids with various ligands.  All values are reported in oC.  Tm
a values are 
reported below while ∆Tm
b are reported in parenthesis.   
co
n
st
a
n
t r
bd
 
 
poly(dA):poly(rU)  
rbd = 9.6 
poly(rA):poly(dT)  
rbd = 9.6 
poly(rA):poly(dT)  
rbd = 6.5 
native 48.9 63.8 63.8 
neomycin 58.7 (9.8) 67.6 (3.8) 68.5 (4.7) 
ethidium 
bromide 
49.6 (0.7) 65.8 (2.0) 66.1 (2.3) 
neomycin +  
ethidium 
bromide 
59.2 (10.3) 67.8 (4.0) 69.8 (6.0) 
DPA200 70.1 (21.2) 68.7 (4.9) 70.3 (6.5) 
sa
tu
ra
tio
n
 
r b
d 
 poly(dA):poly(rU) poly(rA):poly(dT) 
 
native 48.9 63.8 
neomycin 
rbd = 6.0 rbd = 8.0 
64.2 (15.3) 68.6 (4.8) 
ethidium 
bromide 
rbd = 4.4 rbd = 4.2 
50.3 (1.4) 66.4 (2.6) 
DPA200 
rbd = 9.6 rbd = 6.5 
70.1 (21.2) 70.3 (6.5) 
aTm represents the melting temperature of the native duplex.  
b∆Tm represents the 
change in melting temperature upon addition of ligands at carious rbd values.  
Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA (salt and pH conditions noted 
above).    
 
profiles of poly(dA):poly(rU) complexed with saturated amounts of neomycin and 
ethidium bromide were monophastic and 24.9 oC and 20.8 oC higher than the native 
duplex, respectively.  The stabilization of the poly(dA):poly(rU) – DPA200 complex was 
higher, the melting temperature for the complex was 44.9 oC higher than the duplex 
alone.   
 
CD Monitored Thermal Denaturation Experiments.  Complexes of DNA:RNA 
hybrids and ligands were thermally denatured and monitored by circular dichorism (CD).  
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A solution containing ligand and nucleic acid is optically active, changes in the solution 
can be observed by following the difference in absorption for right and left polarized light 
 (87).  As in UV monitored thermal denaturation experiments, the point at which the 
nucleic acid – ligand complex disassociates into its constituent single strands was denoted 
as the melting temperature, Tm, Table 2.3.   
CD monitored thermal denaturation of poly(rA):poly(dT) – ligand complexes 
were conducted at a rbd of 6.5.  The poly(rA):poly(dT) – DPA200 complex denatured at 
6.5 oC higher than the native duplex.  The change in melting temperature of the 
poly(rA):poly(dT) – ligand complexes were 4.7 oC and 2.3 oC higher than the native 
duplex when complexed neomycin and ethidium bromide, respectively.  The 
poly(rA):poly(dT) – neomycin and ethidium bromide complex denatured 6.0 oC higher 
than the unbound duplex, similar in magnitude to the thermal stabilization of the 
poly(rA):poly(dT) – DPA200 complex, Appendix A, Figure A13.     
The melting temperature of poly(dA):poly(rU) – DPA200 complex was 21.2 oC, 
similar to the UV determined melting temperature.  The poly(dA):poly(rU) complex 
denatured at 58.7 oC, 9.8 oC higher than the melting temperature of the native duplex.  
UV monitored melting profiles of poly(dA):poly(rU) complexed with ethidium bromide 
and the non-covalent combination of neomycin and ethidium bromide were biphasic.  CD 
monitored melting profiles of the same complexes were monophasic and denatured at 0.7 
oC and 10.3 oC higher than the unbound duplex, Appendix A, Figure A13.     
CD monitored thermal denaturation of the DNA:RNA hybrid – ligand complexes 
were conducted at saturated amounts of neomycin, ethidium bromide and DPA200 and 
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pH 5.5, Table 2.3, Figure 2.6.  At saturated amounts of ligand, the poly(rA):poly(dT) – 
neomycin complex denatured 4.8 oC higher than the melting temperature of the native 
duplex.  The poly(rA):poly(dT) – ethidium bromide complex denatured 2.6 oC higher 
  
Figure 2.6.  CD thermal denaturation profile of poly(rA):poly(dT) (left) and 
poly(dA):poly(rU) (right).   Each panel represents the duplex (A) was with neomycin (C), 
ethidium bromide (B) and DPA200 (D).  Ligands were added to the duplex [20 µM/bp] 
at saturation: poly(rA):poly(dT) neomycin (rbd = 8.0), ethidium bromide (rbd = 4.2) and 
DPA200 (rbd = 6.5); poly(dA):poly(rU):  neomycin (rbd = 6.0), ethidium bromide (rbd = 
4.4) and DPA200 (rbd = 9.6).   The samples were incubated at 4 oC for 12 h prior to 
analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.   Buffer:  10 mM sodium 
cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl.    
 
than the unbound duplex melting temperature while the melting temperature of the  
poly(rA):poly(dT) – DPA200 complex was a modest 6.5 oC higher than the native duplex 
melting temperature.   
The largest thermal stabilization was observed with the poly(dA):poly(rU) – 
DPA200 complex, a 21.2 oC increase in stabilization over the duplex alone.  CD 
determined melting temperatures of the poly(dA):poly(rU) complex demonstrates a 
minimal increase to the native duplex melting temperature, only 1.5 oC.  The melting 
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temperature of the poly(dA):poly(rU) – neomycin complex was 64.2 oC , 15.3 oC higher 
than the native duplex melting temperature.   
 
Fluorescence Monitored Thermal Denaturation Experiments.  Fluorescence 
techniques were conducted to further corroborate previously described results.  The only 
drawback to this approach is the ligand of interest must contain a chromophore which can 
be excited and the resulting emission can be tracked, therefore complexes of the 
DNA:RNA hybrids and ethidium bromide or DPA200 were the only compounds studied, 
Appendix A, Figure A14.  Ethidium bromide and DPA200 exhibit a strong fluorescence 
signal when complexed with nucleic acids.  As the nucleic acid denatures the bound 
ligand is released into solution and a decrease in fluorescence intensity is observed.  
Fluorescence determined melting temperatures for the DNA:RNA hybrid – ligand 
complexes support previously determined values.   
The following observations were made from thermal denaturation experiments.  
(i) The thermal stabilization of DNA:RNA hybrid duplexes increases when complexed 
with DPA200.  The stabilization increases with increasing amounts of DPA200.  
Furthermore, the melting temperature increase over the native duplex melting 
temperature was larger when DPA200 is complexed with poly(dA):poly(rU) than when 
complexed with poly(rA):poly(dT).  (ii) At equivalent rbd values, DNA:RNA hybrid 
complexation with DPA200 affords a larger increase in thermal stabilization than 
complexation with neomycin or ethidium bromide.  (iii) When the DNA:RNA hybrid is  
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(a) (b) 
  
(c) (d) 
  
Figure 2.7.  CD scans of the titration of neomycin with poly(rA):poly(dT) (a, b) and 
poly(dA):poly(rU) (c, d) at 20 oC.   A plot of CD intensity at 260 (b, d) with respect to rbd 
was plotted, rbd is the ratio of [base pair]/[drug].  In the expanded chromophore regions 
the open circles denote the CD signal of native hybrid without drug, while closed circles 
denote the CD signal after max addition of the ligand.   Ligands were added to the duplex 
[20 µM/bp] at respective rbd values.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, 
pH 6.8, 100 mM NaCl. 
 
complexed with saturating amounts of ligand, the melting temperature of the DNA:RNA 
hybrid – DPA200 complexes are higher than the DNA:RNA hybrid – neomycin or 
ethidium bromide complexes.  This is observed in both poly(dA):poly(rU) and 
poly(rA):poly(dT).  (iv) Finally, when complexed to various nucleic acids at DPA200 
saturation, the largest increase in melting temperature was observed when complexed 
with poly(dA):poly(rU).  The poly(rA):poly(dT) – DPA200, poly(rA):poly(rU) – 
DPA200 and poly(dA-dT)2  – DPA200 complexes were all stabilized by the conjugate, 
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but to a smaller magnitude than observed with the poly(dA):poly(rU) – DPA200 
complex.    
 
DPA200 Thermodynamic Profiles with poly(rA):poly(dT) and poly(dA):poly(rU).  
Ligand saturation points were defined as the number of base pairs per ligand and 
determined by titration of ligand into DNA:RNA hybrid.  Titrations of neomycin into 
DNA:RNA hybrid was monitored by CD while titrations of ethidium bromide and 
DPA200 into DNA:RNA hybrids were monitored by fluorescence.  CD titrations of 
ethidium bromide and DPA200 were also conducted, Appendix A, Figure A15, however 
binding stie size determination could not be made.  A plot of CD intensity with respect to 
rbd was made.  A linear fit of pre- and post-saturation regions was conducted and the 
intersection of these fits defined the binding site size, Figure 2.7.  Neomycin binding 
sites of 8.1 base pairs/ligand and 6.0 base pairs/ligand were determined for and 
poly(dA):poly(rU) and poly(rA):poly(dT), respectively.   
Following fluorescence monitored titrations of DNA:RNA hybrids with ethidium 
bromide and DPA200, the fluorescence emission maxima was plotted with respect to rbd.  
Two clear inflection points were observed following analysis of the titration of ethidium  
bromide into poly(rA):poly(dT).  A primary binding site size was observed at 4.2 base 
pairs/ligand and a secondary binding site was identified at 2.1 base pairs/ligand.  Two 
binding sites were also observed following analysis of the titration of ethidium bromide 
into poly(dA):poly(rU).  A primary binding site size of 4.4 base pairs/ligand and a
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(a) (c)  (e)  (g)  
    
(b) (d) (f) (h) 
    
Figure 2.8.  Fluorescence emission scans of the titration of DPA200 and ethidium bromide with poly(rA):poly(dT) (a, c) and 
poly(dA):poly(rU) (e, g) at 20 oC.   A plot of fluorescence intensity at 634 (b, f) and 261 (d, h) with respect to rbd was plotted, 
rbd is the ratio of [base pair]/[drug].  Ligands were added to the duplex [1 µM/bp] at respective rbd values.  Excitation:  525 nm; 
emission:  550 – 700 nm; slits:  1.5 mm.   Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure 2.9.  DSC melting profiles of poly(rA):poly(dT) (a) and poly(dA):poly(rU) (b).   
The native DNA:RNA hybrid was melted in the absence (a, b) of ligands.   Integration of 
the melting peak yielded ∆Hwc.   The duplex was pre-formed at 100 µM/bp prior to 
analysis, slow heating from 25 oC to 90 oC at 0.75 oC/min.  Buffer:  10 mM sodium 
cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl.  Data collected by Dr. Hongjuan Xi.   
 
secondary binding site of 1.8 base pairs/ligand were identified, Figure 2.8.  Analysis, 
following titration of DPA200 into poly(rA):poly(dT) showed only one inflection point at 
6.5 base pairs/ligand.  A primary binding size of 9.3 base pairs/ligand was identified upon 
analysis of the titration DPA200 into poly(dA):poly(rU).  A secondary binding site size 
was also observed at high ligand concentrations; 5.7 base pairs/ligand, Figure 2.8.    
Watson-Crick duplex enthalpy values, ∆Hwc, were determined using DSC thermal 
denaturation experiments, conducted by Dr. Hongjuan Xi.  The DSC melting profile for  
poly(rA):poly(dT) was exhibited one peak at 65.8 oC, Figure 2.9.  The dissociation of the 
duplex into the single strands of RNA and DNA corresponded to a melting enthalpy of 
9.21 kcal/mol.  The DSC melting profile of poly(dA):poly(rU) showed one peak at 48.5 
oC.  The melting enthalpy of the hybrid duplex was 5.27 kcal/mol, a lower value   
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Figure 2.10.  ITC titration of DPA200 into the duplex poly(dA):poly(rU) 20 oC (a) and 10 oC (b).   Control titration was 
carried out with drug into buffer solution alone (c) and (d).   The sample titration was conducted at a concentration of 100 
µM/bp; DPA200 concentration was 60 µM.   In the profile, the upper panels show the heat burst curves of 10 µL injection of 
DPA200 into a sample containing the DNA:RNA hybrid.  The corrected injection heats shown in the sample titrations were 
derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution heat from control 
titration.  The data points reflect the experimental injection heats.   The average value was calculated as the binding enthalpy.   
Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
78 
 
than observed with poly(rA):poly(dT) which correlates with previous DNA:RNA hybrid 
stability reports (31). 
Table 2.4.  Thermodynamic profile of DNA:RNA hybrids interaction with 
neomycin, ethidium bromide and DPA200.    
po
ly
(d
A
):p
o
ly
(rU
) 
 neomycin  ethidium bromide DPA200 
∆Hwc (kcal/mol)
a 5.27 5.27 5.27 
Tm0 (
oC)b 48.9 48.9 48.9 
Tm (
oC)b 64.2 50.3 70.9 
nc 6.0 4.4 9.6 
L (µM) 1.7 2.3 1.1 
∆H(10 oC)(kcal/mol)
d -2.14±0.07 -7.34±0.07 -11.18±0.11 
∆H(20 oC)(kcal/mol)
d -6.70±0.06 -7.69±0.03 -16.19±0.11 
∆Hd (10 oC)(kcal/mol)
d
 -0.96±0.10 -1.33±0.05 -1.24±0.04 
∆Hd (20 oC)(kcal/mol)
d
 -0.71±0.10 -1.11±0.07 -0.74±0.08 
∆Cp (cal/mol•K)e -427±14 -35±13 -501±22 
po
ly
(rA
):p
o
ly
(d
T)
 
 neomycin ethidium bromide DPA200 
∆Hwc (kcal/mol)
a 9.21 9.21 9.21 
Tm0 (
oC)b 63.8 63.8 63.8 
Tm (
oC)b 68.6 66.4 70.3 
nc 8.1 4.2 6.5 
L (µM) 1.2 2.4 1.5 
∆H(10oC)(kcal/mol)
d -2.48±0.02 -6.51±0.02 -7.76±0.10 
∆H(20 oC)(kcal/mol)
d -3.94±0.11 -7.49±0.02 -12.29±0.07 
∆Hd(10oC)(kcal/mol)
d -0.38±0.07 -1.32±0.30 -1.32±0.07 
∆Hd(20 oC)(kcal/mol)
d -0.16±0.07 -1.14±0.20 -0.80±0.05 
∆Cp (cal/mol•K)e -146±13 -97.6±4 -453±17 
aData obtained from DSC melting profiles.  bData obtained from CD and UV 
thermal denaturation profiles.  cData obtained from titrations, as outlined in 
text.  d∆H is corrected binding heat, derived by integration of heat burst curve 
from the sample tititration, followed by subtraction of the dilution head from 
the control titration.  e∆Cp and fbinding affinities as defined in text.  Buffer:  
10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
 
Enthalpy values (∆H) were determined using excess site ITC titrations.  Excess 
site ITC titrations were conducted at 20 oC and 10 oC.  In a typical experiment, ligands 
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were titrated into a DNA:RNA hybrid duplex.  Experimentally binding enthalpies were 
determined by the integration of the corresponding heat burst curves.  The corrected 
binding enthalpies, ∆H(10 oC) and ∆H(20 oC),  were determined following the subtraction of 
the dilution enthalpy from the binding enthalpy.  Dilution enthalpies, ∆Hd(10 oC) and 
∆Hd(20 oC), for each ligand were determined through integration of the heat burst curves 
following the titration of ligands into buffer at 20 oC and 10 oC, Figure 2.10, Appendix 
A, Figure A16 –Figure A20.  Corrected binding enthalpies and dilution enthalpies for 
the interactions of neomycin, ethidium bromide and DPA200 with poly(rA):poly(dT) and 
poly(dA):poly(rU) are located in Table 2.4.   
Corrected binding enthalpies were used to calculate the observed change in heat 
capacity, ∆Cp.  Equation 1 (88):   
 
∆   ∆H∆T Equation 1 
 
The observed change in heat capacity for the interactions of neomycin and ethidium 
bromide with poly(rA):poly(dT) were -146+13 cal mol-1 K-1 and -97.6+4 cal mol-1 K-1,  
respectively.  The observed heat capacity change for the interaction of DPA200 and 
poly(rA):poly(dT) was -453+22 cal mol-1 K-1.  The observed change in heat capacity for 
the interaction of poly(dA):poly(rU) with neomycin and ethidium bromide were -427+14 
cal mol-1 K-1 and -35+13 cal mol-1 K-1 while the interaction with DPA200 was -501+22 
cal mol-1 K-1.   
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 The design of small synthetic organic molecules is highly dependent on structure-
based principles.  A strong case can be made for the importance of the energetics on 
ligand-nucleic acid interactions (89, 90, 91).  Parsing the energetics of a ligand-nucleic 
acid interaction provides a quantitative detail of the molecular forces that contribute to a 
binding interaction (92).  Observed heat capacity changes, ∆Cp values, are an integral 
component of interaction energetics (93).   
 Observed heat capacity changes, for ligand-macromolecule interactions, can be 
impacted by the following factors.  (i) The hydrophobic effect, which arises from the 
isolation of highly ordered pockets of water molecules surrounded by nonpolar surface 
area burial upon binding of ligand to nucleic acid, is a significant contributor to observed 
heat capacity changes (78, 94, 95, 96). (ii) Changes in electrostatic charge equilibrium 
have been shown to decrease ∆Cp values in aqueous media (93, 97, 98).   However, it has 
been suggested that electrostatic charge equilibrium is not a major contributor to ∆Cp 
values as it is highly unlikely that ligand binding induces significant changes within the 
distribution of exposed electrostatic charges (99).  (iii) Alterations of the internal degrees 
of freedom, ‘soft’ internal vibrational modes, at the polar interface between ligand and 
nucleic acid have been cited as potential sources for ∆Cp values (93, 100, 101).  (iv) 
Finally, changes in equilibrium, defined as a shift between two or more states, contribute 
to changes in ∆Cp values.  Changes in equilibrium can include conformational changes to 
the macromolecule host (92, 92, 93, 101, 102) as well as protonation reactions upon 
ligand binding (103, 104, 105).   
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 Heat capacity changes, upon intercalative binding events, are well studied (92, 
106, 107).  Baldini and Varani suggest the contributions to the binding free energy arise 
from distortion to the DNA at the intercalation site, conformational changes to the 
intercalator upon complexation with the DNA, intramolecular stacking forces, long range 
electrostatic interactions between the intercalator and DNA and intercalator-solvent 
interactions (107).  ∆Cp values associated with ethidium bromide represent the delicate 
balance between the energetic cost of deforming the helical base pairs, necessary for 
forming the intercalation site, and the reduction in translational and rotational freedom of 
ethidium bromide upon binding (92).  ∆Cp values the binding of ethidium bromide has 
been reported as low as 10 cal mol-1 K-1 when complexed with calf thymus DNA (106), 
and -57 cal mol-1 K-1 when complexed with chromatin (108).  Generally, ∆Cp values for 
ethidium bromide-nucleic acid interaction have been reported around -125+40 cal mol-1 
K-1 (92, 107, 109).  Our observed ∆Cp values for ethidium bromide interaction with 
poly(rA):poly(dT) and poly(dA):poly(rU) are consistent with previously reported values.   
  Aminoglycoside-nucleic acid interactions require special consideration.  Groove 
binders exhibit negative ∆Cp values, a result attributed to the displacement of large 
amounts of nonpolar surface area (95, 110).  However, Barbieri and co-workers suggest 
aminoglycosides do not disrupt the spine of hydration (101), even at pH 5.5, and the 
observed negative ∆Cp value is unrelated to change in solvent accessible areas.  
Perturbations to helical structure through disruption of adenine base stacking has been 
observed upon aminoglycoside binding to the A-site and is the main contributor to 
observed negative ∆Cp values (100, 101).  Experiments, to this point, have been 
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conducted at pH 6.8 which is advantageous since the conformations and melting enthalpy 
adopted by the nucleic acids as well as the aminoglycoside binding site size and 
stabilization reflect real biophysical conditions.  Unfortunately, neomycin amino group 
pKa values range from 5.6 to 9.5 (105, 111).  Therefore, neomycin-nucleic acid 
interactions studied at pH values larger than 5.6 include an inherent contribution from 
binding linked protonation.  Binding-linked protonation leads to an increase in observed 
binding enthalpy (32).     
 While the heat capacity associated with the interaction of DPA200 and 
DNA:RNA hybrids,  poly(rA):poly(dT) and poly(dA):poly(rU), includes a dependence 
on drug protonation upon binding, it is clear that the conjugate possesses contributions 
from both the major groove binding and intercalative moieties.  The heat capacity 
associated with the interaction of DPA200 and poly(dA):poly(rU) was -501+14 cal mol-1 
K-1, slightly higher in magnitude than the sum of the neomycin (427+14 cal mol-1 K-1) 
and ethidium bromide (-35+13 cal mol-1 K-1).  The heat capacity associated with the 
interaction of DPA200 and poly(rA):poly(dT) (-453+17 cal mol-1 K-1) was significantly 
higher than the contributions from neomycin (-146+13 cal mol-1 K-1) and ethidium 
bromide (-97.6+4 cal mol-1 K-1).   
 While the thermodynamic profile for the interaction of ligands (neomycin, 
ethidium bromide and DPA200) with DNA:RNA hybrids (poly(rA):poly(dT) and 
poly(dA):poly(rU)), derived at pH 6.8 closely resemble physiological conditions, the 
intrinsic thermodynamic profile, free of the dependence on binding linked protonation 
remains to be determined.  To this end, intrinsic thermodynamic profiles for the ligands 
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with the following duplexs (poly(dA-dT)2, poly(rA):poly(rU) and poly(dA):poly(rU) 
were calculated at pH 5.5.  Furthermore, as parameters calculated at pH 5.5 represent the 
intrinsic binding parameters, binding affinities (KT) were able to be calculated.    
 
Binding Constant Determination – The ∆Tm Method.  The apparent ligand-DNA:RNA 
hybrid association constants were estimated using the following equations.  The change 
in melting temperature of the nucleic acid in the absence and presence of drug was used 
to estimate the association constant, KTm, Equation 2 (112):   
 
1
T	
 
1
T	   

n∆H ln 1   Equation 2 
 
In equation 1, the terms Tm0 and Tm represent the melting temperatures of the nucleic acid 
without ligand and at ligand saturation.  The number of drug molecules bound per duplex, 
n, was determined by CD monitored and fluorescence monitored titrations of ligand into 
duplex.  Watson-Crick duplex enthalpy, ∆Hwc, was determined by differential scanning 
calorimetry, DSC.  The free drug concentration at the melting temperature, L, was 
estimated at one-half the total drug concentration, Equation 3.  The terms in equation 
two are defined as follow; x is the concentration of nucleic acid (20 µM) and n represents 
the number of drug molecules per duplex, as previously discussed:   
 
  n 0.5 Equation 3 
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Table 2.5.  Thermodynamic profile of nucleic acid interactions with neomycin and 
ethidium bromide and DPA200.    
po
ly
(d
A
):p
o
ly
(rU
) 
 neomycin ethidium bromide DPA200 
∆Hwc (kcal/mol)
a 3.84 3.84 3.84 
Tm0 (
oC)b 43.0 43.0 43.0 
Tm (
oC)b 65.8 61.8 90.5 
nc (L, µM) 6.5 (1.5) 4.6 (2.2) 9.7 (1.0) 
∆H(15 oC)(kcal/mol)
d 3.60+0.08 -5.57+0.05 4.44+ 0.03 
∆H(20 oC)(kcal/mol)
d 2.73+0.08 -6.26+0.04 1.90+0.05 
∆H (25 oC)(kcal/mol)
d 2.10+0.06 -6.69+0.04 1.05+0.02 
∆Cp (cal/mol•K)e -150+13 -93+7 -339+16 
KT(20 oC)(M
-1) f (9.93+0.10)x106 (9.38+0.04)x106 (4.77+0.13)x1010 
 
po
ly
(rA
):p
o
ly
(rU
) 
 neomycin ethidium bromide DPA200 
∆Hwc (kcal/mol)
a 6.34 6.34 6.34 
Tm0 (
oC)b 53.4 53.4 53.4 
Tm (
oC)b 64.7 64.2 77.0 
nc (L, µM) 8.0 (1.3) 2.5 (4.0) 9.6 (1.0) 
∆H(15 oC)(kcal/mol)
d 1.76+0.06 -5.84+0.05 3.31+0.04 
∆H(20 oC)(kcal/mol)
d 0.68+0.05 -6.18+0.10 1.89+0.07 
∆H (25 oC)(kcal/mol)
d -0.47+0.08 -6.47+0.04 0.75+0.04 
∆Cp (cal/mol•K)e -223+11 -93+7 -256+9 
KT(20 oC)(M
-1) f (2.56+0.14)x107 (9.98+0.10)x106 (2.14+0.15)x109 
 
po
ly
(d
A
-
dT
):p
o
ly
(d
A
-
dT
)  neomycin ethidium bromide DPA200 
∆Hwc (kcal/mol)
a 315.15 3.90 3.90 
Tm0 (
oC)b 62.4 62.4 62.4 
Tm (
oC)b 62.9 63.2 66.2 
nc (L, µM) 7.3 (1.4) 5.3 (1.9) 9.1 (1.1) 
∆H(15 oC)(kcal/mol)
d -1.10+0.10 -3.71+0.04 1.21+0.06 
∆H(20 oC)(kcal/mol)
d -1.18+0.09 -4.54+0.04 0.76+0.06 
∆H (25 oC)(kcal/mol)
d -1.30+0.08 -5.10+0.02 0.17+0.09 
∆Cp (cal/mol•K)e -29+16 -139+6 -104+12 
KT(20 oC)(M
-1) f (7.01+0.44)x104 (1.97+0.05)x105 (1.04+0.07)x106 
aData obtained from DSC melting profiles.  bData obtained from CD and UV thermal 
denaturation profiles.  cData obtained from titrations, as outlined in text.  d∆H is 
corrected binding heat, derived by integration of heat burst curve from the sample 
tititration, followed by subtraction of the dilution head from the control titration.  
e∆Cp and fbinding affinities as defined in text.   Buffer:  10 mM sodium cacodylate, 
0.5 mM EDTA, pH 5.5, 100 mM NaCl. 
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 (a) (b) 
  
(c) (d) 
  
(e) (f) 
  
Figure 2.11.  Fluorescence emission scans of the titration of DPA200 with various 
nucleic acids at 20 oC.  A plot of fluorescence intensity at 594 nm vs rbd values for each 
respective nucleic acids are located in panels (b), (d) and (f).  A plot of fluorescence 
intensity at 594 with respect to rbd was plotted, rbd is the ratio of [base pair]/[drug].  
DPA200 was titrated into the nucleic acids [1.0 µM/bp], poly(dA):poly(rU) (a), 
poly(rA):poly(rU) (c) and poly(dA-dT)2 (e), at various rbd values.  Excitation:  525 nm; 
emission:  550 – 700 nm; slits:  1.5 mm.   Buffer:  10 mM sodium cacodylate, 0.5 mM 
EDTA, pH 5.5, 100 mM NaCl.   
 
0
0.2
0.4
0.6
0.8
1
550 600 650 700
Wavelength (nm)
-0.2
0
0.2
0.4
0.6
0.8
1
2 4 6 8 10 12
r
bd
9.7
0
2 104
4 104
6 104
8 104
1 105
550 600 650 700
Wavelength (nm)
0
0.2
0.4
0.6
0.8
1
0 5 10 15 20
r
bd
9.6
0
2 104
4 104
6 104
8 104
1 105
1.2 105
550 600 650 700
Wavelength (nm)
0
0.2
0.4
0.6
0.8
1
5 10 15 20
r
bd
9.1
86 
 
The binding constant at the melting temperature, KTm, was calculated.  The 
binding constant at Tm was extrapolated to a reference temperature (T) of 20 oC using the 
integrated van’t Hoff equation, Equation 4 (113): 
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Equation 4 
 
where, ∆Hobs is the observed binding enthalpy, at 20 
oC, of ligand to the nucleic acid 
which is determined experimentally using ITC excess site titrations and R is the gas 
constant. 
 The saturation point, defined as the drug molecules per duplex, n, was determined 
using CD (neomycin) and fluorescence (ethidium bromide and DPA200), Table 2.5.  CD 
titrations were successful in the determination of the n value for neomycin 
withpoly(dA):poly(rU), poly(rA):poly(dT) and poly(dA-dT)2 of 6.5 base pairs/ligand, 8.0 
base pairs/ligand and 7.3 base pairs/ligand, respectively, Appendix A, Figure A21.  
Fluorescence titrations of poly(dA):poly(rU) with ethidium bromide suggest a 
binding site size of 4.6 base pairs/ ligand and the titration of ethidium bromide into 
poly(rA):poly(rU) and poly(dA-dT)2 were determined to be 2.5 base pairs/ligand and 5.3 
base pairs/ligand, Appendix A, Figure A22.  Finally, fluorescence determined binding 
site sizes for DPA200 interaction with poly(dA):poly(rU), poly(rA):poly(rU) and 
poly(dA-dT)2 were 9.7 base pairs/ligand, 9.6 base pairs/ligand and 9.1 base pairs/ligand, 
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respectively, Figure 2.11.  These values were confirmed with CD titrations, Appendix 
A, Figure A23.   
  (a) (b) 
  
(c) (d) 
  
Figure 2.12.  UV thermal denaturation profiles of poly(dA):poly(rU) (a), poly(dA-dT)2 
(b) and poly(rA):poly(rU) (c, d).  The panels represent the duplex (A) with neomycin (B), 
ethidium bromide (C) and NM (D) at saturation.  poly(dA):poly(rU):  neomycin (rbd = 
6.5), ethidium bromide (rbd = 4.6) and NM (rbd = 9.7).  poly(rA):poly(rU):  neomycin (rbd 
= 8.0), ethidium bromide (rbd = 2.5) and NM (rbd = 9.6); poly(dA):poly(dT):  neomycin (r-
bd = 7.3), ethidium bromide (rbd = 5.3) and NM (rbd = 9.1).   Ligands were added to the 
duplxes [20 µM/bp] at varying rbd (ratio of drug:base pairs) values.   The samples were 
incubated at 4 oC for 12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 
oC/min.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl.  
 
Thermal stabilization experiments, at pH 5.5 and 100 mM NaCl, were expanded 
to include the DNA duplex – poly(dA-dT)2 and the RNA duplex – poly(rA):poly(rU), 
Table 2.5, Figure 2.12.  The poly(rA):poly(rU) – DPA200 complex melting temperature 
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was  23.6 oC higher than the melting temperature of the duplex in the absence of ligand 
Figure 2.12.  Melting temperatures of the poly(rA):poly(rU) complexes with neomycin 
and ethidium bromide were 11.3 oC and 10.8 oC, higher than the native duplex melting 
temperature, respectively.  The melting profile of the poly(rA):poly(rU) – neomycin 
complex showed a clear decrease in UV absorbance at 280 nm followed by an increase in 
UV absorbance upon increasing temperatures.   
An equimolar mixture of poly(rA) and poly(rU) not only has the ability to form 
the duplex, poly(rA):poly(rU); this mixture can also form the poly(rA):2poly(rU) triplex 
at highertemperatures (114) or in the presence of magnesium ions (115).  In fact, it has 
been suggested that the formation of poly(rA):2poly(rU) in an equimolar mixture of 
poly(rA) and poly(rU) is an artifact of poly(rA):poly(rU) formation and disappears very 
slowly in ~72 hours at 200 mM sodium concentrations (116).  As seen in Figure 2.12, 
panel (d), in the poly(rA):poly(rU) – neomycin complex disproportionates into a three 
stranded sequence poly(rA):2poly(rU) and single stranded poly(rA), evidenced by the 
gradual decrease in absorbance upon increasing temperature.  The triplex then denatures 
directly from the triplex to the single stranded poly(rA) and poly(rU), as observed in the 
increase in absorbance beginning at 75 oC.   Literature precedent establishes the mid-
point of this transition as the melting temperature of poly(rA):poly(rU) (114, 117).   
Melting temperatures of the poly(dA-dT)2 – ligand complexes were not 
significantly higher than the native DNA duplex melting temperature in the absence of 
ligands.  The melting temperature of the poly(dA-dT)2 – neomycin complex was 0.5 
oC 
higher than the native duplex melting temperature.  The melting temperature of the 
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poly(dA-dT)2 – ethidium bromide complex was 0.8 
oC.  However, the complex between 
the DNA duplex and DPA200 afforded a higher melting temperature (3.8 oC) of the 
native duplex, Table 2.5.   
∆Hwc, Watson-Crick duplex enthalpy, determined using DSC thermal 
denaturation experiments.  Watson-Crick binding enthalpy was 3.84 kcal/mol for 
poly(dA):poly(rU), 6.34 kcal/mol for poly(rA):poly(rU) and 3.90 kcal/mol for poly(dA-
dT)2, Table 2.5, Appendix A, Figure A24.  L, the free drug concentration at Tm, 
estimated at one-half the total drug concentration, was calculated from UV thermal 
denaturation experiments; see Equation 4, as previously discussed, Table 2.5.    
 As in pH 6.8 experiments, enthalpy values (∆H) were determined using binding 
enthalpies from excess site ITC titrations.  In an effort to attain more accurate ∆Cp values, 
∆H values were calculated at three temperatures 15 oC, 20 oC and 25 oC.   .  The corrected 
binding enthalpies, ∆H(15 oC), ∆H(20 oC), and ∆H(25 oC),  were determined following the 
subtraction of the dilution enthalpy from the binding enthalpy.  Dilution enthalpies were 
calculated as previously discussed, Appendix A, Figure A25 – Figure A27, Table 2.5.  
∆H values from the excesses site ITC titrations were used to calculate ∆Cp values, 
Equation 1.   ∆Cp values for neomycin interaction with poly(dA):poly(rU) was 
calculated at -168 cal/mol K-1.  ∆Cp values for the interaction of neomycin with 
poly(rA):poly(rU) was more negative at -224 cal/mol K-1 while the interaction with 
poly(dA-dT)2 was far more positive than the other duplexes at -29 cal/mol K
-1, consistent 
with previously reported results (53, 118).  Furthermore, when comparing the ∆Cp values 
determined at pH 6.8 and the value determined at pH 5.5,  the magnitude of heat capacity 
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changes are consistent as binding-linked protonation leads to an increase in observed 
binding enthalpy (32).   
∆Cp values for the interaction of ethidium bromide with the nucleic acid duplexes 
were -112 cal/mol K-1 (poly(dA):poly(rU)), -90 cal/mol K-1 (poly(rA):poly(rU)) and -139 
cal/mol K-1 (poly(dA-dT)2).  The interaction of DPA200 with poly(dA):poly(rU) 
displayed the lowest ∆Cp value at -339 cal/mol K-1.  The ∆Cp values for the interaction of 
DPA200 with poly(rA):poly(rU) was more positive than the DNA:RNA hybrid duplex, -
256 cal/mol K-1, while the interaction with poly(dA-dT)2 was significantly more positive, 
-104 cal/mol K-1.  As observed at pH 6.8, ∆Cp values for the interaction between the 
ligands and poly(dA):poly(rU) suggest strong contributions from both the intercalative 
and major groove binding moieties.  The ∆Cp value for the interaction of DPA200 with 
poly(dA):poly(rU) and is larger than the sum of the contributions from neomycin and 
ethidium bromide.   
 ∆Cp values were used to calculate binding affinities (KT) for the interactions of 
neomycin, ethidium bromide and DPA200 with poly(dA):poly(rU), poly(rA):poly(rU) 
and poly(dA-dT)2, Table 2.5.  The binding affinity for the interaction of DPA200 and 
poly(dA):poly(rU) was 4.77 x 1010 M-1; this was five-fold higher than observed with 
neomycin or ethidium bromide, 9.93 x 106 M-1 and 9.38 x 106 M-1, respectively.    The 
binding affinity for the interaction of DPA200 and poly(rA):poly(rU), , was around ten-
fold lower than poly(dA):poly(rU).  The binding affinity for the interaction of neomycin 
and poly(rA):poly(rU) was higher, 2.56 x 107 M-1, than observed for the interaction with 
poly(dA):poly(rU).  The affinity of ethidium bromide for poly(dA):poly(rU) was similar 
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to the affinity of ethidium bromide for poly(dA):poly(rU).  In an effort to compare the 
affinity of DPA200 to other nucleic acid structures, KT values were calculated for both 
the RNA and DNA duplexes, Table 2.5.  The conjugate binds the DNA duplex poly(dA-
dT)2 with an affinity of 1.04 x 10
6 M-1 and the RNA duplex poly(rA):poly(rU) with an 
affinity of 2.14 x 109 M-1.  The affinity for the RNA duplex, by DPA200, is higher than 
both neomycin (2.56 x 107 M-1) and ethidium bromide (9.98 x 106 M-1).  The conjugate, 
when binding the duplex DNA, displays an increased affinity over neomycin, 7.01 x 104 
M-1, a duplex which is bound by ethidium bromide at 1.97 x 105 M-1.  Compound 
DPA200 clearly displays the power of conjugation and expansion of aminoglycoside 
based binding to non-traditional targets. In fact, not only does the conjugate bind non-
traditional target, poly(dA):poly(rU), the affinity for this duplex is higher than neomycin 
binding the 16S A-site RNA (9.1x108 M-1) (57).   
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CONCLUSIONS 
The data shown in chapter two illustrates the power of conjugating two ligands 
that bind to a receptor at different sites.  Conjugation of neomycin, a major groove 
binding ligand, to methidium chloride, a deriviative of ethidium bromide affords a 
conjugate which displays a clear preference for the DNA:RNA hybrid, 
poly(dA):poly(rU).  Competition dialysis results were confirmed by UV thermal 
denaturation experiments on a representative class of nucleic acids.  DPA200 preference 
for poly(dA):poly(rU) was corraborated by the magnitude of thermal stabilization 
afforded by the conjugate on poly(dA):poly(rU); larger than stabilization observed by 
DPA200 on other nucleic acids.  In fact, a synergistic combination of the two techniques, 
competition melting, further illustrates the binding preference, as poly(dA):poly(rU) was 
the only nucleic acid stabilized by DPA200 in low micro molar amounts.   
UV thermal denaturation studies of our conjugate clearly show DPA200 is a more 
powerful tool when binding nucleic acids than the individual constituent parts.  When 
binding poly(dA):poly(rU), neomycin stabilizes the duplex by 24.9 oC, ethidium bromide 
binds the duplex by 20.8 oC, while DPA200 affords an amazing 44.9 oC, see text for 
buffer conditions.  This observation even holds true when binding nucleic acids in which 
DPA200 displays a lower observed preference for, poly(rA):poly(dT) and poly(dA-dT)2.   
Finally, due to the high affinity our conjugate displays for poly(dA):poly(rU), we 
were unable to use traditional methods (ITC titrations or fluorescence titrations) of 
binding constant determination.  Using the ∆Tm method for binding constant 
determination allowed us to compare the affinity of DPA200 to neomycin and ethidium 
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bromide when binding poly(dA):poly(rU) and poly(rA):poly(dT).  Even though the 
studies, reported within, were conducted at pH 6.8 and subsequent binding affinities were 
intrinsically overestimated, it was clear that the affinity of DPA200 for either DNA:RNA 
hybrid was higher than neomycin or ethidium bromide.  By parsing the binding affinity 
from effects of drug protonation the true power of conjugate was resolved.    
When binding DNA:RNA hybrids, neomycin binds to the hybrid duplex with high 
106 M-1 affinity, while ethidium bromide also binds the hybrid duplex with high 106 M-1.  
The conjugate, DPA200, shows a 100,000 fold improvement, with an affinity of 4.77 x 
1010 M-1.  Even though the conjugate does not display the energetic additivity estimated 
from the individual binding moieties, the sub-nanomolar binding affinity remains very 
significant and far exceeds the affinities of any known DNA:RNA binding drugs.   
The conjugate reflects the first example of an aminoglycoside ligand that binds to 
a nucleic acid target with affinities higher than the nanomolar affinities shown for the 
eubacterial A-site.  The work will provide a novel paradigm for aminoglycoside-based 
recognition of DNA:RNA hybrid structures with therapeutic applications (telomerase and 
RNAse H inhibitors).  A recent report cites a critical need for development of such high 
affinity DNA:RNA binders (119).   
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CHAPTER III 
 
ADVANCEMENTS IN DNA RECOGNITION: DEVELOPMENT OF  
A TETRAMER POLYAMIDE – NEOMYCIN CONJUGATE LIBRARY 
 
INTRODUCTION 
DNA is the carrier of genetic information and the dominant nucleic acid structure 
in organisms.  DNA is subject to a number of biological processes such as translation and 
transcription.  Ultimately, the genetic information stored in DNA leads to cellular growth.  
Friedrich Miescher isolated DNA from the nuclei of human blood cells in the late 1860s 
(1).  Following the seminal report which proposed the double helical nature of DNA (2), 
reports on the polymorphic nature of DNA began appearing.  Unlike DNA’s nucleic acid 
counterpart RNA, which exists as an A-form conformation with slight variations, DNA is 
capable of existing in three distinct conformational forms (3).  Two of the representative 
forms, A-form and B-form conformation, are both right-handed helixes (4) while a third 
conformation, Z-form, exists as a left-handed helix (5).  Our work focuses on the right-
hand helical forms of DNA, A-form and B-form.   
A-form and B-form DNA share conformational similarities.  Both conformations 
feature a double helix formed by two single strands of DNA that are oriented anti-parallel 
to each other.  Each strand features 2’-deoxy ribose sugars linked by a phosphate group 
which encircles the central core of hydrogen bonded base pairs.  In DNA the pyrimidine 
bases (thymine and cytosine) and the purine bases (adenine and guanine) are hydrogen 
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bonded as defined by Watson and Crick (2).  The topologies are both identical with each 
conformation featuring a major and minor groove (6).   
However, differences between the two conformations are observed in the overall 
shape of the helix.  B-form DNA is believed to be the dominant biological conformation 
and utilizes well order water molecules and biological cations to form a hydrated duplex.  
B-form DNA contains furanose conformations in a C2’-endo conformation and features 
10 base pairs per helical turn, a major groove which is wide and shallow and a minor 
groove which is narrow and deep.  Furthermore, B-form DNA is conformationally 
flexible and features numerous polymorphs defined by B-, B’-, C-, C’-, C”-, D- and E 
(3).  In contrast, A-form DNA is conformationally rigid.  Generally associated with a 
dehydrated form of the duplex, A-form DNA is characterized by 12 – 14 base pairs per 
helical turn, which is a result of the smaller axial rise per residue, 2.5 Å, than observed in 
B-form DNA, 3.4 Å.  This, in turn, affords a helix with a major groove that is more 
narrow and deeper and a minor groove that is wider and shallower that the B-form 
counterpart.  In some cases A-form DNA has been crystallized with furanose sugar 
puckers in a C3’-endo conformation (7).  However, as DNA is polymorphic, it is 
important to note that DNA sugar pucker may exist not only in C3’-endo/C2’-endo 
extremes, but also anywhere within those pseudorotational extremes.   
A number of literature reports suggest a strong correlation between DNA 
sequence and localized conformation.   DNAs of like composition but vary in the 
sequences of bases have been shown to exhibit drastically different structural properties 
(8).  For instance, poly(dA):poly(dT) is generally accepted as a B-form helix at high 
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humidity (9), while poly(dG):poly(dC) demonstrates strong A-form characteristics (10).  
Even when breaking homo-pyrimidine and homo-purine strands with alternating bases, 
poly(dA-dT)2 and poly(dG-dC)2, the duplexes remain conformationally distinct.  
Poly(dA-dT)2 is highly dependent on relative humidity (9, 11) and is capable of existing 
between B-form and a ‘metastable A-form’ (3).  Poly(dG-dC)2, on the other hand, is 
exclusively A-form, even at high humidity (9).   
Isolation of purine bases and pyrimidine bases to a single strand uniquely affects 
DNA conformation.  Poly(dA-dG):poly(dC-dT) exists primarily in B-form unable to 
undergo the B-form to A-form transition, while poly(dA-dC):poly(dG-dT) is capable of 
existing in a number of conformations such as A-form, B-form and even the left handed 
Z-form (12)).  Furthermore, even though mixed base sequence DNA displays 
predominant B-form characteristics, the ability to drive the conformation of these 
duplexes to A-form, through dehydration, becomes increasingly difficult as the 
proportion of G/C content in the helix drops below 30% (13).  It is important to note, 
although these sequence dependent conformations are present, these conformational 
differences are localized and generally do little to influence the overall structure of 
natural occurring DNAs (14)(13)(13)(14)). 
The biological significance for targeting A-form DNA is dependent on the 
relationship between native DNA and the basic mechanisms involved in the flow of 
genetic information.  A strong argument has been made that suggests our current DNA 
based world was preceded by life based on A-form RNA (15).  As such, the mechanisms 
required to copy genetic information most likely proceed through A-form nucleic acids.  
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For example, transcription of RNA to DNA occurs through DNA:RNA hybrids which are 
A-form (16, 17).  And a case can be made that a transition from native B-form DNA to 
A-form DNA occurs during protein – DNA interactions.  The cyclic AMP receptor 
protein induces a B-form to A-form transition in its DNA target (5).   
Furthermore, template DNA is induced to A-form upon the binding of many 
polymerases (18).  Proteins which induce A-form include HIV-1 reverse transcriptase 
(19, 20, 21), polymerase β (22), Taq polymerase (23), Bacillus polymerase I (24), T7 
polymerase (25), DNAse I (26, 27), I-PpoI homing endonuclease (28), PvuII restriction 
endonuclease (29, 30), EcoRV endonuclease (31), HhaI methyltransferase (32) and the 
chromosomal protein Sac7d (33).  It has been suggested that induction of A-form 
facilitates protein binding an as much the shallower minor groove of A-form exposes 
functional groups.  These functional groups, such as the O2 of pyrimidines and the N3 of 
purines, are essential in DNA recognition (6).  Thus, the induction of A-form is a 
necessary requirement influencing replication and transcription of genomic DNA.   
 Currently, we seek an aminoglycoside based approach to nucleic acid recognition.  
Implications of this approach include advancements in the area of drug development as 
well as a deepened understanding of the requirements for nucleic acid recognition.  Our 
group has already identified a number of novel aminoglycoside conjugates for the 
recognition of A-form nucleic acids.  Through the covalent attachment of neomycin to 
pyrene (34), BQQ (35) and methidium chloride (16, 36) we achieved increased affinity to 
a number of A-form nucleic acid structures.   
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At this time, we desire to increase the number of molecules which bind A-form 
DNA.  Unlike B-form recognition, there are very few ligands which select for A-form 
characteristics (5, 18).  We have previously demonstrated the ability to target B-form 
DNA through novel Hoechst 33258 – neomycin conjugates (37, 38).  Covalent 
attachment of neomycin, a major groove binder, to Hoechst 33258, a minor groove 
binder, yielded conjugates capable of significantly enhancing the thermal stability of B-
form DNA through dual recognition.  Using this approach as a paradigm for A-form 
recognition we envision the development of a library of N-methylpyrrole and N-
methylimidazole based polyamide – neomycin conjugates which target A-form DNA.   
Aminoglycoside antibiotics are carbohydrate scaffolds composed of amino sugars 
covalently linked to a central hexose ring.  Streptomycin, an aminoglycoside isolated in 
1944 (39), introduced the world to aminoglycosides and was the first antibiotic effective 
against tuberculosis.  An additional number of streptamine relatives were introduced 
which gave rise to the streptomycin family of antibiotics (6).  Aminoglycoside 
development during the subsequent 20 years focused on the following two areas: 
increasing population of the aminoglycoside class of molecules and deciphering 
aminoglycoside mode of action.   
Second generation aminoglycosides included the 2-deoxystreptamine (DOS) 
family of aminoglycosides, neomycin, neamine, kanamycin A, kanamycin B and 
paromomycin.  Development in understanding aminoglycoside mode of action identified 
protein synthesis as the primary target for the antibacterial action displayed by 
streptomycin (40, 41, 42).  Further studies demonstrated the 30S subunit of ribosomal 
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RNA (rRNA) was the natural target of streptomycin (42).  Binding of aminoglycosides to 
the 30S subunit of rRNA induces a loss of fidelity during translation (40, 41) and occurs 
through electrostatic forces (43, 44, 45).   
Since the 1990s, aminoglycoside antibiotic research has seen resurgence.  A 
major aspect to this revival focused on exploiting the flexible scaffold of polycationic 
charges found on aminoglycosides to bind a number of traditional (RNA) and non-
traditional nucleic acid structures.  To this end, reports have shown the ability of 
aminoglycosides to preferentially bind a number of other RNA targets such as group I 
introns, a hammerhead ribozyme, the RRE transcriptional activator region from HIV, the 
5’-untranslated region of thymidylate synthase a variety of RNA aptamers from in vitro 
selection and human mRNAs (45, 46, 47).  Furthermore, neomycin binding a large 
number of non-traditional nucleic acid targets which include the RNA triplex (48), 
DNA:RNA hybrid duplex (16, 36, 49), RNA duplex (50), DNA triplex (34, 35, 48, 51), 
A-form DNA duplex (52) as well as the DNA tetraplex (53) have been reported.  Our 
group suggests the ability to bind such a diverse group of nucleic acid structures lies in 
the ability of these nucleic acid structures to adopt A-form characteristics (3, 54, 55, 56).   
Lexitropsins are a sub-class of DNA minor groove binding ligands which 
specifically bind DNA sequences (57).  Naturally occurring lexitropsins distamycin A 
and netropsin consist of a polyamide scaffold of repeating pyrrole monomers (58, 59).  
Considerable scholastic attention has been paid to DNA binding by netropsin and 
distamycin A.  Netropsin and distamycin A bind DNA in a sequence-specific manner (57, 
60, 61).  They bind through hydrogen bonds with minor groove base functionalities.  For 
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example, when disatamycin A binds A/T rich DNA, the polyamide carboxyamides 
hydrogen donor groups interact directly with adenine N3 and thymidine O2 acceptor 
groups, Figure 3.1 (62).   
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Figure 3.1.  Mode for antiparallel 2:1 distamycin A binding 5’-AAATT-3’. 
 
Furthermore, repulsion between the amino group on the 2-position on guanine and the 3-
position of the pyrrole monomers drive the sequence selectivity of netropsin and 
distamycin A (61).  Binding affinities for netropsin and distamycin A to A/T rich DNA 
are moderate at ~106 M-1 (63).  Furthermore, distamycin A forms a 2:1, distamycin 
A:DNA, complex in the minor groove where a second molecule aligns head-to-tail, 
antiparallel, with respect to the first distamycin A, Figure 3.1 (64).   
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Figure 3.2.  Mode for 1:1 HImImPyPyDp 18 binding 5’-TGGAAA-3’. 
 
Expanding the polyamide scaffold to include N-methylimidazole monomers 
affords differentiation of G/C base pairs from A/T base pairs (60, 65, 66, 67, 68, 69, 70).  
Replacement of the 3-position hydrogen with a hydrogen bond acceptor at the 3-position 
of imidazole overcomes repulsion between the amino group found on the 2-position of 
guanine and the 3-position of pyrrole (62, 71, 72, 73).  N-methylpyrrole and N-
methylimidazole based polyamides bind the minor groove of DNA through direct 
contacts with the center of each base pair, Figure 3.2 (74).   
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Figure 3.3.  Mode for antiparallel 2:1 HImImPyPyDp 18 binding 5’-TGGCCA-3’. 
 
In a 1:1 polyamide:DNA binding mode, a pyrrole monomer distinguishes A/T 
base pair from G/C base pairs, while an imidazole monomer distinguishes a G/C base 
pair from an A/T base pair, Figure 3.2 (75).  In a 2:1 polyamide:DNA binding mode, a 
pyrrole/imidazole pairing across the floor of the minor groove distinguishes a C/G base 
pair and an imidazole/pyrrole pairing distinguishes a G/C base pair.  A pyrrole/pyrrole 
pairing distinguishes and A/T or T/A base pairs from G/C or C/G base pairs, however the 
pyrrole/pyrrole pairing is incapable of distinguishing an A/T base pair from a T/A base 
pair, Figure 3.3 (62).  While the binding affinity for N-methylpyrrole and N-
methylimidazole based polyamides are sequence dependent, the affinity of 
HImImPyPyβDp for the target sequence 5’-TGGCCA-3’ was reported Ka of 2.4 x 107 M-
1 (76).   
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EXPERIMENTAL 
Materials: 
Nucleic Acids.  16 mer DNA oligomers, 5’-AnGmCmTn-3’ (where n = 2, 3, 4, 5 and 6; m 
= 6, 5, 4, 3 and 2), were purchased from Integrated DNA Technologies (Coralville, IA).  
Concentrations were determined by UV absorbance using extinction coefficients 
provided by IDT.  The self-complementary duplexes were pre-formed at 20 µM/duplex, 
by heating at 90 oC for 10 min, followed by slow annealing at 0.2 oC/min and incubation 
at 4 oC for 12 h.  Target DNA duplexes (target duplex 1 and target duplex 2) were 
purchased from Eurofins MWG Operon (Huntsville, AL).  Concentrations were 
determined by UV absorbance using extinction coefficients provided by Operon.  The 
duplexes were pre-formed at 20 µM/duplex, by heating at 90 oC for 10 min, followed by 
slow annealing at 0.2 oC/min and incubation at 4 oC for 12 h.   
 
Chemicals.  Neomycin B (sulfate salt) was purchased from ICN pharmaceuticals and 
used without further purification (both synthesis and binding experiments); reagents were 
purchased from Acros organics.  Solvents were purchased from VWR with the exception 
of pyridine, DMF and 1,4-dioxane which were purchased from Acros.  Reaction solvents 
were distilled accordingly; dichloromethane and pyridine were distilled over calcium 
hydride and ethanol was distilled over sodium metal.  All non-commercially available 
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intermediates were synthesized as previously reported: heterocyclic monomers (77) and 
neomycin derivatives (36, 37, 78, 79). 
 
Methods: 
UV Thermals Denaturation Experiments.  All experiments were conducted using a 
Cary 100E UV/Vis spectrophotometer (Varian Inc.; Palo Alto, CA) equipped with a 
thermoelectrically controlled 12-cell holder.  All samples were analyzed in quartz cells (1 
cm pathlength).  Lamp stability and wavelength alignment were checked prior to each 
experiment.  UV melting experiments for the denaturation of the 5’-AnGmCmTn-3’ 
duplexes, native and with neomycin, were conducted as follows.  The self-
complementary duplexes were pre-formed at 20 µM/duplex, by heating at 90 oC for 10 
min, followed by slow annealing at 0.2 oC/min and incubation at 4 oC for 12 h.  Samples 
were prepared by diluting the stock solutions to 2 µM/duplex.  Ligands were added and 
the solutions were incubated at 4 oC for 12 h.  Samples were degassed prior to analysis.  
The samples were slowly heated from 10 oC to 90 oC at 0.2 oC/min.  Buffer: 1.5 mM 
Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
 
CD Spectropolarimetry Titrations.  Circular dichroism (CD) experiments were 
conducted at 20 oC using a Jasco J-810 spectropolarimeter (Jasco Inc.; Easton, MD).  CD 
observed titration of ligands into the 5’-A6G2C2T6-3’ and 5’-A2G6C6T2-3’ duplexes were 
conducted as follows.  The self-complementary duplexes were pre-formed at 20 
mM/duplex by heating at 90 oC for 10 min, followed by a slow annealing at 0.2 oC/min 
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and incubation at 4 oC for 12 h.  The duplex was diluted to 40 mM/bp and ligands were 
added at varying rdd (ratio of drug:duplex) values. Buffer: 1.5 mM Na2HPO4, 0.5 mM 
NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl.   
 
Fluorescence Intercalator Displacement Assay.  96 well equilibrium binding 
experiments were conducted using a Varian Eclipse Fluorescence Spectrometer (Varian 
Inc.; Palo Alto, CA) equipped with a 96 well plate reader.  DNA duplexes were pre-
formed at 5 µM/duplex by heating at 90 oC for 10 min, followed by cooling to 10 oC at 
0.2 oC/min and incubation at 4 oC for 12 h.  Buffer was added to each well followed by 
ethidium bromide (7 µM).  DNA duplex was added to the individual wells such that the 
final concentration of DNA was 1 µM.  Ligands were added to each well at a ratio of 
drug to duplex, rdd = 1.0, allowed to equilibrate for 5 min and the subsequent decrease in 
fluorescence was recorded.  The data was normalized such that the well containing 
ethidium bromide and buffer was denoted as 0% fluorescence and the well containing 
buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  In the histogram, 
the values represent the percent decrease in fluorescence upon each addition of ligand.  
Fluorescence parameters; excitation: wavelength = 525 nm, slits = 20, filter = 335-620 nm; 
emission: wavelength = 550 nm; slits = 20, filter = 550-800 nm; PMTV = 610 nm.  Buffer: 
10 mM sodium cacodylate, 0.5 mM EDTA, 50 mM NaCl, pH 7.0.   
 
Fluorescence Intercalator Displacement Titrations.  Equilibrium binding experiments 
were conducted using a Varian Eclipse Fluorescence Spectrometer (Varian Inc.; Palo 
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Alto, CA) at 20 oC.  Duplexes were pre-formed at 20 mM/duplex by heating at 90 oC for 
10 min, followed by a slow annealing at 0.2 oC/min and incubation at 4 oC for 12 h.  The 
DNA duplex was diluted to 1.0 µM/duplex, pre-bound by thiazole orange, 7 µM and 
allowed to equilibrate for a period of 10 min prior to addition of ligand.  Ligand was 
added at various rdd values.  Fluorescence parameters; excitation: wavelength = 504, slits = 
10, filter = auto; emission: wavelength = 510-610 nm; slits = 10, filter = auto; PMTV = 580 
nm.  Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 50 mM NaCl, pH 7.0.   
 
Determination of Binding Constants by Scatchard Analysis.  The ∆F was plotted 
versus molar equivalents of ligand and the ∆Fsat (binding stoichiometry) was determined 
mathematically by simultaneous solving the equations representing the pre- and post- 
saturation regions of the titration curve.  A Scatchard plot was generated utilizing 
equations (1)–(3), generated where ∆F/[ligand] was plotted versus ∆F.  The slope of the 
points representing the region immediately preceding complete saturation of the system 
provided -K. In these equations, [ligand] = concentration of ligand, [DNA]T = total 
concentration of DNA, X = molar equiv of ligand versus DNA, ∆Fx = change in 
fluorescence, and ∆Fsat=change in fluorescence at the point where DNA is saturated with 
ligand.   
 
* ∆F,∆F-./0
1
X  Fraction of DNA  ligand complex 
 
(1) 
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A1    ∆BC∆B#DE
%
FG = Fraction of ligand 
 
(2) 
 
HDNAI JX   ∆F,∆F-./K  HligandI 
 
(3) 
Synthesis.  Synthesis of additional compounds is located in the Appendix B.  Listed in 
the order of appearance: HImImCOOMe (10), p. 278; HImImPyCOOMe (112), p. 280; 
HImImPyPyCOOMe (6), p. 281; azide functionalized tetramer polyamides (DPA202 – 
DPA207), p. 282 – 285; N-Boc neomycin-N3 (DPA11), Appendix A p. 241; N-Boc 
neomycin-‘tri’-alkynes (DPA13 – DPA15), p. 286 – 288; N-Boc neomycin-NH2 
(DPA12), Appendix A p. 242; N-Boc neomycin-NHCH2(O)OCH2CCH (DPA17), p. 
288; Series II tetramer polyamide – neomycin conjugates (DPA214 – DPA219), p. 289 – 
293; Series III tetramer polyamide – neomycin conjugates (DPA220 – DPA225), p. 294 
–  298; Series IV tetramer polyamide – neomycin conjugates (DPA243 – DPA244), p. 
299 – 300; and HImImPyPyDp (18), p. 301.   
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Table 3.1.  Stoichiometry table for the synthesis of HImImPyPyCONH(CH2)n-tri-
CH2OCH2-neomycin-hexahydrochloride, DPA208 – DPA213, n = 2, 3, 5, 6, 8 and 
10.   
S
er
ie
s 
I 
 
DPA13 
‘HImImPy 
PyCONH 
(CH2)nN3’ 
CuI DIPEA 
Compound 
(#) 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
DPA208 5.6 4.1 2.3 4.1 1.6 8.3 103.6 13.4 
DPA209 5.8 4.3 2.5 4.3 1.7 8.6 107.9 13.9 
DPA210 5.5 4.1 2.5 4.1 1.6 8.2 102.1 13.2 
DPA211 5.5 4.0 2.5 4.0 1.6 8.1 101.1 13.1 
DPA212 5.4 4.0 2.6 4.0 1.5 7.9 99.6 12.9 
DPA213 5.3 3.9 2.6 3.9 1.5 7.8 98.2 12.7 
 
DPA13
R = NHBoc
n = 2, DPA208
3, DPA209
5, DPA210
6, DPA211
8, DPA212
10, DPA213
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
 
(DPA208 – DPA213).  To a solution of N-Boc-neomycin-tri-alkyne DPA13 in toluene 
(1.0 mL) was added a solution consisting of CuI and DIPEA in toluene (500 µL).  To this 
solution was a solution containing a single azide functionalized tetramer polyamides 
DPA208 – DPA207 in toluene (500 µL).  The reaction mixture was allowed to stir at 
room temperature for 24 h, and then was concentrated in vacuo.  The resulting residue 
was purified by flash chromatography (silica gel, CH2Cl2:MeOH, 2% incremental 
increases in MeOH) to yield the N-Boc protected conjugates.  The solid was then 
suspended in 4 N HCl in dioxane (5 mL) and the reaction was allowed to stir at room 
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temperature for 30 min.  The solution was concentrated in vacuo and the resulting solid 
was washed with copious amounts of CH2Cl2 and lyophilized to dryness to afford 
conjugates DPA208 – DPA213 as hydrochloride salts.  Coupling and deprotection steps 
were near quantitative and the subsequent yields reflect the overall yield for both steps.  
The reported 1H NMR and MALDI spectra represent the deprotected compounds.  
Furthermore, representative 1H NMR and MALDI spectra of the N-Boc protected 
conjugate of DPA208 are also included.    
 
(N-Boc DPA208):  N-Boc DPA208 (7.9 mg, 99%) was afforded as a light brown solid:  
1H NMR (500 MHz, CDCl3, N-Boc protected) δ 8.17 (br, 2H), 7.59 (s, 1H), 7.48 (s, 1H), 
7.38 (s, 2H), 7.17 (s, 1H), 7.09 (s, 1H), 6.98 (s, 1H), 6.79 (s, 1H), 6.70 (s, 1H), 6.07 (s, 
1H), 5.95 (s, 1H), 5.28 (br, 1H), 5.16 (s, 1H), 4.90 (s, 1H), 4.18 (s, 2H), 4.04 (s, 6H), 3.88 
(s, 3H), 3.75 (s, 3H), 3.96 (s, 1H), 3.82-3.90 (m, 3H), 3.76 (s, 1H), 3.64-3.72 (m, 4H), 
3.48 (m, 6H), 3.32 (br, 2H), 3.23 (m, 2H), 3.19-3.30 (m, 5H), 2.23 (m, 1H), 1.94 (m, 1H), 
1.56 (br, 4H), 1.38–1.46 (m, 54H); MALDI-TOF (N-Boc protected) m/z calcd 
C83H126N22O29 1896.02, found [M + Na]
+ 1919.22;  
 
(DPA208):  DPA208 (5.5 mg, 99%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O, deprotected) δ 8.08 (s, 1H), 7.91 (s, 1H), 7.25 (s, 1H), 7.10 (s, 1H), 7.02 (s, 
1H), 6.98 (s, 1H), 6.88 (s, 1H), 6.69 (s, 1H), 6.59 (s, 1H), 6.07 (s, 1H), 5.56-5.55 (s, 1H), 
5.27-5.24 (s, 1H), 5.16-5.15 (s, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H), 4.23-4.21 (m, 
1H), 4.13-4.10 (m, 2H), 4.04 (s, 3H), 4.01 (s, 3H), 3.98-3.92 (m, 1H), 3.88-3.86 (m, 4H), 
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3.85 (s, 3H), 3.84-3.82 (m, 1H), 3.81-3.77 (m, 2H), 3.76 (s, 1H), 3.74-3.72 (m, 1H), 3.68-
3.66 (m, 1H), 3.65-3.63 (m, 4H); 3.63-3.57 (m, 1H), 3.50-3.46 (m, 1H), 3.40-3.37 (m, 
1H), 3.36 (s, 2H), 3.36-3.32 (m, 2H), 3.32-3.31 (m, 3H), 3.30-3.25 (m, 2H), 3.24-3.23 
(m, 1H), 3.23-3.18 (m, 2H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.23-2.20 (m, 1H), 
1.72-1.63 (m, 1H); MALDI-TOF (deprotected) m/z calcd C53H78N22O17 1295.32, found 
[M + Na]+ 1318.38. 
 
(DPA209):  DPA209 (5.6 mg, 94%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.06 (s, 1H), 7.95 (s, 1H), 7.45 (s, 1H), 7.38 (s, 1H), 7.15 (s, 1H), 7.10 (s, 
1H), 7.01 (s, 1H), 6.95 (s, 1H), 6.88 (s, 1H), 6.38 (s, 1H), 5.59-5.55 (m, 1H), 5.33-5.30 
(m, 1H), 5.21-5.18 (m, 1H), 4.47-4.39 (m, 1H), 4.36-4.33 (m, 1H), 4.25-4.20 (m, 1H), 
4.10-4.09 (m, 2H), 3.93-3.88 (m, 7H), 3.88 (s, 2H), 3.87-3.85 (m, 7H), 3.83-3.81 (m, 
1H), 3.81 (s, 3H), 3.80-3.79 (m, 2H), 3.78 (s, 1H), 3.71-3.70 (m, 1H), 3.70-3.66 (m, 4H), 
3.66-3.63 (m, 1H), 3.61-3.56 (m, 1H), 3.47-3.45 (m, 1H), 3.41-3.38 (m, 2H), 3.38-3.37 
(m, 1H), 3.37-3.30 (m, 2H), 3.35 (s, 2H), 3.35-3.33 (m, 2H), 3.32-3.30 (m, 1H), 3.30-
3.24 (m, 2H), 3.24-3.22 (m, 1H), 3.22-3.15 (m, 3H), 3.14 3.12 (s, 2H), 2.21-2.17 (m, 1H), 
1.82-1.69 (m, 2H), 1.73-1.61 (m, 1H); MALDI-TOF m/z calcd C54H80N22O17 1309.35, 
found [M + Na]+ 1333.01. 
 
(DPA210):  DPA210 (5.9 mg, 97%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.18 (br, 1H) 8.10 (br, 1H), 7.46 (s, 1H), 7.41 (s, 1H), 7.30 (s, 1H), 7.28 (s, 
1H), 7.18 (s, 1H), 6.99 (s, 1H), 6.93 (s, 1H), 6.24 (s, 1H), 5.59-5.56 (m, 1H), 5.33-5.31 
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(m, 1H), 5.20-5.18 (m, 1H), 4.51-4.43 (m, 1H), 4.37-4.33 (m, 1H), 4.28-4.22 (m, 1H), 
4.15-4.11 (m, 2H), 4.02-3.98 (m, 2H), 3.97 (s, 6H), 3.91-3.90 (m, 1H), 3.88 (s, 3H), 3.88-
3.86 (m, 1H), 3.85-3.80 (m, 2H), 3.80 (s, 3H), 3.79 (s, 1H), 3.79-3.75 (m, 1H), 3.72-3.66 
(m, 1H), 3.66-3.59 (m, 1H), 3.60-3.53 (m, 4H), 3.46-3.45 (m, 1H), 3.40-3.38 (m, 2H), 
3.37-3.30 (m, 3H), 3.34 (s, 2H), 3.33-3.31 (m, 2H), 3.30-3.29 (m, 1H), 3.27-3.25 (m, 
2H), 3.25-2.23 (m, 1H), 3.21-3.16 (m, 3H), 3.13-3.10 (s, 2H), 2.27-2.21 (m, 1H), 1.70-
1.61 (m, 1H), 1.58-1.53 (m, 2H), 1.52-1.47 (m, 2H), 1.32-1.28 (m, 2H); MALDI-TOF 
m/z calcd C56H84N22O17 1334.40, found [M + Na]
+ 1360.99. 
 
(DPA211):  DPA211 (6.0 mg, 96%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.11 (s, 1H), 8.07 (s, 1H), 7.48 (s, 1H), 7.41 (s, 1H), 7.32 (s, 1H), 7.22 (s, 
1H), 7.07 (s, 1H), 6.95 (s, 1H), 6.90 (s, 1H), 6.04 (s, 1H), 5.56-5.55 (m, 1H), 5.27-5.24 
(m, 1H), 5.16-5.15 (m, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H), 4.23-4.21 (m, 1H), 
4.13-4.10 (m, 2H), 4.01 (s, 2H), 3.98 (s, 3H), 3.98-3.92 (m, 4H), 3.88-3.86 (m, 1H), 3.85 
(s, 3H), 3.84-3.82 (m, 1H), 3.82 (s, 6H), 3.81-3.77 (m, 2H), 3.76 (s, 1H), 3.74-3.72 (m, 
1H), 3.68-3.66 (m, 1H), 3.65-3.60 (m, 4H), 3.63-3.57 (m, 1H), 3.50-3.46 (m, 1H), 3.40-
3.37 (m, 1H), 3.36 (s, 2H), 3.36-3.32 (m, 2H), 3.32-3.31 (m, 1H), 3.30-3.25 (m, 4H), 
3.24-3.23 (m, 1H), 3.22-3.14 (m, 5H), 3.13-3.11 (s, 2H), 2.23-2.20 (m, 1H), 1.72-1.63 
(m, 1H), 1.55-1.50 (m, 4H), 1.36-1.33 (m, 4H); MALDI-TOF m/z calcd C57H86N22O17 
1351.43, found [M + Na]+ 1375.42. 
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(DPA212):  DPA212 (5.9 mg, 98%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.11 (s, 1H), 7.94 (s, 1H), 7.47 (s, 1H), 7.41 (s, 1H), 7.38 (s, 1H), 7.30 (s, 
1H), 7.02 (s, 1H),  6.83 (s, 1H), 6.08 (s, 1H), 5.92 (s, 1H), 5.57-5.56 (m, 1H), 5.31-5.30 
(m, 1H), 5.18-5.17 (m, 1H), 4.50-4.55 (m, 1H), 4.36-4.34 (m, 1H), 4.25-4.22 (m, 1H), 
4.17-4.15 (m, 2H), 4.08 (s, 3H), 4.06 (s, 3H), 4.00-3.96 (m, 1H), 3.92 (s, 1H), 3.91-3.88 
(m, 1H), 3.88 (s, 3H), 3.86-3.85 (m, 4H), 3.84-3.79 (m, 8H), 3.78 (s, 1H), 3.77-3.74 (m, 
1H), 3.73-3.70 (m, 4H), 3.70-3.64 (m, 1H), 3.65-3.55 (m, 1H), 3.45-3.44 (m, 1H), 3.39-
3.31 (m, 3H), 3.35 (s, 2H), 3.35-3.33 (m, 2H), 3.32-3.28 (m, 1H), 3.27-3.24 (m, 2H), 
3.24-3.20 (m, 2H), 3.23-3.22 (m, 1H), 3.21-3.17 (m, 3H), 3.15-3.10 (s, 2H), 2.25-2.22 
(m, 1H), 1.75-1.64 (m, 1H), 1.57-1.50 (m, 4H), 1.31-1.25 (m, 4H), 1.28-1.20 (m, 4H); 
MALDI-TOF m/z calcd C59H90N22O17 1379.48, found [M + Na]
+ 1403.11. 
 
(DPA213):  DPA213 (5.9 mg, 98%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.06 (s, 2H), 7.49 (s, 1H), 7.41 (s, 1H), 7.23 (s, 2H), 7.09 (s, 1H), 6.98 (s, 
1H), 6.81 (s, 1H), 6.10 (s, 2H), 5.59-5.55 (m, 1H), 5.33-5.30 (m, 1H), 5.21-5.18 (m, 1H), 
4.47-4.39 (m, 1H), 4.36-4.33 (m, 1H), 4.27 (s, 3H), 4.26 (s, 3H), 4.25-4.20 (m, 1H), 4.08 
(s, 3H), 4.10-4.09 (m, 2H), 3.99 (s, 6H), 3.93-3.88 (m, 1H), 3.87-3.85 (m, 1H), 3.83-3.81 
(m, 5H), 3.80-3.79 (m, 4H), 3.78 (s, 1H), 3.71-3.70 (m, 1H), 3.70-3.61 (m, 4H), 3.66-
3.63 (m, 1H), 3.61-3.56 (m, 1H), 3.47-3.45 (m, 1H), 3.39-3.29 (m, 2H), 3.38-3.36 (m, 
1H), 3.35 (s, 2H), 3.35-3.33 (m, 2H), 3.32-3.30 (m, 1H), 3.30-3.24 (m, 4H), 3.24-3.22 
(m, 1H), 3.22-3.15 (m, 3H), 3.14-3.12 (s, 2H), 2.21-2.17 (m, 1H), 1.73-1.61 (m, 1H), 
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1.60-1.47 (m, 4H), 1.31-1.20 (m, 6H); MALDI-TOF m/z calcd C61H94N22O17 1407.54, 
found [M + 2Na]+ 1455.01. 
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RESULTS AND DISCUSSION 
Design of Tetramer Polyamide – Neomycin Conjugates.  Or research group has 
previously demonstrated the ability to target DNA through novel Hoechst 33258 – 
neomycin conjugates (37, 38).  Through the conjugation of neomycin to minor groove 
binding Hoechst 33258 we were able to target B-form DNA.  Utilizing this approach, we 
seek to develop a model for A-form DNA recognition through the conjugation of 
neomycin to a minor groove binding ligand which recognizes GC sequences.  Literature 
suggests the propensity of DNA to adopt A-form characteristics is sequence-dependent; 
increased amounts of continuous guanine or cytosine content increases propensity of the 
duplex to adopt A-form characteristics (3, 9, 11).  Polyamides based on N-methylpyrrole 
and N-methylimidazole have been shown to preferentially bind G/C base pairs over A/T 
base pairs (80, 81, 82, 83, 84).   
 A four-ring ‘tetramer’ polyamide will allow for the recognition of G/C minor 
groove DNA (71, 76).  For example the tetramer polyamide HImImPyPy- allows us to 
target DNA which contains the core sequence 5’-GGAA-3’ in a 1:1 binding mode (85).  
Furthermore, when binding head-to-tail in a 2:1 fashion, the tetramer polyamide allows 
us to potentially target the core sequence 5’-GGCC-3’(71, 72, 76, 86) .  Therefore, 
conjugation of neomycin to the tetramer polyamide will allow us to potentially bind DNA 
which contains the sequence 5’-GGAA-3’ and 5’-GGCC-3’. 
The 20 tetramer polyamide – neomycin conjugates were coupled through 1,2,3-
triazoles (87, 88, 89) and amide bonds (36).  The linker length separating the two 
moieties varied from 10 to 21 atoms, Figure 3.4.  To accommodate the variation in  
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6 HCl
6 HCl
6 HCl
n = 2, DPA208
3, DPA209
5, DPA210
6, DPA211
8, DPA212
10, DPA213
n = 2, DPA220
3, DPA221
5, DPA222
6, DPA223
8, DPA224
10, DPA225
n = 2, DPA214
3, DPA215
5, DPA216
6, DPA217
8, DPA218
10, DPA219
n = 2, DPA243
3, DPA244
HImImPyPyDp (18)neomycin
6 HCl
 
Figure 3.4.  Tetramer polyamide – neomycin conjugates used in this study: DPA208 – 
DPA225, DPA243 – DPA244, neomycin and HImImPyPyDp (18).   
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conjugate linker length, a sub-library of tetramer polyamides DPA202 – DPA207 and a 
sub-library of N-Boc protected neomycin derivatives DPA13 – DPA15 and DPA17 were 
synthesized.  Tetramer polyamide – neomycin conjugate linker length is defined as the 
number of atoms measured from the C-terminal carbonyl group of the tetramer 
polyamide to, but not counting, the 5” nitrogen on ring three of neomycin.  1,2,3-triazoles 
are counted through the alkene such that the lowest total number of atoms were counted.  
Therefore, our library of 20 tetramer polyamide- neomycin conjugates consisted of four 
unique series: series I tetramer polyamide – neomycin conjugates DPA208 – DPA213, 
series II tetramer polyamide – neomycin conjugates DPA214 – DPA219, series III 
tetramer polyamide – neomycin conjugates DPA220 – DPA225 and series IV conjugates 
DPA243 and DPA244, Figure 3.4. 
 
Synthesis of Tetramer Polyamide Neomycin Conjugates.  Solution phase synthesis of 
HImImPyPyOOMe 6 was achieved through the use of three monomeric building blocks 7 
– 9; two imidazole based monomers 7, 8 and a single pyrrole based monomer 9, all of 
which were synthesized as previously reported (77, 90), Scheme 3.1.   
Synthesis of tetramer polyamide 6 was conducted in solution through the 
sequential formation of amide bonds between the C-terminal end of the growing 
heterocyclic polyamide chain and the incoming monomeric building block, as reported in 
literature, Scheme 3.1 (84, 91).  Following each addition of monomer, the desired 
product was recovered following column chromatography.  Amide bond formation was 
conducted in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-
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hydroxybenzotriazole (EDC/HOBt) with the exception of the first step, as described in 
the following paragraph.   
 Compound 8 was reduced to form methyl 4-amino-N-methylimidazole-2-
carboxylate 8a.  The amine 8 was immediately coupled to 7 through the haloform 
reaction (91) which afforded dimer 10, HImImCOOMe.   
iii
iv
8
9
  10 R = 
10a R = OH
ii
v
vi
6
9a
  11 R = 
11a R = OH
i
vii
8a
7
9a
 
Scheme 3.1.  Reagents and conditions:  (i) MeOH, 10% Pd/C, H2 (g), 23 oC; 3.5 h, CH-
2Cl2, 23 
oC, 6 h, 72%; (ii) 1.5 N NaOH, MeOH, 60 oC, 4 h; (iii) MeOH, H2, 10% Pd/C, 23 
oC, 4 h; (iv) DMF, EDC, HOBt, 23 oC, 16 h, 71%; (v) 9a, DMF, EDC, HOBt, 23 oC, 16 
h, 69%. 
 
Saponification of the resulting dimer 10 was carried out in the presence of 1.5 N 
NaOH and was neutralized with HCl to afford intermediate 10a.   Compound 10a was 
activated with EDC/HOBt.  Concurrently, building block 9 was reduced to afford methyl 
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4-amino-N-methylpyrrole-2-carboxylate 9a.  Compound 9a was added dropwise to the 
activated acid of solution 10a.  The desired trimer, HImImPyCOOMe 11, was recovered 
as the major product following column purification.  Trimer 11 was saponified in a  
ii
i
n = 2, 12
3, 13
5, 14
6, 15
8, 16
10, 17
  6 R = 
6a R = OH
n = 2, DPA202 
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
 
Scheme 3.2.  Reagents and conditions:  (i) 1.5 N NaOH:THF, MeOH, 60 oC, 5.5 h; (ii) 
EDC, HOBt, DMF, 23 oC, 24 h, 72% - 91%. 
 
fashion similar to compound 10.  The resulting acid 11a was activated using EDC/HOBt.  
Compound 9a was generated in solution and added to the activated acid.  Tetramer 
polyamide 6 was recovered following column purification and afforded in 69% yield.   
Linker length variation was afforded through  α, ω−amino, azido alkanes 12 – 17 
which were synthesized from corresponding dibromoalkanes using previously established  
procedures (92), Scheme 3.2.  The methyl ester of tetramer polyamide 6 was saponified 
in the presence of 1.5 N NaOH and neutralized with HCl to afford 6a as the major 
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product.  The resulting solid was activated using EDC/HOBt.   α, ω−amino, azido 
alkanes 12 – 17 were dissolved in DMF and added to a solution containing 6a.  The 
desired azide functionalized tetramer polyamides DPA202 – DPA207 were recovered 
following column purification in good yields.   
R = NHBoc
R' = 
v
R' = 
DPA15
iv
DPA14
DPA17
R' = 
R' = 
i
ii
R' = 
iii
R' = 
2
DPA11
DPA12
DPA13
R' = 
vi
  
Scheme 3.3.  Reagents and conditions:  (i) NaN3, DMF, 60 oC, 12 h, 89 %; (ii) CuI, 
DIPEA, propargyl ether, toluene, 14 h, 85%; (iii) CuI, DIPEA, 1,6-heptadiyne, toluene, 
14 h, 88%; (iv) CuI, DIPEA, 1,7-octadiyne, toluene, 14 h, 86%; (v) 10% Pd/C, MeOH, H-
2 (g), 7 h, 98%, (vi) propagyl chloroformate, Et3N, CH2Cl2 (dry), -78 
oC, 30 min, 88 %. 
 
Linker length variation was also afforded on neomycin through the development 
of N-Boc protected, alkyne functionalized neomycin derivatives DPA13 – DPA15 and 
DPA17, Scheme 3.3.  Commercially available neomycin B was prepared for conjugation 
as previously reported (35, 37, 79, 93).  The cornerstone of our synthesis required the 
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preparation of an azido derivative of neomycin B, DPA11, Scheme 3.3.  Beginning with 
natural product neomycin B, the six amino groups were N-Boc protected using di-tert-
butyl dicarbonate.  N-Boc neomycin-TPS 2 was prepared, as the major product, by 
suspending the N-Boc neomycin in anhydrous pyridine followed by the addition of 2,4,6-
triisopropylbenzenesulfonyl chloride and purification by chromatography, as previously 
reported (36, 37, 79, 93).  Compound 2 was dissolved in DMF and sodium azide was 
added. DPA11 was recovered as the major product following column purification, in 
89% yield.   
DPA11 was coupled to commercially available dialkynes using CuI/DIPEA 
mediated 1,2,3-triazole formation in the presence of DMF, Scheme 3.3 (87, 88, 89).  
DPA13 was afforded following CuI/DIPEA mediated 1,2,3-triazole formation with 
propargyl ether with a yield of 85%.  Coupling of DPA11 to 1,6-heptadiyne in the 
presence of CuI/DIPEA afforded DPA14, an aliphatic analog of DPA13, in good yields, 
Scheme 3.3.  Finally, DPA215 was synthesized following CuI/DIPEA mediated coupling 
of DPA211 with 1,7-octadiyne in 88% yield, Scheme 3.3.  DPA11 was reduced in the 
presence of H2 (g) and 10% Pd/C to afford a N-Boc protected nucleophilic neomycin 
derivative DPA12, Scheme 3.3.  DPA12 was coupled to propargyl chloroformate to 
afford DPA17 as the major product following column chromatography, Scheme 3.3.   
 Series I tetramer polyamide – neomycin conjugates DPA208 – DPA213 were 
synthesized through CuI/DIPEA mediated 1,2,3-triazole formation between tetramer 
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ii
R = NHBoc
R = NHBoc
+Cl-
i
DPA13
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
n = 2, DPA208
3, DPA209
5, DPA210
6, DPA211
8, DPA212
10, DPA213
 
Scheme 3.4.  Series I reagents and conditions: (i) CuI, DIPEA, DPA202 – DPA207, 
toluene, 24 h; (v) 4 N HCl in 1,4-dioxane, 1 h.  Overall yields for coupling and 
deprotection steps 94% - 99%. 
 
polyamides, DPA202 – DPA207, and N-Boc protected neomycin DPA13, Scheme 3.4.  
The N-Boc protected conjugates were purified via column chromatography followed by 
deprotection in the presence of 4 N HCl in 1,4-dioxane.  The resulting conjugates 
DPA208 – DPA213 featured linkers of 12, 13, 15, 16, 18 and 20 atoms in length.   
Series II tetramer polyamide – neomycin conjugates DPA214 – DPA219, 
Scheme 3.5 were synthesized in a similar fashion to series I conjugates.  Tetramer 
polyamides DPA202 – DPA207 were coupled to N-Boc protected neomycin DPA14, 
Scheme 3.5.  The purified N-Boc protected conjugates were deprotected in the presence 
of 4 N HCl which afforded tetramer polyamide – neomycin conjugates as hydrochloride 
salts.  Series II conjugates featured the same linker lengths as series I (12, 13, 15, 16, 18 
and 20 atoms in length) while varying the flexibility of the atoms linking the two 1,2,3-
triazoles in the linker.   
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ii
R = NHBoc
R = NHBoc
+Cl-
i
DPA14
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
n = 2, DPA214
3, DPA215
5, DPA216
6, DPA217
8, DPA218
10, DPA219
 
Scheme 3.5.  Series II reagents and conditions: (i) CuI, DIPEA, DPA202 – DPA207, 
toluene, 24 h; (ii) 4N HCl in 1,4-dioxane, 1 h.  Overall yields for coupling and 
deprotection steps 88% - 98%. 
 
 Series III tetramer polyamide – neomycin conjugates DPA202 – DPA207 
afforded linker lengths of 13, 14, 16, 17, 19 and 21 atoms, Scheme 3.6.  Azido 
functionalized tetramer polyamide – neomycin conjugates DPA202 – DPA207 were  
ii
R = NHBoc
R = NHBoc
+Cl-
i
DPA15
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
n = 2, DPA220
3, DPA221
5, DPA222
6, DPA223
8, DPA224
10, DPA225
  
Scheme 3.6.  Series III reagents and conditions: (i) CuI, DIPEA, DPA202 – DPA207, 
toluene, 24 h; (ii) 4N HCl in 1,4-dioxane, 1 h.  Overall yields for coupling and 
deprotection steps 95% - 99%. 
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conjugated to N-Boc protected neomycin DPA15.  Following purification, the resulting 
N-Boc protected congjuates were deprotected in the presence of 4 N HCl in 1,4-dioxane 
which afforded the desired conjugates DPA220 – DPA225 as hydrochloride salts.   
 Series IV tetramer polyamide – neomycin conjugates DPA202 and DPA203 were 
synthesized to afford conjugates with shorter linker length, 10 and 11 atoms, Scheme 3.7.  
These conjugates featured a single 1,2,3-triazole between the two moieties.  Tetramer 
polyamides, DPA202 and DPA203, were conjugated to DPA17.  Following purification, 
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Scheme 3.7.  Series IV reagents and conditions: (i) CuI, DIPEA, DPA202 – DPA203, 
toluene, 24 h; (ii) 4N HCl in 1,4-dioxane, 1 h.  Overall yields for coupling and 
deprotection steps 81% and 88%. 
 
the resulting N-Boc protected conjugates were deprotected in the presence of 4 N HCl in 
1,4-dioxane which afforded the desired conjugates DPA243 and DPA244 as 
hydrochloride salts, Scheme 3.8.   
Finally, tetramer polyamide control 18 was synthesized in a similar fashion to 
compounds DPA202 – DP207, Scheme 3.8.  The methyl ester of tetramer polyamide 6 
was saponified in the presence of 1.5 N NaOH at 60 oC to afford 6a as the major product.  
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The solution was neutralized with HCl and volatiles were removed in vacuo.  The 
resulting solid was coupled to N,N-dimethylaminopropylamine to afford 18.  
  18
  6a
i
 
Scheme 3.8.  Reagents and conditions:  (i) EDC, HOBt, N,N-dimethylaminopropylamine, 
18 h, 55%.   
  
 
Design of DNA Duplexes to Probe Tetramer Polyamide – Neomycin Conjugate 
Library Binding.  Fluorescent intercalator displacement assays were conducted with a 
number of DNA duplex oligomers and our tetramer polyamide – neomycin conjugates, 
neomycin and 18.  The DNA duplexes varied in length and sequence to accommodate a 
number of potential DNA binding sequences.  DNA duplexes were designed with the two 
following considerations: (i) the DNA duplexes contained a potential binding site for the 
tetramer polyamide portion of our conjugates (5’-G2A2-3’ or 5’-G2C2-3’) and (ii) the 
DNA duplexes were lengthened to include a portion for neomycin which acted as a 
potential binding site (5’-G4C4-3’) or control (5’-G4-3’) as identified by our group (94).  
Applying these considerations, the following DNA duplexes were used in this study 5’-
G2A3G4C4-3’, 5’-AG2C2AG4C4-3’, 5’-G2C2AG4C4-3’, 5’-TG2C2G4-3’ and 5’-AG2C2AG4-
3’.  The 5’-G2A3G4C4-3’ duplex contained a binding site for the tetramer polyamide 
portion of our conjugate when it binds in a 1:1 polyamide:DNA ratio (5’-G2A3-3’) (74) 
and a portion for binding by neomycin (5’-G4C4-3’).  The 5’-AG2C2AG4C4-3’ duplex 
contained a binding site for the tetramer polyamide neomycin portion of our conjugate 
133 
 
when it binds in a 2:1 polyamide:DNA ratio (5’-AG2C2A-3’) (62) and a portion for 
neomycin binding (5’-G4C4-3’).  The 5’-G2C2AG4C4-3’ duplex acted as a control to the 
5’-G2A3G4C4-3’ DNA duplex.  The duplexes are equal length and provide insight into the 
behavior of our tetramer polyamide – neomycin library when the duplex contains either a 
match and mismatch sequence for tetramer polyamide neomycin binding.  Both of the 
remaining duplexes 5’-TG2C2G4-3’ and 5’-AG2C2AG4-3’ were shortened duplexes that 
act as controls.  Neither duplex offers an optimized portion for neomycin binding or 
tetramer polyamide when binding in a 1:1 ligand:DNA ratio.  CD scans of each of these 
duplexes is located in Appendix B, Figure B37. 
 
Tetramer Polyamide – Neomycin Conjugate Library Binding as Studied With a 
Fluorescent Intercalator Displacement Assay.  The DNA duplexes were pre-saturated 
with ethidium bromide in a 96-well plate (95, 96, 97).  Neomycin, 18 and tetramer 
polyamide – neomycin conjugates (series I DPA208 – DPA213, series II DPA214 – 
DPA219, series III DPA220 – DPA225 and series IV DPA243 – DPA244) were added 
to the DNA at various ratios of drug to duplex (rdd).  The data was normalized such that 
the well containing ethidium bromide and buffer was denoted as 0% fluorescence and the 
well containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
For each DNA duplex, a histogram of the normalized percent decrease in fluorescence 
intensity with respect to control ligands and tetramer polyamide – neomycin conjugate 
linker length was plotted.   
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When the assay was conducted using the 5’-G2C2AG4C4-3’ DNA duplex, each of 
the tetramer polyamide – neomycin conjugates from series I DPA208 – DPA213, series 
II DPA214 – DPA219, series III DPA220 – DPA225 and series IV DPA243 – DPA244  
 
Figure 3.5.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-G2C2AG4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I DPA208 – DPA213 conjugates 
are shown in blue, series II DPA214 – DPA219 conjugates are shown in green, series III 
DPA220 – DPA225 conjugates are shown in red and series IV DPA243 – DPA244 
conjugates are shown in dark grey.  Data was obtained from a FID assay.  Ligands were 
added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 µM], at 
various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent 
decrease in fluorescence was recorded.  The data was normalized such that the well 
containing ethidium bromide and buffer was denoted as 0% fluorescence and the well 
containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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tetramer polyamide – neomycin conjugates as well the controls, neomycin and 18, 
displaced pre-bound ethidium bromide , Figure 3.5.  At an rdd of 1.0, neomycin displaced  
 
Figure 3.6.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-AG2C2AG4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I DPA208 – DPA213 conjugates 
are shown in blue, series II DPA214 – DPA219 conjugates are shown in green, series III 
DPA220 – DPA225 conjugates are shown in red and series IV DPA243 – DPA244 
conjugates are shown in dark grey.  Data was obtained from a FID assay.  Ligands were 
added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 µM], at 
various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent 
decrease in fluorescence was recorded.  The data was normalized such that the well 
containing ethidium bromide and buffer was denoted as 0% fluorescence and the well 
containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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25% of pre-bound ethidium bromide while HImImPyPyDp 18 displaced 15% of pre-
bound ethidium bromide.  The tetramer polyamide – neomycin conjugate that displaced 
the most pre-bound ethidium bromide was DPA224, linker length (L) 19 atoms, which 
displaced 30%.  While the remaining tetramer polyamide – neomycin conjugates 
displaced pre-bound ethidium bromide, which suggests conjugate binding, the amount of 
displaced pre-bound ethidium bromide was not significantly more than neomycin.  The 
amount of pre-bound ethidium bromide displaced by these conjugates was between 12% 
(DPA209, L = 13 atoms) and 26% (DPA219, L = 20 atoms) the amount displaced by 
neomycin and 18, Figure 3.5.   
The assay was also conducted using 5’-AG2C2AG4-3’, tetramer polyamide – 
neomycin conjugates from series I DPA208 – DPA213, series II DPA214 – DPA219, 
series III DPA220 – DPA225 and series IV DPA243 – DPA244 tetramer polyamide – 
neomycin conjugates as well the controls, neomycin and 18, Figure 3.6.  Each of the 
compounds used in this assay displaced pre-bound ethidium bromide at rdd = 1.0.  The 
control compounds neomycin and 18 displaced 35% and 31% of pre-bound ethidium 
bromide, respectively.  DPA225 (L = 21 atoms), DPA219 (L = 20 atoms) and DPA213 
(L = 20 atoms) displaced significantly more pre-bound ethidium bromide than neomycin 
or 18, ~45%.  These conjugates contain the longest linkers in our library.  A number of 
tetramer polyamide – neomycin conjugates also displaced equivalent or slightly more 
pre-bound ethidium bromide than our control compounds.  DPA224 (L = 19 atoms), 
DPA218 (L = 18 atoms) and DPA212 (L = 18 atoms) displaced ~37% while conjugates 
of shorter linker length, DPA215 (L = 13 atoms), DPA209 (L = 13 atoms), DPA214 (L = 
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12 atoms), DPA208 (L = 12 atoms), DPA244 (L = 11 atoms) and DPA243 (L = 10 
atoms), displaced ~40% of the pre-bound ethidium bromide.  The remaining conjugates  
 
Figure 3.7.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-TG2C2G4-3’.  In the histogram, the values represent 
the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, HImImPyPyDp 
18) are shown in light grey while series I DPA208 – DPA213 conjugates are shown in 
blue, series II DPA214 – DPA219 conjugates are shown in green, series III DPA220 – 
DPA225 conjugates are shown in red and series IV DPA243 – DPA244 conjugates are 
shown in dark grey.  Data was obtained from a FID assay.  Ligands were added to the 
DNA [1 µM/duplex], pre-saturated with ethidium bromide [4 µM], at various ratios of 
drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent decrease in 
fluorescence was recorded.  The data was normalized such that the well containing 
ethidium bromide and buffer was denoted as 0% fluorescence and the well containing 
buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  Fluorescence 
parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 20; Excitation 
filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and triplicate 
measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM 
EDTA, pH 7.0, 50 mM NaCl. 
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of intermediate linker lengths (L = 13 to 17 atoms) displaced less pre-bound ethidium 
bromide than neomycin or 18.   
 
Figure 3.8.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-AG2C2AG4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I DPA208 – DPA213 conjugates 
are shown in blue, series II DPA214 – DPA219 conjugates are shown in green, series III 
DPA220 – DPA225 conjugates are shown in red and series IV DPA243 – DPA244 
conjugates are shown in dark grey.  Data was obtained from a FID assay.  Ligands were 
added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 µM], at 
various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent 
decrease in fluorescence was recorded.  The data was normalized such that the well 
containing ethidium bromide and buffer was denoted as 0% fluorescence and the well 
containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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The assay was also conducted using a DNA duplex which eliminated a single central A/T 
base pair 5’-TG2C2G4-3’, Figure 3.7.  Series I DPA208 – DPA213, series II DPA214 – 
DPA219, series III DPA220 – DPA225 and series IV DPA243 – DPA244 tetramer 
polyamide – neomycin conjugates as well the controls, neomycin and 18 displaced pre-
bound ethidium bromide at rdd = 1.0.  Neomycin displaced 32% of pre-bound ethidium 
bromide while 18 displaced 27% of pre-bound ethidium bromide from the duplex.  
Generally, the tetramer polyamide – neomycin conjugates displaced equivalent amounts 
of pre-bound ethidium bromide as neomycin with few exceptions.  Of note, DPA208 (L = 
12 atoms) displaced the most pre-bound ethidium bromide (47%), followed by DPA209 
(L = 13 atoms) and DPA214 (L = 12 atoms), 42% and 33%, respectively.   
 The FID titration was also conducted using the 5’-AG2C2AG4C4-3’ duplex, 
Figure 3.8.  As observed with previously discussed duplexes, series I DPA208 – 
DPA213, series II DPA214 – DPA219, series III DPA220 – DPA225 and series IV 
DPA243 – DPA244 tetramer polyamide – neomycin conjugates as well the controls, 
neomycin and 18 displaced pre-bound ethidium bromide at rdd = 1.0.  The controls 
displaced 27% and 16% (neomycin and 18, respectively) of the pre-bound ethidium 
bromide from the duplex.  The conjugate with the longest linker length DPA225 (L = 21 
atoms) displaced the most pre-bound ethidium bromide, 40%.  As the linker length 
decreased, the conjugates DPA214 (L = 12 atoms), DPA208 (L = 12 atoms), DPA244 (L 
= 11 atoms) and DPA243 (L = 10 atoms), 33% on average. 
 Results from the assay of 5’-G2A3G4C4-3’ with series I DPA208 – DPA213, 
series II DPA214 – DPA219, series III DPA220 – DPA225 and series IV DPA243 – 
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DPA244 tetramer polyamide – neomycin conjugates as well the controls, neomycin and 
18 is shown in Figure 3.9.  Neomycin displaced 28% of the pre-bound ethidium bromide  
 
Figure 3.9.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-G2A3G4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I DPA208 – DPA213 conjugates 
are shown in blue, series II DPA214 – DPA219 conjugates are shown in green, series III 
DPA220 – DPA225 conjugates are shown in red and series IV DPA243 – DPA244 
conjugates are shown in dark grey.  Data was obtained from a FID assay.  Ligands were 
added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 µM], at 
various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent 
decrease in fluorescence was recorded.  The data was normalized such that the well 
containing ethidium bromide and buffer was denoted as 0% fluorescence and the well 
containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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upon binding the DNA duplex at rdd = 1.0.  The control 18 displaced 20% of the pre-
bound ethidium bromide.  Each of the tetramer polyamide – neomycin conjugates 
displaced pre-bound ethidium bromide upon addition to the duplex.  Tetramer polyamide 
– neomycin conjugates containing linker lengths of 10 to 12 atoms, DPA243 (L = 10 
atoms), DPA244 (L = 11 atoms), DPA208 (L = 12 atoms) and DPA214 (L = 12 atoms), 
displaced the largest amount (~50%) of pre-ethidium bromide.  A second set of tetramer 
polyamide – neomycin conjugates displaced a high amount of pre-bound ethidium 
bromide.  The conjugates DPA212 (L = 18 atoms), DPA218 (L = 18 atoms), DPA224 (L 
= 19), DPA213 (L = 20 atoms) and DPA219 (L = 20 atoms) displaced ~42% of pre-
bound ethidium bromide.   
A strong dependence on conjugate linker length and the amount of displaced pre-
bound ethidium bromide was observed at other rdd values.  At a rdd of 0.5, the tetramer 
polyamide – neomycin conjugates of longer linker length, DPA212 (L = 18 atoms), 
DPA218 (L = 18 atoms), DPA224 (L = 19 atoms), DPA213 (L = 20 atoms), DPA219 (L 
= 20 atoms) and DPA225 (L = 20 atoms) displaced significantly more pre-bound 
ethidium bromide than other tetramer polyamide – neomycin conjugates, neomycin or 18, 
Appendix B, Figure B38.  At a rdd of 2.0, tetramer polyamide – neomycin conjugates of 
longer linker length DPA212 – DPA219 (L = 18-20 atoms) and shorter linker length 
DPA243 – DPA214 (L = 10-12 atoms) clearly displace more pre-bound ethidium 
bromide than any other ligands used in the study, Appendix B, Figure B39.   
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Tetramer Polyamide – Neomycin Conjugate Library Binding as Studied With UV 
Thermal Denaturation Experiments.  UV thermal denaturation concentration 
dependence experiments were conducted using a G/C rich 16 mer duplex 5’-A2G6C6T2-3’ 
and the following ligands: series I DPA208 – DPA213, series II DPA214 – DPA219 and 
series III DPA220 – DPA225 tetramer polyamide – neomycin conjugates as well as 
neomycin and HImImPyPyDp 18, Figure 3.10, Figure 3.11, Table 3.2 and Appendix B, 
Figure B40 – Figure B41.   
Addition of the control HImImPyPyDp 18 stabilized the duplex by 2.7 oC at rdd = 
0.25, Table 3.2, Figure 3.10.  The thermal stabilization at rdd = 1.0 was 9.1 oC and 10.6 
oC at rdd = 2.0.  The thermal stabilization afforded by 18 on the duplex increased with 
increasing concentration such that the stabilization afforded at rdd = 2.5 was the highest at 
12.1 oC.  UV thermal denaturation of the duplex in the presence of neomycin suggests 
neomycin is slightly better at stabilizing the duplex than 18.  At rdd = 1.0, neomycin 
stabilized the duplex by 10.9 oC, 1.8 oC higher than 18 at the same rdd, Figure 3.10.  
Addition of a second equivalent of neomycin increased the thermal stabilization by 1.7 -
oC.  The largest increase in thermal stabilization was observed at rdd = 2.0 (12.6 
oC).   
UV thermal denaturation of 5’-A2G6C6T2-3’ was conducted in the presence of 
series I tetramer polyamide – neomycin conjugates, DPA208 – DPA213, Figure 3.11.  In 
this series, the highest stabilization afforded by a conjugate on, at rdd = 1.0, was observed 
with DPA210 (L = 15 atoms) and DPA211 (L = 16 atoms), Table 3.2.  DPA210 and 
DPA211 stabilized the duplex by 22.2 oC and 21.6 oC, respectively.  These values were 
significantly higher than those observed for either neomycin or 18 alone.  At rdd values 
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greater than 2.0, DPA210 and DPA211 saw little to no increase in thermal stabilization.  
The magnitude of thermal stabilization afforded by shorter linkers, DPA208 (L = 12 
atoms) and DPA209 (L = 13 atoms) on 5’-A2G6C6T2-3’ was very close to the 
stabilization afforded by neomycin and 18.   
UV thermal denaturation of 5’-A2G6C6T2-3’ was conducted in the presence of 
series II tetramer polyamide – neomycin conjugates, DPA214 – DPA219, Appendix B,  
(a) neomycin 
  
(b) HImImPyPyDp (18) 
  
Figure 3.10.  UV melting profiles for 5’-A2G6C6T2-3’ with controls, neomycin (a) and 
HImImPyPyDp 18 (b).  The histograms on the right are a plot of ∆Tm with respect to the 
ratio of drug:duplex (rdd).  Ligands were added to the duplex [2 µM/duplex] at varying rdd 
values.  The samples were incubated at 4 oC for 12 h prior to analysis, slow heating from 
10 oC to 90 oC at 0.2 oC/min.  Each panel represents the duplex with a conjugate at 
varying rdd values.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 
7.0. 
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(a) DPA208 (b) DPA209 
    
(c) DPA210 (d) DPA211 
    
(e) DPA212 (f) DPA213 
    
Figure 3.11.  UV melting profiles for 5’-A2G6C6T2-3’ with series I DPA208 – DPA213 tetramer polyamide – neomycin 
conjugates.  The histograms on the right are a plot of ∆Tm with respect to the ratio of drug:duplex (rdd).  Ligands were added 
to the duplex [2 µM/duplex] at varying rdd values.  The samples were incubated at 4 
oC for 12 h.  prior to analysis, slow 
heating from 10 oC to 90 oC at 0.2 oC/min.  Each panel represents the duplex with a conjugate at varying rdd values.  Buffer:  
1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0. 
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Table 3.2.  UV determined change in thermal denaturation melting 
temperature (∆Tm
a) values for various ligands with 5’-A2G6C6T2-3’.   
 rdd 
 
Nb 0.25 0.50 0.75 1.0 1.5 2.0 2.5 
neomycin 3.3 4.5 7.0 10.9 11.7 12.6 11.9 
HImImPyPyDp 18 2.7 4.1 7.2 9.1 9.8 10.6 12.1 
S
er
ie
s 
I 
DPA208 12 3.3 4.9 7.0 10.6 11.4 13.0 11.9 
DPA209 13 4.6 7.2 11.7 16.1 17.2 17.9 17.9 
DPA210 15 6.6 12.4 16.6 22.2 21.9 20.9 22.0 
DPA211 16 4.5 8.8 14.9 21.6 20.8 21.8 22.3 
DPA212 18 2.6 6.6 13.1 17.7 18.1 17.6 16.5 
DPA213 20 4.5 7.0 12.1 15.2 14.9 16.1 16.5 
S
er
ie
s 
II
 
DPA214 12 2.6 3.8 6.0 9.3 8.9 8.9 10.0 
DPA215 13 2.8 5.6 7.6 11.0 10.8 10.2 11.9 
DPA216 15 3.5 6.8 11.1 17.5 16.2 16.9 17.6 
DPA217 16 4.5 8.5 12.1 15.6 15.7 16.0 17.1 
DPA218 18 3.1 6.4 10.0 14.3 15.3 15.9 15.7 
DPA219 20 3.3 7.3 9.8 12.5 12.7 12.9 14.3 
S
er
ie
s 
II
I 
DPA220 13 2.5 4.8 7.0 9.6 9.8 11.1 11.1 
DPA221 14 2.7 4.6 7.9 11.4 11.7 11.9 12.3 
DPA222 16 6.7 11.4 16.1 20.3 20.9 21.1 21.6 
DPA223 17 3.9 8.6 13.9 19.0 18.8 19.4 18.9 
DPA224 19 4.1 7.2 11.3 16.1 16.3 17.4 16.8 
DPA225 21 4.5 6.4 10.1 15.4 15.2 15.2 15.7 
a∆Tm represents the change in melting temperature upon addition of various 
ligands.  bN represents tetramer polyamide – neomycin conjugate linker length 
in atoms.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 
7.0. 
 
Figure B40.  The highest thermal stabilization afforded on the duplex at rdd value of 1.0 
was observed with DPA216 (L = 15 atoms), 17.5 oC, Table 3.2.  Shorter linkers, 
DPA214 (L = 12 atoms) and DPA215 (L = 13 atoms), as well as longer linkers, DPA217 
– DPA219 (L = 16, 18 and 20 atoms), all stabilized the duplex.  However, the magnitude 
of stabilization was lower than observed with DPA216 (L = 15 atoms).  As observed with 
series I tetramer polyamide – neomycin conjugates, the magnitude of stabilization 
afforded by shorter conjugate linkers DPA214 (L = 12 atoms) and DPA215 (L = 13 
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atoms) upon complexation with 5’-A2G6C6T2-3’ was closer to neomycin and 18.  
Furthermore, these conjugates do not substantially increase the thermal stability of the 5’-
A2G6C6T2-3’ duplex at rdd values larger than 1.0.   
  UV thermal denaturation of 5’-A2G6C6T2-3’ in the presence of series III tetramer 
polyamide – neomycin conjugates, DPA220 – DPA225, Appendix B, Figure B41.  The 
highest UV observed thermal stabilization at rdd = 1.0 was afforded by DPA222 (L = 16 
atoms) and DPA223 (L = 17 atoms), 20.3 oC and 19.0 oC, respectively, Table 3.2.  The 
thermal stabilization afforded by the shorter linkers, DPA220 (L = 13 atoms) and 
DPA221 (L = 14 atoms) were significantly lower at 9.6 oC and 11.4 oC, respectively; 
closer to the values observed for neomycin and 18.  Furthermore, these conjugates do not 
significantly improve the thermal stabilization on the duplex upon increasing rdd values.   
Plots of ∆Tm with respect to linker length at rdd = 0.5, 1.0 and 2.0 were plotted 
and the following generalizations were made, Appendix B, Figure B42.  Generally 
speaking, in each series, the linkers that afforded the duplex with the largest thermal 
stabilization were between 15 – 17 atoms in length, consistent with previous polyamide – 
major groove binding conjugates (98).  Tetramer polyamide – neomycin conjugates of 15 
– 17 atom linkers did not show increased thermal stabilization as the rdd values increased 
past rdd = 1.0.  Finally, the magnitude of stabilization afforded by conjugates with linkers 
shorter than 15 atoms were closer in magnitude to those observed with neomycin and 18.   
 
Expanding UV Monitored Thermal Denaturation Experiments with a Shrinking GC 
Pocket.  UV thermal denaturation experiments were conducted on a number of 16 mer  
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(a) 5’-A2G6C6T2-3’
a (b) 5’-A2G6C6T2-3’ 
 
 
(c) 5’-A3G5C5T3-3’
a (d) 5’-A3G5C5T3-3’ 
  
Figure 3.12a.  Plot of ∆Tm with respect to conjugate linker length upon addition of 
ligands to 5’-AmGnCnTm-3’.  Controls (neomycin, HImImPyPyDp 18) are shown in light 
grey while series II DPA214 – DPA219 conjugates are shown in green and series III 
DPA220 – DPA225 conjugates are shown in red.  Data was obtained from UV thermal 
denaturation experiments.  Ligands were added to the DNA [2.0 µM/duplex] at a ratio of 
drug to duplex 1.0.   The samples were incubated at 4 oC for 12 h.  prior to analysis, slow 
heating from 10 oC to 100 oC at 0.2 oC/min.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl.  
a∆Tm values for the duplex with no 
additional NaCl. 
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(a) 5’-A4G4C4T4-3’ (b) 5’-A5G3C3T5-3’ 
 
 
(c) 5’-A6G2C2T6-3’  
 
 
Figure 3.12b.  Plot of ∆Tm with respect to conjugate linker length upon addition of 
ligands to 5’-AmGnCnTm-3’.  Controls (neomycin, HImImPyPyDp 18) are shown in light 
grey while series II DPA214 – DPA219 conjugates are shown in green and series III 
DPA220 – DPA225 conjugates are shown in red.  Data was obtained from UV thermal 
denaturation experiments.  Ligands were added to the DNA [2.0 µM/duplex] at a ratio of 
drug to duplex 1.0.   The samples were incubated at 4 oC for 12 h.  prior to analysis, slow 
heating from 10 oC to 100 oC at 0.2 oC/min.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl.  
a∆Tm values for the duplex with no 
additional NaCl. 
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DNA duplexes and series II DPA214 – DPA219 and series III DPA220 – DPA225 
tetramer polyamide – neomycin conjugates.  In an effort to focus solely on the primary 
binding site, these studies were conducted at rdd = 1.0 in the presence of 50 mM NaCl.  
Where duplex formation and stability allowed; the duplexes 5’-A2G6C6T2-3’, as 
previously discussed, and 5’-A3G5C5T3-3’ were also conducted in the absence of 
additional salt to the buffer.  Experimental data for these experiments are located in 
Table 3.3 and Figure 3.12a and Figure 3.9b.  Normalized UV thermal denaturation 
curves are located in Appendix B, Figure B43 – Figure B44.   
In an effort to expand our studies, thermal denaturation experiments with the 5’-
A2G6C6T2-3’ duplex were conducted in the presence of 10 mM additional NaCl.  The 
stabilization afforded by neomycin on the 5’-A2G6C6T2-3’ duplex was 8.6 
oC while the 
control polyamide 18 only afforded a 4.2 oC increase in thermal stability.  The largest 
thermal stabilization afforded on the 5’-A2G6C6T2-3’ duplex was observed when 
complexed with conjugates DPA218 (L = 18 atoms), DPA219 (L = 20 atoms), and 
DPA220 (L = 13 atoms), 6.8 oC, 4.2 oC and 4.7 oC, respectively. 
The G/C pocket was decreased by two G/C base pairs and UV thermal 
denaturation experiments were conducted on the 5’-A3G5C5T3-3’ duplex.  In the absence 
of NaCl, the largest stabilization afforded by tetramer polyamide – neomycin conjugates 
was 8.1 oC and 7.5 oC observed with DPA216 (L = 15 atoms) and DPA217 (L = 16 
atoms).  However, these conjugates were better at stabilizing the duplex than 18, 4.9 oC, 
but did not stabilize the duplex as well as neomycin alone, 4.4 oC.  In the presence of 50 
mM NaCl, the largest thermal stabilization afforded by the conjugates on 5’-A3G5C5T3-3’  
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Table 3.3.  UV determined thermal denaturation melting temperatures (Tm) of 5’-
AmGnCnTm-3’ duplexes with tetramer polyamide – neomycin  conjugates DPA214 – 
DPA225, neomycin and 18.  All values are reported in oC.   
Na 
5’-A2G6C6T2-3’
 
d 5’-A2G6C6T2-3’ 
5’-A3G5C5T3-3’
 
d 5’-A3G5C5T3-3’ 
Tm
b ∆Tm
c Tm ∆Tm Tm ∆Tm Tm ∆Tm 
native 59.0 61.9 48.3  58.6 
neomycin 69.9 10.9 70.5 8.6 52.7 4.4 65.5 6.9 
18 68.1 9.1 66.1 4.2 53.2 4.9 60.4 1.8 
DPA214 12 68.3 9.3 63.2 1.3 54.4 6.1 60.2 1.6 
DPA215 13 70.0 11.0 64.1 2.2 55.1 6.8 61.8 3.2 
DPA216 15 76.5 17.5 65.9 4.0 56.4 8.1 61.8 3.2 
DPA217 16 74.6 15.6 65.6 3.7 55.8 7.5 60.9 2.3 
DPA218 18 73.3 14.3 68.7 6.8 54.4 6.1 60.4 1.8 
DPA219 20 71.5 12.5 66.1 4.2 53.9 5.6 61.0 2.4 
DPA220 13 68.6 9.6 66.6 4.7 50.8 2.5 59.6 1.0 
DPA221 14 70.4 11.4 65.7 3.8 53.4 5.1 60.0 1.4 
DPA222 16 79.3 20.3 63.8 1.9 55.7 7.4 58.9 0.3 
DPA223 17 78.0 19.0 61.6 -0.3 56.3 8.0 59.8 1.2 
DPA224 19 75.1 16.1 65.8 3.9 51.5 3.2 60.1 1.5 
DPA225 21 74.4 15.4 63.8 1.9 49.7 1.4 60.3 1.7 
 
 5’-A4G4C4T4-3’ 5’-A5G3C3T5-3’ 5’-A6G2C2T6-3’  
N Tm ∆Tm Tm ∆Tm Tm ∆Tm   
native 51.1 49.8 50.4  
neomycin 55.1 4.0 55.3 5.5 54.7 4.3   
18 51.8 0.7 55.0 5.2 52.2 1.8   
DPA214 12 51.2 0.1 56.1 6.3 52.3 1.9   
DPA215 13 51.6 0.5 54.1 4.3 55.9 5.5   
DPA216 15 51.8 0.7 54.7 4.9 53.8 3.4   
DPA217 16 51.9 0.8 54.4 4.6 53.7 3.3   
DPA218 18 51.5 0.4 54.7 4.9 56.1 5.7   
DPA219 20 50.6 -0.5 52.3 2.5 55.4 5.0   
DPA220 13 50.9 -0.2 54.0 4.2 51.9 1.5   
DPA221 14 51.6 0.5 53.5 3.7 52.5 2.1   
DPA222 16 51.9 0.8 53.3 3.5 52.2 1.8   
DPA223 17 51.6 0.5 52.0 2.2 52.1 1.7   
DPA224 19 51.0 -0.1 49.7 -0.1 51.7 1.3   
DPA225 21 52.8 1.7 50.1 0.3 51.1 0.7   
aN represents conjugate linker length in atoms.  bTm represents the melting temperature of 
the native duplex.  c∆Tm represents the change in melting temperature upon addition of 
neomycin at a rdd.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 
7.0, 50 mM NaCl.  dBuffer used in these melts do not include 50 mM NaCl.   
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was observed with DPA215 (L = 13 atoms) and DPA216 (L = 15 atoms), 3.2 oC.  These 
conjugates were effective in stabilizing the duplex by ~4 oC less than neomycin, but ~1.5 
oC more 18.  As the size of the GC pocket is decreased to 5’-A4G4C4T4-3’, 5’-A5G3C3T5-
3’  and 5’-A6G2C2T6-3’ the magnitude of stabilization afforded by series II and series III 
tetramer polyamide – neomycin conjugates increase.  The average magnitude of 
stabilization afforded by series II and series III conjugates on 5’-A4G4C4T4-3’ was only 
0.4 oC.  The largest stabilization was afforded by DPA225 (L = 21 atoms) at 1.7 oC, 
which was 1 oC higher than the stabilization afforded by 18 and 2.3 oC less than the 
stabilization afforded by neomycin, 4.0 oC.  As the G/C pocket was decreased by a G/C 
base pair, 5’-A5G3C3T5-3’, the average magnitude of stabilization afforded by series II 
and series III conjugates was 3.4 oC.  Neomycin stabilized the duplex by 5.5 oC while 18 
stabilized the duplex by 5.2 oC.  The largest conjugate stabilization was 6.3 oC as 
observed with DPA214 (L = 12 atoms).  As the central pocket was decreased by another 
G/C base pair, 5’-A6G2C2T6-3’, average magnitude of stabilization increased to 5.4 
oC.  
The largest magnitude of stabilization afforded on the duplex was observed with DPA215 
(L = 13 atoms), 5.5 oC and DPA218 (L = 20), 5.7 oC.  The average magnitude of 
stabilization by tetramer polyamide – neomycin conjguates was 2.8 oC.  Neomycin 
stabilized the 5’-A6G2C2T6-3’ duplex by 4.3 
oC while compound 18 stabilized the duplex 
by 1.8 oC.    
 
Binding of HImImPyPyDp 18 to 5’-A2G6C6T2-3' and 5’-A6G2C2T6-3’ duplexes, 
Implications of Target Sequence.  CD monitored titrations of HImImPyPyDp 18 into 
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both 5’-A2G6C6T2-3' and 5’-A6G2C2T6-3’ duplexes were conducted, Figure 3.13.  The 
CD spectra of native 5’-A6G2C2T6-3’ consists of a positive couplet at 270 nm and 
negative couplet at 210 nm which suggests the duplex retains A-form characteristics.  
However the strong negative band at 240 nm and the shoulder at 280 nm suggest the 
duplex also retains B-form characteristics.  The binding of HImImPyPyDp 18 to 5’-A6G-
2C2T6-3’ is clearly illustrated by the increase in CD intensity at 300 nm – 350 nm, the  
(a) (b) 
  
(c) (d) 
  
Figure 3.13.  CD scans for the titration of 5’-A6G2C2T6-3’ (a) and 5’-A2G6C6T2-3' (c) 
with HImImPyPyDp 18 and CD intensity vs rdd value plots, 246 nm (b) and 240 nm (d) 
at 20 oC.  18 was added to the duplex [40 µM/bp] at varying rdd values.  Buffer:  1.5 mM 
Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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polyamide absorption region.  Analysis of the DNA region at 246 nm shows distinct 
inflection points at 1:1 and 2:1, ligand:DNA, ratios as expected (99). 
 The 5’-A2G6C6T2-3’ duplex also displays a positive and negative couplet at 270 
nm and 210 nm in the CD scan of the native duplex.  The CD scan clearly shows a 
negative band at 240 which suggests the duplex still retains B-form characteristics, the 
decreased intensity of this band and the lack of a clear shoulder at 280 nm suggests this 
duplex, when compared to the 5’-A6G2C2T6-3, retains less B-form characteristics.  
However, when 18 is titrated into the 5’-A2G6C6T2-3', no clear ligand absorption bands 
resolve; analysis of the DNA region at 240 nm displays no inflection points upon ligand 
addition.  While this data alone could suggest 18 does not bind the duplex, thermal 
denaturation experiments have clearly suggested 18 is capable of thermally stabilizing the 
5’-A2G6C6T2-3' duplex.   
In an effort to support the results obtained from the CD monitored titration of 5’-
A2G6C6T2-3' and 5’-A6G2C2T6-3’ by 18, the titration was repeated using a fluorescence 
displacement titration (FID).  In this experiment, the 16 mer DNA duplexes were pre-
saturated with thiazole orange.  Compound 18 was added at varying  rdd values.  The 
results from the FID displacement of pre-bound thiazole orange from the 5’-A6G2C2T6-3’ 
duplex by 18 results in a decrease in fluorecscence intensity indicative of ligand binding, 
Figure 3.14.  Plotting the change in fluorescence intensity at 526 nm with respect to the 
rdd clearly shows binding sites at 1:1 and 2:1 ligand:DNA ratios as observed with CD.   
Upon titration of 18 into the 5’-A2G6C6T2-3' duplex pre-bound with thiazole 
orange a clear decrease in fluorescence intensity is observed.  This supports our claim 
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that 18 is capable of binding the 5’-A2G6C6T2-3' duplex.  However, when the change in 
fluorescence intensity at 526 nm is plotted against the rdd value no clear inflection points 
are observed.  Binding of linear polyamides comprised N-methylimidazole and N-
methylpyrrole monomers have shown the ability to bind target sequences in a 1:1 and 2:1 
 (a) (b) 
  
(c) (d) 
  
Figure 3.14.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the self complementary duplex, 5’-
A6G2C2T6-3’, (a) and (b), and 5’-A2G6C6T2-3’ by HImImPyPyDp 18 at 20 oC.  A plot of 
fluorescence intensity vs rbd is located in panel (b), (d).  The duplexes, 1.0 µM/duplex, 
16 µM/base pair, was pre-bound by thiazole orange, 7 µM and allowed to equilibrate for 
a period of 10 min, prior to addition of 18.  18 was added to the duplexes at various rbd 
values. Excitation:  504 nm; emission:  510-610 nm; slits:  1.0 nm.  Buffer:  1.5 mM 
Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 100 mM NaCl. 
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ligand:DNA binding stoichiometry (99).  Furthermore, these polyamides are also capable 
of targeting non-specific sequences as well.  The trimer polyamide HImPyPyDp binds 
duplex DNA with 2:1 ligand:DNA binding stoichiometry and has been reported to bind 
the target sequence 5’-GTAC-3’ with an association constant Ka of 8.6 x 106 M-1 while it 
binding the non-target sequence 5’-GACA-3’ with a Ka of 1.3 x 105 M-1 (99).  Similar 
conclusions have been reported (100, 101).   
Experimental evidence suggests tetramer polyamide – neomycin conjugates 
increase the thermal stability of a number of DNA duplexes.  However, it is clear from 
CD and FID titrations 5’-AmGnCnTm-3' type duplexes with 18 the binding of 18 to DNA 
is strongly sequence dependent.  Optimized 2:1 stoichiometry binding of 18 to DNA 
occurs when DNA contains the sequence 5’-AG2C2T-3’ (76).  In our current design of 5’-
AmGnCnTm-3' type duplexes, the only duplex which contains our target sequence is 5’-A-
6G2C2T6-3’.  Unfortunately, the 5’-A6G2C2T6-3’ duplex contains a large percentage of 
A/T content suggesting a conformation closer to B-form (13) and weakly bound by 
neomycin (37).  Data collected by our group suggests duplexes containing of large 
percentage of G/C content are bound with higher affinities by neomycin (94).  
Unfortunately, the duplex used in this study 5’-A2G6C6T2-3' does not contain the 
optimized target tetramer polyamide sequence.  Therefore, in order to receive synergistic 
contributions from both binding moieties a target DNA duplex must be identified.   
 
Identifying Potential Target Duplexes.  The following two target DNA duplexes were 
used in subsequent studies: target duplex 1 5’-G2A3G4C4-3’ and target duplex 2 5’-
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G2C2AG4C4-3’.  These duplexes each contained a neomycin binding site 5’-G4C4-3’, as 
identified by our group (94).  Target duplex 1 contains the target polyamide sequence for 
the 1:1 binding mode, 5’-G2A3-3’, within the following duplex 5’-G2A3G4C4-3’.  Target 
duplex 2 contains the target polyamide sequence for the 2:1 binding mode, 5’-G2C2A-3’, 
within the following duplex 5’-G2C2AG4C4-3’.   
 
UV Monitored Thermal Denaturation of Target Duplexes.  UV thermal denaturation 
experiments were conducted using both target duplexes.  In an effort to focus solely on 
the primary binding site, these studies were conducted at rdd = 1.0 in the presence of 50 
mM NaCl.  Target duplex 1, 5’-G2A3G4C4-3’, was denatured in the presence of series I 
(DPA208 – DPA213), series II (DPA214 – DPA219), series III (DPA220 – DPA225) 
and series IV (DPA243 and DPA244) tetramer polyamide – neomycin conjugates as well 
as neomycin and 18.  A histogram which plots the ∆Tm with respect to conjugate linker 
length is found in Figure 3.15 while UV thermal denaturation profiles are located in 
Appendix B, Figure B46.  Experimentally determined values are located in Table 3.5. 
Each of the tetramer polyamide – neomycin conjugates, neomycin and 18 
increased the melting temperature of 5’-G2A3G4C4-3’, target duplex 1.  Neomycin 
increased the melting temperature of the duplex by 6.2 oC and the tetramer polyamide 
control 18 increased the melting temperature by a similar magnitude of 6.3 oC.  The 
largest increase in melting temperature was afforded by tetramer polyamide – neomycin 
conjugates which featured the shortest linker lengths between the two moieties.   
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Conjugates DPA243 (L = 10 atoms) and DPA244 (L = 11 atoms) afford a 21.5 oC 
and 24.7 oC increase in thermal stability, respectively.  In each series the two conjugates 
with the shortest linker length increase the thermal stability by a larger magnitude than 
the remaining conjugates in the series.  Furthermore, as the linker length increases, in  
 
Figure 3.15.  Plot of ∆Tm with respect to conjugate linker length upon addition of ligands 
to 5’-G2A3G4C4-3’.  Controls (neomycin, HImImPyPyDp 18) are shown in light grey 
while series I DPA208 – DPA213 are shown in blue, series II DPA214 – DPA219 
conjugates are shown in green, series III DPA220 – DPA225 conjugates are shown in red 
and series IV DPA23  and DPA244 are shown in dark grey.  Data was obtained from UV 
thermal denaturation experiments.  Ligands were added to the DNA [2.0 µM/duplex] at a 
ratio of drug to duplex = 1.0.   The samples were incubated at 4 oC for 12 h prior to 
analysis, slow heating from 10 oC to 100 oC at 0.2 oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 
mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Table 3.4.  UV determined thermal melting temperatures of target 
duplexes in the presence of controls and series I (DPA208 – DPA213), 
series II (DPA214 – DPA219), series III (DPA220 – DPA225) and 
series IV (DPA243 and DPA244) tetramer polyamide – neomycin 
conjugates with target duplexes duplexes.  All values are reported in 
oC.   
5’-G2A3G4C4-3’ 5’-G2C2AG4C4-3’ 
  Na Tm
b ∆Tm
c  N Tm ∆Tm 
native 50.6 - native 52.4 - 
HImImPyPyDp 18 56.8 6.2 HImImPyPyDp 18 54.3 1.9 
Neomycin 56.9 6.3 Neomycin 57.9 5.5 
IV
 DPA243 10 72.1 21.5 
IV
 DPA243 10 63.8 11.4 
DPA244 11 75.3 24.7 DPA244 11 65.6 13.2 
S
er
ie
s 
II
I 
DPA220 13 69.1 18.5 
S
er
ie
s 
II
I 
DPA220 13 54.6 2.2 
DPA221 14 67.7 17.1 DPA221 14 52.6 0.2 
DPA222 16 62.8 12.2 DPA222 16 53.1 0.7 
DPA223 17 59.6 9.0 DPA223 17 52.6 0.2 
DPA224 19 59.1 8.5 DPA224 19 57.3 4.9 
DPA225 21 56.8 6.2 DPA225 21 59.4 7.0 
S
er
ie
s 
II
 
DPA214 12 73.1 22.5 
S
er
ie
s 
II
 
DPA214 12 61.7 9.3 
DPA215 13 66.7 16.1 DPA215 13 58.1 5.7 
DPA216 15 61.9 11.3 DPA216 15 52.9 0.5 
DPA217 16 60.5 9.9 DPA217 16 52.7 0.3 
DPA218 18 60.4 9.8 DPA218 18 56.3 3.9 
DPA219 20 57.0 6.4 DPA219 20 60.4 8.0 
S
er
ie
s 
I 
DPA208 12 71.5 20.9 
aN represents tetramer polyamide 
– neomycin conjugate linker 
length in atoms.  bTm represents 
the melting temperature of the 
native duplex.  c∆Tm represents 
the change in melting temperature 
upon addition of ligands at a rdd.  
Buffer: 1.5 mM Na2HPO4, 0.5 
mM NaH2PO4, 0.25 mM EDTA, 
pH 7.0, 50 mM NaCl. 
DPA209 13 65.8 15.2 
DPA210 15 61.5 10.9 
DPA211 16 56.1 5.5 
DPA212 18 57.3 6.7 
DPA213 20 56.9 6.3 
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each series, the magnitude of thermal stabilization decreases.  Examination of series I 
tetramer polyamide – neomycin conjugates shows DPA208 (L = 12 atoms) and DPA209 
(L = 13 atoms) increase the thermal stability of target duplex 1 by 20.9 oC and 15.2 oC, 
Table 3.5.  As linker length is increased to 15 atoms, the stabilization afforded by 
DPA210 (L = 15 atoms) is 10.9 oC.  DPA211 (L = 16 atoms), DPA212 (L = 18 atoms) 
and DPA213 (L = 20 atoms) stabilize the duplex by 5.5 oC, 6.7 oC and 6.3 oC, 
respectively.  Series II tetramer polyamide – neomycin conjugates DPA214 (L = 12 
atoms) and DPA215 (L = 13 atoms) stabilize target duplex 1 by 22.5 oC and 16.1 oC, 
similar in magnitude to the values obtained with conjugates of the same linker length 
from series I.  As observed with series I conjugates, thermal stabilization decreases with 
increasing linker length such that DPA219 (L = 20 atoms) only stabilizes target duplex 1 
by 6.4 oC.   
Series III tetramer polyamide – neomycin conjugates feature some conjugates 
with intermediate linker lengths, not found in series I or series II.  DPA220 (L = 13 
atoms) is the conjugate with the shortest linker length in the series and increases the 
thermal stabilization of the duplex by 18.5 oC.  The magnitude of stabilization afforded 
by this conjugate is nominally larger than observed with tetramer polyamide – neomycin 
conjugates DPA209 (L = 13 atoms) and DPA215 (L = 13 atoms).  DPA221 (L = 14 
atoms) stabilizes the duplex by 17.1 oC.  DPA222 (L = 16 atoms) features the same linker 
length as DPA217 (L = 16 atoms) and DPA211 (L = 16 atoms) and stabilizes target 
duplex 1 by 9.0 oC.  As linker length increases in series III, the magnitude of stabilization 
decreases such that DPA225 (L =12 atoms) affords 6.2 oC of stabilization.   
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Target duplex 2, 5’-G2C2AG4C4-3’, was denatured in the presence of series II 
(DPA214 – DPA219) and series III (DPA220 – DPA225) tetramer polyamide – 
neomycin conjugates as well as neomycin and 18.  A histogram which plots the ∆Tm with  
 
Figure 3.16.  Plot of ∆Tm with respect to conjugate linker length upon addition of ligands 
to 5’-G2C2AG4C4-3’.  Controls (neomycin, HImImPyPyDp 18) are shown in light grey 
while series II DPA214 – DPA219 conjugates are shown in green, series III DPA220 – 
DPA225 conjugates are shown in red and series IV DPA243 – DPA244 are shown in 
dark grey.  Data was obtained from UV thermal denaturation experiments.  Ligands were 
added to the DNA [2.0 µM/duplex] at a ratio of drug to duplex 1.0.   The samples were 
incubated at 4 oC for 12 h prior to analysis, slow heating from 10 oC to 100 oC at 0.2 
oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM 
NaCl. 
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respect to conjugate linker length is found in Figure 3.16 while UV thermal denaturation 
profiles are located in Appendix B, Figure B47.  Experimentally determined values are 
located in Table 3.5.   
The magnitude of stabilization afforded by neomycin on target duplex 2, 5’-
G2C2AG4C4-3’ is 5.5 
oC, which is similar to the magnitude afforded by neomycin on 
target duplex 1, 5’-G2A3G4C4-3’.  The magnitude of stabilization afforded by the tetramer 
polyamide control 18 on target duplex 2 was only 1.9 oC; much lower in magnitude than 
observed with target duplex 1 (6.2 oC).  Furthermore, of the tetramer polyamide – 
neomycin conjugates studied with target duplex 2, the magnitude of stabilization is lower 
than observed with target duplex 1.  Since UV thermal denaturation experiments focused 
on the primary binding site, rdd = 1.0, the 4.3 
oC difference in stabilization afforded by 18 
on target duplex 1 and target duplex two is not unexpected.  When binding the duplex in 
a 1:1 stoichiometry, 18 prefers the sequence 5’-G2A3-3’ over 5’-G2C2A-3’.   
As observed with target duplex 1, tetramer polyamide – neomycin conjugates 
DPA243 (L = 10 atoms) and DPA244 (L = 11 atoms) stabilize the duplex higher than 
any other conjugates studied.  DPA243 (L = 10 atoms) increased the thermal stability of 
target duplex 2 by 11.4 oC while DPA244 (L = 11 atoms) increased the thermal 
stabilization of target duplex 2 by 13.2 oC.  However, the magnitude of stabilization 
afforded by these two conjugates on target duplex 2 were ~10 oC lower than observed 
than observed with target duplex 1.   
When examining the thermal stability afforded by series II tetramer polyamide – 
neomycin conjugates on target duplex 2, the largest stabilization was afforded by  
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Table 3.5.  UV determined change in thermal melting (∆Tm) temperatures and 
FID assay determined change in fluorescence (∆F) data.  Data for the addition of 
controls and series I (DPA208 – DPA213), series II (DPA214 – DPA219), series 
III (DPA220 – DPA225) and series IV (DPA243 and DPA244) tetramer 
polyamide – neomycin conjugates with target duplexes at rdd = 1.0.   
 5’-G2A3G4C4-3’ 5’-G2C2AG4C4-3’ 
  Na ∆F ∆Tm (
oC)c ∆F ∆Tm 
HImImPyPyDp 18 20.2 6.2 13.3 1.9 
Neomycin 28.6 6.3 25.2 5.5 
IV
 DPA243 10 45.8 21.5 20.1 11.4 
DPA244 11 51.5 24.7 19.7 13.2 
S
er
ie
s 
II
I 
DPA220 13 24.3 18.5 17.1 2.2 
DPA221 14 18.7 17.1 16.1 0.2 
DPA222 16 27.4 12.2 17.8 0.7 
DPA223 17 26.1 9.0 19.1 0.2 
DPA224 19 41.8 8.5 30.2 4.9 
DPA225 21 26.3 6.2 25.2 7.0 
S
er
ie
s 
II
 
DPA214 12 41.5 22.5 15.9 9.3 
DPA215 13 24.0 16.1 18.6 5.7 
DPA216 15 15.7 11.3 17.0 0.5 
DPA217 16 20.5 9.9 21.8 0.3 
DPA218 18 42.3 9.8 22.5 3.9 
DPA219 20 35.5 6.4 26.0 8.0 
S
er
ie
s 
I 
DPA208 12 45.5 20.9 14.3  
DPA209 13 32.6 15.2 12.0  
DPA210 15 15.2 10.9 18.2  
DPA211 16 20.8 5.5 16.1  
DPA212 18 36.8 6.7 25.3  
DPA213 20 36.8 6.3 24.7  
aN represents tetramer polyamide – neomycin conjugate linker length in atoms.  
b∆F represents the change in fluorescence intensity upon addition of ligand at rdd 
= 1.0.  c∆Tm represents the change in melting temperature upon addition of 
ligands at a rdd = 1.0.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM 
EDTA, pH 7.0, 50 mM NaCl. 
 
DPA214 (L = 12 atoms), 9.3 oC.  Unlike the trend observed with series II conjugates and 
target duplex 1, the magnitude of stabilization did not decrease with increasing linker 
length.  In fact, the second largest magnitude of stabilization was observed with DPA219 
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(L = 20 atoms).  DPA215 (L = 13 atoms) stabilized target duplex 2 by 5.7 oC while 
DPA218 (L = 18 atoms) stabilized the duplex by 3.9 oC.  Intermediate linker lengths of 
15 and 16 atoms, DPA216 (L = 15 atoms) and DPA217 (L = 16 atoms), did not change 
the melting temperature of the duplex by any appreciable amount.    
Finally, for ease of comparison, a table comparing ∆Tm values (obtained from UV 
thermal denaturation experiments) and ∆F values (obtained from FID assays) with 
respect to linker length for tetramer polyamide – neomycin conjugates and controls with 
target duplex 1 and target duplex two is located in Table 3.5.    
The largest magnitude of stabilization afforded by series III conjugates on target 
duplex 2 was observed with DPA225 (L = 21 atoms), 7.0 oC.  Tetramer polyamide – 
neomycin conjugates DPA224 (L = 19 atoms) stabilized the duplex by 4.9 oC.  
Surprisingly, DPA220 (L = 13 atoms) only stabilized the melting temperature of target 
duplex 2 by 2.2 oC, while the remaining tetramer polyamide – neomycin conjugates did 
not significantly change the melting temperature of the duplex.   
 
Fluorescence Intercalator Displacement Titrations and Binding Affinity.  In an effort 
to obtain quantitative binding affinities Ka and relate them to the results obtained from 
our assay, full FID titrations were conducted.   Target duplex 1 was pre-saturated with 
thiazole orange.  A departure from ethidium bromide was made due to the large 
difference in fluorescence intensity observed between the bound and unbound states of 
thiazole orange (102).  Ligand was added at varying rdd values and the decrease in 
fluorescence intensity was recorded.   
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(a) (b) 
  
(c) (d) 
  
Figure 3.17.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-G2A3G4C4-3’, by 
neomycin at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). A 
related plot of ∆F vs rdd is located in panel (c).  Scatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of neomycin, the fluorescence intensity is denoted as Fmax.  Neomycin 
was added to the duplex at various rdd values.  Fluorescence parameters: Excitation = 504 
nm; Emission = 510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; 
PMTV = 550 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 
mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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(a) (b) 
  
(c) (d) 
  
Figure 3.18.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-G2A3G4C4-3’, by 
DPA244 at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). A 
related plot of ∆F vs rdd is located in panel (c).  Scatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of DPA244, the fluorescence intensity is denoted as Fmax.  DPA244 was 
added at various rdd values. Fluorescence parameters: Excitation = 504 nm; Emission = 
510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; PMTV = 550 
and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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(a) (b) 
  
(c) (d) 
  
Figure 3.19.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-G2A3G4C4-3’, by 
DPA243 at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). A 
related plot of ∆F vs rdd is located in panel (c).  Schatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of DPA243, the fluorescence intensity is denoted as Fmax.  DPA243 was 
added at various rdd value.  Fluorescence parameters: Excitation = 504 nm; Emission = 
510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; PMTV = 550 
and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Figure 3.20.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-G2A3G4C4-3’, by 
DPA208 at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). A 
related plot of ∆F vs rdd is located in panel (c).  Schatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of DPA208, the fluorescence intensity is denoted as Fmax.  DPA208 was 
added at various rdd values.  Fluorescence parameters: Excitation = 504 nm; Emission = 
510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; PMTV = 550 
and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Figure 3.21.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the duplex, 5’-G2A3G4C4-3’, by 
DPA218 (a) and DPA224 (c) at 20 oC.  A related plot of ∆F vs rdd is located in panel (b 
and d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was pre-bound by thiazole 
orange, 7 µM and allowed to equilibrate for a period of 10 min prior to addition of 
ligand, the fluorescence intensity is denoted as Fmax.  Fluorescence parameters: 
Excitation = 504 nm; Emission = 510-610 nm; Excitation filter = open; Emission filter = 
open; Slits = 20; PMTV = 550 and triplicate measurements were averaged.  Buffer: 1.5 
mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Titration of neomycin into the duplex pre-bound with thiazole orange resulted in a 
decrease in fluorescence intensity, Figure 3.17.  The decrease in fluorescence intensity 
was plotted against rdd and a clear 1:1 binding stoichiometry was observed.  Scatchard 
analysis was performed on the pre-saturation region of the titration curve and provided an 
association constant Ka of 1.1 x 106 M-1.  Titration of the target duplex 1 by potential high 
affinity tetramer polyamide – neomycin conjugates DPA244 (L = 11 atoms), DPA243 (L 
= 10 atoms) and DPA208 (L = 12 atoms) were conducted, Figure 3.18, Figure 3.19 and 
Figure 3.20, respectively.  The following association constants for DPA244 (L = 11 
atoms), DPA43 (L = 10 atoms) and DPA208 (L = 12 atoms) were obtained following 
Scatchard analysis:  Ka of 1.9 x 107 M-1, 8.6 x 106 M-1 and 6.6 x 106 M-1, respectively.    
In an effort to extend this approach to include other tetramer polyamide – 
neomycin conjugates, DPA218 (L = 18 atoms) and DPA214 were titrated into target 
duplex 1 at various rdd values, Figure 3.21.  A decrease in fluorescence intensity was 
observed upon titration of the tetramer polyamide – neomycin conjugates into target 
duplex 1 pre-saturated with thiazole orange.  Surprisingly, we could not extend Scatchard 
analysis to the titration of the tetramer polyamide – neomycin conjugates DPA218 (L = 
18 atoms) and DPA214 (L = 12 atoms).  The lack of a clear saturation point precluded 
the use of Scatchard analysis.  Whether the high amount of displaced ethidium bromide 
observed in our single point FID assay is a result of a secondary binding mode or non-
optimized linker length between neomycin and the tetramer polyamide remains to be 
seen.  While association constants could not be derived for all tetramer polyamide – 
neomycin conjugates the association constants for DPA208 (L = 12 atoms), DPA243 (L 
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= 10 atoms) and DPA244 (L = 11 atoms) are larger than observed with neomycin and 
significantly higher than previously reported association constants for N-methylimidazole 
and N-methylpyrrole polyamides and their target sequences.   
 
(a) (b) 
  
(c)  
 
 
Figure 3.22.  CD scans for the titration of 5’-G2A3G4C4-3’ with DPA244 (a, b).  A plot 
of CD intensity at 265 nm vs rdd value (c).  Titrations were conducted at 20 
oC.  In plot 
(b) the open circle represents the CD scan of the duplex in the absence of neomycin while 
the closed circle represents the CD scan of the duplex in the presence of neomycin rdd = 
2.0.  The conjugate was added to the duplex [40 µM/bp] was added at varying rdd values.  
Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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CD Monitored Titrations of Target Duplexes.  In effort to further characterize the 
binding of tetramer polyamide – conjugates, CD monitored titration of target duplex 1 
(5’-G2A3G4C4-3’) with DPA244 (L = 11atoms) was conducted, Figure 3.22.   The CD 
spectra of native 5’-G2A3G4C4-3’ consists of a positive peak at 270 nm and negative peak 
at 210 nm which suggests the duplex retains A-form characteristics.  However the strong 
negative band at 240 nm and the shoulder at 280 nm suggest the duplex also retains B-
form characteristics.  The binding of DPA244 (L = 11atoms) to 5’-G2A3G4C4-3’ is 
clearly illustrated by the increase in CD intensity at 300 nm – 350 nm, the polyamide 
absorption region.  Furthermore, the CD spectra display an increase in CD intensity at 
270 nm and 210 nm upon addition of DPA244 (L = 11atoms) which suggests an increase 
in A-form characteristics of the duplex occurs upon conjugate addition.   
  
172 
 
CONCLUSIONS 
A library consisting of 20 tetramer polyamide – neomycin conjugates DPA208 – 
DPA219, DPA243 and DPA244 was design and synthesized.  The tetramer polyamide 1 
consists of N-methylimidazole and N-methylpyrrole monomeric units which were 
coupled through EDC/HOBt mediated amide bond coupling in solution.  Tetramer 
polyamide 1 was functionalized with the azide functional group through amide bond 
coupling with a number of  α,ω-amino, azido alkanes to afford DPA202 – DPA207.  
Tetramer polyamide – neomycin conjugates were synthesized through 1,2,3,-triaole 
formation between DPA202 – DPA207 and neomycin derivatives DPA13, DPA14, 
DPA15 and DPA17.   
 Spectroscopic techniques were used to characterize the binding of neomycin, 18 
and tetramer polyamide –neomycin conjugates DPA208 – DPA219, DPA243 and 
DPA244 and the following conclusions were drawn: (i) Tetramer polyamide – neomycin 
conjugates increase the thermal stability of DNA.  UV thermal denaturation experiments 
increased the melting temperature of 5’-A2G6C6T2-3'.  The increase in thermal stability 
was dependant on linker length.  The melting temperature of the duplex was stabilized by 
~20 oC with conjugates of intermediate linker lengths of 16 and 17 atoms, which was 
double the increase in melting temperature afforded by neomycin or 18.   (ii) Thermal 
stabilization afforded by tetramer polyamide – neomycin conjugates suggests strong 
sequence dependence.  Series II and series III tetramer polyamide – neomycin conjugates 
afforded the largest increase in melting temperature when complexed with 5’-A6G2C2T6-
3' at 50 mM NaCl.  Generally, as the size of the G/C pocket increased the magnitude of 
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the thermal stabilization decreased.  (iii) Compound 18 offers insight into tetramer 
polyamide – neomycin conjugate binding.  Our polyamide control 18 was titrated into 5’-
A6G2C2T6-3' and 5’-A2G6C6T2-3' was monitored by CD and fluorescence.  Upon titration 
of 18 in 5’-A6G2C2T6-3' clear binding stoichiometries are observed at 1:1 and 2:1 
polyamide:DNA.  However, no clear changes in the CD signal for 5’-A2G6C6T2-3' when 
titrated by 18.  In fact binding was only confirmed by the decrease in fluorescence 
intensity upon addition of 18 to the 5’-A2G6C6T2-3' duplex.  (iv)  A target duplex for 
quantitative binding studies is paramount.  CD and FID titrations suggested optimal 
binding to DNA by the polyamide occurred complexed with the DNA at 2:1 and 
contained the sequence 5’-AG2C2A-3’.  Unfortunately, the duplex that met the criteria, 
5’-A6G2C2T6-3', featured two A/T rich tails which are not suitable for neomycin binding.  
Therefore we designed target duplex 1, 5’-G2A3G4C4-3’, which featured the target DNA 
sequence for 18 when bound 1:1 and 5’-G2C2AG4C4-3’, which feature the target DNA 
sequence for 18 when bound 2:1.  (v) FID assay identified potential high affinity binding 
tetramer polyamide – neomycin conjugates.  We assayed each of the conjugates with 
target duplex 1 and target duplex 2.  A clear preference for target duplex 1 was displayed 
by tetramer polyamide – neomycin conjugates.  Target duplex 1 was the only duplex in 
the conjugates displaced more pre-bound ethidium bromide than neomycin.  In fact, the 
assay identified two separate groups of conjugates which potentially bind target duplex 1 
with affinities larger than neomycin or 18.  (vi) UV thermal denaturation experiments 
aids in the identification of potential high affinity binding tetramer polyamide – neomycin 
conjugates.  Tetramer polyamide – neomycin conjugates increase the thermal 
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stabilization of target duplex 1 better than target duplex 2.  The largest magnitude of 
thermal stabilization afforded by the conjugates on 5’-G2A3G4C4-3’ occurs with linker 
lengths between 10 and 14 atoms.  (vii)  CD Titration of 5’-G2A3G4C4-3’ by DPA244 
suggests binding.  Binding of DPA244 (L = 11 atoms) to 5’-G2A3G4C4-3’ is clearly 
illustrated by the increase in CD intensity at 300 nm – 350 nm.  Furthermore, CD 
suggests addition of DPA244 (L = 11 atoms) to 5’-G2A3G4C4-3’ increase A-form 
conformation in the duplex.  (viii) Full FID titrations suggest tetramer polyamide – 
neomycin conjugates bind the sequence with Ka of 106 - 107 M-1.  Full FID titrations were 
conducted with tetramer polyamide – neomycin conjugates identified in the assay.  The 
highest Scatchard derived association constant for 5’-G2A3G4C4-3’ was observed with 
DPA244 (L = 11 atoms) Ka of 1.9 x 107 M-1.  Binding constants were determined for the 
target duplex and DPA243 (L = 10 atoms), Ka of 8.6 x 106 M-1, and DPA208 (L = 8 
atoms) Ka of 6.6 x 106 M-1.   
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 CHAPTER IV 
 
RECOGNITION OF A-FORM DNA BY  
HAIRPIN POLYAMIDE – NEOMYCIN CONJUGATES  
 
INTRODUCTION 
In our ongoing effort to target DNA we report continued advancements in A-form 
DNA recognition.  A-form DNA is an enticing nucleic acid target since it differs in 
conformation from biologically dominant B-form DNA (1).  The A-form DNA duplex 
features an axial rise per residue of 2.5 Å and 12 – 14 base pairs per helical turn.  The 
major groove of A-form DNA is narrow and deep, while the minor groove is wide and 
shallow.  Some A-form DNA duplexes have even been crystallized with furanose sugar 
puckers in a C3’-endo conformation (2).   
Changes in the relative humidity can induce A-form conformation.  For example, 
a decrease in humidity drives to conformation of poly(dA-dT)2 to A-form (3, 4).  The 
ability of a duplex to adopt A-from conformation is sequence dependent.  While changes 
in humidity drives the B to A transition in poly(dA-dT)2, poly(dG-dC)2 is 
conformationally rigid and exists exclusively in A-form (3).  Furthermore, several self-
complementary DNA oligomers d(CCGG)2, d(GGCCGGCC)2 and d(GGTATACC)2 
crystallized as A-form duplexes (5, 6, 7).  Since numerous other oligomers, in 
conjunction with the self-complementary DNA oligomers, were crystallized as B-form 
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duplexes in similar conditions, a strong emphasis was placed on A-form sequence 
dependence.  And while it is accepted that mixed base sequence adopts B-form, the 
ability of a DNA duplex to adopt A-form decrease when the percentage of G/C content 
drops below 30% (8).   
A transition from B-form to A-form DNA is also observed upon protein and small 
molecule binding.  Proteins which induce A-form upon binding include HIV-1 reverse 
transcriptase (9, 10, 11), polymerase β (12), Taq polymerase (13), Bacillus polymerase I 
(14), T7 polymerase (15) and DNAse I (16, 17), to name a few.  Furthermore, small 
molecules neomycin, spermine and hexaamminecobalt (III) induce A-form upon binding 
(18).   
Recent advancements by our group and others suggest aminoglycoside 
(neomycin) is capable of binding a number of non-traditional A-form nucleic acid 
structures: RNA triplex (19), DNA:RNA hybrid duplex (20, 21, 22), RNA duplex (23), 
DNA triplex (19, 24, 25, 26), A-form DNA duplex (18) as well as the DNA tetraplex 
(27).  We currently desire to expand our polyamide – neomycin conjugates approach to 
DNA recognition by targeting DNA sequences with a high propensity to adopt the A-
form conformation.  To this end we desire to target DNA sequences of high G/C content.   
Aminoglycosides feature polycationic charges about a flexible carbohydrate 
scaffold which allows them to preferentially bind prokaryotic rRNA as well as a number 
of other RNA targets such as group I introns, a hammerhead ribozyme, the RRE 
transcriptional activator region from HIV, the 5’-untranslated region of thymidylate 
synthase a variety of RNA aptamers from in vitro selection and human mRNAs (28, 29, 
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30).  Since their discovery by Selman Waksman (31), considerable attention has been 
paid to understanding aminoglycoside mode of action.  Previous work by our group 
suggests conjugation of neomycin to a minor groove binding ligand can act as a paradigm 
for an aminoglycoside based approach to DNA recognition (32, 33).   
Significant work has been conducted on the lexitropsin sub-class of DNA minor 
groove binding ligands (34).  Natural products netropsin and disamycin A are di-N-  
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Figure 4.1.  Mode for HImImPyPyγImImPyPyDp 28 binding 5’-AGGCCA-3’. 
 
184 
 
methylpyrrole and tri-N-methylpyrrole polyamides, respectively, which bind A/T rich 
DNA sequence (35, 36, 37).  Advancements in polyamide design allow polyamides to 
read G/C sequences (38, 39, 40, 41, 42, 43, 44).  Substitution of N-methylpyrrole with N-
methylimidazole offers a solution to overcome the repulsion between the amino group 
found on the 2-position of guanine and the 3-position of pyrrole (45, 46, 47, 48).  
However, true recognition of DNA base pairs requires linear polyamide to bind in a 2:1 
head-to-tail fashion in the minor groove.  Pairing heterocyclic monomers across the floor 
of the minor groove in a 2:1 binding stoichiometry, a pyrrole/imidazole pairing 
recognizes a C/G base pair while an imidazole/pyrrole pairing recognizes a G/C base 
pair.  A pyrrole/pyrrole pairing recognizes A/T containing base pairs from G/C 
containing base pairs, but does not recognize A/T base pairs from T/A base pairs (49). 
 Hairpin polyamides offer a unique method for preserving minor groove 
specificity/pairing rules by convalently linking two linear polyamides (50), Figure 4.1.  
Hairpin polyamides are advantageous as the use of a γ-aminobutyrate linker when 
covalently linking linear polyamides allows the polyamides align staggered, hear-to-tail, 
in the minor groove (51, 52).  Second, compared to linear homodimers, the hairpin motif 
displays ~100 fold higher affinity (53).  Six-ring hairpin polyamides bind their target 
sequences at low 107 M-1 affinity (54).  Eight-ring hairpin polyamides have been 
successfully used to target the sequence 5’-TGGCCA-3’ with an association constant Ka 
=  9.7 x 109 M-1, significantly higher than the affinity observed for the linear tetramer 
polyamide < 2 x 105 M-1 (55).   
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EXPERIMENTAL 
Materials: 
Nucleic Acids.  DNA oligomers were purchased from Eurofins MWG Operon 
(Huntsville, AL).  Concentrations were determined by UV absorbance using extinction 
coefficients provided by Operon.  The duplexes were pre-formed at 20 µM/duplex, by 
heating at 90 oC for 10 min, followed by slow annealing at 0.2 oC/min and incubation at 4 
oC for 12 h.   
 
Chemicals.  Neomycin B (sulfate salt) was purchased from ICN pharmaceuticals and 
used without further purification (both synthesis and binding experiments); reagents were 
purchased from Acros organics.  Solvents were purchased from VWR with the exception 
of pyridine, DMF and 1,4-dioxane which were purchased from Acros.  Reaction solvents 
were distilled accordingly; dichloromethane and pyridine were distilled over calcium 
hydride and ethanol was distilled over sodium metal.  All non-commercially available 
intermediates were synthesized as previously reported: heterocyclic monomers (56) and 
neomycin derivatives (33, 57, 58, 59). 
 
Methods: 
Fluorescence Intercalator Displacement Assay.  96 well equilibrium binding 
experiments were conducted using a Varian Eclipse Fluorescence Spectrometer (Varian 
Inc.; Palo Alto, CA) equipped with a 96 well plate reader.  DNA duplexes were pre-
formed at 5 µM/duplex by heating at 90 oC for 10 min, followed by cooling to 10 oC at 
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0.2 oC/min and incubation at 4 oC for 12 h.  Buffer was added to each well followed by 
ethidium bromide (7 µM).  DNA duplex was added to the individual wells such that the 
final concentration of DNA was 1 µM.  Ligands were added to each well at a ratio of 
drug to duplex, rdd = 1.0, allowed to equilibrate for 5 min and the subsequent decrease in 
fluorescence was recorded.  The data was normalized such that the well containing 
ethidium bromide and buffer was denoted as 0% fluorescence and the well containing 
buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  In the histogram, 
the values represent the percent decrease in fluorescence upon each addition of ligand.  
Fluorescence parameters; excitation: wavelength = 525 nm, slits = 20, filter = 335-620 nm; 
emission: wavelength = 550 nm; slits = 20, filter = 550-800 nm; PMTV = 610 nm.  Buffer: 
10 mM sodium cacodylate, 0.5 mM EDTA, 50 mM NaCl, pH 7.0.   
 
Fluorescence Intercalator Displacement Titrations.  Equilibrium binding experiments 
were conducted using a Varian Eclipse Fluorescence Spectrometer (Varian Inc.; Palo 
Alto, CA) at 20 oC.  Duplexes were pre-formed at 20 mM/duplex by heating at 90 oC for 
10 min, followed by a slow annealing at 0.2 oC/min and incubation at 4 oC for 12 h.  The 
DNA duplex was diluted to 1.0 µM/duplex, pre-bound by thiazole orange, 7 µM and 
allowed to equilibrate for a period of 10 min prior to addition of ligand.  Ligand was 
added at various rdd values.  Fluorescence parameters; excitation: wavelength = 504, slits = 
10, filter = auto; emission: wavelength = 510-610 nm; slits = 10, filter = auto; PMTV = 580 
nm.  Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 50 mM NaCl, pH 7.0.   
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Determination of Binding Constants by Scatchard Analysis.  The ∆F was plotted 
versus molar equivalents of ligand and the ∆Fsat (binding stoichiometry) was determined 
mathematically by simultaneous solving the equations representing the pre- and post- 
saturation regions of the titration curve.  A Scatchard plot was generated utilizing 
equations 1 – 3, generated where ∆F/[ligand] was plotted versus ∆F.  The slope of the 
points representing the region immediately preceding complete saturation of the system 
provided -Ka. In these equations, [ligand] = concentration of ligand, [DNA]T = total 
concentration of DNA, X = molar equiv of ligand versus DNA, ∆Fx = change in 
fluorescence, and ∆Fsat = change in fluorescence at the point where DNA is saturated with 
ligand.   
 
* ∆F,∆F-./0
1
X  Fraction of DNA  ligand complex 
 
(1) 
 
A1    ∆BC∆B#DE
%
FG = Fraction of ligand 
 
(2) 
 
HDNAI JX   ∆F,∆F-./K  HligandI 
 
(3) 
 
Synthesis.  Synthesis of intermediate compounds is located in the Appendix C.  Listed in 
the order of appearance: HImImCOOMe (10), Appendix B p. 278; HImImPyCOOMe 
(11) Appendix B  p. 280; BocNHPyγCOOMe (25), p. 360; BocNHPyγImCOOMe (20), 
p. 361; BocNHImPyCOOMe (26), p. 362; BocNHImPyPyCOOMe (21), p. 363; 
HImImPyPyγImCOOMe (27), p. 364; HImImPyPyγImImPyPyCOOMe (19), p. 366; 
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azide functionalized tetramer polyamides (DPA226 – DPA231), p. 367 – 370; N-Boc 
neomycin-NHC(O)CCH (DPA16), p. 372; and HImImPyPyγImImPyPyDp (28), p. 373.   
R = NHBoc
n = 2, DPA226
3, DPA227
5, DPA228
6, DPA229
8, DPA230
10, DPA231
n = 2, DPA232
3, DPA233
5, DPA234
6, DPA235
8, DPA236
10, DPA237
DPA13
 
(DPA232 – DPA237).  To a solution of DPA13 (10.0 mg, 7.3 µmol) in DMF (1.0 mL) 
was added a homogeneous solution consisting of CuI (2.8 mg, 14.6 µmol) and DIPEA 
(47.4 mg, 366.4 µmol) in DMF (500 µL).    To this solution was added a solution 
containing a single azide functionalized hairpin polyamides DPA226 – DPA231 (7.3 
µmol) suspended in DMF.  The solution was allowed to stir at 80 oC for 24 h.  The 
solution was concentrated in vacuo.  The resulting residue was purified by flash 
chromatography (silica gel, CH2Cl2:MeOH, 2% incremental increases in MeOH) to yield 
the N-Boc protected conjugate which was suspended in 1,4-dioxane (2.0 mL).  4N HCl in 
1,4-dioxane (4.0 mL) was added and the solution was stirred for 1 h.  The solid was 
decanted, and washed with copious amounts of CH2Cl2 and lyophilized to afford 
DPA232 – DPA237 as hydrochloride salts.  The reported data reduction of 1H NMR and 
MALDI spectra reflect the deprotected compounds.  Furthermore, representative 1H 
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NMR and MALDI spectra of the N-Boc protected conjugate of DPA232 are also 
included.    
 
(N-Boc DPA232).  N-Boc DPA232 (3.0 mg, 15%) was afforded as a light brown solid:  
TLC (protected, 90:10 CH2Cl2:MeOH v/v) Rf 0.48; 1H NMR (500 MHz, (CD3)2CO, N-
Boc protected) δ 8.11 (br, 2H), 7.51 (s, 1H), 7.26 (s, 2H), 7.18 (s, 1H), 7.07 (s, 1H), 6.91 
(s, 1H), 6.80 (s, 1H), 6.74 (s, 1H), 6.67 (s, 1H), 6.61 (s, 2H), 6.55 (s, 2H), 6.10 (br, 1H), 
5.95 (br, 1H), 5.28 (br, 1H), 5.16 (s, 1H), 4.90 (s, 1H), 4.18 (s, 2H), 4.04 (s, 6H), 3.88 (s, 
12H), 3.75 (s, 3H), 3.96 (s, 1H), 3.82-3.90 (m, 4H), 3.76 (s, 1H), 3.64-3.72 (m, 4H), 3.48 
(m, 6H), 3.32 (br, 2H), 3.23 (m, 2H), 3.19-3.30 (m, 5H), 2.23 (m, 1H), 1.94 (m, 1H), 1.56 
(br, 4H), 1.38–1.46 (m, 54H); MALDI-TOF (N-Boc protected) m/z calcd C109H155N33O34 
2471.60, found [M + Na]+ 2495.22;  
 
(DPA232).  DPA232 (2.3 mg, 98%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.09 (s, 1H), 9.01 (s, 1H), 7.94 (s, 1H), 7.78 (s, 1H), 7.61 (s, 2H), 7.51 (s, 
1H), 7.20 (s, 1H), 7.16 (s, 1H), 6.95 (s, 1H), 6.88 (s, 1H), 6.56 (s, 2H), 6.50 (s, 2H), 6.48 
(s, 1H), 5.67-5.66 (s, 2H), 5.31-5.30 (m, 1H), 5.18 (br, 1H), 4.50-4.55 (m, 1H), 4.36-4.34 
(m, 1H), 4.25-4.22 (m, 1H), 4.22 (s, 6H), 4.17-4.15 (m, 2H), 4.15 (s, 6H), 4.00 (s, 6H), 
4.00-3.96 (m, 1H), 3.96 (s, 3H), 3.90 (s, 4H), 3.86-3.85 (m, 1H),3.84 (s, 3H), 3.84-3.79 
(m, 2H), 3.78 (s, 1H), 3.77-3.74 (m, 1H), 3.73-3.59 (m, 4H), 3.70-3.64 (m, 1H), 3.65-
3.55 (m, 1H), 3.45 (br, 1H), 3.39-3.36 (m, 1H), 3.35 (s, 4H), 3.35-3.33 (m, 4H), 3.32-3.28 
(m, 1H), 3.27 (br, 2H), 3.23-3.22 (m, 1H), 2.81-2.78 (m, 3H), 3.15-3.10 (s, 2H), 2.66-
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2.55 (t, J = 5.1, 2H), 2.25-2.22 (m, 1H), 2.18-1.95 (t, J = 6.4, 2H), 1.75-1.64 (m, 1H), 
1.55-1.41 (m, J1 = 6.4, J2 = 5.2, 2H); MALDI-TOF (deprotected) m/z calcd C79H107N33O22 
1870.90, found [M + Na]+ 1896.19.   
 
(DPA233).  DPA233 (3.3 mg, 22%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 8.06 (s, 2H), 7.71 (s, 1H), 7.52 (s, 2H), 7.50 (s, 1H), 7.46 (s, 1H), 7.09 (s, 
1H), 7.00 (s, 1H), 6.75 (s, 2H), 6.68 (s, 1H), 6.60 (s, 1H), 6.55 (s, 1H), 6.48 (s, 1H), 6.03 
(s, 2H), 5.69-5.65 (m, 1H), 5.33-5.30 (m, 1H), 5.21-5.18 (m, 1H), 4.47-4.39 (m, 1H), 
4.36-4.33 (m, 1H), 4.25-4.20 (m, 1H), 4.10-4.09 (m, 2H), 3.93-3.88 (m, 1H), 3.78 (s, 
6H), 3.70 (s, 6H), 3.60 (s, 6H), 3.54 (s, 3H), 3.50 (s, 3H), 3.87-3.85 (m, 1H), 3.83-3.81 
(m, 4H), 3.80-3.79 (m, 2H), 3.78 (s, 1H), 3.71 (br, 1H), 3.70-3.65 (m, 4H), 3.66-3.63 (m, 
1H), 3.61-3.56 (m, 1H), 3.47-3.45 (m, 1H), 3.38-3.36 (m, 1H), 3.35 (s, 2H), 3.35 (br, 
2H), 3.33-3.25 (m, 7H), 3.24-3.22 (m, 1H), 3.22-3.15 (m, 3H), 3.14-3.12 (s, 2H), 2.67-
2.54 (t, J = 5.1, 2H), 2.21-2.17 (m, 1H), 2.18-1.90 (t, J = 6.4, 2H), 1.86 (m, 2H), 1.73-
1.61 (m, 1H); MALDI-TOF m/z C80H109N33O22 1884.93, found [M + Na]
+ 1907.22. 
 
(DPA234).  DPA234 (3.5 mg, 23%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 8.01 (br, 2H), 7.53 (s, 1H), 7.18 (s, 1H), 7.12 (s, 2H), 6.89 (s, 1H), 6.85 (s, 
1H), 6.79 (s, 1H), 6.75 (s, 1H), 6.68 (s, 2H), 6.60 (s, 1H), 6.56 (s, 1H), 6.49 (s, 1H), 6.11 
(s, 1H), 5.36-5.35 (m, 1H), 5.27-5.24 (m, 1H), 5.16 (br, 1H), 4.47-4.40 (m, 1H), 4.35-
4.34 (m, 1H), 4.27 (s, 3H), 4.23-4.21 (m, 1H), 4.18 (s, 3H), 4.13-4.10 (m, 2H), 3.99 (s, 
6H), 3.96 (s, 6H), 3.94 (s, 7H), 3.87 (m, 4H), 3.84-3.82 (m, 4H), 3.81-3.77 (m, 4H), 3.76 
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(s, 1H), 3.74-3.72 (m, 1H), 3.68-3.66 (m, 1H), 3.63-3.57 (m, 5H), 3.50-3.46 (m, 1H), 
3.41-3.31 (m, 5H), 3.36 (s, 2H), 3.36-3.32 (m, 2H), 3.32-3.31 (m, 1H), 3.30-3.25 (m, 
2H), 3.24-3.23 (m, 1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.66-2.54 (t, J = 5.1, 2H), 
2.23-2.20 (m, 1H), 2.18-1.90 (t, J = 6.3, 2H), 1.72-1.63 (m, 1H), 1.55-1.52 (m, 6H); 
MALDI-TOF m/z calcd C82H113N33O22 1912.98, found [M + Na]
+ 1934.71.    
 
(DPA235).  DPA235 (4.2 mg, 27%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 8.09 (br, 2H), 7.53 (s, 2H), 7.47 (s, 2H), 7.18 (s, 2H), 7.12 (s, 1H), 6.89 (s, 
2H), 6.85 (s, 1H), 6.79 (s, 1H), 6.75 (s, 1H), 6.68 (s, 1H), 6.60 (s, 1H), 6.81 (s, 1H), 6.56 
(s, 1H), 6.49 (s, 1H), 5.59-5.56 (m, 1H), 5.33-5.31 (m, 1H), 5.20 (br, 1H), 4.51-4.43 (m, 
1H), 4.37-4.33 (m, 1H), 4.28-4.22 (m, 1H), 4.22 (s, 3H), 4.15-4.11 (m, 2H), 4.00 (s, 7H), 
3.96 (s, 6H), 3.90 (s, 6H), 3.91-3.90 (m, 1H), 3.88-3.86 (m, 4H), 3.85-3.80 (m, 5H), 3.79 
(s, 1H), 3.79-3.75 (m, 1H), 3.72-3.66 (m, 1H), 3.65-3.61 (m, 1H), 3.60-3.53 (m, 4H), 
3.46 (br, 1H), 3.37-3.34 (m, 1H), 3.34 (s, 2H), 3.33-3.32 (m, 2H), 3.30-3.29 (m, 3H), 
3.27-3.25 (m, 4H), 3.25-2.23 (m, 1H), 3.21-3.16 (m, 3H), 3.13-3.10 (s, 2H), 2.27-2.21 
(m, 1H), 2.63-2.54 (t, J = 5.1, 2H), 2.18-1.95 (t, J = 6.4, 2H), 1.70-1.61 (m, 1H), 1.55-
1.41 (m, 8H); MALDI-TOF m/z calcd C83H115N33O22 1927.01, found [M + Na]
+ 1951.33. 
 
(DPA236).  DPA236 (2.8 mg, 18%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 8.11 (s, 1H), 8.06 (s, 1H), 7.68 (s, 1H), 7.55 (s, 2H), 7.50 (s, 1H), 7.46 (s, 
1H), 7.40 (s, 2H), 7.18 (s, 1H), 7.10 (s, 1H), 6.79 (s, 2H), 6.71 (s, 1H), 6.64 (s, 1H), 6.09 
(s, 1H), 5.59-5.56 (m, 1H), 5.33-5.31 (m, 1H), 5.20-5.18 (m, 1H), 4.51-4.43 (m, 1H), 
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4.37-4.33 (m, 1H), 4.30 (s, 3H), 4.28-4.22 (m, 1H), 4.20 (m, 1H), 4.15-4.11 (m, 2H), 4.00 
(s, 1H), 4.02-3.98 (m, 6H), 3.93 (s, 6H), 3.91-3.90 (m, 1H), 3.90 (s, 6H), 3.88-3.86 (m, 
1H), 3.85-3.80 (m, 4H), 3.79 (s, 4H), 3.79-3.75 (m, 1H), 3.72-3.66 (m, 1H), 3.66-3.59 
(m, 1H), 3.57-3.53 (m, 4H), 3.46-3.45 (m, 1H), 3.37-3.34 (m, 1H), 3.34 (s, 2H), 3.33-
3.31 (m, 2H), 3.30-3.29 (m, 1H), 3.27-3.25 (m, 2H), 3.25-2.23 (m, 3H), 3.21-3.16 (m, 
5H), 3.13-3.10 (s, 2H), 2.67-2.54 (t, J  = 5.2, 2H), 2.27-2.21 (m, 1H), 2.18-1.90 (t, J = 6.4, 
2H), 1.70-1.61 (m, 1H), 1.59 (m, 4H) 1.31 (m, 4H), 1.28 (m, 4H); MALDI-TOF m/z 
calcd C85H119N33O22 1955.06, found [M + Na]
+ 1978.01. 
 
(DPA237).  DPA237 (3.3 mg, 21%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 8.01 (s, 2H), 7.71 (s, 1H), 7.50 (s, 2H), 7.45 (s, 1H), 7.41 (s, 1H), 7.13 (s, 
1H), 7.00 (s, 1H), 6.98 (s, 1H), 6.75 (s, 2H), 6.68 (s, 1H), 6.60 (s, 1H), 6.55 (s, 1H), 6.18 
(s, 1H), 5.57-5.56 (m, 1H), 5.31 (br, 1H), 5.18-5.17 (m, 1H), 4.50-4.55 (m, 1H), 4.36-
4.34 (m, 1H), 4.27 (s, 3H), 4.25-4.22 (m, 1H), 4.17-4.15 (m, 2H), 4.18 (s, 3H), 4.00-3.96 
(m, 1H), 3.97 (s, 12H), 3.90 (s, 9H), 3.87 (m, (4H), 3.84-3.79 (m, 2H), 3.78 (s, 1H), 3.77-
3.74 (m, 1H), 3.70-3.64 (m, 5H), 3.65-3.55 (m, 1H), 3.45-3.44 (m, 1H), 3.39-3.36 (m, 
1H), 3.35 (s, 2H),3.35-3.36-3.23 (m, 9H), 3.23-3.22 (m, 1H), 3.21-3.17 (m, 3H), 3.15-
3.10 (s, 2H), 2.67-2.54 (t, J = 5.2, 2H), 2.25-2.22 (m, 1H), 2.18-1.90 (t, J = 6.4, 2H), 
1.75-1.64 (m, 1H), 1.66 (m, 4H), 1.38 (m, 8H); MALDI-TOF m/z calcd C87H123N33O22 
1983.12, found [M + Na]+ 2007.19. 
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R = NHBoc
n = 2, DPA238
3, DPA239
5, DPA240
n = 2, DPA226
3, DPA227
5, DPA228
DPA16
 
(DPA238 – DPA240).  To a solution of DPA16 (9.2 mg, 7.3 µmol) in DMF (1.0 mL) 
was added a solution of the azide-terminal hairpin polyamides (7.3 µmol) suspended in 
DMF.  To this solution was added a homogeneous solution consisting of CuI (2.8 mg, 
14.6 µmol) and DIPEA (47.4 mg, 366.4 µmol) in DMF (500 µL).  The reaction was 
allowed to stir for 18 h at 80 oC.  The solution was concentrated in vacuo.  The resulting 
residue was purified by flash chromatography (silica gel, CH2Cl2:MeOH, 2% incremental 
increases in MeOH) ) to yield the N-Boc protected conjugate which was suspended in 
1,4-dioxane (2.0 mL).  4N HCl in 1,4-dioxane (4.0 mL) was added and the solution was 
stirred for 1 h.  The solid was decanted, and washed with copious amounts of CH2Cl2 and 
lyophilized to afford DPA238 – DPA240 as a hydrochloride salts.  The reported data 
reduction reflects the deprotected compounds.   
 
(DPA238).  DPA238 (3.8 mg, 26%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 7.91 (s, 1H), 7.73 (s, 1H), 7.63 (s, 1H), 7.60 (s, 2H), 7.56 (s, 1H), 7.43 (s, 
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1H), 7.26 (s, 1H), 7.17 (s, 1H), 7.07 (s, 1H), 6.93 (s, 1H), 6.77 (s, 2H), 6.69 (s, 1H), 5.97 
(s, 2H), 5.59-5.56 (m, 1H), 5.33-5.31 (m, 1H), 5.20-5.18 (m, 1H), 4.47-4.40 (m, 1H), 
4.35-4.34 (m, 1H), 4.23-4.22 (m, 1H), 4.22 (s, 1H), 4.15 (s, 6H), 4.13-4.10 (m, 6H), 4.02-
3.98 (m, 7H), 3.91 (s, 3H), 3.91-3.90 (m, 1H), 3.90 (s, 3H), 3.88-3.86 (m, 1H), 3.84 (s, 
3H), 3.83-3.80 (m, 2H), 3.79 (s, 1H), 3.79-3.75 (m, 1H), 3.72-3.66 (m, 1H), 3.66-3.59 
(m, 1H), 3.50-3.46 (m, 1H), 3.40-3.37 (m, 1H), 3.36 (s, 2H), 3.36-3.32 (m, 6H), 3.32-
3.31 (m, 1H), 3.30-3.25 (m, 2H), 3.24-3.23 (m, 1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 
2H), 2.66-2.55 (t, J = 5.1, 2H), 2.25-2.22 (m, 1H), 2.18-1.95 (t, J = 6.4, 2H), 1.75-1.64 
(m, 1H), 1.55-1.41 (m, J1=6.4, J2=5.2, 2H); MALDI-TOF m/z calcd C77H107N31O22 
1818.87, found [M + Na]+ 1843.62.   
 
(DPA239).  DPA239 (3.9 mg, 27%) was afforded as a light brown solid: 1H NMR (500 
MHz, CDCl3) δ 8.20 (s, 1H), 7.57 (s, 1H), 7.33 (s, 1H), 7.21 (s, 2H), 7.06 (s, 1H), 7.00 (s, 
1H), 6.90 (s, 1H), 6.84 (s, 1H), 6.61 (s, 2H), 6.58 (s, 1H), 6.50 (s, 2H), 6.11 (s, 2H), 5.56-
5.55 (m, 1H), 5.27-5.24 (m, 1H), 5.16-5.15 (m, 1H), 4.47-4.39 (m, 1H), 4.36-4.33 (m, 
1H), 4.27 (s, 3H), 4.25-4.20 (m, 1H), 4.18 (s, 3H), 4.10-4.09 (m, 2H), 4.07 (s, 6H), 4.02-
3.98 (m, 7H), 3.96 (s, 6H), 3.94 (m, 2H), 3.91-3.90 (m, 1H), 3.88-3.86 (m, 4H), 3.85-3.80 
(m, 5H), 3.79 (s, 1H), 3.79-3.75 (m, 1H), 3.72-3.66 (m, 1H), 3.66-3.59 (m, 1H), 3.45-
3.44 (m, 1H), 3.39-3.36 (m, 1H), 3.35 (s, 2H), 3.35-3.33 (m, 2H), 3.32-3.28 (m, 5H), 
3.27-3.24 (m, 2H), 3.23-3.22 (m, 1H), 3.21-3.17 (m, 3H), 3.15-3.10 (s, 2H), 2.66-2.54 (t, 
J = 5.4, 2H), 2.21-2.18 (m, 1H), 2.18-1.90 (t, J = 6.2, 2H), 1.73-1.61 (m, 1H), 1.55-1.52 
(m, 2H); MALDI-TOF m/z calcd for C78H109N31O22 1832.89, found [M + Na]+ 1854.99.   
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(DPA240).  DPA240 (4.4 mg, 30%) was afforded as a light brown solid: 1H NMR (500 
MHz, D2O) δ 8.11 (s, 1H), 7.34 (s, 2H), 7.32 (s, 2H), 7.19 (s, 2H), 7.09 (s, 1H), 6.94 (s, 
3H), 6.81 (s, 1H), 6.61 (s, 1H), 6.60 (s, 1H), 5.59-5.55 (m, 1H), 5.33-5.30 (m, 1H), 5.21-
5.18 (m, 1H), 4.51-4.43 (m, 1H), 4.37-4.33 (m, 1H), 4.30 (s, 3H), 4.28-4.22 (m, 1H), 4.20 
(s, 3H), 4.15-4.11 (m, 2H), 4.10 (s, 6H), 4.00-3.96 (m, 1H), 3.93 (s, 6H), 3.91-3.88 (m, 
7H), 3.86-3.85 (m, 1H), 3.84-3.79 (m, 5H), 3.78 (s, 1H), 3.77-3.74 (m, 4H), 3.70-3.64 
(m, 1H), 3.65-3.55 (m, 1H), 3.50-3.46 (m, 1H), 3.40-3.37 (m, 1H), 3.36 (s, 2H), 3.36-
3.32 (m, 2H), 3.32-3.25 (m, 7H), 3.24-3.23 (m, 1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 
2H), 2.67-2.54 (t, J = 5.1, 2H), 2.27-2.21 (m, 1H), 2.18-1.90 (t, J = 6.2, 2H), 1.70-1.61 
(m, 1H), 1.59 (m, 2H); MALDI-TOF m/z calcd for C80H113N31O22 1860.95, found [M + 
Na]+ 1883.00. 
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R = NHBoc
DPA1019
DPA241
 
(DPA241).  To a solution of compound 19 (10.0 mg, 9.2 µmol) in methanol (10 mL) was 
added 1.5 M NaOH (1 mL) and the solution was allowed to stir for 3.0 h at 60 oC.  The 
ester solution was neutralized with HCl.  Volatiles were removed in vacuo.  The resulting 
solid was dissolved in DMF (10 mL).  EDC (2.2 mg, 11.5 µmol) and HOBt (1.6 mg, 11.5 
µmol) were added and the reaction was allowed to stir for 30 min.  Compound DPA10 
(11.8 mg, 9.2 µmol) was added and reaction was allowed to stir at room temperature for 
12 h.  DMF was evaporated in vacuo and the resulting solid was purified via flash 
chromatography (silica gel, inc. CH2Cl2:MeOH, 2% incremental increases in MeOH) ) to 
yield the N-Boc protected conjugate which was suspended in 1,4-dioxane (2.0 mL).  4N 
HCl in 1,4-dioxane (4.0 mL) was added and the solution was stirred for 1 h.  The solid 
was decanted, and washed with copious amounts of CH2Cl2 and lyophilized to afford 
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DPA241 (13.9 mg, 88%) as a light yellow hydrochloride salt: 1H NMR (500 MHz, D2O 
) δ 7.61 (s, 1H), 7.48 (s, 2H), 7.41 (s, 1H), 7.20 (s, 1H), 7.17 (s, 1H), 7.03 (s, 1H), 7.01 (s, 
1H), 6.78 (s, 2H), 6.70 (s, 1H), 6.64 (s, 2H), 6.10 (s, 2H), 5.57-5.56 (m, 1H), 5.31-5.30 
(m, 1H), 5.18-5.17 (m, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H),4.29 (s, 1H), 4.23-4.21 
(m, 2H), 4.19 (s, 1H), 4.13-4.10 (m, 8H), 4.00 (s, 6H), 3.90 (s, 6H), 3.93-3.88 (s, 7H), 
3.87-3.85 (m, 4H), 3.83-3.81 (m, 4H), 3.80-3.79 (m, 2H), 3.78 (s, 1H), 3.71-3.70 (m, 
1H), 3.66-3.63 (m, 1H), 3.61-3.56 (m, 1H), 3.46-3.45 (m, 1H), 3.37-3.34 (m, 1H), 3.34 
(s, 2H), 3.33-3.31 (m, 2H), 3.30-3.29 (m, 1H), 3.27-3.25 (m, 2H), 3.25-2.23 (m, 1H), 
3.21-3.16 (m, 3H), 3.13-3.10 (s, 2H), 2.68-2.55 (m, 4H), 2.60-2.54 (t, J = 5.3, 2H), 2.23-
2.20 (m, 1H), 2.18-1.95 (t, J = 6.1, 2H); MALDI-TOF m/z calcd for C73H101N27O21S 
1724.82, found [M + Na]+ 1747.65. 
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R = NHBoc
DPA1119
DPA242
 
(DPA242).  To a solution of compound 19 (10.0 mg, 9.2 µmol) in methanol (10 mL) was 
added 1.5 M NaOH (1 mL) and the solution was allowed to stir for 3.0 h at 60 oC.  The 
ester solution was neutralized with HCl.  Volatiles were removed in vacuo.  The resulting 
solid was dissolved in DMF (10 mL).  EDC (2.2 mg, 11.5 µmol) and HOBt (1.6 mg, 11.5 
µmol) were added and the reaction was allowed to stir for 30 min.  Compound DPA11 
(11.1 mg, 9.2 µmol) was added and reaction was allowed to stir at room temperature for 
18 h.  DMF was evaporated in vacuo and the resulting solid was purified via flash 
chromatography (silica gel, inc. CH2Cl2:MeOH, 5% incremental increases in MeOH) ) to 
yield the N-Boc protected conjugate which was suspended in 1,4-dioxane (2.0 mL).  4N 
HCl in 1,4-dioxane (4.0 mL) was added and the solution was stirred for 1 h.  The solid 
was decanted, and washed with copious amounts of CH2Cl2 and lyophilized to afford 
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DPA242 (14.3 mg, 81%) as a light yellow hydrochloride salt: 1H NMR (500 MHz, D2O-
) δ 7.65 (s, 1H), 7.45 (s, 2H), 7.41 (s, 1H), 7.23 (s, 1H), 7.19 (s, 1H), 7.00 (s, 1H), 6.95 (s, 
1H), 6.78 (s, 2H), 6.70 (s, 1H), 6.65 (s, 2H), 6.10 (s, 2H), 5.59-5.56 (m, 1H), 5.33-5.31 
(m, 1H), 5.20-5.18 (m, 1H), 4.50-4.55 (m, 1H), 4.36-4.34 (m, 1H), 4.25-4.22 (m, 1H), 
4.18 (s, 1H), 4.17-4.15 (m, 2H), 4.07 (s, 1H), 3.98-3.96 (m, 2H), 3.94 (s, 6H), 3.88-3.86 
(m, 6H), 3.84-3.82 (m, 6H), 3.81-3.77 (m, 2H), 3.76 (s, 4H), 3.74-3.72 (m, 3H), 3.68-
3.66 (m, 1H), 3.63-3.57 (m, 1H), 3.47-3.45 (m, 1H), 3.38-3.36 (m, 1H), 3.36-3.23 (m, 
4H), 3.35-3.33 (m, 2H), 3.32-3.30 (m, 1H), 3.30-3.24 (m, 2H) 3.24-3.22 (m, 1H), 3.22-
3.15 (m, 3H), 3.14-3.12 (s, 2H), 2.67-2.54 (t, J = 6.2, 2H), 2.25-2.22 (m, 1H), 2.18-1.90 
(t, J = 5.1, 2H), 1.75-1.64 (m, 2H); MALDI-TOF m/z calcd for C71H97N27O21 1664.70, 
found [M + Na]+ 1687.13. 
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RESULTS AND DISCUSSION 
Design of Hairpin Polyamide – Neomycin Conjugates.  Advancements by our research 
group have led to the development of a model for aminoglycoside, neomycin recognition 
of DNA.  Conjugation of neomycin to minor groove binding ligands have allowed us to 
target B-form DNA (32, 33) as well as DNA containing GC sequences, Chapter 4.  We 
seek to expand the scope of our model to include the ability to target DNA which 
contains a core sequence of four GC base pairs.  Literature suggests an increase in 
guanine or cytosine content in DNA increases the ability of the duplex to adopt A-form 
characteristics (1, 3, 4).  Chapter 4 utilized the ability of N-methylpyrrole and N-
methylimidazole to preferentially bind G/C base pairs over A/T base pairs (60, 61, 62, 63, 
64).  In this chapter, N-methylpyrrole and N-methylimidazole heterocycles are paired 
across the floor of the minor groove to preferentially bind stretches of G/C base pairs, a 
technique previously established (60, 61, 62, 63, 64). 
 An eight-ring hairpin polyamide will allow for the recognition of a core sequence 
of four G/C base pairs (55, 60).  While the tetramer polyamide HImImPyPy- allowed us 
to target DNA which contained the core sequence 5’-GGAA-3’ in a 1:1 binding mode, 
the pairing of this tetramer polyamide, head-to-tail, in the floor of the minor groove 
allows us to potentially target the core sequence 5’-GGCC-3’ in the 2:1 fashion (55).  
Hairpin polyamides afford a method of controlling the binding stoichiometry, in turn 
allow for the recognition of a core sequence of four G/C base pairs (54, 55, 64, 65, 66, 
67). 
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6 HCl
n = 2, DPA238
3, DPA239
5, DPA240
n = 2, DPA232
3, DPA233
5, DPA234
6, DPA235
8, DPA236
10, DPA237
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6 HCl 6 HCl
HImImPyPyγImImPyPyDp (28)
neomycin
6 HCl
 
Figure 4.2.  Hairpin polyamide – neomycin conjugates used in this study: DPA232 – DPA242, neomycin and 
HImImPyPyγImImPyPyDp (28).   
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The 11 hairpin polyamide – neomycin conjugates were coupled through 1,2,3-triazoles, 
‘single- and double-Click’ (68, 69, 70) and amide bonds (21).  The linker length 
separating the two moieties varied from one to 20 atoms, Figure 4.2.  To accommodate 
the variation in conjugate linker length, a sub-library of hairpin polyamides 18, DPA226 
– DPA231 and a sub-library of N-Boc protected neomycin derivatives DPA10, DPA12, 
DPA13 and DPA16 were synthesized.  Hairpin polyamide – neomycin conjugate linker 
length is defined as the number of atoms measured from the C-terminal carbonyl group of 
the hairpin polyamide to, but not including, the 5” nitrogen on ring three of neomycin.  
Conjugates containing 1,2,3-triazoles are counted through the alkene bond such that the 
lowest total number of atoms were counted.  Therefore, our library of 11 hairpin 
polyamide – neomycin conjugates ‘single-Click’ hairpin polyamide – neomycin 
conjugates DPA238 – DPA240, ‘double-Click’ hairpin polyamide – neomycin 
conjugates DPA232 – DPA237, and amide bond conjugates DPA241 and DPA242, 
Figure 4.2.    
 
Synthesis of Hairpin Polyamide – Neomycin Conjugates.  In the design of our hairpin 
polyamide – neomycin conjugates DPA232 – DPA242 we focused on the following 
retrosynthetic approach, Figure 4.3.  Each of our hairpin polyamide – neomycin 
conjugates DPA232 – DPA242 contained the same 8-ring hairpin polyamide 
HImImPyPyγImImPyPyCOOMe 19 as shown in Figure 4.3.  We envisioned this parent 
hairpin polyamide, 19, as a product of sequential couplings of three intermediate  
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20
21
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CONJUGATES
DPA232 - DPA242
 
Figure 4.3.  Retrosynthetic strategy for the convergent solution-phase synthesis of 8-ring hairpin polyamide 1.   
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polyamide trimers.  The three trimers consisted of an ImImPy containing trimer 11, 
PyγIm 20 a γ-turn moiety containing trimer and ImPyPy containing trimer 21, Figure 4.3.  
Furthermore, we envisioned the preparation of intermediate trimers 11, 20 and 21 as 
coupling products of monomeric building blocks.  For example, the ImImPy containing 
trimer could be constructed from three monomeric building blocks: 2-trichloroacetyl-1-
methylimidazole 7, methyl 4-nitro-1-methylimidazole-2-carboxylate 8 and methyl 4-
nitro-1-methylpyrrole-2-carboxylate 9, Figure 4.3.  In a similar fashion, the γ-turn moiety 
containing PyγIm 20 could be assembled from commercially available methyl 4- 
aminobutyrate 24, and two monomeric building blocks: methyl 4-[(tert-butoxy 
carbonyl)amino]-1-methylpyrrole-2-carboxylate 23 and methyl 4-nitro-1-
methylimidazole-2-carboxylate 8, Figure 4.3.  Finally, the ImPyPy containing trimer 21 
was easily prepared using two monomeric building blocks: methyl 4-[(tert-butoxy 
78
9
i ii
iii
v
11
iv
8a
  10 R = 
10a R = OH
10a
9a
 
Scheme 4.1.  Reagents and conditions:  (i) dry MeOH, H2 (g), 10% Pd/C, 23 oC, 3.5 h, 
99%; (ii) CH2Cl2, 23 
oC, 6 h, 72%; (iii) MeOH, 1.5 N NaOH, 23 oC, 4 h; (iv) MeOH, H2, 
10% Pd/C, 23 oC, 4 h, 97%; (v) DMF, EDC, HOBt, 23 oC, 16 h, 71%. 
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carbonyl)amino]-1-methylimidazole-2-carboxylate 22 and methyl 4-nitro-1-
methylpyrrole-2-carboxylate 9, Figure 4.3.   
Compound 19, and the subsequent trimers were conducted in solution in a 
modification of Dervan’s method (64).  The intermediate trimers were prepared from 
building blocks 7 – 9 and 22 - 24, which were synthesized as previously reported (56, 
71).  Synthesis of trimer 11 was conducted as previously discussed in chapter 4 (Scheme 
3.1, page 155) and shown in Scheme 4.1 (72).  
The γ-turn trimer 20 was synthesized in two coupling steps from methyl 4-[(tert-
butoxy carbonyl)amino]-1-methylpyrrole-2-carboxylate 23, Scheme 4.2.  Compound 23 
was saponified with 1.5 N NaOH followed by neutralization with HCl to afford 23a.  
Compound 23a was activated with benzotriazol-1-yl-oxytripyrrolidinophosphonium 
8a
iiii
  25 R = 
25a R = OH
  23 R = 
23a R = OH
ii
iv
20
25a
 
Scheme 4.2.  Reagents and conditions:  (i) MeOH, 1.5 N NaOH, 60 oC, 4 h; (ii) DMF, 
24, PyBOP, DIPEA, 23 oC, 15 h, 89%; (iii) MeOH, 1.5 N NaOH, 60 oC, 3.5 h; (iv) DMF, 
EDC, HOBt, 23 oC, 16 h, 89%. 
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hexafluorophosphate/N,N-diisopropylethylamine (PyBOP/DIPEA).  Commercially 
available methyl 4-aminobutyrate 24 was added to the solution containing the activated 
acid of 23a.  The desired dimer, BocNHPyγCOOMe 25, was recovered as major product.  
Dimer 25 was saponified in a fashion similar to compound 23.  The resulting acid 25a 
was activated using EDC/HOBt.  Compound 8a was added dropwise to the activated acid 
solution of 25a.  The γ-turn moiety BocNHPyγImCOOMe 20, was recovered in 58% 
yield.   
i iii
  22 R = 
22a R = OH
  26 R = 
26a R = OH
21
ivii
 
Scheme 4.3.  Reagents and conditions:  (i) MeOH, 1.5 N NaOH, 60 oC, 4 h; (ii) DMF, 
9a, EDC, HOBt, 23 oC, 15 h, 71%; (iii) MeOH, 1.5 N NaOH, 60 oC, 6 h; (iv) DMF, 9a, 
EDC, HOBt, 23 oC, 15 h, 71%. 
 
Trimer 21 was synthesized in two steps from methyl 4-[(tert-butoxy 
carbonyl)amino]-1-methylimidazole-2-carboxylate 22, Scheme 4.3.  The monomer 22 
was saponified in the presence of 1.5 N NaOH at neutralized with HCl to afford 22a.  
Compound 22a activated with EDC/HOBt.  Compound 8a was added dropwise to the 
activated acid solution of 22a.  The desired dimer, BocNHImPyCOOMe 26, was 
recovered as the major product.  Dimer 26 was saponified in a fashion similar to 
compound 22.  The resulting acid 26a was activated using EDC/HOBt followed by the 
dropwise addition of compound 9a.  Trimer 21, BocNHImPyPyCOOMe, was afforded in 
63% yield.   
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 Parent hairpin polyamide 19 was synthesized as follows, Scheme 4.4.   
Compound 11 was saponified with NaOH and neutralized with HCl to afford 11a.  
Compound 11a activated using PyBOP/DIPEA.  Congruently, compound 20 was  
27a
v
ii ivi
  27 R = 
27a R = OH
  21 R = NHBoc
21a R =        +
  11 R = 
11a R = OH
  20 R = NHBoc
20a R =        +
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Scheme 4.4.  Reagents and conditions:  (i) MeOH, 1.5 N NaOH, 60 oC, 5.5 h; (ii) diethyl 
ether, 4 N HCl in 1,4-dioxane, 6 h; (iii) PyBOP, DIPEA, DMF, 23 oC, 16 h, 88%; (iv) 
MeOH, 1.5 N NaOH, 60 oC, 4.5 h; (v) diethyl ether, 4 N HCl in 1,4-dioxane, 6 h; (vi) 
PyBOP, DIPEA, DMF, 23 oC, 24 h, 89%. 
 
deprotected using 4 N HCl.  Compound 20a was coupled 11a to afford 27.  Compound 
27 was recovered following precipitation and subsequent filtration in 88% yield.  
Compound 27 was saponified to afford the corresponding acid 27a in a method similar to 
compound 11.  The resulting acid 27a was activated using PyBOP/DIPEA.  At the same 
time, trimer 21 was deprotected in the presence of 4 N HCl.  Compound 21a was added 
to a solution containing 27a to afford the parent hairpin polyamide 19, as the major 
product, in 89% yield. 
208 
 
Linker length variation was afforded through  α, ω−amino, azido alkanes 12 – 17 
which were synthesized from corresponding dibromoalkanes using previously established 
procedures (73), Scheme 4.5.  Parent hairpin polyamide was saponified in the presence of 
1.5 N NaOH and neutralized with HCl to afford 19a.  Comound 19a was activated using 
EDC/HOBt.  In individual reactions, α, ω−amino, azido alkanes 12 – 17 were added to 
the solution containing 19a.  The desired azide functionalized tetramer polyamides 
DPA226 – DPA231 were recovered following column purification in good yields.   
ii
i
n = 2, 12 
3, 13
5, 14
6, 15
8, 16
10, 17
  19 R = 
19a R = OH
n = 2, DPA226 
3, DPA227
5, DPA228
6, DPA229
8, DPA230
10, DPA231
 
Scheme 4.5.  Reagents and conditions:  (i) MeOH, 1.5 N NaOH, 60 oC, 5.5 h; (ii) EDC, 
HOBt, DMF, 23 oC, 24 h, 77% - 91%.   
 
Commercially available neomycin B was prepared for conjugation as previously 
reported (25, 32, 59, 74), Scheme 4.6.  The six amino groups on neomycin B were N-Boc 
protected using di-tert-butyl dicarbonate.  N-Boc neomycin-TPS 2 was prepared as the 
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major product following the suspension of N-Boc neomycin in anhydrous pyridine and 
addition of 2,4,6-triisopropylbenzenesulfonyl chloride followed purification via 
chromatography, as previously reported (21, 32, 59, 74).  Synthesis of DPA10 was  
R = NHBoc
iv
DPA16
R' = R' = 
R' = 
i
R' = 
ii
R' = 
2
DPA10
DPA11
DPA12
DPA13
R' = 
iii
 
Scheme 4.6.  Reagents and conditions:  (i) NaN3, DMF, 60 oC, 12 h, 89 %; (ii) 10% 
Pd/C, MeOH, H2 (g), 7 h, 98%, (iii) propiolic acid, DCC, CH2Cl2 (dry), 0 
oC, 30 min, 
DPA12, rt, 18 h, 86 %; (iv) CuI, DIPEA, propargyl ether, toluene, 14 h, 85%.   
 
conducted as previously discussed in chapter 2 (Scheme 2.1, page 57) and shown in 
Scheme 4.1.  Following addition of sodium azide to compound 2, DPA11 was recovered 
as the major product following purification, in 89% yield, Scheme 4.6.  DPA11 was 
reduced in the presence of H2 (g) and 10% Pd/C to afford DPA12, Scheme 4.6.  DPA12 
was coupled to propiolic acid to afford DPA16 as the major product following column 
chromatography (75), Scheme 4.6.  Finally, DPA13 was synthesized following the 
coupling of DPA11 to commercially available propargyl ether using CuI/DIPEA 
mediated 1,2,3-triazole formation with a yield of 85%, Scheme 4.6 (68, 69, 70). 
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Scheme 4.7.  Reagents and conditions:  (i) CuI, DIPEA, DPA13, DPA226 – DPA231, 
DMF, 36 h; (ii) 4N HCl in 1,4-dioxane, 1 h.  Overall yields for coupling and deprotection 
steps 15% - 27%. 
 
‘Double-Click’ hairpin polyamide – neomycin conjugates DPA232 – DPA237 
were synthesized through CuI/DIPEA mediated 1,2,3-triazole formation between hairpin 
polyamides, DPA226 – DPA231, and N-Boc protected neomycin DPA1, Scheme 4.7.  
The N-Boc protected conjugates were purified with flash column chromatography 
followed by deprotection in the presence of 4 N HCl to afford DPA232 – DPA237, 
Scheme 4.7.  These conjugates represent the longest linkers in our library where the 
linker length was 12, 13, 15, 16, 18 and 20 atoms in length DPA232 – DPA237, 
respectively.   
‘Single-Click’ hairpin polyamide – neomycin conjugates DPA238 – DPA240, 
Scheme 4.8 were synthesized in a similar fashion to ‘Double-Click’ hairpin polyamide – 
neomycin conjugates.  Hairpin polyamides (DPA226 – DPA231) were coupled to 
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DPA16 through CuI/DIPEA mediated 1,2,3-triazole formation., Scheme 4.8.  The 
desired conjugates DPA238 – DPA240 were afforded following flash column 
chromatography purification of the N-Boc protected conjugates followed by deprotection 
in the presence of 4 N HCl.  The resulting conjugates feature intermediate linker lengths 
of 8, 9 and 11 atoms. 
ii
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Scheme 4.8.  Reagents and conditions:  (i) CuI, DIPEA, DPA16, DPA226 – DPA228, 
DMF, 36 h; (ii) 4N HCl in 1,4-dioxane, 1 h.  Overall yields for coupling and deprotection 
steps 26% - 30%. 
 
 Amide bond coupled hairpin polyamide – neomycin conjugates DPA241 and 
DPA242 were afforded by EDC/HOBt mediated amide bond formation, Scheme 4.9.  
Parent hairpin polyamide was saponified in the presence of 1.5 N NaOH to afford to 19a, 
as previously discussed in Scheme 4.4.  N-Boc protected neomycin DPA10 was 
dissolved added to 19a.  Following column purification of the N-Boc protected conjugate 
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and deprotection in the presence of 4 N HCl, the desired azide hairpin polyamide – 
neomycin conjugate DPA241 was recovered in 88% yield, Scheme 4.9.  DPA241  
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Scheme 4.9.  Reagents and conditions: (i) EDC, HOBt, DMF, DPA10, 12 h; (ii) 4N HCl 
in 1,4-dioxane, 1 h, 88%; (iii) EDC, HOBt, DMF, DPA12, 18 h; (iv) 4N HCl in 1,4-
dioxane, 1 h, 81%; (v) EDC, HOBt, N,N-dimethylaminopropylamine, 12 h, 94%.  Yields 
for the synthesis of DPA241 and DPA242 are reported as overall yields for coupling and 
deprotection steps. 
 
featured a linker length of four atoms.  Analogous to the synthesis of DPA241, 
compound DPA12 was added the activated acid solution of 19a.  The desired azide 
hairpin polyamide – neomycin conjugate DPA242 was recovered following column 
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purification of the N-Boc protected conjugate and deprotection in the presence of 4 N 
HCl.  DPA242 was recovered in 81% yield and featured a single atom linker length 
between the two moieties, Scheme 4.9. 
Finally, the synthesis of the hairpin polyamide, HImImPyPyγImImPyPyDp 28, 
was conducted using EDC/HOBt mediated coupling between 19a and N,N-
dimethylaminopropylamine, Scheme 4.9; similar to the synthesis of DPA241 and 
DPA242.  The major product 28 was recovered, with 94% yield, following purification.   
 
Design of DNA Duplexes to Probe Hairpin Polyamide – Neomycin Conjugate 
Library Binding.  Fluorescent intercalator displacement assays were conducted with a 
number of DNA duplex oligomers and our hairpin polyamide – neomycin conjugates, 
neomycin and 28.  The DNA duplexes varied in length and sequence to accommodate a 
number of potential DNA binding sequences.  DNA duplexes were designed with the two 
following considerations: (i) the DNA duplexes contained a potential binding site for the 
tetramer polyamide portion of our conjugates (5’-AG2C2A-3’), mismatch site (5’-G2A3-
3’) or control (5’-G2C2A-3’ or 5’-G2C2A-3’).  (ii) The DNA duplexes were lengthened to 
include a portion for neomycin which acted as a potential binding site (5’-G4C4-3’) or 
control (5’-G4-3’) as identified by our group (76).  Applying these considerations, the 
following DNA duplexes were used in this study 5’-AG2C2AG4C4-3’, 5’-G2A3G4C4-3’, 
5’-G2C2AG4C4-3’, 5’-TG2C2G4-3’ and 5’-AG2C2AG4-3’.  The 5’-AG2C2AG4C4-3’ was 
the target duplex for our studies and featured a binding site for the hairpin polyamide 
portion of our conjugate (5’-AG2C2A-3’) (55) and a portion for binding by neomycin (5’-
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G4C4-3’).  The 5’-G2A3G4C4-3’ duplex acted as a control in our study as it contained a 
mismatch site (5’-G2A3-3’) which does not bind the hairpin polyamide portion of our 
conjugates but does include a portion for binding by neomycin (5’-G4C4-3’).  In an effect 
to see if loss of a the 5’ terminal A/T base pair effects the binding of our tetramer 
polyamide – neomycin conjugate, the 5’-G2C2AG4C4-3’ duplex was designed.  Both of 
the remaining duplexes 5’-TG2C2G4-3’ and 5’-AG2C2AG4-3’ were shortened duplexes 
that act as controls.  CD scans of each of these duplexes is located in Appendix B, 
Figure B37. 
 
Hairpin Polyamide – Neomycin Conjugate Library Binding as Studied With a 
Fluorescent Intercalator Displacement Assay.  An assay was conducted in which 
neomycin, 28 and hairpin polyamide – neomycin conjugates DPA232 – DPA242 were 
added to individual wells that contained the target duplex, pre-saturated with ethidium 
bromide, at various drug:duplex ratio (rdd) in a 96-well plate (77, 78, 79).  A histogram of 
the normalized percent decrease in fluorescence intensity with respect to control ligands 
and hairpin polyamide – neomycin conjugate linker length was plotted.  
 Each of the hairpin polyamide – neomycin conjugates as well as neomycin and 28 
displaced pre-bound ethidium bromide DPA232 – DPA242 upon addition to wells 
containing the 5’-G2A3G4C4-3’ duplex at rdd = 1.0, Figure 4.4.  The 5’-G2A3G4C4-3’ 
duplex acted as a control in our study as it contained a mismatch site (5’-G2A3-3’) which 
does not bind the hairpin polyamide portion of our conjugates but does include a portion 
for binding by neomycin (5’-G4C4-3’).  As the neomycin binding portion of this DNA  
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Figure 4.4.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-G2A3G4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Data was obtained from a FID 
assay.  Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium 
bromide [7 µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min 
and the subsequent decrease in fluorescence was recorded.  The data was normalized 
such that the well containing ethidium bromide and buffer was denoted as 0% 
fluorescence and the well containing buffer, DNA and ethidium bromide was denoted as 
100% fluorescence.  Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; 
slitsex = 20; slitsem = 20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 
nm; PMT V = 810 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO-
4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
 
duplex (5’-G4C4-3’) was identical to our target duplex, 5’-AG2C2AG4C4-3’, the amount 
of pre-bound ethidium bromide, 26%, was nearly identical.  However, as the 5’-
G2A3G4C4-3’ duplex contains a mismatch site, the decreased amount of displaced pre-
bound ethidium bromide upon addition of 28 to the duplex (only 7%) was expected.  
Each of the hairpin polyamide – neomycin conjugates DPA232 – DPA242 used in our 
study displaced pre-bound ethidium bromide upon addition to the 5’-G2A3G4C4-3’ 
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duplex.  However, none of these conjugates displaced more pre-bound ethidium bromide 
than neomycin.   
 
Figure 4.5.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-G2C2AG4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Data was obtained from a FID 
assay.  Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium 
bromide [7 µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min 
and the subsequent decrease in fluorescence was recorded.  The data was normalized 
such that the well containing ethidium bromide and buffer was denoted as 0% 
fluorescence and the well containing buffer, DNA and ethidium bromide was denoted as 
100% fluorescence.  Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; 
slitsex = 20; slitsem = 20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 
nm; PMT V = 810 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO-
4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
  
An FID assay was used to study the effect of the loss of the 5’ terminal A/T base pair (5’-
G2C2AG4C4-3’) on the binding of our tetramer polyamide – neomycin conjugates, 
DPA232 – DPA242, Figure 4.5.  Neomycin displaced 24% of pre-bound ethidium 
bromide while compound 18 displaced 18% at rdd = 1.0.  The assay identified four hairpin 
polyamide – neomycin conjugates which displaced more pre-bound ethidium bromide 
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that neomycin and 28.  DPA237 (L = 20 atoms) displaced 31% of pre-bound ethidium 
bromide while hairpin polyamide – neomycin conjugates of intermediate linker 
 
Figure 4.6.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-TG2C2G4-3’.  In the histogram, the values represent 
the percent decrease in fluorescence at rdd = 1.0.  Data was obtained from a FID assay.  
Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 
µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the 
subsequent decrease in fluorescence was recorded.  The data was normalized such that 
the well containing ethidium bromide and buffer was denoted as 0% fluorescence and the 
well containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
 
lengths DPA232, DPA239 and DPA240 (L = 12, 9, 11 atoms, respectively) displaced 
~29%.   
The control ligands neomycin and HImImPyPyDp 28 displaced pre-bound 
ethidium bromide from the remaining duplexes 5’-TG2C2G4-3’ and 5’-AG2C2AG4-3’ 
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shortened duplexes.  The same was true for our hairpin polyamide – neomycin conjugates 
DPA232 – DPA242 in our library.   
 Addition of neomycin to wells containing the 5’-TG2C2G4-3’ duplex pre-bound 
with ethidium bromide resulted in a 36% decrease in fluorescence intensity at rdd = 1.0, 
Figure 4.6.  The hairpin polyamide control 28 only displaced 17% or pre-bound ethidium 
bromide upon addition to the duplex.  The only hairpin polyamide – neomycin conjugate 
that displaced more pre-bound ethidium bromide was DPA237 (L = 20 atoms) at 45%.  
All remaining hairpin polyamide – neomycin conjugates of shorter linker length did not 
displace as much pre-bound ethidium bromide as neomycin.  Hairpin polyamide – 
neomycin conjugates of intermediate linker length DPA232 (L = 12 atoms), DPA239 (L 
= 9 atoms) and DPA240 (L = 11 atoms) all displaced approximately equivalent amounts 
of pre-bound ethidium bromide from the 5’-TG2C2G4-3’ duplex, ~35%.   
 Addition of neomycin (at rdd = 1.0) to the 5’-AG2C2AG4-3’ duplex pre-bound 
with ethidium bromide displaced 21% of the pre-bound intercalator, while 28 (at rdd = 
1.0) displaced 29%, Figure 4.7.  Each of the tetramer polyamide – neomycin conjugates 
DPA232 – DPA242 displaced pre-bound ethidium bromide at rdd = 1.0.  However, none 
of these conjugates displaced appreciably more ethidium bromide than neomycin or 28.  
The only hairpin polyamide – neomycin conjugates which displace more pre-bound 
ethidium bromide were DPA232 (L = 12 atoms), DPA233 (L = 13 atoms) and DPA238 – 
DPA240 (L = 8, 9, 11 atoms, respectively).  As conjugate linker length increase the 
amount of stabilization was DPA238 (L = 8 atoms) 30%, DPA239 (L = 9 atoms) 32%, 
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DPA240 (L = 11 atoms) 31%, DPA232 (L = 12 atoms) 30% and DPA233 (L = 13 atoms) 
31%.   
 
Figure 4.7.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-AG2C2AG4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Data was obtained from a FID 
assay.  Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium 
bromide [7 µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min 
and the subsequent decrease in fluorescence was recorded.  The data was normalized 
such that the well containing ethidium bromide and buffer was denoted as 0% 
fluorescence and the well containing buffer, DNA and ethidium bromide was denoted as 
100% fluorescence.  Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; 
slitsex = 20; slitsem = 20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 
nm; PMT V = 810 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO-
4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
 
Neomycin displaced 30% of the pre-bound ethidium bromide upon binding the 
DNA duplex, Figure 4.8.  The control hairpin polyamide 28 displaced 20% of the pre-
bound ethidium bromide, not surprising with respect to neomycin, since the binding site 
for the hairpin polyamide is smaller than the binding site for neomycin.  Each of the 
hairpin polyamide – neomycin conjugates DPA232 – DPA242 displaced pre-bound 
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ethidium bromide upon addition to wells containing the pre-saturated target duplex at rdd 
= 1.0.  The assay identified five hairpin neomycin conjugates that displaced more pre- 
 
Figure 4.8.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-AG2C2AG4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Data was obtained from a FID 
assay.  Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium 
bromide [7 µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min 
and the subsequent decrease in fluorescence was recorded.  The data was normalized 
such that the well containing ethidium bromide and buffer was denoted as 0% 
fluorescence and the well containing buffer, DNA and ethidium bromide was denoted as 
100% fluorescence.  Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; 
slitsex = 20; slitsem = 20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 
nm; PMT V = 810 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO-
4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
 
bound ethidium bromide than neomycin or 28.  DPA237, which featured the 
longest linker (L = ) of 20 atoms, displaced the most pre-bound ethidium bromide, 41%.  
Conjugates DPA236 (L = 18 atoms) and DPA235 (L = 16 atoms) displaced 38% and 
35% of pre-bound ethidium bromide, respectively.  There were also two more hairpin 
polyamide – neomycin conjugates which displaced more pre-bound ethidium bromide 
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than neomycin or 28.  These conjugates DPA232 (L = 12 atoms) and DPA240 (L = 11 
atoms) displaced 34% and 36% of pre-bound ethidium bromide.   
 Furthermore, a plot of linker length with respect to percent decrease in 
fluorescence intensity was plotted at rdd = 0.5 and rdd = 2.0, Appendix C, Figure C26 
and Figure C27.  A rdd = 0.5, neomycin displaced 19% and 28 displaced 14% of pre-
bound ethidium bromide.  However, conjugates of linker length of 11 and 12 atoms 
(DPA240 and DPA232) displaced significantly more pre-bound ethidium bromide at 
26% and 30%, respectively, Appendix C, Figure C26.  Increasing the rdd value to 2.0, 
DPA232 (L = 12 atoms) and DPA240 (L = 11 atoms) both displace significantly more 
amounts of pre-bound ethidium bromide than neomycin or 28.  Furthermore, the ability 
of hairpin polyamide – neomycin conjugates of longer linker length DPA235 (L = 16 
atoms), DPA236 (L = 18 atoms)   DPA237 (L = 20 atoms) to displace more pre-bound 
ethidium bromide than neomycin or 28, previously observed at rdd = 1.0 was also 
observed at rdd = 2.0, Appendix C, Figure C27.     
 
UV Monitored Thermal Denaturation of Target Duplex.  UV thermal denaturation 
experiments were conducted using the target duplex 5’-AG2C2AG4C4-3’.  The target 
duplex was denatured in the presence of hairpin polyamide – neomycin conjugates, 
neomycin and the hairpin polyamide control 28, Figure 4.9 and Table 4.1.  In an effort to 
focus solely on the primary binding site, these studies were conducted at rdd = 1.0 in the 
presence of 50 mM NaCl.  Each of the compounds studied increased the melting 
temperature of the duplex as seen in the histogram, Figure 4.10.    
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 (a) (b) 
  
Figure 4.9.  UV melting profiles for 5’-AG2C2AG4C4-3’ with hairpin polyamide - 
neomycin conjugates DPA232 – DPA242, neomycin and 18 (a, b).  Ligands were added 
to the duplex [2 µM/duplex] at rdd = 1.0.  The samples were incubated at 4 
oC for 12 h.  
prior to analysis, slow heating from 10 oC to 100 oC at 0.2 oC/min.  The panels above 
correspond to the melts.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, 
pH 7.0, 50 mM NaCl. 
 
Neomycin increased the melting temperature of the duplex by 7.1 oC and the 
hairpin polyamide control 28 increased the melting temperature of the duplex by 5.4 oC.  
The largest increase in thermal stabilization was afforded by DPA233 (L = 13 atoms) at 
22.8 oC.  As the linker length decreased, the thermal stabilization afforded by the 
conjugates on the duplex decreased in magnitude.  DPA232 (L = 12 atoms) increased the 
melting temperature by 21.9 oC.  Decreasing the linker length to 11 atoms (DPA240) and 
9 atoms (DPA239) stabilized the duplex by 20.8 oC and 18.0 oC, respectively.  The lowest 
increase in thermal stabilization afforded by hairpin polyamide – neomycin conjugates on 
the duplex 5’-AG2C2AG4C4-3’occurred with DPA241 (L = 4 atoms), which increased the 
thermal stability of the duplex by 12.6 oC.  DPA234 (L = 15 atoms) increases the melting 
temperature of the duplex by 16.3 oC.  As linker length increases beyond 15 atoms, the 
increase in melting temperature afforded by hairpin polyamide – neomycin conjugates 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
native
HImImPyPyγIm
ImPyPyDp (28)
Neomycin
DPA238 - 8
DPA239 - 9
DPA240 - 11
DPA241 - 1
DPA242 - 3
T (oC)
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
native
DPA232 - 12
DPA233 - 13
DPA234 - 15
DPA235 - 16
DPA236 - 18
DPA237 - 20
T (oC)
223 
 
remains constant.  DPA235 (L = 16 atoms), DPA236 (L = 18 atoms) and DPA237 (L = 
20 atoms) which feature linker lengths of 16, 18 and 20 atoms all increase the melting 
temperature of the duplex by ~19 oC.   
 
Figure 4.10.  Plot of ∆Tm with respect to conjugate linker length upon addition of ligands 
to 5’-AG2C2AG4C4-3’ with controls and hairpin polyamide – neomycin conjugates 
DPA232 – DPA242.  Data was obtained from UV thermal denaturation experiments.  
Ligands were added to the DNA [2.0 µM/duplex] at a ratio of drug to duplex 1.0.   The 
samples were incubated at 4 oC for 12 h.  prior to analysis, slow heating from 10 oC to 
100 oC at 0.2 oC/min.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, 
pH 7.0, 50 mM NaCl.    
 
Finally, for ease of comparison, a table comparing ∆Tm values (obtained from UV 
thermal denaturation experiments) and ∆F values (obtained from FID assays) with 
respect to linker length for hairpin polyamide – neomycin conjugates DPA32 – DPA242 
and controls with 5’-AG2C2AG4C4-3’ is located in Table 4.1.  
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Table 4.1.  UV determined thermal melting (Tm) change in thermal melting 
(∆Tm) temperatures and FID assay determined change in fluorescence (∆F) 
data.  Data for the addition of hairpin polyamide – neomycin conjugates 
DPA232 – DPA242, neomycin and 28 to 5’-AG2C2AG4C4-3’ at rdd = 1.0.   
  Tm
a ∆Tm
b ∆Fc  Tm ∆Tm ∆F
c 
native 56.1 - - HImImPyPyγIm 
ImPyPyDp (28) 61.5 5.4 20.0 Neomycin 63.2 7.1 29.8 
 Nd    N   
DPA232 12 78.0 21.9 32.9 DPA241 4 68.7 12.6 20.7 
DPA233 13 78.9 22.8 23.6 DPA242 1 70.1 14.0 22.3 
DPA234 15 72.4 16.3 27.5 DPA238 8 73.5 17.4 17.0 
DPA235 16 75.2 19.1 33.7 DPA239 9 74.1 18.0 25.6 
DPA236 18 75.5 19.4 37.3 DPA240 11 76.9 20.8 36.9 
DPA237 20 75.3 19.2 45.1     
aTm represents the melting temperature of the native duplex, values are 
reported in oC.  b∆Tm represents the change in melting temperature upon 
addition of neomycin at a rdd, values are reported in 
oC.  c∆F represents the 
change in fluorescence intensity upon addition of ligand at rdd = 1.0.  
dN 
represents tetramer polyamide – neomycin conjugate linker length in atoms.  
Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 
mM NaCl. 
 
 
Fluorescence Intercalator Displacement Titrations and Binding Affinity.  In an effort 
to obtain quantitative binding affinities Ka and relate them to the results obtained from 
our assay and thermal denaturation experiments, full FID titrations were conducted.  The 
target duplex was pre-saturated with thiazole orange.  A departure from ethidium 
bromide was made due to the large difference in fluorescence intensity observed between 
the bound and unbound states of thiazole orange (80).  Ligand was added at varying rdd 
values and the decrease in fluorescence intensity was recorded.   
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28 HImImPyPyγImImPyPyβDp  
Figure 4.11.  Comparison of compounds 28 and HImImPyPyγImImPyPyβDp. 
 
 
Dervan has established the affinity of hairpin polyamides to a number of target sequences 
(55, 67).  The hairpin polyamide HImImPyPyγImImPyPyβDp analogous to our control 
28, Figure 4.11, was reported to recognize the target sequence 5’-TGGCCA-3’ with an 
equilibrium constant Ka of 9.7 x 109 M-1 as determined by DNase I footprint titration 
experiments (55).  A decrease in fluorescence intensity upon the titration of 28 into the 
target duplex was observed.  A clear inflection point was observed at rdd = 1.0, Appendix 
C, Figure C28.  However, addition of 28 beyond rdd = 1.0 resulted in a continued 
decrease in fluorescence intensity.  We believe the continued decrease in fluorescence 
intensity is a result of 28 binding the lower affinity mismatch site found the target duplex 
as previously reported (54, 55, 63, 67).  As a result, we were unable to perform Scatchard 
analysis on the pre-saturation region of the titration curve, observed at rdd = 1.0 and an 
association constant Ka for out control 28 with 5’-AG2C2AG4C4-3’ was not determined.   
Titration of neomycin into the 5’-AG2C2AG4C4-3’ duplex pre-bound with thiazole 
orange resulted in a decrease in fluorescence intensity, Figure 4.12.  The decrease in 
fluorescence intensity was plotted against rdd and a clear 1:1binding stoichiometry was 
observed.  Scatchard analysis was performed on the pre-saturation region of the titration 
curve and provided an association constant Ka of 3.3 x 106 M-1.  Fluorescence intensity  
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(a) (b) 
  
(c) (d) 
  
Figure 4.12.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-AG2C2AG4C4-3’, 
by neomycin at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). 
A related plot of ∆F vs rdd is located in panel (c).  Scatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of neomycin, the fluorescence intensity is denoted as Fmax.  Neomycin 
was added at various rdd values.  Fluorescence parameters: Excitation = 504 nm; 
Emission = 510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; 
PMTV = 550 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 
mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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(a) (b) 
  
(c) (d) 
  
Figure 4.13.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-AG2C2AG4C4-3’, 
by DPA232 at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). A 
related plot of ∆F vs rdd is located in panel (c).  Scatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of DPA232, the fluorescence intensity is denoted as Fmax.  DPA232 was 
added at various rdd values.  Fluorescence parameters: Excitation = 504 nm; Emission = 
510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; PMTV = 550 
and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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(a) (b) 
  
(c) (d) 
  
Figure 4.14.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-AG2C2AG4C4-3’, 
by DPA240 at 20 oC (a).  A plot of fluorescence intensity vs rdd is located in panel (b). A 
related plot of ∆F vs rdd is located in panel (c).  Schatchard analysis of the pre-saturation 
region is located in panel (d).  The DNA duplex, 1.0 µM/duplex, 14 µM/base pair, was 
pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 10 min 
prior to addition of DPA240, the fluorescence intensity is denoted as Fmax.  DPA240 was 
added at various rdd values.  Fluorescence parameters: Excitation = 504 nm; Emission = 
510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; PMTV = 550 
and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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 (a) (b) 
  
Figure 4.15.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-AG2C2AG4C4-3’, 
by DPA239 (a) at 20 oC.  A related plot of ∆F vs rdd is located in panel (b).  The DNA 
duplex, 1.0 µM/duplex, 14 µM/base pair, was pre-bound by thiazole orange, 7 µM and 
allowed to equilibrate for a period of 10 min prior to addition of ligand, the fluorescence 
intensity is denoted as Fmax.  Fluorescence parameters: Excitation = 504 nm; Emission = 
510-610 nm; Excitation filter = open; Emission filter = open; Slits = 20; PMTV = 550 
and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH-
2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
 
decreased upon titration of DPA232 (L = 12 atoms) and DPA240 (L = 11 atoms) into the 
duplex pre-bound with thiazole orange.  Both hairpin polyamide – neomycin conjugates 
clearly demonstrate 1:1 binding with the target duplex, Figure 4.13 and Figure 4.14, 
respectively.   Scatchard analysis of the pre-saturation region of the titration cure afforded 
association constants for the conjugates with the target duplex; DPA232 (L = 12 atoms), 
Ka = 3.8 x 109 M-1, and DPA240 (L = 11 atoms), Ka = 7.8 x 108 M-1.  Surprisingly, we 
could not extend Scatchard analysis to the titration of the remaining hairpin polyamide – 
neomycin conjugates.   
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Titration of DPA239 into the target duplex resulted in a decrease in fluorescence 
intensity, Figure 4.15, as observed with previously discussed hairpin polyamide – 
neomycin conjugates.  Unfortunately, the lack of a clear saturation point precluded the 
use of Scatchard analysis.   
Furthermore, similar observations were made upon the titration of hairpin polyamide – 
neomycin conjugates of longer linker length DPA236 (L = 18 atoms) and DPA237 (L = 
20 atoms) into the target duplex, Appendix C, Figure C29.   
While the decrease in fluorescence intensity suggests conjugate binding, the 
inability to fit this data may be a result of the insufficient linker length.  Although we still 
observe a decrease in fluorescence intensity, the linker separating the two binding 
moieties may not allow the conjugate to bind in its preferred orientation.  Assuming the 
hairpin polyamide portion of our conjugates binds at a similar magnitude to analogous 
hairpin polyamides developed by Dervan 108 – 109 M-1 (55), the hairpin polyamide 
portion drives the binding of our conjugates as neomycin (from our Scatchard analysis 
binds 5’-AG2C2AG4C4-3’ with Ka of 3.3 x 106 M-1).  It is possible that if linker length is 
insufficient the hairpin portion binds 5’-AG2C2AG4C4-3’ leaving neomycin to bind in a 
less preferential orientation.  However, this leaves space for additional amounts of 
conjugate to bind the duplex thus resulting in the continuing decrease in fluorescence 
intensity as observed with DPA236 (L = 18 atoms), DPA232 (L = 12 atoms) and 
DPA240 (L = 11 atoms).   
Our group has previously shown the ability of neomycin minor groove binding 
conjugates of longer linker length to bind DNA (32).  Unfortunately, we were unable to  
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(a) (b) (c) 
   
(d) (e) (f) 
   
Figure 4.16.  CD scans for the titration of 5’-AG2C2AG4C4-3’ with neomycin (a, d), HImImPyPyγImImPyPyDp 28 (b, e), 
DPA232 (c, f) at 20 oC.  In plot (d, e, f) the open circle represents the CD scan of the duplex in the absence of neomycin while 
the closed circle represents the CD scan of the duplex in the presence of ligand rdd = 2.0.  The conjugate was added to the 
duplex [40 µM/bp] was added at varying rdd values.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 
50 mM NaCl. 
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derive quantitative association constants for hairpin polyamide – neomycin conjugates of 
longer linker lengths.  Whether the high amount of displaced ethidium bromide observed 
in our single point FID assay is a result of a secondary binding mode or non-optimized 
linker length remains to be seen.  While association constants could not be derived for all 
hairpin polyamide – neomycin conjugates the association constants for DPA232 (L = 12 
atoms) and DPA240 (L = 11 atoms) to the target duplex are the highest observed 
association constants for neomycin binding DNA.   
 
CD Monitored Titrations of Target Duplexes.  In effort to further characterize the 
binding of hairpin polyamide – conjugates, CD monitored titration of the target duplex 
5’-AG2C2AG4C4-3’ with neomycin, 18 and DPA232 (L = 12 atoms), Figure 4.16.  The  
CD spectra of native 5’-AG2C2AG4C4-3’ consists of a positive band at 270 nm which 
suggests the duplex retains A-form characteristics.  However the negative band at 240 nm 
and the slight shoulder at 280 nm suggest the duplex also retains some B-form 
characteristics.  Addition of neomycin to the duplex results in an increase in CD intensity 
at 270 nm and the appearance of a negative peak at 210 nm which suggests an increase in 
A-form characteristics upon binding.  The addition of 18 to the duplex does little to 
change the overall shape of the CD spectra between 200 nm – 300 nm.  Binding of 18 is 
illustrated by the increase in CD intensity between 300 nm – 400 nm.  The positive band 
at 270 nm and a negative band decreases in intensity upon addition of 18.  The negative 
band at 240 nm and the slight shoulder at 280 nm suggest addition of 18 results in an 
increase in B-form characteristics.  The binding of DPA232 (L = 12 atoms) to 5’-5’-
233 
AG2C2AG4C4-3’ is clearly illustrated by the increase in CD intensity at 300 nm – 350 nm, 
the polyamide absorption region.  Furthermore, the CD spectra displays an increase in 
CD intensity at 270 nm and 210 nm upon addition of DPA232 (L = 12 atoms) which 
suggests an increase in A-form characteristics of the duplex occurs upon conjugate 
addition.    
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CONCLUSIONS 
This chapter reflects our current advancements in an aminoglycoside based 
approach to DNA recognition.  A library of hairpin polyamide – neomycin conjugates 
DPA232 – DPA240 which differ in linker length between the two binding moieties was 
synthesized.  The hairpin polyamide was designed to target the sequence 5’-AG2C2A-3’ 
and synthesized in solution through the sequential coupling of polyamide trimers.  The 
hairpin polyamide was functionalized with the azide functional group through the 
coupling with a number of  α,ω-amino, azido alkanes with our parent polyamide 19 to 
afford DPA226 – DPA231.  Hairpin polyamide – neomycin conjugates DPA232 – 
DPA240 were synthesized through 1,2,3,-triaole formation between DPA226 – DPA231 
and neomycin derivatives DPA13 and DPA16.  Shorter hairpin polyamide – neomycin 
conjugates were afforded through amide bond formation between 19 and neomycin 
derivatives DPA10 and DPA12.   
Spectroscopic techniques were used to characterize the binding of neomycin, 
HImImPyPyγImImPyPyDp 28, and hairpin polyamide – neomycin conjugates DPA232 – 
DPA240 and the following conclusions were drawn.  (i) FID assay identified potential 
high affinity binding tetramer polyamide – neomycin conjugates.  Each of the conjugates 
was assayed against a DNA duplex containing the hairpin target sequence as well as a 
GC rich pocket for neomycin.  The assay clearly illustrated the binding of each hairpin 
polyamide – neomycin conjugate to the target duplex.  Furthermore, results from the FID 
single point assay identified five conjugates which displaced more pre-bound ethidium 
bromide than neomycin or the control polyamide.  (ii) UV thermal denaturation 
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experiments aids in the identification of potential high affinity binding tetramer 
polyamide – neomycin conjugates.  Each of the compounds used in our study stabilized 
the target duplex.  In fact, each of the hairpin polyamide – neomycin conjugates DPA232 
– DPA242 stabilized the thermal stability of the target duplex better than neomycin of 28.  
Furthermore, hairpin polyamide – neomycin conjugates of linker length 11, 12 and 13 
atoms in length (DPA240 (L = 11 atoms), DPA232 (L = 12 atoms) and DPA233 (L = 13 
atoms), respectively) stabilized the duplex by the largest magnitude.   (iii) CD Titration of 
5’-AG2C2AG4C4-3’ by DPA232 suggests binding.  Binding of DPA232 (L = 12 atoms) to 
5’-AG2C2AG4C4-3’ is clearly illustrated by the increase in CD intensity at 300 nm – 350 
nm.  Furthermore, CD suggests addition of DPA232 (L = 12 atoms) to 5’-AG2C2AG4C4-
3’ increase A-form conformation in the duplex.  (iv) Full FID titrations suggest tetramer 
polyamide – neomycin conjugates bind the sequence with Ka of 108 – 109 M-1.  In an 
effort to obtain quantitative association constants, full FID titrations were conducted with 
the hairpin polyamide – neomycin conjugates and the target duplex.  While each of these 
conjugates displaced pre-bound thiazole orange, indicative of conjugate binding, the lack 
of a clear saturation point was not observed for a number of these conjugates.  When 
saturation was observed upon titration of DPA232 (L = 12 atoms) and DPA240 (L = 11 
atoms) into the target duplex, Scatchard analysis was performed to determine quantitative 
association constants Ka.  Scatchard derived association constants for DPA232 (L = 12 
atoms) and DPA240 (L = 11 atoms) with the target duplex were Ka = 3.8 x 109 M-1 for Ka 
= 7.8 x 108 M-1, respectively.   
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APPENDIX A 
TPS =
R = NHBocDPA102
 
N-Boc neomycin-S(CH2)2NH2 (DPA10).  Synthesized as previously described:  1H 
NMR (300 MHz, CDCl3) δ 6.28 (s, 1H), 6.22 (s, 1H), 5.25 (s, 1H), 5.05 (s, 1H), 4.88 (s, 
2H), 4.80 (s, 1H), 4.61 (s, 1H), 4.30-4.00 (m, 5H), 3.89 (s, 2H), 3.80 (s, 1H), 3.74 (s, 2H), 
3.70 (s, 2H), 3.65 (s, 2H), 3.60 (s, 3H), 3.40 (s, 1H), 3.31 (s, 2H), 3.14 (s, 2H), 1.57-1.34 
( m, 54 H); MALDI-TOF m/z calcd for C55H99N7O24S 1274.47, found [M + Na]+ 
1298.36.   
 
TPS =
R = NHBocDPA112
S
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O
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O
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OH
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OH
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TPS N3
 
N-Boc neomycin-N3 (DPA11).  To a solution of 2 (100.0 mg, 67.5 mmol) in DMF (10 
mL) was added sodium azide (21.9 mg, 337.4 mmol).  The solution was allowed to stir at 
60 oC for 12 h.  The solution was suspended in brine (250 mL) and washed with CH2Cl2 
(150 mL).  The organic layer was dried over Na2SO4 and concentrated in vacuo.  The 
residue was purified by flash chromatography (silica gel, CH2Cl2:MeOH, 0.5% 
incremental increases in MeOH) to yield DPA11 (74.5 mg, 89%) as a white solid:  TLC 
242 
(92:8 CH2Cl2:MeOH v/v) Rf 0.68; 
1H NMR (500 MHz, CDCl3) δ 6.21 (s, 1H), 6.15 (s, 
1H), 5.22 (s, 1H), 4.97 (s, 1H), 4.89 (s, 2H), 4.74 (s, 1H), 4.60 (s, 1H), 4.29-4.00 (m, 5H), 
3.86 (s, 2H), 3.76 (s, 1H), 3.70 (s, 2H), 3.50 (s, 3H), 3.45 (s, 1H), 3.25 (s, 2H), 3.00 (s, 
2H), 1.55-1.36 (m, 54H); MALDI-TOF m/z calcd for C53H93N9O24Na 1240.35, found [M 
+ Na]+ 1264.71. 
 
DPA11 R = NHBocDPA12  
N-Boc neomycin-NH2 (DPA12).  To a solution of DPA11 (100.0 mg, 80.6 mmol) in 
MeOH (20 mL) was added 10% Pd/C (15.0 mg, 140.9 mmol).  The reaction was allowed 
to stir for 7 h under slightly positive H2 (g), afforded via submerged syringe needle.  The 
catalyst filtered and the solvent was removed in vacuo to afford DPA12 (95.8 mg, 98%), 
sufficiently pure, as a yellowish oil:  TLC (90:10 CH2Cl2 v/v) Rf 0.25; 1H NMR (500 
MHz, CDCl3) δ 7.84 (br, 2H), 6.41 (s, 1H), 6.33 (s, 1H), 5.28 (s, 1H), 5.16 (s, 1H), 4.80 
(s, 2H), 4.72 (s, 1H), 4.60(s, 1H), 4.30-4.00 (m, 5H), 3.95 (s, 2H), 3.87 (s, 1H), 3.76 (s, 
2H), 3.71 (s, 2H), 3.60 (s, 2H), 3.55 (s, 3H), 3.54 (s, 2H), 3.47 (s, 1H), 3.30 (s, 2H), 1.66-
1.38 ( m, 54 H); MALDI-TOF m/z calcd for C53H95N7O24 1214.35, found [M + Na]+ 
1238.58.   
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3 R = NHBocDPA12
5
 
Boc-protected Neomycin-Methidium Conjugate (5).  To a solution of 6-(4-
carboxyphenyl)-3,8-diamino-5-methylphenanthridinium chloride (3) (10.0 mg, 26.7 
µmol) in dry DMF (5.5 mL), dicyclohexylcarbodiimide (5.5 mg, 26.7 µmol) and 
dimethylaminopyridine (1.5 mg, 15.0 µmol) were added. The solution was allowed to stir 
under positive N2 gas for 3 h. A solution of DPA12 (34.8 mg, 26.7 µmol) in dry DMF 
(4.0 mL) was added via cannula. The reaction was allowed to stir at room temperature 
under positive N2 for 28 h. The volatiles were removed in vacuo. The dry solid was 
washed with CH2Cl2. The resulting solid was dried in vacuo. Flash chromatography (0%-
25% MeOH:CH2:Cl2) afforded 5 (33.8 mg, 83%) as a purple solid: Rf 0.2 in 85:15 
CH2Cl2:MeOH); 
1H NMR  (500 MHz, methanol-d4, 25 
oC) δ 8.52 (d, 1H, J = 9.0), 8.48 
(d, 1H, J = 9.0), 7.80 (d, 2H, J = 8.8), 7.58 (d, 2H, J = 8.8), 7.47 (m, 1H, J = 9.1), 7.30-
7.25 (m, 3H), 5.31 (br, 1H), 5.22 (s, 1H), 4.64 (br, 2H), 4.54 (s, 1H), 4.40-3.98 (m, 1H), 
3.89-3.80 (m, 1H), 3.77-3.70 (m, 1H), 3.69-3.60 (m, 2H), 3.59-3.54 (m, 4H), 3.50 (d, 
2H), 3.41 (br, 4H), 3.40-3.20 (m, 1H), 3.19 (m, 1H), 3.13-1.01 (m, 4H), 2.95-2.93 (m, 
4H), 2.91 (d, 2H), 1.96-1.86 (m, 2H), 1.71 (br, 1H), 1.36-1.48 (m, 54H); MALDI-TOF 
m/z (rel. intensity) calculated for  C73H108N10O25 [M + Na]+ 1525.69 found 1549.16. 
 
244 
R = NHBoc
DPA201
5
 
Neomycin-Methidium Conjugate (DPA201).  To a solution of 5 (33.8 mg, 22.2 µmol) 
in 3.0 mL dichloromethane was added trifluoroacetic acid (3.0 mL). 1,2-ethanedithiol 
(100.0 µL) was added and the solution was allowed to stir for 30 min. The volatiles were 
removed under vacuum. The resulting oil was washed with diethylether affording a 
maroon solid. The solid was dissolved in nanopure water. The solution was purified with 
preparatory HPLC using a reverse phase column, (0%-100% H2O:MeCN 0.1%TFA, 15 
min). The compound eluted at 20.93 min. Fractions containing the compound were 
lyophilized affording DPA201 (34.1 mg, 95%) as a maroon solid: 1H NMR (500 MHz, 
MEOD) 8.56 (d, 1H, J = 9.5 Hz), 8.71 (d, 1H, J = 9.4), 7.56 (d, 2H, J = 8.7), 7.50 (d, 2H, 
J = 8.8), 7.32 (m, 1H, J = 9.6), 7.31-7.30 (m, 3H), 6.27 (br, 1H), 4.33-4.23 (s, 3H), 4.01-
3.88 (m, 2H), 3.99-3.81 (m, 1H), 3.75-3.71 (m, 1H), 3.61-3.59 (m, 2H), 3.29-3.21 (m, 
4H), 3.17-3.03 (m, 4H), 2.91-2.89 (m, 2H), 2.89-2.85 (m, 2H), 2.85 (m, 2H), 2.77 (m, 
2H), 1.93-1.70 (m, 4H), 1.89 (m, 2H); MALDI m/z (rel intensity) calculated for 
C44H63N10O13 [M + H]
+ 940.03 found [M + Na]+ 961.60.  
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure A1. Characterization of compound DPA10.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure A2. Characterization of compound DPA11.   
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(a) 1H NMR 
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Figure A3. Characterization of compound DPA12.   
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(c) MALDI-TOF 
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Figure A4.  Characterization of compound 
 
(a) 1H NMR 
4.   
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(b) IR 
 
(h) UV-vis 
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(i) MALDI-TOF 
 
(j) Reverse phase HPLC chromatograph of purified NM. Column and conditions: 
Phenomenex Luna Su-C18(2) reverse phase column, 250 x 10.00 mm 5 u micro, (0%-
100% H2O:MeCN 0.1%TFA, 30 min). Y-axis units AU488. 
 
Figure A5.  Characterization of compound DPA200.   
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Figure A6.  Characterization of compound
 
 5.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure A7.  Characterization of compound DPA201.   
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Figure A8.  Competition dialysis results of DPA200 with various nucleic acids.  The 
histograms show the amount of DPA200 bound to individual nucleic acids following 
dialysis.  Nucleic acids were dialyzed with DPA200 in buffer solution for 72 h.  In the 
panel [DPA200] = 100 nM, [nucleic acids] = 750 nM per base unit of each polymer.  
Buffer:  6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM EDTA, pH 7.0, 100 mM NaCl.    
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A-site RNA calf thymus DNA poly(dA):2poly(dT) poly(rA):poly(rU) 
    
poly(dA):poly(dT) poly(dA-dT):poly(dA-dT) poly(dG):poly(dC) poly(dA-dT):poly(dA-dT) 
    
poly(dG):poly(dC) poly(rA):poly(rU) Figure A9.  UV thermal denaturation profiles of various 
nucleic acids.  In each panel the native nucleic acids, dotted 
red line, DPA200, solid lie.   DPA200 was added to the 
nucleic acids [20 µM/bp] at rbd = 2.2 µM.  The samples were 
incubated at 4 oC for 6 h.  prior to analysis, slow heating from 
10 oC to 90 oC at 0.2 oC/min.  Buffer:  10 mM sodium 
cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl 
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(a) (b) (c) (d) 
    
(e) (f) (g) (h) 
    
Figure A10.  Mixed melting profile of various nucleic acids.  Each panel shows the melting mixture of poly(dG):poly(dC); 
peak 5, poly(dA):poly(dT); peak 4, poly(rA):poly(dT); peak 3, poly(rA):poly(rU); peak 2, poly(dA):poly(rU); peak 1.  Panel 
(a) is the melting of the mixed polynucleotide solution without DPA200.  Panels (b), (c) and (d) are the melting of the mixed 
polynucleotide solution in the presence of DPA200 (rbd = 20, 10, and 8, respectively).  Panel (e) is the melting profiles of all 
mixed melting experiments.  Panels (f), (g) and (h) are the first derivative plots melting of the mixed polynucleotide solution in 
the presence of DPA200 (rbd = 20, 10, and 8, respectively).  In each panel, the solid line reflects the melting in the absence of 
ligand, while the dashed line represents the mixed melting in the presence of DPA200.  The concentration of each 
polynucleotide was 10 µM/bp, the total concentration of polynucleotide was 50 µM/bp.  Data was normalized for ease of 
comparison.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.50 mM EDTA, pH 7.0, 46.25 mM NaCl.   
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Figure A11.  UV thermal denaturation profiles of poly(rA):poly(dT) (a, b) and 
poly(dA):poly(rU) (c, d).   Panels (a, c) represent the duplex with DPA200 at varying rbd 
values, while panels (b, d) represent the duplex (A) was with neomycin (B), ethidium 
bromide (C), neomycin and ethidium bromide (D) and DPA200 (E) at 5 µM.  The  
ligands were added to the duplex [20 µM/bp] at varying rbd (ratio of drug:base pairs) 
values.   The samples were incubated at 4 oC for 12 h.  prior to analysis, slow heating 
from 10 oC to 90 oC at 0.2 oC/min.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, 
pH 6.8, 20 mM NaCl. 
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Figure A12.  UV thermal denaturation profiles of poly(rA):poly(dT) (a, b) and 
poly(dA):poly(rU) (c, d).  Panels (a, c) represent the duplex (A) was with neomycin (B), 
ethidium bromide (C), neomycin and ethidium bromide (D) and DPA200 (E) at 2.1 µM, 
while panels ((b, d) represent the duplex (A) with neomycin (B), ethidium bromide (C) 
and DPA200 (D) at saturation.   poly(rA):poly(dT):  neomycin (rbd = 8.0), ethidium 
bromide (rbd = 4.2) and DPA200 (rbd = 6.5); poly(dA):poly(rU):  neomycin (rbd = 6.5), 
ethidium bromide (rbd = 4.6) and DPA200 (rbd = 9.7).  The ligands were added to the 
duplex [20 µM/bp] at varying rbd (ratio of drug:base pairs) values.   The samples were 
incubated at 4 oC for 12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 
oC/min.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl. 
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Figure A13.  CD thermal denaturation profiles of poly(rA):poly(dT) (a, b) and poly(dA):poly(rU) (c) in the presence of 
various ligands.   Panels (a, c) represent the duplex with ligands at rbd = 9.6, while panel (b) represents the duplex with ligands 
at rbd = 6.5.  Ligands, neomycin (C), ethidium bromide (B), DPA200 (D), neomycin and ethidium bromide (E) were added to 
the duplex (A) [20 µM/bp] and the added at varying rbd (ratio of drug:base pairs) values.   The samples were incubated at 4 
oC 
for 12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, 
pH 6.8, 100 mM NaCl. 
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Figure A14.  Fluorescence melting profiles of poly(rA):poly(dT) (a), poly(dA):poly(rU) (b) and poly(rA):poly(dT) (c) with 
DPA200 and ethidium bromide (EtBr).  The ligands were added to the duplex [20 µM/bp].  DNA:RNA hybrid (20.0 µM/bp) 
was mixed with ligands at rbd values of 9.6, 9.6 and 6.5 (a, b, c, respectively).  The samples were incubated at 4 
oC for 12 h.  
prior to analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.   Exictation, 525 nm – emission λmax, 595 nm (ethidium 
bromide), 614 nm (DPA200) ; slits:  1.5 mm.   Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A15.  CD scans of the titration of ethidium bromide and DPA200 with 
poly(rA):poly(dT) and poly(dA):poly(rU) at 20 oC, (a, b; c, d; respectively).  In the 
expanded chromophore regions the open circles denote the CD signal of native hybrid 
without drug, while closed circles denote the CD signal after max addition of the ligand.  
Ligands were added to the duplex [20 µM/bp] at respective rbd values.   Buffer:  10 mM 
sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A16.  ITC titration of neomycin into the duplex poly(rA):poly(dT) 20 oC (a) and 10 oC (b).   Control titration was 
carried out with drug into buffer solution alone (c) and (d).   The sample titration was conducted at a concentration of 200 
µM/bp; neomycin concentration was 150 µM.   In the profile, the upper panels show the heat burst curves of 8 µL injection of 
neomycin into a sample containing the DNA:RNA hybrid.  The corrected injection heats shown in the sample titrations were 
derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution heat from control 
titration.  The data points reflect the experimental injection heats.   The average value was calculated as the binding enthalpy.   
Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A17.  ITC titration of neomycin into the duplex poly(dA):poly(rU) 20 oC (a) and 10 oC (b).   Control titration was 
carried out with drug into buffer solution alone (c) and (d).   The sample titration was conducted at a concentration of 100 
µM/bp; neomycin concentration was 100 µM.   In the profile, the upper panels show the heat burst curves of 10 µL injection of 
neomycin into a sample containing the DNA:RNA hybrid.  The corrected injection heats shown in the sample titrations were 
derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution heat from control 
titration.  The data points reflect the experimental injection heats.   The average value was calculated as the binding enthalpy.   
Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A18.  ITC titration of ethidium bromide into the duplex poly(rA):poly(dT) 20 oC (a) and 10 oC (b).   Control titration 
was carried out with drug into buffer solution alone (c) and (d).   The sample titration was conducted at a concentration of 75 
µM/bp; ethidium bromide concentration was 80 µM.   In the profile, the upper panels show the heat burst curves of 10 µL 
injection of ethidium bromide into a sample containing the DNA:RNA hybrid.  The corrected injection heats shown in the 
sample titrations were derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution 
heat from control titration.  The data points reflect the experimental injection heats.   The average value was calculated as the 
binding enthalpy.   Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A19.  ITC titration of ethidium bromide into the duplex poly(dA):poly(rU) 20 oC (a) and 10 oC (b).   Control titration 
was carried out with drug into buffer solution alone (c) and (d).   The sample titration was conducted at a concentration of 100 
µM/bp; ethidium bromide concentration was 80 µM.   In the profile, the upper panels show the heat burst curves of 10 µL 
injection of ethidium bromide into a sample containing the DNA:RNA hybrid.  The corrected injection heats shown in the 
sample titrations were derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution 
heat from control titration.  The data points reflect the experimental injection heats.   The average value was calculated as the 
binding enthalpy.   Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A20.  ITC titration of DPA200 into the duplex poly(rA):poly(dT) 20 oC (a) and 10 oC (b).   Control titration was 
carried out with drug into buffer solution alone (c) and (d).   The sample titration was conducted at a concentration of 75 
µM/bp; DPA200 concentration was 60 µM.   In the profile, the upper panels show the heat burst curves of 10 µL injection of 
DPA200 into a sample containing the DNA:RNA hybrid.  The corrected injection heats shown in the sample titrations were 
derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution heat from control 
titration.  The data points reflect the experimental injection heats.   The average value was calculated as the binding enthalpy.   
Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, 100 mM NaCl. 
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Figure A21.  CD scans of the titration of neomycin with poly(dA):poly(rU) (a, b), 
poly(rA):poly(rU) (c, d) and poly(dA-dT)2 (e, f) at 20 
oC.   A plot of CD intensity at 243 
(b), 244 (d) and 246 (f) with respect to rbd was plotted, rbd is the ratio of [base 
pair]/[drug].  In the expanded chromophore regions the open circles denote the CD signal 
of native hybrid without drug, while closed circles denote the CD signal after max 
addition of the ligand.  Ligands were added to the duplex [20 µM/bp] at respective rbd 
values.   Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl.   
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Figure A22.  Fluorescence emission scans of the titration of ethidium bromide with 
various nucleic acids at 20 oC.   Ethidium bromide was titrated into poly(dA):poly(rU) 
(a), poly(rA):poly(rU) (c) and poly(dA-dT)2 (e) at various rbd values.  A plot of 
fluorescence intensity at 594 nm vs rbd values for each respective nucleic acids are 
located in panels (b), (d) and (f).  A plot of fluorescence intensity at 594 with respect to 
rbd was plotted, rbd is the ratio of [base pair]/[drug].  Ligand was added to the duplex [1 
µM/bp] at respective rbd values.  Excitation:  525 nm; emission:  550 – 700 nm; slits:  1.5 
mm.   Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl.   
 
 
0
0.2
0.4
0.6
0.8
1
550 600 650 700
Wavelength (nm)
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10 12 14
r
bd
4.6
0
1
2
3
4
5
6
7
550 600 650 700
Wavelength (nm)
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10 12
r
bd
2.5 
0
0.4
0.8
1.2
1.6
2
2.4
2.8
550 600 650 700
Wavelength (nm)
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10 12 14
r
bd
5.3
270 
(a) (b) 
  
(c) (d) 
 
 
Figure A23.  CD scans of the titration of DPA200 with poly(rA):poly(rU) (a, b) and 
poly(dA-dT)2 (c, d) at 20 
oC.  A plot of CD intensity at 264 (b) and 277 (d) with respect 
to rbd was plotted, rbd is the ratio of [base pair]/[drug].  In the expanded chromophore 
regions the open circles denote the CD signal of native hybrid without drug, while closed 
circles denote the CD signal after max addition of the ligand. Ligands were added to the 
duplex [20 µM/bp] at respective rbd values.   Buffer:  10 mM sodium cacodylate, 0.5 mM 
EDTA, pH 5.5, 100 mM NaCl.   
 
 
 
 
 
 
 
 
 
 
-30
-20
-10
0
10
20
30
40
50
220 240 260 280 300 320 340
Wavelength (nm)
5
10
15
20
25
30
35
40
45
4 6 8 10 12 14 16 18
r
bd
9.6
-4
-2
0
2
4
6
8
220 240 260 280 300 320 340
Wavelength (nm)
3
3.5
4
4.5
5
5.5
6
6.5
7
4 6 8 10 12 14
r
bd
9.1
271 
(a) (b) 
-500
0
500
1000
25 30 35 40 45 50 55 60
C p
 
(ca
l/m
o
lo C
)
T (oC)
∆H
wc
= 3.84 kcal/mol
 
-500
0
500
1000
1500
2000
2500
40 45 50 55 60 65 70 75 80
C p
 
(ca
l/m
o
lo C
)
T (oC)
∆H
wc
 = 6.34 kcal/mol
 
(c)  
0
400
800
1200
45 50 55 60 65 70 75 80
C p
 
(ca
l/m
o
lo C
)
T (oC)
∆H
wc
 = 3.90 kcal/mol
 
 
Figure A24.  DSC melting profiles of poly(dA):poly(rU) (a), poly(rA):poly(rU) (b) and 
poly(dA-dT)2 (c).  Integration of the melting peak yielded ∆Hwc.   The duplex was pre-
formed at 100 µM/bp prior to analysis, slow heating from 25 oC to 90 oC at 0.75 oC/min.   
Buffer:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl. Data 
collected by Dr. Hongjuan Xi. 
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Figure A25.  ITC titration of 50 µM neomycin into various solutions.  Control titrations were conducted of neomycin into 
buffer alone at 15 oC (a), 20 oC (e) and 25 oC (i).  Sample titrations of neomycin into poly(dA):poly(rU) [(b), (f) and (j)], 
poly(rA):poly(rU) [(c), (g) and (k)] and poly(dA-dT)2 [(d), (h) and (l)] were conducted at 15 
oC, 20 oC and 25 oC, respectively.  
Sample cell titrations were conducted at a concentration of 350 µM/bp nucleic acids.  In each profile, the upper panels show 
the heat burst curves of 8 µL injection of neomycin into sample.  The corrected injection heats shown in the sample titrations 
were derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution heat from control 
titration.  The data points reflect the experimental injection heats.  The average value was calculated as the binding enthalpy.  
∆Cp plots were plotted according to Equation 3.  Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 
mM NaCl. 
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Figure A26.  ITC titration of 50 µM ethidium bromide into various solutions.  Control titrations were conducted of ethidium 
bromide into buffer alone at 15 oC (a), 20 oC (e) and 25 oC (i).  Sample titrations of ethidium bromide into poly(dA):poly(rU) 
[(b), (f) and (j)], poly(rA):poly(rU) [(c), (g) and (k)] and poly(dA-dT)2 [(d), (h) and (l)] were conducted at 15 
oC, 20 oC and 25 
oC, respectively.  Sample cell titrations were conducted at a concentration of 350 µM/bp nucleic acids.  In each profile, the 
upper panels show the heat burst curves of 8 µL injection of ethidium bromide into sample.  The corrected injection heats 
shown in the sample titrations were derived by integration of heat burst curve from sample titration, followed by subtraction of 
the dilution heat from control titration.  The data points reflect the experimental injection heats.  The average value was 
calculated as the binding enthalpy.  ∆Cp plots were plotted according to Equation 3.  Buffer conditions:  10 mM sodium 
cacodylate, 0.5 mM EDTA, pH 5.5, 100 mM NaCl. 
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Figure A27.  ITC titration of 50 µM DPA200 into various solutions.  Control titrations were conducted of DPA200 into buffer 
alone at 15 oC (a), 20 oC (e) and 25 oC (i).  Sample titrations of DPA200 into poly(dA):poly(rU) [(b), (f) and (j)], 
poly(rA):poly(rU) [(c), (g) and (k)] and poly(dA-dT)2 [(d), (h) and (l)] were conducted at 15 
oC, 20 oC and 25 oC, respectively.  
Sample cell titrations were conducted at a concentration of 350 µM/bp nucleic acids.  In each profile, the upper panels show 
the heat burst curves of 8 µL injection of DPA200 into sample.  The corrected injection heats shown in the sample titrations 
were derived by integration of heat burst curve from sample titration, followed by subtraction of the dilution heat from control 
titration.  The data points reflect the experimental injection heats.  The average value was calculated as the binding enthalpy.  
∆Cp plots were plotted according to Equation 3.  Buffer conditions:  10 mM sodium cacodylate, 0.5 mM EDTA, pH 5.5, 100 
mM NaCl.  
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APPENDIX B 
8 8a
 
Methyl 4-amino-1-methylimidazole-2-carboxylate (8a).  To a solution of compound 8 
(3.0 g, 16.2 mmol) in dry MeOH (80.0 mL) was added 10% Pd/C (0.3 g).  The mixture 
was stirred under positive hydrogen atmosphere, afforded by slow bubbling of H2 (g) via 
submerged syringe, for 3.5 h.  The catalyst was filtered over Celite and the solvent was 
removed in vacuo to afford 8a (2.5 mg, 99%) as a yellow oil: TLC (70:30 
CH2Cl2:Acetone v/v) Rf 0.25; 
1H NMR (500 MHz, CDCl3) δ 7.28 (s, 2H), 6.30 (s, 1H), 
3.84 (s, 3H), 3.78 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 158.9, 145.5, 131.6, 109.4, 
53.5, 35.7; MALDI-TOF m/z calcd for C6H9N3O2 155.15, found [M + H]+ 156.55.   
 
8 8a 10
7
O
N
N
O
N
N
O
N
N
NH 2 N
H
O
N
N N
N
O
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O2N
CCl3
OMe OMe
 
HImImCOOMe (10).  To a solution of compound 8 (925.9 mg, 5 mmol) in dry MeOH 
(80.0 mL) was added 10% Pd/C (92.5 mg).  The solution was stirred under positive 
hydrogen atmosphere, afforded by slow bubbling of H2 (g) via submerged syringe, for 3.5 
h.  The catalyst was filtered over Celite and the solvent was removed in vacuo to afford 
8a as yellow oil.  To a solution of 7 (1.4 g, 4.0 mmol) in CH2Cl2 (100 mL) was added 8a, 
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suspended in CH2Cl2 (10 mL), and the solution was stirred for 6 h.  The solution was 
concentrated in vacuo.  The residue was purified by flash chromatography (silica gel, 
hexane:acetone 0.5% incremental increases in acetone) to yield 10 (758.2 mg, 72%) as a 
light yellow solid:  TLC (1:1 hexane:acetone v/v) Rf 0.23; 
1H NMR (500 MHz, CDCl3) δ 
9.60 (s, 1H), 7.49 (s, 1H), 6.96 (s, 1H), 6.92 (s, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.86 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 159.3,156.5, 138.2, 136.6, 131.6, 128.4, 126.2, 
114.9, 52.4, 36.0, 35.6; MALDI-TOF m/z calcd for C11H13N5O3 263.26, found [M + H]+ 
263.37.   
 
9 9a
 
Methyl 4-amino-1-methylpyrrole-2-carboxylate (9a).  To a solution of compound 9 
(3.0 g, 16.2 mmol) in dry MeOH (80.0 mL) was added 10% Pd/C (0.3 g).  The mixture 
was stirred under positive hydrogen atmosphere, afforded by slow bubbling of H2 (g) via 
submerged syringe, for 4 h.  The catalyst was filtered over Celite and the solvent was 
removed in vacuo to afford 9a (2.3 mg,  97%) as a yellow oil: TLC (70:30 
CH2Cl2:Acetone v/v) Rf 0.30; 
1H NMR (500 MHz, CDCl3) δ 9.91 (s, 2H), 7.23 (s, 1H), 
6.78 (s, 1H), 3.85 (s, 3H), 3.74 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 160.8, 124.2, 
121.6, 111.9, 51.9, 37.2; MALDI-TOF m/z calcd for C7H10N3O2 154.17, found [M - H]+ 
153.55.   
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10 11  
HImImPyCOOMe (11).  To a solution of compound 9 (194.4 mg, 1.1 mmol) in dry 
MeOH (80.0 mL) was added 10% Pd/C (19.4 mg).  The solution was stirred under 
positive hydrogen atmosphere, afforded by slow bubbling of H2 (g) via submerged 
syringe, for 4 h.  The catalyst was filtered over Celite and the solvent was removed in 
vacuo to afford 9a as a yellow oil.  To a solution of 10 (200.0 mg, 0.7 mol) in methanol 
(10 mL) was added 1.5 M NaOH (2 mL) and the solution was allowed to stir for 4 h.  The 
solution was neutralized with HCl.   Volatiles were removed in vacuo.  The resulting 
solid was dissolved in DMF (30 mL), EDC (172.1 mg, 0.9 mmol) and HOBt (121.6 mg, 
0.9 mmol), were added and the reaction was allowed to stir for 1 h.   A solution of 9a 
(139.7 mg, 0.9 mmol) in DMF, 10 mL, was added dropwise over the period of 10 min 
and the reaction was allowed to stir for 16 h.  DMF was evaporated in vacuo and the 
resulting solid was purified via flash chromatography (silica gel, acetone:CH2Cl2, 5.0 % 
incremental increases of acetone) to yield pure 11 (164.2 mg, 71%) as a dark brown 
solid:  TLC (50:50 CH2Cl2:acetone v/v) Rf 0.80; 1H NMR (500 MHz, CDCl3) δ 9.51 (s, 
1H), 8.88 (s, 1H), 7.49 (s, 1H), 7.44 (d, 1H, J = 3.0), 7.09 (s, 1H), 7.04 (s, 1H), 6.84 (d, 
1H J = 3.0), 4.12, (s, 3H), 4.11 (s, 3H), 3.94 (s, 3H), 3.84 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 161.6, 156.3, 155.9, 138.5, 135.5, 130.9, 128.9, 128.3, 126.2, 121.2, 120.1, 
281 
 
114.1, 108.4, 51.2, 36.8, 35.8, 35.7; MALDI-TOF m/z calcd for C17H19N7O4 385.38, 
found [M]+ 385.22. 
 
11 6
 
HImImPyPyCOOMe (6).  To a solution of 11 (150.0 mg, 0.4 mol) in 
methanol:tetrahydrofuran (1:3, v:v) was added 1.5 M NaOH (5 mL) and the solution was 
allowed to stir at 60 oC for 3 h.  The solution was neutralized with HCl.   Volatiles were 
removed in vacuo.  The resulting solid was dissolved in DMF (30 mL), EDC (114.7 mg, 
0.6 mmol) and HOBt (81.1 mg, 0.6 mmol) were added and the reaction was allowed to 
stir for 1 h.  A solution of 9a (93.1 mg, 0.6 mmol) in DMF, 10 mL, was added dropwise 
over the period of 10 min and the reaction was allowed to stir for 16 h.  DMF was 
evaporated in vacuo and the resulting solid was purified via flash chromatography (silica 
gel, acetone:CH2Cl2, 5.0 % incremental increases of acetone) to yield pure 6 (102.5 mg, 
69%) as a dark brown solid:  TLC (50:50 CH2Cl2:acetone v/v) Rf 0.81; 1H NMR (500 
MHz, CDCl3) δ 9.47 (s, 1H), 8.87 (s, 1H), 7.57 (s, 1H), 7.41 (s, 1H), 7.35 (s, 1H), 7.13 (s, 
1H), 6.96 (s, 1H), 6.70 (s, 1H), 6.69 (s, 1H), 4.03, (s, 3H), 4.02 (s, 3H), 3.89 (s, 3H), 3.84 
(s, 3H), 3.71 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 161.5, 158.8, 156.2, 156.0, 138.3, 
135.4, 134.1, 128.2, 126.2, 123.3, 121.7, 121.0, 120.9, 119.9, 119.1, 114.15, 108.2, 103.4, 
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51.1, 36.8, 36.7, 35.7, 35.6; MALDI-TOF m/z calcd for C23H25N9O5 507.50, found [M - 
H]+ 505.56. 
 
Table B1.  Stoichiometry table for the synthesis of HImImPyPyCONH(CH2)nN3, 
DPA202 – DPA207, where n = 2, 3, 5, 6, 8 and 10.   
 (6) amino-azido alkane EDC HOBt 
Compound  
(#) 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
DPA202 100.0 203.0 32.7 406.1 75.2 406.1 53.2 406.1 
DPA203 100.0 203.0 38.0 406.1 75.2 406.1 53.2 406.1 
DPA204 100.0 203.0 48.9 406.1 75.2 406.1 53.2 406.1 
DPA205 80.0 162.4 46.1 324.9 61.3 324.9 43.2 324.9 
DPA206 75.0 152.3 50.2 304.6 56.5 304.6 39.8 304.6 
DPA207 75.5 153.3 58.6 306.6 56.5 306.6 39.8 306.6 
 
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
6
 
HImImPyPyCONH(CH2)nN3 (DPA 202 – DPA207).  Compound 6 was dissolved in 
MeOH:THF (1:3; v:v; 10 mL).  1.5 N NaOH (2.0 mL) was added and the reaction was 
stirred at 60 oC and followed by TLC.  When TLC showed the starting material was no 
longer present, 4 – 6 h, the reaction was neutralized with HCl.  The solution was 
evaporated to dryness.  The resulting acid was suspended in DMF (20 mL), EDC and 
HOBt were added and the solution was stirred for 1 h.  The amino-azido alkane (12 - 17) 
was added and the solution was allowed to stir overnight.  DMF was removed in vacuo 
and the resulting solid was purified by flash chromatography (silica gel, CH2Cl2:acetone 
25% incremental increases in acetone) to yield DPA202 – DPA207. 
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HImImPyPyCONH(CH2)2N3 (DPA202):  DPA202 was afforded (109.8 mg, 84%) as a 
light yellow solid:  TLC (70:30, hexane:ethyl acetate, v/v) Rf 0.60.  1H NMR (500 MHz, 
CDCl3) δ 9.54 (br, 1H), 8.97 (s, 1H), 7.91 (s, 1H), 7.41 (s, 1H), 7.15 (s, 1H), 7.10 (s, 1H), 
7.02 (s, 1H), 6.98 (s, 1H), 6.69 (s, 1H), 6.59 (s, 1H), 6.07 (s, 1H), 4.04 (s, 3H), 4.01 (s, 
3H), 3.88 (s, 3H), 3.85 (s, 3H), 3.32 (t, J = 6.5, 2H), 3.23 (t, J = 6.3, 2H); 13C NMR (125 
MHz, CDCl3) δ 162.1, 159.1, 156.1, 155.9, 138.3, 135.4, 134.3, 126.2, 126.1, 123.3, 
122.8, 121.7, 120.9, 119.3, 119.1, 114.4, 103.8, 103.4, 51.5, 41.2, 36.9, 36.4, 35.7, 35.6; 
MALDI-TOF m/z calcd C24H27N13O4 561.57, found [M – 2H]
+ 559.85.   
 
HImImPyPyCONH(CH2)3N3 (DPA203):  DPA203 was afforded (86.0 mg, 76%) as an 
off white solid:  TLC (70:30, hexane:ethyl acetate, v/v) Rf 0.60.  IR (neat) 2933, 2867, 
2053, 1667, 1648 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.59 (s, 1H), 9.03 (s, 1H), 8.09 (s, 
1H), 7.39 (s, 1H), 7.15 (s, 1H), 7.14 (s, 1H), 7.00 (s, 1H), 6.97 (s, 1H), 6.66 (s, 1H), 6.58 
(s, 1H), 6.38 (s, 1H), 4.02 (s, 3H), 4.00 (s, 3H), 3.88 (s, 3H), 3.80 (s, 3H), 3.41 (t, J1 = 
6.5, 2H), 3.37 (t, J2 = 6.4, 2H), 1.82 (p, J1 = 6.4, J2 = 6.5, 2H); 13C NMR (125 MHz, 
CDCl3) δ 162.1, 159.1, 156.3, 155.9, 138.4, 135.5, 134.3, 128.2, 126.3, 123.4, 123.3, 
121.3, 120.9, 119.2, 119.0, 114.4, 103.6, 103.4, 49.5, 39.9, 36.8, 36.7, 36.6, 35.8, 29.0; 
MALDI-TOF m/z calcd C25H29N13O4 575.59, found [M – 2H]
+ 572.97. 
 
HImImPyPyCONH(CH2)5N3 ( DPA204):  DPA204 was afforded (104.3 mg, 91%) as a 
yellow solid:  TLC (70:30, hexane:ethyl acetate, v/v) Rf 0.58.  IR (neat) 2923, 2853, 
284 
 
2093, 1675, 1657, 1539 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.58 (s, 1H), 9.03 (s, 1H), 
8.04 (s, 1H), 7.39 (s, 1H), 7.16 (s, 1H), 7.11 (s, 1H), 7.03 (s, 1H), 6.997 (s, 1H), 6.68 (s, 
1H), 6.63 (s, 1H), 6.44 (s, 1H), 4.00 (s, 3H), 3.97 (s, 3H), 3.88 (s, 3H), 3.80 (s, 3H), 3.40 
(t, J1 = 6.1, 2H), 3.37 (t, J2 = 6.7, 2H), 1.55 (p, J1 = 6.0, 2H), 1.52 (p, J2 = 6.7, 2H), 1.82 
(m, 2H); 13C NMR (125 MHz, CDCl3) δ 162.0, 159.6, 156.3, 156.2, 138.2, 135.6, 134.3, 
128.2, 126.7, 123.5, 123.2, 121.2, 121.1, 119.3, 119.1, 114.4, 103.3, 103.1, 49.5, 39.3, 
36.9, 36.8, 36.7, 36.6, 31.8, 28.7, 23.0; MALDI-TOF m/z calcd C27H33N13O4 603.65, 
found [M – 2H]+ 601.21.   
 
HImImPyPyCONH(CH2)6N3 (DPA205):  DPA205 was afforded (71.1 mg, 72%) was a 
light yellow powder:  TLC (70:30, hexane:ethyl acetate, v/v) Rf 0.53.  IR (neat) 2922, 
2841, 2075, 1671, 1663 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.44 (br, 1H), 8.94 (s, 1H), 
7.88 (s, 1H), 7.38 (s, 1H), 7.13 (s, 1H), 7.07 (s, 1H), 6.99 (s, 1H), 6.95 (s, 1H), 6.66 (s, 
1H), 6.56 (s, 1H), 6.04 (s, 1H), 4.01 (s, 3H), 3.98 (s, 3H), 3.85 (s, 3H), 3.82 (s, 3H), 3.29 
(t, J1 = 5.7, 2H), 3.20 (t, J2 = 6.1, 2H), 1.55 (m, 4H), 1.36 (m, 4H); 13C NMR (125 MHz, 
CDCl3) δ 161.8, 159.0, 156.3, 156.2, 138.4, 135.5, 134.2, 128.2, 126.3, 123.6, 123.4, 
121.5, 121.0, 119.2, 118.7, 114.3, 103.6, 103.3, 51.3, 39.1, 36.8, 36.7, 35.8, 35.7, 29.8, 
29.5, 28.6, 24.2; MALDI-TOF m/z calcd C28H35N13O4 617.68, found [M]
+ 617.54. 
 
HImImPyPyCONH(CH2)8N3 (DPA206):  DPA206 was afforded (72.6 mg, 75%) as a 
yellow solid:  TLC (70:30, hexane:ethyl acetate, v/v) Rf 0.50.  IR (neat) 2928, 2841, 
2065, 1675, 1665, 1531 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.53 (s, 1H), 8.94 (s, 1H), 
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7.71 (s, 1H), 7.45 (s, 1H), 7.17 (s, 1H), 7.11 (s, 1H), 7.08 (s, 1H), 7.00 (s, 1H), 6.73 (s, 
1H), 6.58 (s, 1H), 5.92 (s, 1H), 4.08 (s, 3H), 4.06 (s, 3H), 3.92 (s, 3H), 3.88 (s, 3H), 3.38 
(m, 2H), 3.21 (m, 2H), 1.55 (m, 4H), 1.31 (m, 4H), 1.28 (m, 4H); 13C NMR (125 MHz, 
CDCl3) δ 161.8, 159.0, 156.3, 156.0, 138.4, 135.5, 134.2, 128.2, 126.3, 123.8, 123.4, 
121.3, 121.1, 119.1, 118.5, 114.2, 103.4, 103.2, 51.5, 39.7, 36.8, 36.7, 35.8, 35.7, 29.8, 
29.5, 28.6, 27.9, 26.7, 26.2; MALDI-TOF m/z calcd C30H37N13O4 645.73, found [M – 
3H]+ 642.00. 
 
HImImPyPyCONH(CH2)10N3 (DPA207):  DPA207 was afforded (88.9 mg, 88%) as an 
off white crystalline solid:  TLC (70:30, hexane:ethyl acetate, v/v) Rf 0.50.  IR (neat) 
2911, 2831, 2054, 1661, 1653, 1581 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.61 (br, 1H), 
9.06 (s, 1H), 7.80 (s, 1H), 7.49 (s, 1H), 7.23 (s, 1H), 7.11 (s, 1H), 7.06 (s, 1H), 7.05 (s, 
1H), 6.81 (s, 1H), 6.64 (s, 1H), 6.00 (s, 1H), 4.27 (s, 3H), 4.26 (s, 3H), 4.08 (s, 3H), 3.91 
(s, 3H), 3.39 (m, 2H), 3.27 (m, 2H), 1.60 (m, 4H), 1.31 (m, 6H); 13C NMR (125 MHz, 
CDCl3) δ 161.9, 159.1, 156.1, 156.0, 135.5, 135.2, 132.1, 130.2, 126.3, 123.8, 123.4, 
121.4, 121.2, 119.2, 118.7, 114.9, 103.5, 103.1, 51.7, 39.4, 37.1, 36.9, 36.8, 35.9, 29.8, 
29.5, 29.3, 29.2, 28.9, 27.1, 26.8; MALDI-TOF m/z calcd C32H43N13O4 673.78, found [M 
- H]+ 672.97. 
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N-Boc neomycin-N3 (DPA11).  See Appendix A for synthetic procedure, compound data 
reduction and characterization. 
 
 
Table B2.  Stoichiometry table for the synthesis of N-Boc-neomycin alkynes, 
DPA13, DPA14 and DPA15.   
 DPA11 dialkyne CuI DIPEA 
Compound  
(#) 
amnt.   
(mg) µmol 
amnt.   
(g) 
mmol 
amnt.   
(mg) µmol 
amnt.  
(mg) 
mmol 
DPA13 150.0 121.0 1.2 12.1 46.1 242.0 781.9 6.1 
DPA14 156.0 125.8 1.3 12.6 47.9 251.7 813.1 6.2 
DPA15 129.2 104.2 1.1 10.4 39.6 208.0 781.9 6.1 
 
R = NHBoc
R' = DPA13
DPA14
DPA15
DPA11
 
N-Boc neomycin-‘tri’-alkynes (DPA13 – DPA15).  To a solution of dialkyne in toluene 
(2 mL) was added copper iodide and DIPEA.  A solution of DPA11, in toluene (2 mL), 
was added and the reaction was allowed to stir at 60 oC for 12 h.  Volatiles were removed 
in vacuo and the resulting solid was purified by chromatography (silica gel, CH2Cl2:2-
propanol, 1.0 % incremental increases of 2-propanol) to afford the desired N-Boc 
neomycin-alkynes, DPA25, DPA26 and DPA27.   
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N-Boc neomycin-‘tri’-CH2OCH2CCH (DPA13).  DPA13 was afforded (155.2 mg, 
85%) as a white solid TLC (90:10 CH2Cl2:EtOH v/v) Rf 0.60; FT-IR (neat) 3383, 2180, 
1686, 1523, 1366, 1169 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.61 (br, 1H), 6.12 (s, 1H), 
6.00 (s, 1H), 5.27 (s, 1H), 4.97 (s, 1H), 4.88 (s, 2H), 4.76 (s, 1H), 4.61 (s, 1H), 4.21-4.05 
(m, 5H), 3.87 (s, 2H), 3.76 (s, 1H), 3.68 (s, 2H), 3.51 (s, 3H), 3.44 (s, 1H), 3.25 (s, 2H), 
3.02 (s, 2H), 2.79 (s, 2H), 2.61-2.59 (t, 2H), 1.56-1.36 (m, 54 H); MALDI-TOF m/z calcd 
for C59H99N9O25 1334.46, found [M + Na]
+ 1356.14.   
 
N-Boc neomycin-‘tri’-(CH2)3CCH (DPA14).  DPA14 was afforded (166.3 mg, 88%) as 
a white solid TLC (90:10 CH2Cl2:EtOH v/v) Rf 0.55; FT-IR (neat) 3376, 2185, 1677, 
1520, 1300, 1100 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.73 (br, 1H), 6.10 (s, 1H), 5.87 (s, 
1H), 5.23 (s, 1H), 4.90 (s, 1H), 4.89 (s, 2H), 4.77 (s, 1H), 4.63 (s, 1H), 4.21-4.05 (m, 5H), 
3.91 (s, 2H), 3.73 (s, 1H), 3.64 (s, 2H), 3.50 (s, 3H), 3.37 (s, 1H), 3.22 (s, 2H), 3.00 (s, 
2H), 2.68-2.59 (m, 6H), 1.59-1.32 (m, 54 H); MALDI-TOF m/z calcd for C60H101N9O24 
1332.49, found [M + Na]+ 1355.29.   
 
N-Boc neomycin-‘tri’-(CH2)4CCH (DPA15).  DPA15 was afforded (680.2 mg, 86%) as 
a white solid TLC (90:10 CH2Cl2:EtOH v/v) Rf 0.55; FT-IR (neat) 3386, 2100, 1674, 
1520, 1333, 1115 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.76 (br, 1H), 6.21 (s, 1H), 5.91 (s, 
1H), 5.24 (s, 1H), 4.99 (s, 1H), 4.84 (s, 2H), 4.77 (s, 1H), 4.60 (s, 1H), 4.31-4.15 (m, 5H), 
3.90 (s, 2H), 3.75 (s, 1H), 3.61 (s, 2H), 3.59 (s, 3H), 3.32 (s, 1H), 3.20 (s, 2H), 3.15 (s, 
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2H), 2.90-2.41 (t, 8H), 1.55-1.33 (m, 54 H); MALDI-TOF m/z calcd for C61H103N9O24 
1346.52, found [M + Na]+ 1367.49.   
 
DPA11 R =         NHBocDPA12
 
N-Boc neomycin-NH2 (DPA12).  See Appendix A for synthetic procedure, compound 
data reduction and characterization. 
 
R = NHBoc
DPA12 DPA17  
N-Boc neomycin-NHCH2(O)OCH2CCH (DPA17).  A solution of DPA12 (78.3 mg, 
64.5 µmol) in dry CH2Cl2 (20 mL) was cooled to -78 
oC under inert atmosphere afforded 
by Ar (g).  Triethylamine (13.0 mg, 129.0 µmol) was added via syringe and the solution 
was stirred for 10 min.   Propargyl chloroformate (764.5 mg, 6.5 mmol) was added 
dropwise via syringe and the solution was stirred for 30 min.  The solution was allowed 
to come to room temperature.  Volatiles were removed in vacuo and the resulting solid 
was purified by chromatography (silica gel, CH2Cl2:2-propanol, 1.0 % incremental 
increases of 2-propanol) to afford DPA17 (73.5 mg, 88%) as a white solid TLC (90:10 
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CH2Cl2:EtOH v/v) Rf 0.71; 1H NMR (300 MHz, CDCl3) δ 6.12 (s, 1H), 6.00 (s, 1H), 5.27 
(s, 1H), 4.97 (s, 1H), 4.88 (s, 2H), 4.76 (s, 1H), 4.61 (s, 1H), 4.21-4.05 (m, 5H), 3.87 (s, 
2H), 3.76 (s, 1H), 3.68 (s, 2H), 3.51 (s, 3H), 3.44 (s, 1H), 3.25 (s, 2H), 3.02 (s, 2H), 2.79 
(s, 2H), 2.61-2.59 (t, 2H), 1.56-1.36 ( m, 54 H); MALDI-TOF m/z calcd for C57H98N8O26 
1295.28.43, found [M + Na]+ 1317.29.   
 
Table B3.  Stoichiometry table for the synthesis of HImImPyPyCONH(CH2)n-tri-
(CH2)3-neomycin-hexahydrochloride, DPA214 – DPA219, n = 2, 3, 5, 6, 8 and 10.   
S
er
ie
s 
II
 
 
DPA14 
‘HImImPy 
PyCONH 
(CH2)nN3’ 
CuI DIPEA 
Compound 
(#) 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
DPA214 5.5 4.1 2.3 4.1 1.6 8.2 101.9 13.2 
DPA215 5.4 3.9 2.3 3.9 1.5 7.9 99.5 12.9 
DPA216 5.6 4.1 2.5 4.1 1.6 8.3 103.5 13.4 
DPA217 4.9 3.7 2.3 3.7 1.4 7.4 92.2 11.9 
DPA218 5.8 4.3 2.8 4.3 1.6 8.6 107.0 13.9 
DPA219 4.5 3.4 2.3 3.4 1.3 6.7 83.7 10.8 
 
R = NHBoc
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
n = 2, DPA214
3, DPA215
5, DPA216
6, DPA217
8, DPA218
10, DPA219
DPA14
 
(DPA214 – DPA219).  To a solution of N-Boc neomycin-tri-alkyne (DPA14) in toluene 
(1.0 mL) was added a solution consisting of CuI and DIPEA in toluene (500 µL).  To this 
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solution was added a suspension of the azide functionalized tetramer polyamides in 
toluene (500 µL).  The reaction mixture was allowed to stir at room temperature for 24 h, 
and then was concentrated in vacuo.  The resulting residue was purified by flash 
chromatography (silica gel, CH2Cl2:MeOH, 2% incremental increases in MeOH) to yield 
the N-Boc protected conjugates.  The solid was then suspended in 4 N HCl in dioxane (5 
mL) and the reaction was allowed to stir at room temperature for 30 min.  The solution 
was concentrated in vacuo and the resulting solid was washed with copious amounts of 
CH2Cl2 and lyphilized to dryness to afford conjugates DPA214 – DPA219 as 
hydrochloride salts.  Coupling and deprotection steps were near quantitative and the 
subsequent yields reflect the overall yield for both steps.  The reported 1H NMR and 
MALDI spectra represent the deprotected compounds.   
 
(DPA214):  DPA214 (2.8 mg, 95%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.10 (s, 2H), 7.48 (s, 1H), 7.42 (s, 1H), 7.35 (s, 1H), 7.25 (s, 1H), 7.08 (s, 
1H), 6.89 (s, 1H), 6.79 (s, 1H), 6.12 (s, 2H), 5.57-5.56 (m, 1H), 5.31-5.30 (m, 1H), 5.18-
5.17 (m, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H), 4.23-4.21 (m, 1H), 4.13-4.10 (m, 
2H), 4.10 (s, 1H), 3.93-3.89 (m, 1H), 3.89 (s, 6H), 3.88 (s, 3H), 3.87-3.85 (m, 1H), 3.83-
3.81 (m, 1H), 3.80-3.79 (m, 6H), 3.78 (s, 1H), 3.71-3.70 (m, 1H), 3.66-3.63 (m, 1H), 
3.61-3.56 (m, 1H), 3.46-3.45 (m, 1H), 3.37-3.34 (m, 1H), 3.34 (s, 2H), 3.33-3.31 (m, 
2H), 3.30-3.29 (m, 1H), 3.30-3.28 (m, 2H), 3.27-3.20 m, 5H), 3.20-3.16 (m, 3H), 3.13-
3.10 (s, 2H), 2.23-2.20 (m, 1H), 1.72-1.63 (m, 1H), 7.98 (s, 2H) 2.68-2.55 (m, 4H) 1.78-
1.70 (m, 2H); MALDI-TOF m/z calcd C54H80N22O16 1293.35, found [M + Na]
+ 1316.00.   
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(DPA215):  DPA215 (3.2 mg, 97%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.15 (s, 2H) 7.45 (s, 1H), 7.40 (s, 1H), 7.31 (s, 1H), 7.23 (s, 1H), 7.02 (s, 
1H), 6.97 (s, 1H), 6.76 (s, 1H), 6.05 (s, 1H), 6.303 (s, 1H), 5.59-5.56 (m, 1H), 5.33-5.31 
(m, 1H), 5.20-5.18 (m, 1H), 4.50-4.55 (m, 1H), 4.36-4.34 (m, 1H), 4.25-4.22 (m, 1H), 
4.17-4.15 (m, 2H), 4.09 (s, 1H), 4.00 (s, 3H), 3.98-3.92 (m, 1H), 3.89 (s, 3H), 3.88-3.86 
(m, 4H), 3.84-3.82 (m, 4H), 3.81-3.77 (m, 5H), 3.76 (s, 1H), 3.74-3.72 (m, 1H), 3.68-
3.66 (m, 1H), 3.63-3.57 (m, 1H), 3.47-3.45 (m, 1H), 3.43-3.36 (m, 2H), 3.37-3.36 (m, 
1H), 3.36-3.27 (m, 7H), 3.24-3.22 (m, 1H), 3.22-3.15 (m, 3H), 3.14-3.12 (s, 2H), 2.74-
2.62 (m, 4H), 2.25-2.22 (m, 1H), 1.88-1.77 (m, 4H), 1.75-1.64 (m, 1H); MALDI-TOF 
m/z calcd C55H82N22O16 1307.38, found [M + Na]
+ 1331.71. 
 
(DPA216):  DPA216 (3.8 mg, 98%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.10 (s, 2H), 7.48 (s, 1H), 7.43 (s, 1H), 7.36 (s, 1H), 7.29 (s, 1H), 7.01 (s, 
1H), 6.91 (s, 1H), 6.79 (s, 1H), 6.03 (s, 1H), 5.88 (s, 1H), 5.59-5.55 (m, 1H), 5.33-5.30 
(m, 1H), 5.21-5.18 (m, 1H), 4.51-4.43 (m, 1H), 4.37-4.33 (m, 1H), 4.28-4.22 (m, 1H), 
4.15-4.11 (m, 2H), 4.00 (s, 1H), 4.00-3.96 (m, 1H), 3.98 (s, 6H), 3.91-3.88 (m, 1H), 3.87 
(s, 3H), 3.86-3.85 (m, 1H), 3.85 (s, 3H), 3.84-3.79 (m, 2H), 3.78 (s, 1H), 3.77-3.74 (m, 
1H), 3.70-3.64 (m, 1H), 3.65-3.55 (m, 1H), 3.50-3.46 (m, 1H), 3.44-3.42 (m, 2H), 3.41-
3.36 (m, 3H), 3.36 (s, 2H), 3.36-3.32 (m, 2H), 3.32-3.31 (m, 1H), 3.30-3.25 (m, 2H), 
3.24-3.23 (m, 1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.27-2.21 (m, 5H), 1.77-1.59 
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(m, 2H), 1.70-1.61 (m, 1H), 1.58-1.56 (m, 2H), 1.55-1.50 (m, 2H), 1.38-1.29 (m, 2H); 
MALDI-TOF m/z calcd C57H86N22O16 1335.43, found [M]
+ 1357.44. 
 
(DPA217):  DPA217 (3.0 mg, 98%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.15 (s, 1H), 8.10 (s, 1H), 7.45 (s, 1H), 7.40 (s, 1H), 7.31 (s, 1H), 7.23 (s, 
1H), 7.02 (s, 1H), 6.97 (s, 1H), 6.76 (s, 1H), 6.05 (s, 1H), 5.59-5.56 (m, 1H), 5.33-5.31 
(m, 1H), 5.20-5.18 (m, 1H), 4.50-4.55 (m, 1H), 4.36-4.34 (m, 1H), 4.25-4.22 (m, 1H), 
4.17-4.15 (m, 2H), 4.08 (s, 1H), 3.99 (s, 2H), 3.98-3.92 (m, 1H), 3.91 (s, 1H), 3.88 (s, 
6H), 3.88-3.86 (m, 1H), 3.84-3.82 (m, 1H), 3.81-3.77 (m, 5H), 3.76 (s, 4H), 3.74-3.72 
(m, 1H), 3.68-3.66 (m, 1H), 3.63-3.57 (m, 1H), 3.47-3.45 (m, 1H), 3.38-3.36 (m, 1H), 
3.35 (s, 2H), 3.35-3.33 (m, 2H), 3.32-3.30 (m, 1H), 3.30-3.24 (m, 3H), 3.24-3.22 (m, 
1H), 3.22-3.16 (m, 5H), 3.14-3.12 (s, 2H), 2.74-2.62 (m, 4H), 2.25-2.22 (m, 1H), 1.82-
1.66 (m, 3H), 1.57-1.47 (m, 4H), 1.36-1.29 (m, 4H); MALDI-TOF m/z calcd 
C58H88N22O16 1349.46, found [M + Na]
+ 1373.90.   
 
(DPA218):  DPA218 (3.5 mg, 96%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.17 (s, 1H), 8.03 (s, 1H), 7.35 (s, 1H), 7.30 (s, 1H), 7.26 (s, 1H), 7.21 (s, 
1H), 7.06 (s, 1H), 6.98 (s, 1H), 6.88 (s, 1H), 5.94 (s, 1H), 5.59-5.55 (m, 1H), 5.33-5.30 
(m, 1H), 5.21-5.18 (m, 1H), 4.51-4.43 (m, 1H), 4.37-4.33 (m, 1H), 4.28-4.22 (m, 1H), 
4.15-4.11 (m, 2H), 4.07 (s, 3H), 4.00 (s, 1H), 4.00-3.96 (m, 1H), 3.91 (s, 6H), 3.91-3.88 
(m, 1H), 3.86 (s, 2H), 3.86-3.85 (m, 1H), 3.84-3.79 (m, 5H), 3.78 (s, 1H), 3.77-3.74 (m, 
1H), 3.70-3.64 (m, 1H), 3.65-3.55 (m, 1H), 3.50-3.46 (m, 1H), 3.40-3.37 (m, 1H), 3.36 
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(s, 2H), 3.36-3.33 (m, 2H), 3.32-3.31 (m, 3H), 3.30-3.25 (m, 2H), 3.24-3.23 m, 3H), 
3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.66-2.61 (m, 4H), 2.27-2.21 (m, 1H), 1.77-1.59 
(m, 2H), 1.70-1.61 (m, 1H), 1.57-1.48 (m, 4H), 1.35-1.31 (m, 4H), 1.31-1.27 (m, 4H); 
MALDI-TOF m/z calcd C60H92N22O16 1377.51, found [M + H + Na]
+ 1402.47.   
 
(DPA219):  DPA219 (3.1 mg, 88%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.09 (s, 2H), 7.47 (s, 1H), 7.40 (s, 1H), 7.32 (s, 1H), 7.22 (s, 1H), 7.02 (s, 
1H), 6.98 (s, 1H), 6.76 (s, 1H), 5.92 (s, 1H), 5.56-5.55 (m, 1H), 5.27-5.24 (m, 1H), 5.16-
5.15 (m, 1H), 4.47-4.39 (m, 1H), 4.36-4.33 (m, 1H), 4.25-4.20 (m, 1H), 4.10-4.09 (m, 
2H), 4.08 (s, 2H), 4.06 (s, 1H), 4.02-3.98 (m, 1H), 3.92 (s, 3H), 3.91-3.90 (m, 4H), 3.88 
(s, 3H), 3.88-3.86 (m, 1H), 3.85-3.80 (m, 5H), 3.79 (s, 1H), 3.79-3.75 (m, 1H), 3.72-3.66 
(m, 1H), 3.66-3.59 (m, 1H), 3.45-3.44 (m, 1H), 3.39-3.36 (m, 1H), 3.36-3.35 (m, 2H), 
3.35 (s, 2H), 3.35-3.33 (m, 2H), 3.32-3.28 (m, 1H), 3.27-3.24 (m, 2H), 3.24-3.20 (m, 
2H), 3.23-3.22 (m, 1H), 3.21-3.17 (m, 3H), 3.15-3.10 (s, 2H), 2.70-2.63 (m, 4H), 2.21-
2.17 (m, 1H), 1.80-1.69 (m, 2H), 1.73-1.61 (m, 1H), 1.57-1.50 (m, 4H), 1.31-1.25 (m, 
6H); MALDI-TOF m/z calcd C62H96N22O16 1405.56, found [M + Na]
+ 1427.72.   
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Table B4.  Stoichiometry table for the synthesis of HImImPyPyCONH(CH2)n-tri-
(CH2)4-neomycin-hexahydrochloride, DPA220 – DPA225, n = 2, 3, 5, 6, 8 and 
10.   
S
er
ie
s 
II
I 
 
DPA15 
‘HImImPy 
PyCONH 
(CH2)nN3’ 
CuI DIPEA 
Compound 
(#) 
amnt. 
(mg) 
µmo
l 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
amnt. 
(mg) µmol 
DPA220 4.9 3.7 2.0 3.7 1.4 7.3 91.5 11.8 
DPA221 4.9 3.7 2.1 3.7 1.4 7.3 90.7 11.7 
DPA222 4.9 3.5 2.2 3.5 1.4 7.1 89.2 11.5 
DPA223 4.8 3.5 2.2 3.5 1.3 7.0 87.9 11.4 
DPA224 4.7 3.4 2.2 3.4 1.3 6.8 85.6 11.1 
DPA225 4.2 3.1 2.1 3.1 1.2 6.1 76.4 9.9 
 
R = NHBoc
DPA15
n = 2, DPA220
3, DPA221
5, DPA222
6, DPA223
8, DPA224
10, DPA225
n = 2, DPA202
3, DPA203
5, DPA204
6, DPA205
8, DPA206
10, DPA207
 
(DPA220 – DPA225).  To a solution of N-Boc-neomycin-tri-alkyne DPA15 in toluene 
(1.0 mL) was added a solution consisting of CuI and DIPEA in toluene (500 µL).  To this 
solution was added a suspension of the azide functionalized tetramer polyamides in 
toluene (500 µL).  The reaction mixture was allowed to stir at room temperature for 24 h, 
and then was concentrated in vacuo.  The resulting residue was purified by flash 
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chromatography (silica gel, CH2Cl2:MeOH, 2% incremental increases in MeOH) to yield 
the N-Boc protected conjugates.  The solid was then suspended in 4 N HCl in dioxane (5 
mL) and the reaction was allowed to stir at room temperature for 30 min.  The solution 
was concentrated in vacuo and the resulting solid was washed with copious amounts of 
CH2Cl2 and lyphilized to dryness to afford conjugates DPA220 – DPA225 as 
hydrochloride salts.  Coupling and deprotection steps were near quantitative and the 
subsequent yields reflect the overall yield for both steps.  The reported 1H NMR and 
MALDI spectra represent the deprotected compounds.   
 
(DPA220):  DPA220 (4.9 mg, 98%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 7.88 (s, 2H), 7.48 (s, 1H), 7.42 (s, 1H), 7.35 (s, 1H), 7.25 (s, 1H), 7.08 (s, 
1H), 6.89 (s, 1H), 6.79 (s, 1H), 6.05 (s, 2H), 5.57-5.56 (m, 1H), 5.31-5.30 (m, 1H), 5.18-
5.17 (m, 1H), 4.47-4.39 (m, 1H), 4.36-4.33 (m, 1H), 4.25-4.20 (m, 1H), 4.10-4.09 (m, 
2H), 4.09 (s, 1H), 4.08 (s, 2H), 4.00-3.96 (m, 1H), 3.91 (s, 6H), 3.91-3.88 (m, 1H), 3.88 
(s, 3H), 3.86-3.85 (m, 1H), 3.84-3.79 (m, 2H), 3.78 (s, 4H), 3.77-3.74 (m, 1H), 3.70-3.64 
(m, 1H), 3.65-3.55 (m, 1H), 3.47-3.45 (m, 1H), 3.38-3.36 (m, 1H), 3.35 (s, 2H), 3.35-
3.33 (m, 2H), 3.33-3.28 (m, 2H), 3.32-3.30 (m, 1H), 3.30-3.24 (m, 2H), 3.24-3.21 (m, 
3H), 3.22-3.15 (m, 3H), 3.14-3.12 (s, 2H), 2.65-2.59 (m, 4H), 2.23-2.20 (m, 1H), 1.77-
1.58 (m, 4H), 1.72-1.63 (m, 1H); MALDI-TOF m/z calcd C55H82N22O16 1307.38, found 
[M + Na]+ 1330.73. 
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(DPA221):  DPA221 (5.0 mg, 97%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.16 (s, 2H), 7.38 (s, 1H), 7.32 (s, 1H), 7.31 (s, 1H), 7.26 (s, 1H), 7.08 (s, 
1H), 6.99 (s, 1H), 6.89 (s, 1H), 6.17 (s, 1H), 5.59-5.56 (m, 1H), 5.33-5.31 (m, 1H), 5.20-
5.18 (m, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H), 4.23-4.21 (m, 1H), 4.13-4.10 (m, 
2H), 4.09 (s, 1H), 4.06-4.01 (m, 1H), 4.00 (s, 1H), 3.91-3.90 (m, 1H), 3.88-3.86 (m, 4H), 
3.85-3.80 (m, 2H), 3.80 (s, 3H), 3.79 (s, 4H), 3.79-3.75 (m, 4H), 3.74 (s, 3H), 3.72-3.66 
(m, 1H), 3.66-3.59 (m, 1H), 3.50-3.46 (m, 1H), 3.44-3.39 (m, 2H), 3.40-3.37 (m, 1H), 
3.36 (s, 2H), 3.36-3.32 (m, 3H), 3.32-3.31 (m, 1H), 3.30-3.25 (m, 2H), 3.24-3.23 (m, 
1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.70-2.55 (m, 4H), 2.25-2.22 (m, 1H), 1.93-
1.89 (m, 2H), 1.75-1.44 (m, 5H); MALDI-TOF m/z calcd C56H84N22O16 1321.40, found 
[M + Na]+ 1344.56. 
 
(DPA222):  DPA222 (5.2 mg, 97%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.11(s, 2H), 7.35 (s, 1H), 7.27 (s, 1H), 7.20 (s, 1H), 7.17 (s, 1H), 7.00 (s, 
1H), 6.95 (s, 1H), 6.82 (s, 1H), 6.09 (s, 1H), 5.59 (s, 1H), 5.33-5.30 (m, 1H), 5.21-5.18 
(m, 1H), 4.50-4.55 (m, 1H), 4.36-4.34 (m, 1H), 4.25-4.22 (m, 1H), 4.17-4.15 (m, 2H), 
4.10 (s, 1H), 3.97 (s, 1H), 3.93-3.88 (m, 1H), 3.88 (s, 3H), 3.87-3.85 (m, 7H), 3.83-3.81 
(m, 1H), 3.81 (s, 3H), 3.80-3.79 (m, 2H), 3.78 (s, 4H), 3.71-3.70 (m, 1H), 3.66-3.63 (m, 
1H), 3.61-3.56 (m, 1H), 3.45-3.40 (m, 2H), 3.45-3.44 (m, 1H), 3.41-3.31 (m, 3H), 3.35 
(s, 2H), 3.35-3.33 (m, 2H), 3.32-3.28 (m, 1H), 3.27-3.24 (m, 2H), 3.23-3.22 (m, 1H), 
3.21-3.17 (m, 3H), 3.15 3.10 (s, 2H), 2.60-2.51 (m, 4H), 2.27-2.21 (m, 1H), 1.70-1.61 (m, 
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5H), 1.56-1.50 (m, 2H), 1.50-1.47 (m, 2H), 1.33-1.27 (m, 2H); C58H88N22O16 1349.46, 
found [M + Na]+ 1374.10.   
 
(DPA223):  DPA223 (4.8 mg, 96%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.11 (s, 1H), 8.04 (s, 1H), 7.47 (s, 1H), 7.40 (s, 1H), 7.32 (s, 1H), 7.22 (s, 
1H), 7.02 (s, 1H), 6.98 (s, 1H), 6.76 (s, 1H),  6.02 (m, 2H), 5.56-5.55 (m, 1H), 5.37-5.34 
(m, 1H), 5.16-5.15 (m, 1H), 4.51-4.43 (m, 1H), 4.37-4.33 (m, 1H), 4.28-4.22 (m, 1H), 
4.15-4.11 (m, 2H), 4.07 (s, 1H), 3.98-3.92 (m, 1H), 3.92 (s, 1H), 3.88 (s, 6H), 3.88-3.86 
(m, 1H), 3.86 (s, 3H), 3.84-3.82 (m, 4H), 3.81-3.77 (m, 5H), 3.76 (s, 1H), 3.74-3.72 (m, 
1H), 3.68-3.66 (m, 1H), 3.63-3.57 (m, 1H), 3.46-3.45 (m, 1H), 3.37-3.34 (m, 1H), 3.34 
(s, 2H), 3.33-3.31 (m, 2H), 3.30-3.30 (m, 1H), 3.30-3.27 (m, 2H), 3.27-3.25 (m, 2H), 
3.26-2.23 (m, 3H), 3.21-3.16 (m, 3H), 3.13-3.10 (s, 2H), 2.73-2.66 (m, 4H), 2.21-2.17 
(m, 1H), 1.83-1.71 (m, 4H), 1.73-1.61 (m, 1H), 1.55-1.51 (m, 2H), 1.51-1.44 (m, 2H), 
1.36-1.30 (m, 4H); MALDI-TOF m/z calcd C59H90N22O16 1363.48, found [M + Na]
+ 
1386.47.   
 
(DPA224):  DPA224 (5.3 mg, 99%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.11 (br, 2H), 7.45 (s, 1H), 7.40 (s, 1H), 7.31 (s, 1H), 7.25 (s, 1H), 7.08 (s, 
1H), 6.98 (s, 1H), 6.76 (s, 1H), 6.14 (s, 1H), 5.65-5.64 (m, 1H), 5.27-5.24 (m, 1H), 5.16-
5.15 (m, 1H), 4.51-4.43 (m, 1H), 4.37-4.33 (m, 1H), 4.28-4.22 (m, 1H), 4.15-4.11 (m, 
2H), 4.07 (s, 1H), 4.00 (s, 1H), 3.98-3.92 (m, 1H), 3.91 (s, 3H), 3.89 (s, 3H), 3.88-3.86 
(m, 1H), 3.84-3.82 (m, 4H), 3.81-3.77 (m, 5H), 3.76 (s, 1H), 3.74-3.72 (m, 1H), 3.68-
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3.66 (m, 1H), 3.63-3.57 (m, 1H), 3.46-3.45 (m, 1H), 3.37-3.34 (m, 1H), 3.34 (s, 2H), 
3.33-3.29 (m, 4H), 3.29-3.28 (m, 2H), 3.28-3.27 (m, 1H), 3.27-3.25 (m, 2H), 3.25-2.23 
(m, 1H), 3.21-3.16 (m, 3H), 3.13-3.10 (s, 2H), 2.73-2.66 (m, 4H), 2.21-2.17 (m, 1H), 
1.83-1.74 (m, 4H), 1.73-1.61 (m, 1H), 1.57-1.48 (m, 4H), 1.35-1.31 (m, 4H), 1.31-1.27 
(m, 4H); MALDI-TOF m/z calcd C61H94N22O16 1391.54, found [M + Na]
+ 1414.55.  
  
(DPA225):  DPA225 (4.3 mg, 95%) was afforded as a light brown solid:  1H NMR (500 
MHz, D2O) δ 8.06 (s, 2H), 7.35 (s, 1H), 7.28 (s, 1H), 7.21 (s, 1H), 7. 14 (s, 1H), 7.03 (s, 
1H), 6.81 (s, 1H), 6.07 (s, 1H), 5.51 (s, 1H), 5.49-5.46 (m, 1H), 5.33-5.31 (m, 1H), 5.20-
5.18 (m, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H), 4.28 (s, 3H), 4.23-4.21 (m, 1H), 4.17 
(s, 3H), 4.13-4.10 (m, 2H), 4.07 (s, 1H), 4.02-3.98 (m, 1H), 3.96 (s, 3H), 3.91-3.90 (m, 
1H), 3.88-3.86 (m, 4H), 3.85-3.80 (m, 2H), 3.79 (s, 1H), 3.79-3.75 (m, 4H), 3.72-3.66 
(m, 4H), 3.66-3.59 (m, 1H), 3.50-3.46 (m, 1H), 3.46-3.41 (m, 2H), 3.40-3.37 (m, 1H), 
3.36 (s, 2H), 3.36-3.32 (m, 2H), 3.32-3.31 (m, 1H), 3.30-3.25 (m, 4H), 3.24-3.23 (m, 
1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.70-2.55 (m, 4H), 2.25-2.22 (m, 1H), 1.80-
1.49 (m, 5H), 1.61-1.55 (m, 4H), 1.31-1.22 (m, 6H); MALDI-TOF m/z calcd 
C63H98N22O16 1419.59, found [M + Na]
+ 1442.25.   
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(DPA243).  To a solution of DPA17 (15 mg, 11.6 µmol) suspended in toluene (1.0 mL) 
was added a homogeneous solution consisting of CuI and DIPEA in toluene (500 µL).  
To this solution was added a solution of DPA202 (6.5 mg, 11.6 µmol) suspended in 
toluene (500 µL).  The reaction was allowed to stir at room temperature for 24 h.  The 
solution was concentrated in vacuo.  The resulting residue was purified by flash 
chromatography (silica gel, CH2Cl2:MeOH, 2% incremental increases in MeOH) to yield 
the N-Boc protected conjugate.  The solid was then suspended in 4 N HCl in dioxane (5 
mL) and the reaction was allowed to stir at room temperature for 30 min.  The solution 
was concentrated in vacuo and the resulting solid was washed with copious amounts of 
CH2Cl2 and lypholized to dryness to afford DPA243 as a hydrochloride salt.  1H NMR 
(500 MHz, D2O) δ 7.41 (s, 1H), 7.39 (s, 1H), 7.28 (s, 1H), 7.21 (s, 1H), 7.03 (s, 1H), 6.97 
(s, 1H), 6.87 (s, 1H), 6.05 (s, 1H), 5.57-5.56 (m, 1H), 5.31-5.30 (m, 1H), 5.18-5.17 (m, 
1H), 4.47-4.39 (m, 1H), 4.36-4.33 (m, 1H), 4.25-4.20 (m, 1H), 4.10-4.09 (m, 2H), 4.09 
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(s, 3H), 4.08 (s, 3H), 4.00-3.96 (m, 1H), 3.91 (s, 3H), 3.91-3.88 (m, 1H), 3.88 (s, 3H), 
3.86-3.85 (m, 1H), 3.84-3.79 (m, 2H), 3.78 (s, 1H), 3.77-3.74 (m, 1H), 3.70-3.64 (m, 
1H), 3.65-3.55 (m, 1H), 3.47-3.45 (m, 1H), 3.38-3.36 (m, 1H), 3.35 (s, 2H), 3.35-3.33 
(m, 2H), 3.33-3.28 (m, 2H), 3.32-3.30 (m, 1H), 3.30-3.24 (m, 2H), 3.24-3.21 (m, 3H), 
3.22-3.15 (m, 3H), 3.14-3.12 (s, 2H), 2.65-2.59 (m, 4H), 2.23-2.20 (m, 1H), 1.77-1.58 
(m, 4H), 1.72-1.63 (m, 1H); MALDI-TOF m/z calcd C51H76N20O18 1257.27, found [M + 
H2O]
+ 1276.11. 
 
R = NHBoc
DPA203 DPA17
DPA244
 
(DPA244).  To a solution of DPA17 (15 mg, 11.6 µmol) suspended in toluene (1.0 mL) 
was added a homogeneous solution consisting of CuI and DIPEA in toluene (500 µL).  
To this solution was added a solution of DPA203 (6.5 mg, 11.6 µmol) suspended in 
toluene (500 µL).  The reaction was allowed to stir at room temperature for 24 h.  The 
solution was concentrated in vacuo.  The resulting residue was purified by flash 
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chromatography (silica gel, CH2Cl2:MeOH, 2% incremental increases in MeOH) to yield 
the N-Boc protected conjugate.  The solid was then suspended in 4 N HCl in dioxane (5 
mL) and the reaction was allowed to stir at room temperature for 30 min.  The solution 
was concentrated in vacuo and the resulting solid was washed with copious amounts of 
CH2Cl2 and lypholized to dryness to afford DPA244 as a hydrochloride salt.  1H NMR 
(500 MHz, D2O) δ 7.38 (s, 1H), 7.32 (s, 1H), 7.31 (s, 1H), 7.26 (s, 1H), 7.08 (s, 1H), 6.99 
(s, 1H), 6.89 (s, 1H), 6.57 (s, 1H), 6.37 (s, 1H), 5.89-5.86 (m, 1H), 5.33-5.31 (m, 1H), 
5.20-5.18 (m, 1H), 4.47-4.40 (m, 1H), 4.35-4.34 (m, 1H), 4.23-4.21 (m, 1H), 4.13-4.10 
(m, 2H), 4.09 (s, 3H), 4.06-4.01 (m, 1H), 4.00 (s, 3H), 3.91-3.90 (m, 1H), 3.88-3.86 (m, 
1H), 3.85-3.80 (m, 2H), 3.80 (s, 3H), 3.79 (s, 1H), 3.79-3.75 (m, 1H), 3.74 (s, 3H), 3.72-
3.66 (m, 1H), 3.66-3.59 (m, 1H), 3.50-3.46 (m, 1H), 3.44-3.39 (m, 2H), 3.40-3.37 (m, 
1H), 3.36 (s, 2H), 3.36-3.32 (m, 3H), 3.32-3.31 (m, 1H), 3.30-3.25 (m, 2H), 3.24-3.23 
(m, 1H), 3.22-3.14 (m, 3H), 3.13-3.11 (s, 2H), 2.70-2.55 (m, 4H), 2.25-2.22 (m, 1H), 
1.93-1.89 (m, 2H), 1.75-1.44 (m, 5H); MALDI-TOF m/z calcd C52H78N20O18 1271.30, 
found [M + H2O]
+ 1289.71. 
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HImImPyPyDp (18).  Compound 6 (50 mg, 0.09 mmol) was dissolved in MeOH:THF 
(1:3; v:v; 10 mL).  1.5 N NaOH (2.0 mL) was added and the reaction was stirred at 60 oC 
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and followed by TLC.  When TLC showed the starting material was no longer present, 4 
– 6 h, the reaction was neutralized with HCl.  The solution was evaporated to dryness.  
The resulting acid was suspended in DMF (20 mL), EDC and HOBt were added and the 
solution was stirred for 1 h.  N,N-dimethylaminopropylamine (19.4 mg, 0.19 mmol) was 
added and the solution was allowed to stir for 18 h.  DMF was removed in vacuo and the 
resulting solid was suspended in CH2Cl2 (25 mL).  The solution was decanted and the 
resulting solid was suspended in MeOH (15 mL).  The solution filtered and dried to 
afford 18 as an off white solid (28.6 mg, 55%):  1H NMR (500 MHz, D2O) δ 9.53 (s, 1H), 
8.88 (s, 1H), 7.66 (s, 1H), 7.44 (s, 1H), 7.36 (s, 1H), 7.24 (s, 1H), 7.00 (s, 1H), 6.77 (s, 
1H), 6.63 (s, 1H), 4.03, (s, 6H), 4.02 (s, 3H), 3.91 (s,3 H), 3.89 (s, 3H), 3.80 (s, 3H), 3.22 
(t, J1 = 4.2, 2H), 2.75 (t, J2 = 6.1, 2H), 2.63 (q,  J1 = 4.3, J2 = 6.1, 2H); 13C NMR (125 
MHz, CDCl3) δ 162.5, 158.9, 154.2, 139.6, 138.7, 138.0, 1.37.0, 136.6, 133.1, 127.6, 
126.3, 125.8, 122.1, 121.4, 120.3, 119.9, 119.0, 114.18, 108.9, 105.9, 66.4, 63.8, 50.1, 
36.3, 36.4, 34.2, 32.6; MALDI-TOF m/z calcd for C27H35N11O4 577.64, found [M + Na]+ 
599.64.   
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(a) 1H NMR 
 
(b) 13C NMR 
 
304 
 
(c) MALDI-TOF 
 
Figure B1. Characterization of compound 8a.   
 
 (a) 1H NMR 
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Figure B2. Characterization of compound 10.   
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Figure B3. Characterization of compound 9a.   
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Figure B4. Characterization of compound 11.   
  
(a) 1H NMR 
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(c) MALDI-TOF 
 
Figure B5. Characterization of compound 6.   
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Figure B6. Characterization of compound DPA202. 
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Figure B7. Characterization of compound DPA203. 
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Figure B8. Characterization of compound DPA204. 
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Figure B9. Characterization of compound DPA205. 
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Figure B10. Characterization of compound DPA206. 
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Figure B11. Characterization of compound DPA207. 
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Figure B12. Characterization of compound DPA13.   
 
(a) 1H NMR 
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Figure B13. Characterization of compound DPA14.   
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 (b) MALDI-TOF 
Figure B14. Characterization of compound 
 
(a) 1H NMR 
DPA12.   
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(b) MALDI-TOF 
 
Figure B15. Characterization of compound DPA17.   
 
(a) 1H NMR (N-Boc protected) 
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(b) MALDI-TOF (N-Boc protected) 
 
(a) 1H NMR (deprotected) 
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(b) MALDI-TOF (deprotected) 
 
Figure B16. Characterization of compound DPA208. 
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(b) MALDI-TOF 
 
Figure B17. Characterization of compound DPA209. 
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(b) MALDI-TOF 
 
Figure B18. Characterization of compound DPA210. 
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(b) MALDI-TOF 
 
Figure B19. Characterization of compound DPA211. 
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Figure B20. Characterization of 
 
(a) 1H NMR 
compound DPA212. 
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Figure B21. Characterization of compound DPA213. 
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Figure B22. Characterization of compound DPA214. 
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(b) MALDI-TOF 
 
Figure B23. Characterization of compound DPA215. 
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Figure B24. Characterization of compound DPA216. 
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Figure B25. Characterization of compound DPA217. 
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(b) MALDI-TOF 
 
Figure B26. Characterization of compound DPA218. 
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(b) MALDI-TOF 
 
Figure B27. Characterization of compound DPA219. 
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(b) MALDI-TOF 
 
Figure B28. Characterization of compound DPA220. 
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Figure B29. Characterization of compound DPA221. 
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(b) MALDI-TOF 
 
Figure B30. Characterization of compound DPA222. 
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(b) MALDI-TOF 
 
Figure B31. Characterization of compound DPA223. 
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(b) MALDI-TOF 
 
Figure B32. Characterization of compound DPA224. 
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(b) MALDI-TOF 
 
Figure B33. Characterization of compound DPA225. 
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(b) MALDI-TOF 
 
Figure B34. Characterization of compound DPA243. 
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(b) MALDI-TOF 
 
Figure B35. Characterization of compound DPA244. 
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Figure B36. Characterization of compound 
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(a) 5’-G2A3G4C4-3’ (b) 5’-AG2C2AG4C4-3’ 
 
 
(c) 5’-G2C2AG4C4-3’ (d) 5’-TG2C2G4-3’ 
  
(e) 5’-AG2C2AG4-3’  
 
Figure B37.  CD scans for the following duplexes: 5’-G2A3G4C4-3’ (a), 5’-
AG2C2AG4C4-3’ (b), 5’-G2C2AG4C4-3’ (c), 5’-TG2C2G4-3’ (d) and 5’-AG2C2AG4-3’ (e).  
Scans were conducted at 20 oC.  The concentration of the duplexes was 40 µM/bp.  
Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Figure B38.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-G2A3G4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I DPA208 – DPA213 conjugates 
are shown in blue, series II DPA214 – DPA219 conjugates are shown in green, series III 
DPA220 – DPA225 conjugates are shown in red and series IV DPA243 – DPA244 
conjugates are shown in dark grey.  Data was obtained from a FID assay.  Ligands were 
added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 µM], at 
various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent 
decrease in fluorescence was recorded.  The data was normalized such that the well 
containing ethidium bromide and buffer was denoted as 0% fluorescence and the well 
containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged. Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Figure B39.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-G2A3G4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 1.0.  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I DPA208 – DPA213 conjugates 
are shown in blue, series II DPA214 – DPA219 conjugates are shown in green, series III 
DPA220 – DPA225 conjugates are shown in red and series IV DPA243 – DPA244 
conjugates are shown in dark grey.  Data was obtained from a FID assay.  Ligands were 
added to the DNA [1 µM/duplex], pre-saturated with ethidium bromide [7 µM], at 
various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min and the subsequent 
decrease in fluorescence was recorded.  The data was normalized such that the well 
containing ethidium bromide and buffer was denoted as 0% fluorescence and the well 
containing buffer, DNA and ethidium bromide was denoted as 100% fluorescence.  
Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; slitsex = 20; slitsem = 
20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 nm; PMT V = 810 and 
triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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(a) DPA214 (b) DPA215 
    
(c) DPA216 (d) DPA217 
    
(e) DPA218 (f) DPA219 
    
Figure B40.  UV melting profiles for 5’-A2G6C6T2-3’ with series II DPA214 – DPA219 tetramer polyamide – neomycin conjugates.  
The histograms on the right are a plot of ∆Tm with respect to the ratio of drug:duplex (rdd).  Ligands were added to the duplex [2 
µM/duplex] at varying rdd values.  The samples were incubated at 4 
oC for 12 h.  prior to analysis, slow heating from 10 oC to 90 oC at 
0.2 oC/min.  Each panel represents the duplex with a conjugate at varying rdd values.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0. 
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(a) DPA220 (b) DPA221 
    
(c) DPA222 (d) DPA223 
    
(e) DPA224 (f) DPA225 
    
Figure B41.  UV melting profiles for 5’-A2G6C6T2-3’ with series III DPA220 – DPA225 tetramer polyamide – neomycin conjugates.  
The histograms on the right are a plot of ∆Tm with respect to the ratio of drug:duplex (rdd).  Ligands were added to the duplex [2 
µM/duplex] at varying rdd values.  The samples were incubated at 4 
oC for 12 h.  prior to analysis, slow heating from 10 oC to 90 oC at 
0.2 oC/min.  Each panel represents the duplex with a conjugate at varying rdd values.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 
0.25 mM EDTA, pH 7.0. 
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(a) (b) 
  
(c) Figure B42.  Plot of ∆Tm with respect to conjugate linker 
length upon addition of ligands to 5’-A2G6C6T2-3’ at rdd = 0.5 
(a), rdd = 1.0 (b) and rdd = 2.0 (c).  Controls (neomycin, 
HImImPyPyDp 18) are shown in light grey while series I 
DPA208 – DPA213 are shown in blue, series II DPA214 – 
DPA219 conjugates are shown in green and series III 
DPA220 – DPA225 conjugates are shown in red.  Data was 
obtained from UV thermal denaturation experiments.  Ligands 
were added to the DNA [2.0 µM/duplex] at varying ratios of 
drug to duplex.   The samples were incubated at 4 oC for 12 h.  
prior to analysis, slow heating from 10 oC to 100 oC at 0.2 
oC/min.  Buffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 
mM EDTA, pH 7.0, 50 mM NaCl.  a∆Tm values for the duplex 
with no additional NaCl.  
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(a) 5’-A2G6C6T2-3’ (b) 5’-A3G5C5T3-3’
a (c) 5’-A3G5C5T3-3’ 
   
(d) 5’-A4G4C4T4-3’ (e) 5’-A5G3C3T5-3’ (f) 5’-A6G2C2T6-3’ 
   
Figure B43.  UV melting profiles for 5’-AmGnCnTm-3’ type duplexes with controls, neomycin and HImImPyPyDp 18 (a – f).  
Controls were added to the duplex [2.0 µM/duplex] at rdd = 1.0.  The samples were incubated at 4 
oC for 12 h prior to analysis, 
slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 
mM NaCl.  aBuffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0.   
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(a) 5’-A2G6C6T2-3’ (b) 5’-A3G5C5T3-3’
a (c) 5’-A3G5C5T3-3’ 
   
(d) 5’-A4G4C4T4-3’ (e) 5’-A5G3C3T5-3’ (f) 5’-A6G2C2T6-3’ 
   
Figure B44a.  UV melting profiles for 5’-AmGnCnTm-3’ type duplexes with series II DPA214 – DPA219 tetramer polyamide - 
neomycin conjugates.  Ligands were added to the duplex [2.0 µM/duplex] at rdd = 1.0.  The samples were incubated at 4 
oC for 
12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM 
EDTA, pH 7.0, 50 mM NaCl.  aBuffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0.     
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(a) 5’-A2G6C6T2-3’ (b) 5’-A3G5C5T3-3’
a (c) 5’-A3G5C5T3-3’ 
   
(d) 5’-A4G4C4T4-3’ (e) 5’-A5G3C3T5-3’ (f) 5’-A6G2C2T6-3’ 
   
Figure B44b.  UV melting profiles for 5’-AmGnCnTm-3’ type duplexes with series II DPA214 – DPA219 tetramer polyamide - 
neomycin conjugates.  Ligands were added to the duplex [2.0 µM/duplex] at rdd = 1.0.  The samples were incubated at 4 
oC for 
12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM 
EDTA, pH 7.0, 50 mM NaCl.  aBuffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0.     
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(a) 5’-A2G6C6T2-3’ (b) 5’-A3G5C5T3-3’
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(d) 5’-A4G4C4T4-3’ (e) 5’-A5G3C3T5-3’ (f) 5’-A6G2C2T6-3’ 
   
Figure B45a.  UV melting profiles for 5’-AmGnCnTm-3’ type duplexes with series III DPA220 – DPA225 tetramer polyamide 
- neomycin conjugates.  Ligands were added to the duplex [2.0 µM/duplex] at rdd = 1.0.  The samples were incubated at 4 
oC 
for 12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 
mM EDTA, pH 7.0, 50 mM NaCl.  aBuffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0.     
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Figure B44b.  UV melting profiles for 5’-AmGnCnTm-3’ type duplexes with series III DPA220 – DPA225 tetramer polyamide 
- neomycin conjugates.  Ligands were added to the duplex [2.0 µM/duplex] at rdd = 1.0.  The samples were incubated at 4 
oC 
for 12 h prior to analysis, slow heating from 10 oC to 90 oC at 0.2 oC/min.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 
mM EDTA, pH 7.0, 50 mM NaCl.  aBuffer:  1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0.     
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Figure B46.  UV melting profiles for 5’-G2A3G4C4-3’ with series I DPA208 – DPA213 
(a), series II DPA214 – DPA219 (b), series III DPA220 – DPA225 (c) and series IV 
DPA243 and DPA244 (d) tetramer polyamide - neomycin conjugates.  UV melting 
profiles for the controls are also plotted in panel (d).  Ligands were added to the duplex 
[2.0 µM/duplex] at rdd (ratio of drug:duplex) = 1.0.  The samples were incubated at 4 
oC 
for 12 h.  prior to analysis, slow heating from 10 oC to 100 oC at 0.2 oC/min.  The panels 
above correspond to the melts.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM 
EDTA, pH 7.0, 50 mM NaCl. 
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Figure B47.  UV melting profiles for 5’-G2C2AG4C4-3’ with series II DPA214 – 
DPA219 (a), series III DPA220 – DPA225 (b) and series IV DPA243 and DPA244 (c) 
tetramer polyamide - neomycin conjugates.  UV melting profiles for the controls are also 
plotted in panel (c).  Ligands were added to the duplex [2.0 µM/duplex] at rdd (ratio of 
drug:duplex) = 1.0.  The samples were incubated at 4 oC for 12 h.  prior to analysis, slow 
heating from 10 oC to 100 oC at 0.2 oC/min.  The panels above correspond to the melts.  
Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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APPENDIX C 
8 8a
 
Methyl 4-amino-1-methylimidazole-2-carboxylate (8a).  See Appendix B for synthetic 
procedure, compound data reduction and characterization. 
 
8a 107  
HImImCOOMe (10).  See Appendix B for synthetic procedure, compound data 
reduction and characterization. 
 
9 9a
 
Methyl 4-amino-1-methylpyrrole-2-carboxylate (9a).  See Appendix B for synthetic 
procedure, compound data reduction and characterization. 
 
10 11  
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HImImPyCOOMe (11).  See Appendix B for synthetic procedure, compound data 
reduction and characterization. 
 
23 25  
BocNHPyγCOOMe (25).  To a solution of 23 (313.0 mg, 1.2 mmol) in methanol (10 
mL) was added 1.5 M NaOH (2 mL) and the solution was allowed to stir for 4 h at 60 oC.  
The ester solution was neutralized with HCl.   Volatiles were removed in vacuo.  The 
resulting solid was dissolved in DMF (10 mL).  PyBOP (768.7 mg, 1.5 mmol) and 
DIPEA (1.072 mL, 6.1 mmol) were added and the reaction was allowed to stir for 30 
min.  Methyl-4-aminobutyrate hydrochloride, 24, (207.4 mg, 1.4 mmol) was added and 
the reaction was allowed to stir for 15 h.  DMF was evaporated in vacuo and the resulting 
solid was purified via flash chromatography (silica gel, 75:25 hexane:EtOAc v/v) to yield 
pure 25 (371.5 mg, 89%) as a light brown solid:  TLC (EtOAc) Rf 0.80; 1H NMR (300 
MHz, CDCl3) δ 6.84 (s, 1H), 6.64 (br, 1H), 6.45 (s, 1H), 6.23 (br, 1H), 3.85 (s, 3H), 3.69 
(s, 3H), 3.88-3.66 (m, 2H), 2.41-2.37 (d, J = 9.3, 2H), 2.02-1.79 (m, J1 = 6.1, J2 = 9.2, 
2H), 1.47 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 162.8, 159.3, 154.5, 123.2, 120.9, 119.7, 
102.7, 80.8, 51.1, 38.9, 36.7, 35.7, 33.8, 28.4; MALDI-TOF m/z calcd for C16H25N3O5 
339.39, found [M + H]+ 340.11.   
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25
20  
BocNHPyγImCOOMe (20).  Compound 8 (204.1 mg, 1.1 mmol) was dissolved in 
MeOH (20 mL).  10% Pd/C (20.4 mg) was added and the solution was stirred under 
positive H2 atmosphere, supplied by submerged syringe needle in the solution.  The 
solution was stirred for 3.5 h.  The catalyst was filtered over celite and the filtrate was 
concentrated in vacuo, followed by co-evaporation with copious amounts of CH2Cl2.  The 
resulting oil was suspended in DMF and placed under vacuum for addition to the 
activated acid solution.  To a solution of 25 (371.5 mg, 1.1 mmol) in methanol (10 mL) 
was added 1.5 M NaOH (2 mL) and the solution was allowed to stir for 4 h at 60 oC.  The 
ester solution was neutralized with HCl.   Volatiles were removed in vacuo.  The 
resulting solid was dissolved in DMF (10 mL).  EDC (229.9 mg, 1.2 mmol) and HOBt 
(162.0 mg, 1.2 mmol) were added and the reaction was allowed to stir for 30 min.  The 
amine solution, in 10 mL of DMF, was added dropwise to the activated acid solution over 
the period of 10 min and the reaction was allowed to stir for 16 h.  DMF was evaporated 
in vacuo and the resulting solid was purified via flash chromatography (silica gel, 50:50 
CH2Cl2:Acetone v/v) to yield pure 20 (511.7 mg, 89%) as a light brown solid:  TLC 
(50:50 CH2Cl2:Acetone v/v) Rf 0.71; 1H NMR (300 MHz, CDCl3)  δ 9.08 (s, 1H), 7.46 (s, 
1H), 6.83 (s, 1H), 6.51 (s, 1H), 6.49 (s, 1H), 6.39 (s, 1H), 3.96 (s, 3H), 3.88 (s, 3H), 3.83 
(s, 3H), 3.42-3.40 (m, 2H), 2.46-2.42 (d, J = 6.1, 2H), 1.96-1.93 (m, J1 = 6.1, J2 = 5.7, 
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2H), 1.25 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.6, 161.9, 159.0, 153.3, 137.1, 131.3, 
123.2, 121.7, 117.6, 115.5, 103.6, 80.0, 52.2, 38.6, 36.5, 35.9, 33.8, 30.9, 29.3; MALDI-
TOF m/z calcd for C21H30N6O6 462.50, found [M + Na+]+ 485.49.   
 
9 26  
BocNHImPyCOOMe (26).  Compound 9 (152.2 mg, 0.8 mmol) was dissolved in MeOH 
(20 mL).  10% Pd/C (15.2 mg) was added and the solution was stirred under positive H2 
atmosphere, supplied by submerged syringe needle in the solution.  The solution was stir 
red for 3 h.  The catalyst was filtered over celite and the filtrate was concentrated in 
vacuo, followed by co-evaporation with copious amounts of CH2Cl2.  The resulting oil 
was suspended in DMF and placed under vacuum for addition to the activated acid 
solution.  Compound 22 (211.1 mg, 0.8 mmol) was dissolved in MeOH (20 mL) and 1.5 
M NaOH (2 mL) was added.  The solution was allowed to stir for 4 h at 60 oC.  The ester 
solution was quenched by neutralized with HCl.   Volatiles were removed in vacuo.  The 
resulting solid was dissolved in DMF (10 mL).  EDC (158.5 mg, 0.8 mmol) and HOBt 
(111.7 mg, 0.8 mmol) were added and the reaction was allowed to stir for 30 min.  The 
amine solution, in 8 mL of DMF, was added dropwise to the activated acid solution over 
the period of 10 min and the reaction was allowed to stir for 15 h.  DMF was evaporated 
in vacuo and the resulting solid was purified via flash chromatography (silica gel, 
acetone:CH2Cl2, 5.0 % incremental increases of acetone) to yield pure 26 (218.4 mg, 
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71%) as a white solid:  TLC (50:50 CH2Cl2:Acetone v/v) Rf 0.71; 1H NMR (500 MHz, 
CDCl3) δ 8.98 (s, 1H), 7.92 (s, 1H), 7.39 (s, 1H), 7.17 (s, 1H), 6.73 (s, 1H), 4.03 (s, 3H), 
3.87 (s, 3H), 3.78 (s, 3H), 1.47 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 161.5, 155.9, 
152.6, 136.7, 133.8, 121.2, 120.8, 119.8, 112.5, 108.4, 80.8, 51.1, 36.7, 35.7, 28.2; 
MALDI-TOF m/z calcd for C17H23N5O5 377.40 found [M + H]+ 377.37. 
 
26 21
 
BocNHImPyPyCOOMe (21).  Compound 9 (106.6 mg, 0.6 mmol) was dissolved in 
MeOH (20 mL).  10% Pd/C (10.6 mg) was added and the solution was stirred under 
positive H2 atmosphere, supplied by submerged syringe needle in the solution.  The 
solution was stirred for 3 h.  The catalyst was filtered over celite and the filtrate was 
concentrated in vacuo, followed by co-evaporation with copious amounts of CH2Cl2.  The 
resulting oil was suspended in DMF and placed under vacuum for addition to the 
activated acid solution.  Compound 26 (218.4 mg, 0.6 mmol) was dissolved in MeOH (20 
mL) and 1.5 M NaOH (2 mL) was added.  The solution was allowed to stir for 6 h at 60 
oC.  The ester solution was quenched by neutralized with HCl.   Volatiles were removed 
in vacuo.  The resulting solid was dissolved in DMF (10 mL).  EDC (110.9 mg, 0.6 
mmol) and HOBt (78.2mg, 0.6 mmol) were added and the reaction was allowed to stir for 
30 min.  The amine solution, in 8 mL of DMF, was added dropwise to the activated acid 
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solution over the period of 10 min and the reaction was allowed to stir for 15 h.  DMF 
was evaporated in vacuo and the resulting solid was purified via flash chromatography 
(silica gel, acetone:CH2Cl2, 5.0 % incremental increases of acetone) to yield pure 21 
(218.4 mg, 71%) as a white solid:  TLC (50:50 CH2Cl2:Acetone v/v) Rf 0.71; 1H NMR 
(500 MHz, CDCl3) δ 8.86 (s, 1H), 8.04 (s, 1H), 7.68 (s, 1H), 7.44 (s, 1H), 7.28 (s, 1H), 
7.18 (s, 1H), 6.78 (s, 1H), 6.66 (s, 1H), 4.05 (s, 3H), 3.94 (s, 3H), 3.92 (s, 3H), 3.83 (s, 
3H), 1.53 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.8, 161.3, 156.8, 153.3, 138.2, 134.1, 
123.5, 121.8, 120.9, 120.0, 119.4, 118.3, 112.5, 107.2, 106.3, 80.9, 51.0, 37.2, 36.7, 35.0, 
27.9; MALDI-TOF m/z calcd for C23H29N7O6 499.52, found [M + H]+ 500.01. 
   
2011 27  
HImImPyPyγImCOOMe (27).  Compound 20 (69.2 mg, 149.6 µmol) was suspended in 
diethyl ether (5 mL) and 4 N HCl in 1,4-dioxane was added (5 mL) and the reaction was 
allowed to stir for 5.5 h.  The solvent was removed in vacuo and the resulting solid was 
washed multiple times with excessive amounts of diethyl ether to afford a dry white 
solid, sufficiently pure for addition to the activated acid.  To a solution of compound 11 
(57.6 mg, 149.6 µmol) in methanol (10 mL) was added 1.5 M NaOH (2 mL) and the 
solution was allowed to stir for 5.5 h at 60 oC.  The ester solution was neutralized with 
HCl.   Volatiles were removed in vacuo.  The resulting solid was dissolved in DMF (10 
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mL).  PyBOP (77.9 mg, 149.6 µmol) and DIPEA (19.3 mg, 149.6 µmol) were added and 
the reaction was allowed to stir for 30 min.  The amine hydrochloride solid was added to 
the activated acid solution over the period of 10 min and the reaction was allowed to stir 
for 16 h.  DMF was evaporated in vacuo and the resulting solid was purified via flash 
chromatography (silica gel, Acetone v/v) to yield pure 27 (94.3 mg, 88%) as a light 
brown solid:  TLC (Acetone) Rf 0.48; 1H NMR (500 MHz, MeOD) δ 9.28 (br, 1H), 9.01 
(br, 1H), 8.73 (br, 1H), 8.26 (br, 1H), 8.19 (br, 1H), 7.72 (s, 1H), 7.70 (s, 1H), 7.62 (s, 
1H), 7.58 (s, 1H), 7.31 (s, 1H), 7.18 (s, 1H), 7.00 (s, 1H), 6.79 (s, 1H), 4.22 (s, 3H), 4.10 
(s, 3H), 4.05 (s, 3H), 3.94 (s, 6H), 3.87 (s, 3H), 2.53-2.51 (t, J = 5.7, 2H), 2.03-1.99 (t, J = 
6.3, 2H), 1.52-1.42 (m, J1=6.3, J2=5.7, 2H); 13C NMR (75 MHz, MeOD) δ 172.6, 161.9, 
161.6, 159.0, 156.3, 155.9, 153.3, 138.5, 137.1, 135.5, 131.3, 130.9, 128.9, 128.3, 126.2, 
123.2, 121.7, 121.2, 120.1, 117.6, 115.5, 114.1, 108.4, 103.6, 80.0, 52.2, 51.2, 38.6, 36.8, 
36.5, 35.9, 35.8, 35.7, 33.8, 30.9, 29.3; MALDI-TOF m/z calcd for C32H37N13O7 715.72, 
found [M + Na]+ 739.21.   
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27 21
19
 
HImImPyPyγImImPyPyCOOMe (19).  Compound 21 (69.2 mg, 149.6 µmol) was 
suspended in diethyl ether (5 mL) and 4 N HCl in 1,4-dioxane was added (5 mL) and the 
reaction was allowed to stir for 6 h.  The solvent was removed in vacuo and the resulting 
solid was washed multiple times with excessive amounts of diethyl ether to afford a dry 
white solid, sufficiently pure for addition to the activated acid.  To a solution of 
compound 27 (90.0 mg, 125.7 µmol) in methanol (10 mL) was added 1.5 M NaOH (3 
mL) and the solution was allowed to stir for 4.5 h at 60 oC.  The ester solution was 
neutralized with HCl.   Volatiles were removed in vacuo.  The resulting solid was 
dissolved in DMF (10 mL).  PyBOP (81.8 mg, 157.2 µmol) and DIPEA (20.4 mg, 157.2 
µmol) were added and the reaction was allowed to stir for 30 min.  The amine 
hydrochloride solid was added to the activated acid solution over the period of 10 min 
and the reaction was allowed to stir for 24 h.  DMF was evaporated in vacuo and the 
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resulting solid was purified via flash chromatography (silica gel, acetone) to yield pure 19 
(110.6 mg, 89%) as a light brown solid:  TLC (95:5 CH2Cl2:MeOH v/v) Rf 0.48; 1H NMR 
(500 MHz, (CD3)2CO) δ 7.75 (s, 1H), 7.70 (s, 1H), 7.68 (s, 1H), 7.66 (s, 1H), 7.60 (s, 
1H), 7.49 (s, 1H), 7.33 (s, 1H), 7.31 (s, 1H), 7.18 (s, 2H), 7.05 (s, 1H), 6.85 (s, 1H), 6.78 
(s, 1H), 6.66 (s, 1H), 4.22 (s, 3H), 4.10 (s, 3H), 4.05 (s, 6H), 3.94 (s, 6H), 3.90 (s, 6H), 
3.81 (s, 3H), 2.60-2.54 (t, J = 5.1, 2H), 2.18-1.95 (t, J = 6.4, 2H), 1.55-1.41 (m, J1=6.4, J-
2=5.2, 2H); 
13C NMR (75 MHz, MeOD) δ 174.6, 171.3, 162.5, 161.6, 161.0, 159.9, 
156.9, 156.1, 155.7, 154.1, 153.8, 138.6, 138.1, 137.5, 136.1, 133.7, 131.4, 130.1, 128.5, 
128.0, 126.1, 123.5, 123.0, 121.9, 121.1, 121.0, 120.7, 120.4, 120.2, 119.7, 118.0, 117.6, 
115.5, 114.1, 112.8, 108.7, 107.6, 106.9, 103.2, 80.8, 80.0, 52.7, 51.1, 51.0, 38.6, 37.2, 
36.5, 36.3, 36.0, 35.8, 35.4, 35.7, 34.4, 33.7, 30.1; MALDI-TOF m/z calcd for 
C49H54N20O10 1083.08, found [M + Na]
+ 1106.07.   
 
n = 2, DPA226
3, DPA227
5, DPA228
6, DPA229
8, DPA230
10, DPA231
19  
HImImPyPyγImImPyCONH(CH2)nN3 (DPA226 – DPA231).  To a solution of 
compound 19 (10.0 mg, 9.2 µmol) in methanol (10 mL) was added 1.5 M NaOH (1 mL) 
and the solution was allowed to stir for 5.5 h at 60 oC.  The ester solution was neutralized 
with HCl.   Volatiles were removed in vacuo.  The resulting solid was dissolved in DMF 
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(10 mL).  EDC (2.2 mg, 11.5 µmol) and HOBt (1.6 mg, 11.5 µmol) were added and the 
reaction was allowed to stir for 30 min.  The α,ω-amino, azido alkanes (11.5 µmol) were 
added to the activated acid solution over the period of 10 min and the reaction was 
allowed to stir for 24 h.  DMF was evaporated in vacuo and the resulting solid was 
purified via flash chromatography (silica gel, inc. % of MeOH in CH2Cl2) to yield the 
desired pure azide-terminal hairpin polyamides, DPA226 – DPA231. 
 
HImImPyPyγImImPyCONH(CH2)2N3 (DPA226).  DPA226 (9.2 mg, 88%) was 
afforded as a light brown solid:  TLC (85:15 CH2Cl2:MeOH v/v) Rf 0.50; 1H NMR (500 
MHz, (CD3)2CO) δ 7.81 (s, 1H), 7.77 (s, 1H), 7.71 (s, 1H), 7.68 (s, 1H), 7.61 (s, 1H), 
7.43 (s, 1H), 7.33 (s, 1H), 7.30 (s, 1H), 7.26 (s, 2H), 7.15 (s, 1H), 6.94 (s, 1H), 6.88 (s, 
1H), 6.61 (s, 1H), 4.22 (s, 6H), 4.15 (s, 6H), 4.00 (s, 6H), 3.96 (s, 3H), 3.90 (s, 3H), 3.36-
3.23 (m, 4H), 2.66-2.55 (t, J = 5.1, 2H), 2.18-1.95 (t, J = 6.4, 2H), 1.55-1.41 (m, J1=6.4, 
J2=5.2, 2H); MALDI-TOF m/z calcd C50H56N24O9 1137.14, found [M + Na]+ 1161.07.   
 
HImImPyPyγImImPyCONH(CH2)3N3 (DPA227).  DPA227 (9.7 mg, 91%) was 
afforded as a light brown solid:  TLC (85:15 CH2Cl2:MeOH v/v) Rf 0.50; 1H NMR (500 
MHz, (CD3)2CO) δ 7.81 (s, 1H), 7.72 (s, 1H), 7.69 (s, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 
7.43 (s, 1H), 7.35 (s, 1H), 7.28 (s, 1H), 7.20 (s, 2H), 7.17 (s, 1H), 6.94 (s, 1H), 6.89 (s, 
1H), 6.63 (s, 1H), 4.30 (s, 6H), 4.20 (s, 6H), 4.00 (s, 6H), 3.94 (s, 3H), 3.90 (s, 3H), 3.33-
3.25 (m, 4H), 2.67-2.54 (m, 2H), 2.18-1.90 (m, 4H), 1.86 (m, 2H); MALDI-TOF m/z 
calcd C51H58N24O9 1151.16, found [M + Na + H2O]
+ 1176.67.   
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HImImPyPyγImImPyCONH(CH2)5N3 (DPA228).  DPA228 (9.9 mg, 91%) was 
afforded as a light brown solid:  TLC (85:15 CH2Cl2:MeOH v/v) Rf 0.50; 1H NMR (500 
MHz, (CD3)2CO) δ
 1H NMR (500 MHz, (CD3)2CO) δ 7.84 (s, 1H), 7.73 (s, 1H), 7.71 (s, 
1H), 7.66 (s, 1H), 7.63 (s, 1H), 7.40 (s, 1H), 7.35 (s, 1H), 7.31 (s, 1H), 7.22 (s, 2H), 7.18 
(s, 1H), 6.96 (s, 1H), 6.89 (s, 1H), 6.61 (s, 1H), 4.27 (s, 6H), 4.18 (s, 6H), 4.07 (s, 6H), 
3.96 (s, 3H), 3.94 (s, 3H), 3.41-3.31 (m, 4H), 2.66-2.54 (m, 2H), 2.18-1.90 (m, 4H), 1.55-
1.52 (m, 6H); MALDI-TOF m/z calcd C53H62N24O9 1179.21, found [M + Na]
+ 1202.21.   
 
HImImPyPyγImImPyCONH(CH2)6N3 (DPA229).  DPA229 (8.5 mg, 77%) was 
afforded as a light brown solid:  TLC (85:15 CH2Cl2:MeOH v/v) Rf 0.50; 1H NMR (500 
MHz, (CD3)2CO) δ 7.84 (s, 1H), 7.73 (s, 1H), 7.70 (s, 1H), 7.65 (s, 1H), 7.60 (s, 1H), 
7.40 (s, 1H), 7.33 (s, 1H), 7.30 (s, 1H), 7.26 (s, 2H), 7.20 (s, 1H), 6.94 (s, 1H), 6.88 (s, 
1H), 6.61 (s, 1H), 4.22 (s, 6H), 4.15 (s, 6H), 4.00 (s, 6H), 3.96 (s, 3H), 3.90 (s, 3H), 3.32-
3.21 (m, 4H), 2.63-2.54 (m, 2H), 2.18-1.95 (m, 4H), 1.55-1.41 (m, 8H); MALDI-TOF 
m/z calcd C54H64N24O9 1193.24, found [M + Na]
+ 1215.99. 
 
HImImPyPyγImImPyCONH(CH2)8N3 (DPA230).  DPA230 (9.6 mg, 85%) was 
afforded as a light brown solid:  TLC (85:11 CH2Cl2:MeOH v/v) Rf 0.45; 1H NMR (500 
MHz, (CD3)2CO) δ 7.84 (s, 1H), 7.72 (s, 1H), 7.69 (s, 1H), 7.61 (s, 1H), 7.55 (s, 1H), 
7.43 (s, 1H), 7.36 (s, 1H), 7.28 (s, 1H), 7.22 (s, 2H), 7.20 (s, 1H), 6.94 (s, 1H), 6.89 (s, 
1H), 6.61 (s, 1H), 4.30 (s, 6H), 4.20 (s, 6H), 4.10 (s, 6H), 3.93 (s, 3H), 3.90 (s, 3H), 3.38-
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3.21 (m, 4H), 2.67-2.54 (m, 2H), 2.18-1.90 (m, 4H), 1.59 (m, 4H) 1.31 (m, 4H), 1.28 (m, 
4H); MALDI-TOF m/z calcd C56H68N24O9 1221.29, found [M + Na]
+ 1245.22.   
 
HImImPyPyγImImPyCONH(CH2)10N3 (DPA231).  DPA231 (10.1 mg, 91%) was 
afforded as a light brown solid:  TLC (85:15 CH2Cl2:MeOH v/v) Rf 0.40; 1H NMR (500 
MHz, (CD3)2CO) δ 
1H NMR (500 MHz, (CD3)2CO) δ 7.84 (s, 1H), 7.73 (s, 1H), 7.70 (s, 
1H), 7.66 (s, 1H), 7.63 (s, 1H), 7.40 (s, 1H), 7.35 (s, 1H), 7.31 (s, 1H), 7.22 (s, 2H), 7.18 
(s, 1H), 6.96 (s, 1H), 6.89 (s, 1H), 6.61 (s, 1H), 4.27 (s, 6H), 4.18 (s, 6H), 4.07 (s, 6H), 
3.96 (s, 3H), 3.94 (s, 3H), 3.36-3.23 (m, 4H), 2.67-2.54 (t, J = 5.2, 2H), 2.18-1.90 (t, J = 
6.4, 2H), 1.66 (m, 4H), 1.38 (m, 8H); MALDI-TOF m/z calcd C58H72N24O9 1249.35, 
found [M + Na]+ 1273.01.   
 
TPS =
R = NHBocDPA102
 
N-Boc neomycin-S(CH2)2NH2 (DPA10).  See Appendix A for compound data reduction 
and characterization. 
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TPS =
R = NHBocDPA112
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N-Boc neomycin-N3 (DPA11).  See Appendix A for synthetic procedure, compound data 
reduction and characterization. 
 
DPA11 R = NHBocDPA12  
N-Boc neomycin-NH2 (DPA12).  See Appendix A for synthetic procedure, compound 
data reduction and characterization. 
 
R = NHBoc
DPA11 DPA13  
N-Boc neomycin-‘tri’-CH2OCH2CCH (DPA13).  See Appendix B for compound data 
reduction and characterization. 
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R = NHBoc
DPA12 DPA16  
N-Boc neomycin-NHC(O)CCH (DPA16).  To a flame dried round bottom flask under 
inert atmosphere, afforded by argon gas, was added DCC (12.9 mg, 62.6 µmol) and 
anhydrous CH2Cl2 (10 mL).  The solution was cooled to 0 
oC and propiolic acid (3.7 mg, 
52.7 µmol) was added via syringe.  The solution was allowed to stir at 0 oC for 30 min.  
Compound DAP12 (32.0 mg, 26.3 µmol) was dissolved in anhydrous CH2Cl2 and added 
dropwise to the activated acid solution, via syringe, under positive Ar (g), over a period 
of 15 min.  The solution was allowed to warm to room temperature and was stirred for 18 
h.  Volatiles were removed in vacuo and the resulting solid was purified by 
chromatography (silica gel, CH2Cl2:2-propanol, 1.0 % incremental increases of 2-
propanol) to afford DPA16 (28.7 mg, 86%) as an off white solid TLC (90:10 
CH2Cl2:EtOH v/v) Rf 0.55; 1H NMR (500 MHz, CDCl3) δ 7.61 (br, 1H), 6.12 (s, 1H), 
6.00 (s, 1H), 5.27 (s, 1H), 4.97 (s, 1H), 4.88 (s, 2H), 4.76 (s, 1H), 4.61 (s, 1H), 4.21-4.05 
(m, 5H), 3.87 (s, 2H), 3.76 (s, 1H), 3.68 (s, 2H), 3.51 (s, 3H), 3.44 (s, 1H), 3.25 (s, 2H), 
3.02 (s, 2H), 2.79 (s, 2H), 2.61-2.59 (m, 2H), 1.56-1.36 (m, 54 H); MALDI-TOF m/z 
calcd for C56H95N7O25 1266.38, found [M + H2O]
+ 1277.91 
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19 28  
HImImPyPyγImImPyPyDp (28).  To a solution of compound 19 (10.0 mg, 9.2 µmol) in 
methanol (10 mL) was added 1.5 M NaOH (1 mL) and the solution was allowed to stir 
for 3.0 h at 60 oC.  The ester solution was neutralized with HCl.   Volatiles were removed 
in vacuo.  The resulting solid was dissolved in DMF (10 mL).  EDC (2.2 mg, 11.5 µmol) 
and HOBt (1.6 mg, 11.5 µmol) were added and the reaction was allowed to stir for 30 
min.  N,N-dimethylaminopropylamine (9.4 mg, 92.0 µmol) was added and the solution 
was allowed to stir for 18 h.  DMF was removed in vacuo and the resulting solid was 
suspended in CH2Cl2 (25 mL).  The solution was decanted and the resulting solid was 
suspended in MeOH (15 mL).  The solution was decanted and the resulting solid was 
suspended in water (15 mL).  The solution was decanted and the solid was dried to afford 
28 as an off white solid (8.9 mg, 84%):  1H NMR (500 MHz, acetone-d6) δ 7.81 (s, 1H), 
7.78 (s, 1H), 7.71 (s, 1H), 7.70 (s, 1H), 7.67 (s, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 7.37 (s, 
1H), 7.22 (s, 2H), 7.00 (s, 1H), 6.91 (s, 1H), 6.84 (s, 1H), 6.74 (s, 1H), 4.29 (s, 3H), 4.20 
(s, 3H), 4.19 (s, 3H), 4.12 (s, 6H), 4.00 (s, 6H), 3.90 (s, 6H), 3.88 (s, 6H), 2.60-2.54 (t, J 
= 5.6, 2H), 2.18-1.95 (t, J = 6.6, 2H), 1.55-1.41 (m, J1=6.6, J2=5.5, 2H); MALDI-TOF 
m/z calcd for C53H64N22O9 1153.22, found [M + Cl-]+ 1188.54.   
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 (a) 1H NMR 
 
(b) 13C NMR 
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(c) MALDI-TOF 
 
Figure C1. Characterization of compound 25.   
 
(a) 1H NMR 
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(b) 13C NMR 
 
(c) MALDI-TOF 
 
Figure C2. Characterization of compound 20.   
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(a) 1H NMR 
 
(b) 13C NMR 
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(c) MALDI-TOF 
 
Figure C3. Characterization of compound 26.   
 
(a) 1H NMR 
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(b) 13C NMR 
 
(c) MALDI-TOF 
 
Figure C4. Characterization of compound 21.   
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(a) 1H NMR 
 
(b) 13C NMR 
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(c) MALDI-TOF 
 
Figure C5. Characterization of compound 27.   
 
(a) 1H NMR 
s  
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(b) 13C NMR 
 
(c) MALDI-TOF 
 
Figure C6. Characterization of compound 19.   
 
 (a) 1H NMR 
(b) MALDI-TOF 
Figure C7. Characterization of compound 
 
DPA226. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C8. Characterization of compound DPA227. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C9. Characterization of compound DPA228. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C10. Characterization of compound DPA229. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C11. Characterization of compound DPA230. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C12. Characterization of compound DPA231. 
 
 (a) 1H NMR 
(b) MALDI-TOF 
Figure C13. Characterization of compound 
 
DPA16.   
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(a) 1H NMR (N-Boc protected) 
 
(b) MALDI-TOF (N-Boc protected) 
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 (c) 1H NMR (deprotected) 
 
(d) MALDI (deprotected) 
 
Figure C14. Characterization of compound DPA232.   
 
 (a) 1H NMR 
(b) MALDI-TOF 
Figure C15. Characterization of compound 
 
DPA233.   
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 (a) 1H NMR 
(b) MALDI-TOF 
Figure C16. Characterization of compound 
 
DPA234.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C17. Characterization of compound DPA235.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C18. Characterization of compound DPA236.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C19. Characterization of compound DPA237.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C20. Characterization of compound DPA238. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C21. Characterization of compound DPA239.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C22. Characterization of compound DPA240.   
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C23. Characterization of compound DPA241. 
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C24. Characterization of compound DPA242.  
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(a) 1H NMR 
 
(b) MALDI-TOF 
 
Figure C25. Characterization of compound 28.   
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Figure C26.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-AG2C2AG4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 0.5.  Data was obtained from a FID 
assay.  Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium 
bromide [7 µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min 
and the subsequent decrease in fluorescence was recorded.  The data was normalized 
such that the well containing ethidium bromide and buffer was denoted as 0% 
fluorescence and the well containing buffer, DNA and ethidium bromide was denoted as 
100% fluorescence.  Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; 
slitsex = 20; slitsem = 20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 
nm; PMT V = 810 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO-
4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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Figure C27.  Plot of normalized fluorescence intensity with respect to conjugate linker 
length upon addition of ligands to 5’-AG2C2AG4C4-3’.  In the histogram, the values 
represent the percent decrease in fluorescence at rdd = 2.0.  Data was obtained from a FID 
assay.  Ligands were added to the DNA [1 µM/duplex], pre-saturated with ethidium 
bromide [7 µM], at various ratios of drug to duplex (rdd), allowed to equilibrate for 5 min 
and the subsequent decrease in fluorescence was recorded.  The data was normalized 
such that the well containing ethidium bromide and buffer was denoted as 0% 
fluorescence and the well containing buffer, DNA and ethidium bromide was denoted as 
100% fluorescence.  Fluorescence parameters: Excitation = 525 nm; Emission = 608 nm; 
slitsex = 20; slitsem = 20; Excitation filter = 335 – 620 nm; Emission filter = 550 – 1100 
nm; PMT V = 810 and triplicate measurements were averaged.  Buffer: 1.5 mM Na2HPO-
4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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(c)  
 
 
Figure C28.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-AG2C2AG4C4-3’, 
by hairpin polyamide – neomycin control 28 at 20 oC (a).  The DNA duplex, 1.0 
µM/duplex, 14 µM/base pair, was pre-bound by thiazole orange, 7 µM and allowed to 
equilibrate for a period of 10 min prior to addition of 28, the fluorescence intensity is 
denoted as Fmax.  Compound 28 was added at various rdd values, a plot of fluorescence 
intensity vs rdd is located in panel (b). A related plot of ∆F vs rdd is located in panel (c).  
Fluorescence parameters: Excitation = 504 nm; Emission = 510-610 nm; Excitation filter 
= open; Emission filter = open; Slits = 20; PMTV = 550 and triplicate measurements 
were averaged.  Buffer: 1.5 mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 
50 mM NaCl. 
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(a) (b) 
  
(c) (d) 
  
Figure C29.  Fluorescence intercalator displacement titration spectra for the 
displacement of pre-bound thiazole orange from the DNA duplex, 5’-AG2C2AG4C4-3, by 
DPA237 (a) and DPA236 (c) at 20 oC.  The DNA duplex, 1.0 µM/duplex, 14 µM/base 
pair, was pre-bound by thiazole orange, 7 µM and allowed to equilibrate for a period of 
10 min prior to addition of ligand, the fluorescence intensity is denoted as Fmax.  A 
related plot of ∆F vs rdd is located in panel (b and d).  Fluorescence parameters: 
Excitation = 504 nm; Emission = 510-610 nm; Excitation filter = open; Emission filter = 
open; Slits = 20; PMTV = 550 and triplicate measurements were averaged.  Buffer: 1.5 
mM Na2HPO4, 0.5 mM NaH2PO4, 0.25 mM EDTA, pH 7.0, 50 mM NaCl. 
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